0001144204-15-023067.txt : 20150415 0001144204-15-023067.hdr.sgml : 20150415 20150415172612 ACCESSION NUMBER: 0001144204-15-023067 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20150415 DATE AS OF CHANGE: 20150415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AmpliPhi Biosciences Corp CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23930 FILM NUMBER: 15772655 BUSINESS ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 BUSINESS PHONE: 650-888-2422 MAIL ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 FORMER COMPANY: FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/ DATE OF NAME CHANGE: 19940331 10-Q/A 1 v407147_10qa.htm FORM 10-Q/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934		  

  

For the quarterly period ended June 30, 2014

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934		  

  

For the transition period from _________________ to _______________________

 

Commission file number: 000-23930

 

AMPLIPHI BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)

 

Washington

(State or other jurisdiction of

incorporation or organization)

91-1549568
I.R.S. Employer Identification Number)

 

   

4870 Sadler Road, Suite 300

Glen Allen, Virginia

23060

(Zip Code)

   
(Address of principal executive offices)  

 

Registrant’s telephone number, including area code: (804) 205-5069

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ¨    No    x

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes x    No    ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company as defined in Rule 12b-2 of the Exchange Act. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  ¨ Accelerated filer  ¨
Non-accelerated filer ¨ (Do not check if a small reporting company) Smaller reporting company  x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ¨    No x

 

The number of shares of the Registrant’s Public Common Stock outstanding at August 7, 2014 was 187,159,093.

 

 
 

 

EXPLANATORY NOTE

 

Amended Financial Statements

 

The Company’s previously issued June 30, 2014 financial statements have been amended to:

 

·reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at June 30, 2014 of $1,337,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000.
·recognize deferred revenue and deferred costs related certain sub-licensing agreements. This change resulted in a reduction in revenues of $209,000 and a reduction in G&A expense of $164,000 in the second quarter of 2014 and a reduction in revenues of $105,000 and a reduction in G&A expense of $103,000 for the six months ended June 30, 2014.
·reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $460,000 as of June 30, 2014.
·adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.
·modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $7,298,000 increase in the compound derivative liability and a $158,000 reduction in the warrant liability related to 2013 warrants. Gain on derivative liabilities was reduced by $1,499,000 and $844,000 for the second quarter of 2014 and the six months ended June 30, 2014, respectively.

 

As a result of these corrections, the Company’s net income attributable to common stockholders for the second quarter of 2014, as amended, was reduced by $1,848,000 to $13,555,000. Net income per share attributable to common stockholders fell by $0.01 per share to $0.07 per share. Net income attributable to common stockholders for the six months ended June 30, 2014, as amended, fell by $1,440,000 to $1,934,000. Net income per share attributable to common stockholders was reduced by $0.01 per share to $0.01 per share for the period.

 

The Company’s net loss attributable to common stockholders for the second quarter of 2013, as amended, increased by $(1,933,000) to $(14,746,000). The net loss per share attributable to common stockholders increased by $(0.02) per share to $(0.16) per share. The net loss attributable to common stockholders for the six months ended June 30, 2013, as amended, increased by $(1,959,000) to $(16,391,000). The net loss per share attributable to common stockholders increased by $(0.03) per share to $(0.21) per share for the period.

 

 
 

 

TABLE OF CONTENTS

 

    Page
     
PART I - FINANCIAL INFORMATION  
     
Consolidated Balance Sheets 2
   
Consolidated Statements of Operations 3
   
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) 4
   
Consolidated Statements of Cash Flows 5
   
Condensed Notes to Consolidated Financial Statements 6
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14
     
PART II.  OTHER INFORMATION 19
     
Item 1. Legal Proceedings 19
     
Item 1A. Risk Factors 19
     
Item 1A. Unregistered Sales of Equity Securities and Use of Proceeds 19
     
Item 3. Defaults upon Senior Securities 19
     
Item 4. Mine Safety Disclosures 19
     
Item 5. Other Information 19
     
Item 6. Exhibits 19
     
Signatures   21

 

 
 

 

AmpliPhi Biosciences Corporation
Consolidated Balance Sheets  

 

   June 30, 2014   December 31, 2013 
   (Unaudited)     
   (Restated)   (Restated) 
Assets          
Current assets          
Cash and cash equivalents  $12,550,000   $20,355,000 
Accounts receivable   136,000    8,000 
Prepaid expenses and other current assets   526,000    297,000 
Total current assets   13,212,000    20,660,000 
Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of June 30, 2014 and December 31, 2013, respectively   1,119,000    145,000 
Intangible assets          
In process research and development   12,446,000    12,446,000 
Patents, net of accumulated amortization of $108,000 and $93,000 as of June 30, 2014 and December 31, 2013, respectively   385,000    400,000 
Goodwill   7,562,000    7,562,000 
Total intangible assets   20,393,000    20,408,000 
Total assets  $34,724,000   $41,213,000 
Liabilities, Series B Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)          
Current liabilities          
Accounts payable and accrued expenses  $1,366,000   $2,147,000 
Deferred revenue   349,000    244,000 
Total current liabilities   1,715,000    2,391,000 
Long term liabilities          
Derivative preferred shares conversion liability   33,402,000    40,791,000 
Derivative warrants liability   13,115,000    16,871,000 
Deferred tax liability   3,078,000    3,078,000 
Total long term liabilities   49,595,000    60,740,000 
Total liabilities   51,310,000    63,131,000 
           
Series B redeemable convertible preferred stock          
$0.01 par value, 10,000,000 shares authorized, 8,671,000 shares issued and outstanding at June 30, 2014 and 8,859,978 shares issued and outstanding at December 31, 2013 (liquidation preference of $13,390,000 and $13,022,000 at June 30, 2014 and December 31, 2013, respectively)   1,337,000    707,000 
           
Stockholders’ equity (deficit)          
Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at June 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013   1,872,000    1,825,000 
Additional paid-in capital   360,917,000    358,828,000 
Paid-in-capital – contingent shares   1,837,000    1,837,000 
Accumulated deficit   (382,549,000)   (385,115,000)
Total stockholders’ equity (deficit)   (17,923,000)   (22,625,000)
Total liabilities, Series B redeemable convertible preferred stock and stockholders’ equity (deficit)  $34,724,000   $41,213,000 

 

See accompanying condensed notes to consolidated financial statements.

 

2
 

 

AmpliPhi Biosciences Corporation

Consolidated Statements of Operations

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2014   2013   2014   2013 
   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
   (Restated)   (Restated)   (Restated)   (Restated) 
Revenue  $101,000   $314,000   $205,000   $336,000 
Operating expenses                    
Research and development   1,888,000    3,595,000    2,899,000    4,236,000 
General and administrative   1,961,000    2,843,000    3,588,000    3,557,000 
Total operating expenses   3,849,000    6,438,000    6,487,000    7,793,000 
Loss from operations   (3,748,000)   (6,124,000)   (6,282,000)   (7,457,000)
Other income (expense)                    
Gain (loss) on derivative liabilities   17,621,000    (6,057,000)   8,848,000    (5,970,000)
Amortization of note discount   —    (2,334,000)   —    (2,637,000)
Interest expense, net   —    (128,000)   —    (224,000)
Other income (expense), net   17,621,000    (8,519,000)   8,848,000    (8,831,000)
Net loss   13,873,000    (14,643,000)   2,566,000    (16,288,000)
Accretion of Series B redeemable convertible preferred stock   (318,000)   (103,000)   (632,000)   (103,000)
Net loss attributable to common stockholders  $13,555,000   $(14,746,000)  $1,934,000   $(16,391,000)
Per share information:                    
Net income (loss) per share – basic  $0.07   $(0.16)  $0.01   $(0.21)
Net income (loss) per share – diluted   0.04    (0.16)   0.01    (0.21)
Weighted average number of shares of common stock outstanding – basic   183,590,053    90,645,074    183,065,721    78,842,512 
Weighted average number of shares of common stock outstanding – diluted   324,880,957    90,645,074    325,709,071    78,842,512 

 

 

 See accompanying condensed notes to consolidated financial statements.

 

3
 

 

AmpliPhi Biosciences Corporation

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

 

   Redeemable Convertible
Preferred Stock		   Stockholders' Equity (Deficit) 
   Series B   Common Stock             
   Shares   Amount   Shares   Amount   Additional
Paid-in Capital		   Accumulated
Deficit		   Total
Stockholders'
Equity
(Deficit)		 
Balances, December 31, 2012 (Restated)   —   $—    66,908,810   $669,000   $332,806,000   $(320,532,000)  $12,943,000 
Net loss   —    —    —    —    —    (64,583,000)   (64,583,000)
Stock-based compensation   —    —    —    —    1,437,000    —    1,437,000 
Beneficial conversion feature and warrants associated with issuance of convertible loan notes   —    —    —    —    2,635,000    —    2,635,000 
Shares issued for Intrexon   —    —    24,000,000    240,000    2,760,000    —    3,000,000 
Accretion of Series B convertible preferred stock to its redemption value   —    618,000    —    —    (618,000)   —    (618,000)
Issuance of preferred stock from conversion of convertible loan notes   5,016,081    50,000    —    —    —    —    — 
Issuance of preferred stock   4,999,999    50,000    —    —    —    —    — 
Preferred shares converted to common stock   (1,156,102)   (11,000)   11,561,020    115,000    6,969,000    —    7,084,000 
Stock options exercised   —    —    61,018    1,000    12,000    —    13,000 
Shares released from escrow   —    —    8,000,000    80,000    (80,000)   —    — 
Issuance of common stock for December financing   —    —    72,007,000    720,000    14,744,000    —    15,464,000 
Escheat shares   —    —    (2,286)   —    —    —    — 
Balances, December 31, 2013 (Restated)   8,859,978   $707,000    182,535,562   $1,825,000   $360,665,000   $(385,115,000)  $(22,625,000)
Net income (loss)   —    —    —    —    —    2,566,000    2,566,000 
Warrants exercised   —    —    2,734,151    28,000    1,563,000    —    1,591,000 
Preferred stock converted to common stock   (188,938)   (2,000)   1,889,380    19,000    690,000    —    709,000 
Accretion of Series B convertible preferred stock to its redemption value   —    632,000    —    —    (632,000)   —    (632,000)
Stock-based compensation   —    —    —    —    468,000    —    468,000 
Balances, June 30, 2014 (Unaudited) (Restated)   8,671,040   $1,337,000    187,159,093   $1,872,000   $362,754,000   $(382,549,000)  $(17,923,000)

 

See accompanying condensed notes to consolidated financial statements.

 

4
 

 

AmpliPhi Biosciences Corporation
Consolidated Statements of Cash Flows

 

   Six Months Ended June 30, 
   2014   2013 
   (Unaudited)   (Unaudited) 
   (Restated)   (Restated) 
Cash flows from operating activities          
Net income (loss) from operations  $2,566,000   $(16,288,000)
Adjustments required to reconcile net income (loss) to cash used in operating activities:          
Derivative liability (gain) loss   (8,848,000)   5,970,000 
Shares issued for technology access fee   —    3,000,000 
Amortization of patents   15,000    15,000 
Amortization of note discount   —    2,637,000 
Warrants issued as investment fees   —    759,000 
Depreciation   86,000    45,000 
Stock-based compensation   468,000    958,000 
Changes in operating assets and liabilities net of acquisitions:          
Accounts receivable   (128,000)   (117,000)
Tax refund   —    618,000 
Accounts payable and accrued expenses   (675,000)   (120,000)
Prepaid expenses and other current assets   (229,000)   (87,000)
Interest on loan notes   —    224,000 
Net cash used in operating activities   (6,745,000)   (2,386,000)
Cash flows from investing activities          
Purchases of property and equipment   (1,060,000)   (65,000)
Net cash used in investing activities   (1,060,000)   (65,000)
Cash flows from financing activities          
Proceeds from Series B redeemable convertible preferred stock   —    7,000,000 
Proceeds from convertible loan notes   —    2,000,000 
Payment of convertible loan note   —    (26,000)
Net cash provided by financing activities   —    8,974,000 
Net increase (decrease) in cash and cash equivalents   (7,805,000)   6,523,000 
Cash and cash equivalents, beginning of period   20,355,000    862,000 
Cash and cash equivalents, end of period  $12,550,000   $7,385,000 
Supplemental schedule of non-cash financing activities:          
Accretion of Series B redeemable convertible preferred stock  $1,337,000   $618,000 

 

See accompanying condensed notes to consolidated financial statements.

 

5
 

 

AmpliPhi Biosciences Corporation

Condensed Notes to Consolidated Financial Statements
June 30, 2014
(Unaudited) (Restated)

 

1. Nature of Business and Significant Accounting Policies

 

Nature of Business

 

AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.

 

Basis of Presentation

 

The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.

 

The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months and six months ended June 30, 2014 and 2013, our cash flows for the six months ended June 30, 2014 and 2013 and our financial position as of June 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

 

Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.

 

Accounts Receivable

 

Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of June 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.

 

6
 

 

Property and Equipment

 

Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.

 

Prepaid Expenses and Other Current Assets

 

Prepaid and other current assets as of June 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.

 

Goodwill

 

Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.

 

During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management’s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.

 

During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management’s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.

 

Patents

 

Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.

 

During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.

 

Stock-Based Compensation

 

The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.

 

Warrant and Preferred Shares Conversion Feature Liability

 

The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require such warrants and the Series B redeemable convertible preferred stock shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.

 

7
 

 

Fair Value of Financial Assets and Liabilities — Derivative Instruments

 

The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.

 

GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities.

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.

 

Level 3 — inputs that are unobservable.

 

The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.

 

The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.

 

Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.

 

Revenue Recognition

 

The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.

 

The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:

 

  • The delivered items have value to the customer on a stand-alone basis;

 

  • Any undelivered items have objective and reliable evidence of fair value; and

 

  • Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.

 

The Company classifies advance payments received in excess of amounts earned as deferred revenue.

 

8
 

 

Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.

 

Research and Development

 

Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.

 

In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. At December 31, 2012, IPR&D in the amount of $5,161,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of June 30, 2014 and December 31, 2013.

 

During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. At December 31, 2011, IPR&D in the amount of $7,285,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of June 30, 2014 and December 31, 2013.

 

Net Income (Loss) per Common Share

 

Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For the three months ended June 30, 2014 and the six months ended June 30, 2014, both basic and diluted net income are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended June 30, 2013 and the six months ended June 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total numbers of shares that the Company excluded from the calculations of net loss per share were 24,976,557 shares for the three month period ending June 30, 2013 and 22,348,566 shares for the six month period ending June 30, 2013.

 

Recent Accounting Pronouncements

 

On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.

 

 

9
 

  

2. Preferred Shares

 

On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $1.40 and par value of $0.01. Each Series B redeemable convertible preferred stock share is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shares shall be entitled to receive dividends of 10% of the Series B redeemable convertible preferred stock stated value per annum.

 

In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013(dates of issuance) and recorded the initial liability as part of the private placement proceeds.

 

On June 26, 2013, the Company issued 4,999,999 shares of the Company’s newly-created Series B redeemable convertible preferred stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $5,064,000. As part of the same transaction, the Company converted $5,491,001 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B redeemable convertible preferred stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $3,804,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B redeemable convertible preferred stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $155,000.

 

10
 

 

In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for the conversion feature that contains a provision that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision). The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds.

 

On May 16, 2014, 188,938 preferred shares were converted into 1,889,380 shares of common stock. Due to this conversion, a gain on derivative liabilities of $142,000 was recognized and $709,000 was reclassified out of the derivative liability account and into equity.

 

The Company re-measured the fair value of the conversion feature at the end of the quarter and recorded $6.7 million gain on derivative liabilities during the second quarter to adjust the liability associated with the conversion feature to its estimated fair value of $33.4 million as of June 30, 2014.

 

3. Warrants and Warrants Liability

 

The Company follows ASC 815-40, Contracts in an Entity’s Own Equity, as it relates to outstanding warrants.

 

In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.

 

In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,195 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $1.4 million for the warrants issued to the placement agent.

 

We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:

 

   June 26, 2013   July 15, 2013   December 23, 2013 
Warrants issued   28,394,834    1,645,361    4,320,420 
Risk free interest rate   .0109    .0109    0.0167 
Volatility   160.94%   163.08%   155.24%
Expected term   5 years    5 years    5 years 
Exercise price  $0.14   $0.14   $0.25 

 

From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity.

 

On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity.

 

11
 

 

On June 26, 2014, 3,855,714 warrants, issued on June 26, 2013, were exercised. Due to this exercise, 2,734,151 shares of common stock were issued and $1,590,000 was classified out of the derivative liability account and into equity.

 

4. Stock Options

 

In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to 35,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants.

 

In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to 4,200,000 shares of our common stock in stock incentive awards to employees, directors and consultants.

 

In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to 40,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014.

 

The Company’s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company’s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plans.

 

Under ASC 718 Stock Compensation, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.

 

Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three and six month period ended June 30, 2013 and 2014.

 

Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:

 

   Three Months Ended   Six Months Ended 
   June 30, 2014   June 30, 2013   June 30, 2014   June 30, 2013 
Stock options:                    
General and administrative expense  $195,000   $733,000   $390,000   $845,000 
Research and development expense   40,000    70,000    78,000    113,000 
Total stock-based compensation expense  $235,000   $803,000   $468,000   $958,000 

 

12
 

 

The following table summarizes Option activity:

 

   Shares   Weighted Average Exercise
Price		   Average Remaining
Contractual Term
(Years)		   Intrinsic Value 
Outstanding at December 31, 2013   25,721,000   $0.20    9.15   $6,451,441 
Granted   —    —           
Exercised   —    —           
Forfeited   —    —           
Expired   2,000    13.10           
Outstanding at June 30, 2014   25,719,000   $0.19    8.63   $6,442,700 
Exercisable at June 30, 2014   11,651,493   $0.19    8.65   $3,017,673 

 

The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $0.44 on June 30, 2014.

 

As of June 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $1,918,638 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years.

 

As of June 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:

 

   Shares Reserved 
Stock options outstanding   25,719,000 
Available for future grants under the 2013 Stock Incentive Plan   40,000,000 
Warrants   38,890,451 
Total Shares reserved   104,609,451 

 

5. Correction of Errors

 

The Company’s previously issued June 30, 2014 financial statements have been amended to:

 

·reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at June 30, 2014 of $1,337,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000.
·recognize deferred revenue and deferred costs related certain sub-licensing agreements. This change resulted in a reduction in revenues of $209,000 and a reduction in G&A expense of $164,000 in the second quarter of 2014 and a reduction in revenues of $105,000 and a reduction in G&A expense of $103,000 for the six months ended June 30, 2014.
·reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $460,000 as of June 30, 2014.
·adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.
·modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $7,298,000 increase in the compound derivative liability and a $158,000 reduction in the warrant liability related to 2013 warrants. Gain on derivative liabilities was reduced by $1,499,000 and $844,000 for the second quarter of 2014 and the six months ended June 30, 2014, respectively.

 

As a result of these corrections, the Company’s net income attributable to common stockholders for the second quarter of 2014, as amended, was reduced by $1,848,000 to $13,555,000. Net income per share attributable to common stockholders fell by $0.01 per share to $0.07 per share. Net income attributable to common stockholders for the six months ended June 30, 2014, as amended, fell by $1,440,000 to $1,934,000. Net income per share attributable to common stockholders was reduced by $0.01 per share to $0.01 per share for the period.

 

13
 

 

The Company’s net loss attributable to common stockholders for the second quarter of 2013, as amended, increased by $(1,933,000) to $(14,746,000). The net loss per share attributable to common stockholders increased by $(0.02) per share to $(0.16) per share. The net loss attributable to common stockholders for the six months ended June 30, 2013, as amended, increased by $(1,959,000) to $(16,391,000). The net loss per share attributable to common stockholders increased by $(0.03) per share to $(0.21) per share for the period.

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with “Selected Consolidated Financial Data” and the Unaudited Condensed Consolidated Financial Statements and related Notes included in Part I Item 1 of this Form 10-Q.

 

This discussion contains forward-looking statements that involve risks and uncertainties. Such statements, which include statements concerning product development plans, the use of bacteriophages to kill bacterial pathogens, future revenue sources, selling and marketing expenses, general and administrative expenses, clinical trial and other research and development expenses, capital resources, capital expenditures, tax credits and carry-forwards, the Company’s ability to raise capital through additional financings or borrowings, are subject to risks and uncertainties, including, but not limited to, those discussed below and elsewhere in this Form 10-Q, particularly in Part II Item 1A. “Risk Factors,” that could cause actual results to differ materially from those projected. The forward-looking statements set forth in this Form 10-Q are as of the close of business on September 4, 2014, and we do not intend to update this forward-looking information.

 

Overview

 

AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacterial pathogens, including the so-called multi-drug-resistant (MDR) or “Superbug” strains.

 

We are combining our proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current medicines.

 

Our lead program is AmpliPhage-002, for the treatment of methicillin-resistant S. aureus (MRSA) infections. We have two other product candidates in development: AmpliPhage-001 for the treatment of P. aeruginosa lung infections in CF patients and AmpliPhage-004 for the treatment of C. difficile infections.

 

We have incurred net losses since our inception. Our operations to date have been limited to research and development and raising capital. Since November 2010, we have raised approximately $5.6 million through the sale and issuance of convertible notes and warrants to purchase common stock. In June and July of 2013, we completed a private placement of shares of Series B redeemable convertible preferred stock and warrants to purchase common stock, with proceeds to the Company of approximately $7.0 million. At the same time we converted approximately $6.3 million in outstanding convertible notes to Series B redeemable convertible preferred stock. In December 2013, we completed a private placement of shares of common stock, with gross proceeds of approximately $18 million, prior to commissions. To date, we have not generated any revenue and have primarily financed our operations through the sale and issuance of convertible notes and the private placement of our equity securities. As of June 30, 2014, we had an accumulated deficit of $382.5 million. We recorded annual net losses of $64.6 million in 2013 and $1.1 million in 2012. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and obtaining regulatory approval of our product candidates.

 

14
 

 

We expect our research and development expenses to increase as we increase our development activities and commence clinical trials to pursue regulatory approval for our product candidates. We also expect to incur additional expenses associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates.

 

We currently expect to use our existing cash and cash equivalents for the continued research and development of our product candidates and for working capital and other general corporate purposes.

 

We may also use a portion of our cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. We expect that our current cash and cash equivalents will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through other public offerings, debt financing, collaboration and licensing arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs.

 

Results of Operations

 

Revenue

 

For the quarter ended June 30, 2014, we recognized $101 000 in revenue related to sublicensing agreements involving our former gene therapy program. For the three month period ended June 30, 2013, we recognized revenues of $314,000 in revenue from such sublicenses. For the six month period ending June 30, 2014, we recognized revenues of $205,000 in revenue from sublicensing arrangements, a decrease from $336,000 for the same period in 2013, as a result of reduced grant revenue.

 

Research and Development

 

Research and development expenses were $1.9 million for the quarter ended June 30, 2014, compared to $3.6 million for the quarter ended June 30, 2013. Research and development expenses were $2.9 million for the six month period ended June 30, 2014, compared to $4.2 million for the six month period ended June 30, 2013. The decreases in research and development costs for both periods are due to a non-cash $3.0 million one-time technology access fee we incurred in April of 2013. Excluding this non-cash technology access fee, research and development expense increased $1.2 million for the quarter ended June 30, 2014 compared to the quarter ended June 30, 2013 and increased $1.6 million for the six month period ended June 30, 2014 compared to the six month period ended June 30, 2013 due to an increase in discovery, laboratory, nonclinical testing, research and development collaborations, consulting, and clinical development planning expenses for all of our product candidates.

 

Research and development expenses are expected to increase in 2014 compared to 2013 as we plan to continue investing substantial resources to research and development as we prepare to initiate clinical trials and continue our discovery efforts.

 

General and Administrative

 

General and administrative expenses were $2.0 million for the quarter ended June 30, 2014 compared to $2.8 million for the quarter ended June 30, 2013. The $0.8 million decrease in general and administrative expense was due to investment fees incurred in 2013 for our Series B redeemable convertible preferred stock private placement. General and administrative expenses were $3.6 million for the six month period ended June 30, 2014 compared to $3.6 million for the six month period ended June 30, 2013. This increase is due to higher legal expenses to satisfy our obligations as a public company and staffing expenses, offset by reduced investment fees resulting from the fees incurred in 2013 for our Series B redeemable convertible preferred stock private placement.

 

15
 

 

General and administrative expenses for the quarter ended June 30, 2014 and six month period ended June 30, 2014 included $190,000 accrued in penalties to certain shareholders as a result of our registration statement on Form S-1 not becoming effective within a prescribed period of time after the closing of our December financing.

 

We currently expect our general and administrative expenses to increase in 2014 compared to 2013 due to additional costs associated with being a public company.

 

Derivative Liabilities

 

During the quarter ended June 30, 2014, we recognized gains on derivative liabilities of $17.6 million for warrants issued in June, July, and December 2013 and the conversion feature of the shares of Series B redeemable convertible preferred stock issued in June and July 2013. During the quarter ended June 30, 2013, we recognized a loss on derivative liabilities of $6.1 million for warrants issued in June 2013 and the conversion feature of the shares of Series B redeemable convertible preferred stock issued in June 2013. For the six month period ended June 30, 2014, we recognized a gain on derivative liabilities of $8.9 million compared to $6.0 million loss for the six month period ended June 30, 2013. Derivative liabilities are adjusted to fair value each reporting period and are influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On June 30, 2014, the price per share of the Company’s common stock was $0.44 per share compared to $0.50 per share at December 31, 2013.

 

Income Taxes

 

We incurred net operating losses for the years ended December 31, 2013 and 2012 and, accordingly, we did not pay any federal or state income taxes. As of December 31, 2013, we had accumulated approximately $176.3 million in U.S., Australian and UK operating loss carry-forwards and research tax credit carry-forwards of approximately $3.7 million. The carry-forwards began to expire in 2012. Our net operating loss carry-forwards are subject to certain limitations on annual utilization as a result of changes in ownership of the Company, as defined by federal and state tax laws.

 

Net Operating Losses

 

We have not recorded a benefit from our net operating loss or research credit carry-forwards because we believe that it is uncertain that we will have sufficient income from future operations to realize the carry-forwards prior to their expiration. Accordingly, we have established a 100% valuation allowance against the deferred tax asset arising from the carry-forwards.

 

Liquidity and Capital Resources

 

We have incurred net losses since inception through June 30, 2014 of $382.5 million, of which $315.5 million was incurred in the Company’s prior focus on gene therapy in 2010 and years earlier. We have not generated any product revenues and do not expect to generate revenue from the sale of product candidates in the near term.

 

We had cash and cash equivalents of $12.6 million and $20.4 million at June 30, 2014 and December 31, 2013, respectively.

 

Net cash used in operating activities for the six month periods ended June 30, 2014 and 2013 was $6.7 million and $2.4 million, respectively. For the six month period ended June 30, 2014, cash used in operations was attributable to the net loss for the year, after adding back the impact of non-cash income related to derivative liabilities, stock-based compensation expense, and depreciation expenses, a decrease in accrued liabilities and an increase in receivables and prepaid expenses. For the six month period ended June 30, 2013, cash used in operations was attributable to the net loss for the year after adding back non-cash charges for shares issued for technology access fee, amortization of loan discount, stock-based compensation expense, depreciation expenses and loss on disposal of equipment, offset by a decrease in accrued liabilities and a decrease in receivables. Net cash used in investing activities for the six month period ended June 30, 2014 and June 30, 2013 were $1.1 million and $.06 million, respectively, due to purchases of equipment. Net cash provided by financing activities for the six month period ended June 30, 2013 was $9.0 million due to proceeds from Series B redeemable convertible preferred stock and convertible loan notes. We expect 2014 cash requirements to be in the range of $15.0 million to $17.0 million. We believe that our cash as of June 30, 2014, will be sufficient to fund our projected operating requirements into the first quarter of 2015.

 

16
 

 

We expect to need to raise additional capital or incur indebtedness to continue to fund our future operations. We may seek to raise capital through a variety of sources, including:

 

  · the public equity market;
  · private equity financing;
  · collaborative arrangements;
  · licensing arrangements; and/or
  · public or private debt.

 

Our ability to raise additional funds will depend on our clinical and regulatory developments, our product development activities, our ability to identify promising in-licensing opportunities and factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on satisfactory terms. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain of our products, technologies or potential markets, any of which could delay or require that we curtail our development programs or otherwise have a material adverse effect on our business, financial condition and results of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to our existing stockholders.

 

If we are unable to secure additional financing on a timely basis or on terms favorable to us, we may be required to cease or reduce certain research and development projects, to sell some or all of our technology or assets or to merge all or a portion of our business with another entity. Insufficient funds may require us to delay, scale back or eliminate some or all of our activities, and if we are unable to obtain additional funding, there is uncertainty regarding our continued existence.

 

Off-Balance Sheet Arrangements

 

As of June 30, 2014, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. Therefore, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

 

Recent Accounting Pronouncements

 

None.

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

17
 

 

Item 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer, have concluded that our financial disclosure controls and procedures were effective during the period covered by this report.

 

Changes in Internal Controls Over Financial Reporting.

 

There were no changes in our internal control over financial reporting during the first half of 2014 that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

18
 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time we are involved in legal proceedings or subject to claims arising in the ordinary course of our business. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

Item 1A. Risk Factors

 

There have been no material changes from the risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013 as amended and filed with the SEC on September 12, 2014.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

  (a) Exhibits

 

Number   Description
  3.1   Amended and Restated Articles of Incorporation, effective May 21, 2009 (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form 10 filed December 16, 2013).
  3.2   Articles of Amendment to Amended and Restated Articles of Incorporation, effective June 26, 2013 (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form 10 filed December 16, 2013).
  3.3   Articles of Correction to Amended and Restated Articles of Incorporation, effective June 26, 2013 (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form 10 filed December 16, 2013).
  3.4   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form 10 filed December 16, 2013).
  4.1   Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form 10 filed December 16, 2013).
  4.2   Form of Warrant to Purchase Shares of Common Stock (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form 10 filed December 16, 2013).
  4.3   Subscription Agreement to Purchase Series B Preferred Stock and Warrants, dated June 26, 2013 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form 10 filed December 16, 2013).
  4.4   Registration Rights Agreement, dated December 16, 2013 (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form 10 filed December 16, 2013).

 

19
 

 

  4.5   Subscription Agreement, dated December 16, 2013 (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form 10 filed December 16, 2013).
       
  31.1*   Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
  31.2*   Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
  32.1*   Certification of the Chief Executive Officer Required by Rule 13a-14(b)  or Rule 15d-14(b) and 18 U.S.C. 1350.
  32.2*   Certification of the Chief Financial Officer Required by Rule 13a-14(b)  or Rule 15d-14(b) and 18 U.S.C. 1350.
  101.INS   XBRL Instance Document.
  101.SCH   XBRL Taxonomy Extension Schema Document.
  101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.
  101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.
  101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.
  101.LAB   XBRL Taxonomy Extension Label Linkbase Document.

 

* Furnished electronically with this report.

 

20
 

 

AMPLIPHI BIOSCIENCES CORPORATION

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  AMPLIPHI BIOSCIENCES CORPORATION
   
Date: April 15, 2015  By /s/ Jeremy Curnock Cook
   

Name: Jeremy Curnock Cook

Title: Chief Executive Officer

(Principal Executive Officer)

 

21

 EX-31.1 2 v407147_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION

 

I, Jeremy Curnock Cook, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 15, 2015

 

  /s/ Jeremy Curnock Cook
  Jeremy Curnock Cook
  Chief Executive Officer

 

 

 EX-31.2 3 v407147_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION

 

I, David E. Bosher, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 15, 2015

 

  /s/ David E. Bosher
  David E. Bosher
  Chief Financial Officer

 

 

 EX-32.1 4 v407147_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Jeremy Curnock Cook, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

 

Date: April 15, 2015

 

  /s/ Jeremy Curnock Cook
  Jeremy Curnock Cook
  Chief Executive Officer

 

 

 EX-32.2 5 v407147_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, David E. Bosher, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

 

Date: April 15, 2015

 

  /s/ David E. Bosher
  David E. Bosher
  Chief Financial Officer

 

 

 EX-101.INS 6 aphb-20140630.xml XBRL INSTANCE DOCUMENT 0000921114 2013-01-01 2013-06-30 0000921114 2013-01-01 2013-12-31 0000921114 2014-01-01 2014-06-30 0000921114 2013-04-01 2013-06-30 0000921114 2014-04-01 2014-06-30 0000921114 2014-06-30 0000921114 2014-08-07 0000921114 2013-12-31 0000921114 2012-12-31 0000921114 2013-06-30 0000921114 aphb:BiocontrolLimitedMember 2011-01-01 2011-12-31 0000921114 aphb:SphHoldingsPtyLtdMember 2012-01-01 2012-12-31 0000921114 aphb:BiocontrolLimitedMember 2011-12-31 0000921114 aphb:SphHoldingsPtyLtdMember 2012-12-31 0000921114 aphb:BiocontrolLimitedMember us-gaap:InProcessResearchAndDevelopmentMember 2011-12-31 0000921114 aphb:SphHoldingsPtyLtdMember us-gaap:InProcessResearchAndDevelopmentMember 2012-12-31 0000921114 aphb:BiocontrolLimitedMember 2014-01-01 2014-06-30 0000921114 aphb:SphHoldingsPtyLtdMember 2014-01-01 2014-06-30 0000921114 aphb:SeriesBConvertiblePreferredStockMember 2013-12-31 0000921114 aphb:SeriesBConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember aphb:SeriesBConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableTwoMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableTwoMember aphb:SeriesBConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnDecember232013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnJuly152013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnDecember232013MemberMember 2013-12-31 0000921114 aphb:WarrantsIssuedOnJuly152013MemberMember 2013-12-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2013-12-31 0000921114 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:PrivatePlacementMember aphb:SeriesBConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-12-31 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0000921114 us-gaap:EmployeeStockOptionMember 2013-12-31 0000921114 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-06-30 0000921114 us-gaap:EmployeeStockOptionMember 2014-06-30 0000921114 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember 2014-06-30 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember 2013-12-31 0000921114 us-gaap:PreferredStockMember 2012-12-31 0000921114 us-gaap:CommonStockMember 2012-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000921114 us-gaap:RetainedEarningsMember 2012-12-31 0000921114 us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2014-01-01 2014-06-30 0000921114 us-gaap:PreferredStockMember 2014-01-01 2014-06-30 0000921114 us-gaap:CommonStockMember 2014-01-01 2014-06-30 0000921114 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-06-30 0000921114 us-gaap:PreferredStockMember 2013-12-31 0000921114 us-gaap:CommonStockMember 2013-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2013-12-31 0000921114 us-gaap:PreferredStockMember 2014-06-30 0000921114 us-gaap:CommonStockMember 2014-06-30 0000921114 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0000921114 us-gaap:RetainedEarningsMember 2014-06-30 0000921114 us-gaap:PatentsMember 2014-06-30 0000921114 us-gaap:PatentsMember 2013-12-31 0000921114 us-gaap:WarrantMember 2013-12-31 0000921114 us-gaap:WarrantMember aphb:ConvertibleNotesPayableOneMember 2013-12-31 0000921114 us-gaap:WarrantMember aphb:ConvertibleNotesPayableTwoMember 2013-12-31 0000921114 us-gaap:PreferredStockMember aphb:ConvertibleNotesPayableTwoMember 2013-12-31 0000921114 us-gaap:PreferredStockMember aphb:ConvertibleNotesPayableOneMember 2013-12-31 0000921114 us-gaap:WarrantMember 2014-01-01 2014-06-30 0000921114 aphb:TwoThousandAndTwelveStockIncentivePlanMember us-gaap:EmployeeStockOptionMember 2014-06-30 0000921114 aphb:TwoThousandAndNineStockIncentivePlanMember us-gaap:EmployeeStockOptionMember 2014-06-30 0000921114 aphb:TwoThousandAndThirteenStockIncentivePlanMember us-gaap:EmployeeStockOptionMember 2014-06-30 0000921114 us-gaap:PatentsMember 2011-12-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2014-01-01 2014-06-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-01-01 2014-06-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-04-01 2014-06-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-06-30 0000921114 us-gaap:RestatementAdjustmentMember aphb:BiocontrolMember 2014-06-30 0000921114 us-gaap:RestatementAdjustmentMember aphb:SphMember 2014-06-30 0000921114 us-gaap:RestatementAdjustmentMember 2013-01-01 2013-06-30 0000921114 us-gaap:RestatementAdjustmentMember 2013-04-01 2013-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>4. Stock Options</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000,000</font> shares of our common stock in stock incentive awards to employees, directors and consultants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,200,000</font> shares of our common stock in stock incentive awards to employees, directors and consultants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40,000,000</font> shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company&#8217;s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company&#8217;s Incentive Plans.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Under ASC 718 <i>Stock Compensation</i>, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company&#8217;s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company&#8217;s estimates for the three and six month period ended June 30, 2013 and 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock options:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>195,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>733,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>390,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>845,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>78,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>113,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>235,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>803,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>468,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>958,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes Option activity:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average&#160;Remaining<br/> Contractual&#160;Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,451,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,719,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,442,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercisable at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,651,493</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,017,673</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The aggregate intrinsic value is determined using the closing price of the Company&#8217;s common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.44</font> on June 30, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As of June 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,918,638</font> net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of June 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares&#160;Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Stock options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,719,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Available for future grants under the 2013 Stock Incentive Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,890,451</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>Total Shares reserved</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>104,609,451</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months and six months ended June 30, 2014 and 2013, our cash flows for the six months ended June 30, 2014 and 2013 and our financial position as of June 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Cash and Cash Equivalents</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Accounts Receivable</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of June 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Property and Equipment</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">three to seven years</font>.&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Prepaid Expenses and Other Current Assets</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Prepaid and other current assets as of June 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Goodwill</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s know-how and phage libraries were acquired in a business combination with an aggregate value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,172,000</font>. At December 31, 2012, goodwill in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,929,000</font> has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents and phage libraries were acquired in a business combination with an aggregate value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,584,000</font>. At December 31, 2011, goodwill in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,633,000</font> has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Stock-Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <i>Stock Compensation</i>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Warrant and Preferred Shares Conversion Feature Liability</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company accounts for warrants and the preferred shares conversion feature of the Company&#8217;s Series B preferred stock with anti-dilution (&#8220;down-round&#8221;) provisions under the guidance of ASC 815, <i>Derivatives</i>, <i>and Hedging</i> and Emerging Issue Task Force Statement 07-5: <i>Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity&#8217;s Own Stock</i>, which require such warrants and the Series B redeemable convertible preferred stock shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Fair Value of Financial Assets and Liabilities&#160;&#151;&#160;Derivative Instruments</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 1&#160;&#151;&#160;quoted prices in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 2&#160;&#151;&#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 3&#160;&#151;&#160;inputs that are unobservable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Revenue Recognition</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <i>Multiple Element Arrangements</i>, which requires the Company to satisfy the following before revenue can be recognized:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 7%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> &#8226;</font></div> </td> <td style="WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> The delivered items have value to the customer on a stand-alone basis;</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> &#8226;</font></div> </td> <td style="WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Any undelivered items have objective and reliable evidence of fair value; and</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> &#8226;</font></div> </td> <td style="WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Delivery or performance is probable and within the Company&#8217;s control for any delivered items that have a right of return.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company classifies advance payments received in excess of amounts earned as deferred revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Research and Development</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least annually. During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s know-how and phage libraries were acquired by a business combination for $7,172,000. At December 31, 2012, IPR&amp;D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,161,000</font> has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of June 30, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents and phage libraries were acquired by a business combination $8,584,000. At December 31, 2011, IPR&amp;D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,285,000</font> has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of June 30, 2014 and December 31, 2013.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Net Income (Loss) per Common Share</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For the three months ended June 30, 2014 and the six months ended June 30, 2014, both basic and diluted net income are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended June 30, 2013 and the six months ended June 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total numbers of shares that the Company excluded from the calculations of net loss per share were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24,976,557</font> shares for the three month period ending June 30, 2013 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 22,348,566</font> shares for the six month period ending June 30, 2013.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Recent Accounting Pronouncements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.21in; WIDTH: 97%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;26,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;15,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,394,834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,645,361</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,320,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock options:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>195,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>733,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>390,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>845,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>78,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>113,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>235,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>803,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>468,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>958,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The following table summarizes Option activity:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average&#160;Remaining<br/> Contractual&#160;Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,451,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,719,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,442,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercisable at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,651,493</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,017,673</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As of June 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares&#160;Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Stock options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,719,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Available for future grants under the 2013 Stock Incentive Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,890,451</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>Total Shares reserved</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>104,609,451</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 8584000 7172000 3633000 3929000 7285000 5161000 22348566 24976557 0 0 three to seven years 10016080 1.40 0.01 10 0.1 7000000 4999999 12499996 10894839 1645361 0.14 0.14 7000000 5491001 829277 4357936 658145 6700000 4320420 1645361 28394834 0.000109 0.000167 0.000109 1.5524 1.6308 1.6094 P5Y P5Y P5Y 0.25 0.14 0.14 72007000 0.25 December 2016 December 2018 June 2018 February through May 2018 1355164 30040195 7030387 0.46 0.14 0.14 1400000 12550000 20355000 136000 8000 526000 297000 13212000 20660000 1119000 145000 12446000 12446000 7562000 7562000 34724000 41213000 1366000 2147000 1715000 2391000 33402000 40791000 13115000 16871000 49595000 60740000 51310000 63131000 1872000 1825000 360917000 358828000 1837000 1837000 -382549000 -385115000 -17923000 -22625000 34724000 41213000 958000 113000 845000 468000 390000 78000 803000 70000 733000 235000 195000 40000 25721000 0 0 0 2000 25719000 11651493 0.20 0 0 0 13.10 0.19 0.19 P9Y1M24D P8Y7M17D P8Y7M24D 6442700 6451441 3017673 40000000 38890451 104609451 0.44 1918638 P2Y6M 559000 473000 0.01 0.01 10000000 10000000 8671000 8859978 8671000 8859978 0.01 0.01 445000000 445000000 187159093 182535562 187159093 182535562 336000 205000 314000 101000 4236000 2899000 3595000 1888000 3557000 3588000 2843000 1961000 7793000 6487000 6438000 3849000 -7457000 -6282000 -6124000 -3748000 -5970000 8848000 -6057000 17621000 2637000 0 2334000 0 224000 0 128000 0 -16288000 2566000 -14643000 13873000 103000 632000 103000 318000 -16391000 1934000 -14746000 13555000 -0.21 0.01 -0.16 0.07 78842512 183065721 90645074 183590053 12943000 0 669000 332806000 -320532000 0 66908810 -64583000 0 0 0 -64583000 2566000 0 0 0 1437000 0 0 1437000 0 468000 0 0 468000 0 2635000 0 0 2635000 0 3000000 0 240000 2760000 0 0 24000000 0 50000 0 0 0 5016081 0 0 0 50000 0 0 4999999 0 7084000 -11000 115000 6969000 0 -2000 19000 690000 0 709000 -1156102 11561020 -188938 1889380 13000 0 1000 12000 0 0 61018 0 0 80000 -80000 0 0 8000000 15464000 0 720000 14744000 0 0 72007000 0 2286 707000 1825000 360665000 -385115000 1337000 1872000 362754000 -382549000 8859978 182535562 8671040 187159093 3000000 0 759000 0 45000 86000 958000 468000 117000 128000 -618000 0 -120000 -675000 87000 229000 224000 0 -2386000 -6745000 65000 1060000 -65000 -1060000 7000000 0 2000000 0 8974000 0 6523000 -7805000 862000 7385000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>1. Nature of Business and Significant Accounting Policies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Nature of Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> AmpliPhi Biosciences Corporation (the &#8220;Company&#8221;) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months and six months ended June 30, 2014 and 2013, our cash flows for the six months ended June 30, 2014 and 2013 and our financial position as of June 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts Receivable</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of June 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">three to seven years</font>.&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Prepaid Expenses and Other Current Assets</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Prepaid and other current assets as of June 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Goodwill</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s know-how and phage libraries were acquired in a business combination with an aggregate value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,172,000</font>. At December 31, 2012, goodwill in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,929,000</font> has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents and phage libraries were acquired in a business combination with an aggregate value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,584,000</font>. At December 31, 2011, goodwill in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,633,000</font> has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Patents</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents were acquired in a business combination. At December 31, 2011, patents in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">493,000</font> have been recorded. These patents are amortized over their useful life through December 2026.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <i>Stock Compensation</i>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Warrant and Preferred Shares Conversion Feature Liability</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company accounts for warrants and the preferred shares conversion feature of the Company&#8217;s Series B preferred stock with anti-dilution (&#8220;down-round&#8221;) provisions under the guidance of ASC 815, <i>Derivatives</i>, <i>and Hedging</i> and Emerging Issue Task Force Statement 07-5: <i>Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity&#8217;s Own Stock</i>, which require such warrants and the Series B redeemable convertible preferred stock shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Assets and Liabilities&#160;&#151;&#160;Derivative Instruments</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 1&#160;&#151;&#160;quoted prices in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 2&#160;&#151;&#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 3&#160;&#151;&#160;inputs that are unobservable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <i>Multiple Element Arrangements</i>, which requires the Company to satisfy the following before revenue can be recognized:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 7%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> &#8226;</font></div> </td> <td style="WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> The delivered items have value to the customer on a stand-alone basis;</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> &#8226;</font></div> </td> <td style="WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Any undelivered items have objective and reliable evidence of fair value; and</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> &#8226;</font></div> </td> <td style="WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Delivery or performance is probable and within the Company&#8217;s control for any delivered items that have a right of return.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company classifies advance payments received in excess of amounts earned as deferred revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least annually. During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s know-how and phage libraries were acquired by a business combination for $7,172,000. At December 31, 2012, IPR&amp;D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,161,000</font> has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of June 30, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents and phage libraries were acquired by a business combination $8,584,000. At December 31, 2011, IPR&amp;D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,285,000</font> has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of June 30, 2014 and December 31, 2013.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Net Income (Loss) per Common Share</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For the three months ended June 30, 2014 and the six months ended June 30, 2014, both basic and diluted net income are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended June 30, 2013 and the six months ended June 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total numbers of shares that the Company excluded from the calculations of net loss per share were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24,976,557</font> shares for the three month period ending June 30, 2013 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 22,348,566</font> shares for the six month period ending June 30, 2013.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>2. Preferred Shares</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On June 13, 2013, the Company&#8217;s Board of Directors approved a resolution designating <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,016,080</font> shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.40</font> and par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font>. Each Series B redeemable convertible preferred stock share is convertible into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shares shall be entitled to receive dividends of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Series B redeemable convertible preferred stock stated value per annum.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013(dates of issuance) and recorded the initial liability as part of the private placement proceeds.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On June 26, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,999,999</font> shares of the Company&#8217;s newly-created Series B redeemable convertible preferred stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,499,996</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.0</font> million. The value of the derivative liability related to the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,886,000</font> and the value of the derivative liability related to the preferred shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,064,000</font>. As part of the same transaction, the Company converted $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,491,001</font> in outstanding convertible loan notes (principal and interest) into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,357,936</font> shares of Series B redeemable convertible preferred stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,894,839</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. The value of the derivative liability related to the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,644,000</font> and the value of the derivative liability related to the preferred shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,804,000</font>. As part of this issuance, the Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,999,999</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share with an initial fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">759,000</font> and paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> redeemable convertible preferred stock</font> and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">829,277</font> in principal and interest, were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 658,145</font> shares of Series B <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> redeemable convertible preferred stock</font> and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,645,361</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. The value of the derivative liability related to the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">674,000</font> and the value of the derivative liability related to the preferred shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">155,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In connection with the private placement of Series B <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> redeemable convertible preferred stock</font>, the Company recorded a liability for the conversion feature that contains a provision that protect holders from a decline in the issue price of the Company&#8217;s common stock (&#8220;down-round&#8221; provision). The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On May 16, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 188,938</font> preferred shares were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,889,380</font> shares of common stock. Due to this conversion, a gain on derivative liabilities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">142,000</font> was recognized and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">709,000</font> was reclassified out of the derivative liability account and into equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company re-measured the fair value of the conversion feature at the end of the quarter and recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.7</font> million gain on derivative liabilities during the second quarter to adjust the liability associated with the conversion feature to its estimated fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33.4</font> million as of June 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 10-Q/A true 2014-06-30 2014 Q2 AmpliPhi Biosciences Corp 0000921114 --12-31 Smaller Reporting Company APHB 187159093 -0.21 0.01 -0.16 0.04 78842512 325709071 90645074 324880957 -8831000 8848000 -8519000 17621000 385000 400000 20393000 20408000 108000 93000 1886000 1644000 674000 155000 5064000 3804000 4999999 0.14 0.14 759000 350000 1889380 188938 142000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>3. Warrants and Warrants Liability</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company follows ASC 815-40, <i>Contracts in an Entity&#8217;s Own Equity</i>, as it relates to outstanding warrants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In connection with the December 2013 private placement of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 72,007,000</font> shares of the Company's common stock at a price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font>, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 2018</font>. These warrants contain provisions that protect holders from a decline in the issue price of the Company&#8217;s common stock (&#8220;down-round&#8221; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,040,195</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">June 2018</font>. These warrants contain provisions that protect holders from a decline in the issue price of the Company&#8217;s common stock (&#8220;down-round&#8221; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million for the warrants issued to the placement agent.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.21in; WIDTH: 97%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;26,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;15,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,394,834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,645,361</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,320,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 13.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,030,387</font> shares of its common stock. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February through May 2018</font> and are exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. These warrants are considered to be equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,355,164</font> shares of its common stock. These warrants expire in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 2016</font> and are exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.46</font> per share. These warrants are considered to be equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On June 26, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,855,714</font> warrants, issued on June 26, 2013, were exercised. Due to this exercise, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,734,151</font> shares of common stock were issued and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,590,000</font> was classified out of the derivative liability account and into equity.&#160;&#160;&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 709000 1591000 0 28000 1563000 0 0 2734151 15000 15000 26000 0 35000000 4200000 40000000 493000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Patents</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents were acquired in a business combination. At December 31, 2011, patents in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">493,000</font> have been recorded. These patents are amortized over their useful life through December 2026.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 0 0 0 0 3855714 2734151 1590000 Amended Financial Statements The Company&#8217;s previously issued June 30, 2014 financial statements have been amended to: &#8901; reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders&#8217; Equity (Deficit) to temporary equity due to the stock&#8217;s redemption features. This adjustment resulted in a reclassification at June 30, 2014 of $1,337,000 of Stockholders&#8217; Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock&#8217;s redemption value of $1,250,000. &#8901; recognize deferred revenue and deferred costs related certain sub-licensing agreements. This change resulted in a reduction in revenues of $209,000 and a reduction in G&A expense of $194,000 in the second quarter of 2014 and a reduction in revenues of $105,000 and a reduction in G&A expense of $161,000 for the six months ended June 30, 2014. &#8901; reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $460,000 as of June 30, 2014. &#8901; adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. &#8901; modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company&#8217;s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $7,298,000 increase in the compound derivative liability and a $158,000 reduction in the warrant liability related to 2013 warrants. Gain on derivative liabilities was reduced by $1,499,000 and $844,000 for the second quarter of 2014 and the six months ended June 30, 2014, respectively. As a result of these corrections, the Company&#8217;s net income attributable to common stockholders for the second quarter of 2014, as amended, was reduced by $1,848,000 to $13,555,000. Net income per share attributable to common stockholders fell by $0.01 per share to $0.07 per share. Net income attributable to common stockholders for the six months ended June 30, 2014, as amended, fell by $1,440,000 to $1,934,000. Net income per share attributable to common stockholders was reduced by $0.01 per share to $0.01 per share for the period. The Company&#8217;s net loss attributable to common stockholders for the second quarter of 2013, as amended, increased by $(1,933,000) to $(14,746,000). The net loss per share attributable to common stockholders increased by $(0.02) per share to $(0.16) per share. The net loss attributable to common stockholders for the six months ended June 30, 2013, as amended, increased by $(1,959,000) to $(16,391,000). The net loss per share attributable to common stockholders increased by $(0.03) per share to $(0.21) per share for the period. 349000 244000 3078000 3078000 1337000 707000 618000 -618000 0 618000 0 -632000 0 632000 0 618000 1337000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>5. Correction of Errors</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company&#8217;s previously issued June 30, 2014 financial statements have been amended to:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div>reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders&#8217; Equity (Deficit) to temporary equity due to the stock&#8217;s redemption features. This adjustment resulted in a reclassification at June 30, 2014 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,337,000</font> of Stockholders&#8217; Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">87,000</font> and the accretion of the stock&#8217;s redemption value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,250,000</font>.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div>recognize deferred revenue and deferred costs related certain sub-licensing agreements. This change resulted in a reduction in revenues of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">209,000</font> and a reduction in G&amp;A expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">164,000</font> in the second quarter of 2014 and a reduction in revenues of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">105,000</font> and a reduction in G&amp;A expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">103,000</font> for the six months ended June 30, 2014.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div>reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">460,000</font> as of June 30, 2014.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div>adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,685,000</font> in goodwill related to the Biocontrol acquisition and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,548,000</font> in goodwill related to the acquisition of SPH.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div>modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company&#8217;s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,298,000</font> increase in the compound derivative liability and a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">158,000</font> reduction in the warrant liability related to 2013 warrants. Gain on derivative liabilities was reduced by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,499,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">844,000</font> for the second quarter of 2014 and the six months ended June 30, 2014, respectively.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As a result of these corrections, the Company&#8217;s net income attributable to common stockholders for the second quarter of 2014, as amended, was reduced by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,848,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,555,000</font>. Net income per share attributable to common stockholders fell by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.07</font> per share. Net income attributable to common stockholders for the six months ended June 30, 2014, as amended, fell by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,440,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,934,000</font>. Net income per share attributable to common stockholders was reduced by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share for the period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company&#8217;s net loss attributable to common stockholders for the second quarter of 2013, as amended, increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(1,933,000)</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(14,746,000)</font>. The net loss per share attributable to common stockholders increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.02)</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.16)</font> per share. The net loss attributable to common stockholders for the six months ended June 30, 2013, as amended, increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(1,959,000)</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(16,391,000)</font>. The net loss per share attributable to common stockholders increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.03)</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.21)</font> per share for the period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1250000 105000 209000 103000 164000 460000 1685000 1548000 7298000 844000 1499000 158000 -1959000 1440000 -1933000 1848000 -0.03 0.01 -0.02 0.01 87000 13390000 13022000 EX-101.SCH 7 aphb-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Preferred Shares link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Warrants and Warrants Liability link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stock Options link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Correction of Errors link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Warrants and Warrants Liability (Tables) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Stock Options (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Nature of Business and Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Preferred Shares (Details Textual) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Warrants and Warrants Liability (Details) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Warrants and Warrants Liability (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Stock Options (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Stock Options (Details 1) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Stock Options (Details 2) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock Options (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Correction of Errors (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 aphb-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 aphb-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 aphb-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 aphb-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#X\2[1P@$``,X0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-]*PS`4QN\%WZ'D5M8L M];^L\V+JI0KJ`\3D;"U+DY!DNKV]IYT.D;DQ''AN&MKDG._7%+[R97`];TSV M!B'6SI9,Y'V6@55.UW92LI?GN]X%RV*25DOC+)1L`9%=#P\/!L\+#S'#:AM+ M5J7DKSB/JH)&QMQYL#@S=J&1"6_#A'NIIG("O.CWS[AR-H%-O=3V8,/!#8SE MS*3L=HZ/ER0!3&39:+FPU2J9]-[42B8DY6]6_U#I?2KD6-FMB57MXQ%B,+Y6 MH9WY7>"S[@&W)M0:LD<9TKUL$(//#7]W8?KJW#3?W&0-I1N/:P7:J5F#.Y!' M'T#J6`&DQN3=F#>RME_<&_2[Q9%W@]@S2/M^7>,=.0HB',=$.$Z(<)P2X3@C MPG%.A.."",YY;`0AU;"*V.NB MZDH1L_ON@C^R,K2G`QKT&FW>G48,/P```/__`P!02P,$%``&``@````A`+55 M,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX< M85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]H MJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`]6F^?;(! M``!]#P``&@`(`7AL+U]R96QS+W=O6 M.OM&ZW8`(>T*XP=$;=96:],J"1_[]T1CI$P"PR'R95)I1-=+Y/]FJ M[FWBLVB;LJE7;4]4K[)_O.M-+YHREY+_.#+!47:3KCYGL.MK[( MF6R+C)EMX>_?'7M_\]^YN_V^SM5]E[^T2KL?KN!OG3G82BGGDTI3*I>Q$++\ M]&0Q\HH9_UD,C(G5P!B50PT'4#IB%I..K:11Q9,SWHIVJ-=%&(-#72JT4@)B MH@F>';"$T-G&`C`VE8=VS\!`_3[_.,X:`N M#EZ;J!,F],S`(X3.;00SE(U_6Y*^G$2*R:&>,>B(H:X46B@@1X.R$9.8OG%^ MV5*#A4]'?OI%142=*Z%O!ATA=&ZE*6I=:C6`RA'4RX-`MP>@GC.`SYEE3/L& MG_QN'5ABWHG:3/]0,\'$4*-!R0`U&D#9"/)=`ETF1-1%+Y=-?E?)6@\V#J$O MP_"+C^;U!P```/__`P!02P,$%``&``@````A`#%!E&6V`@``"`@```\```!X M;"]W;W)K8F]O:RYX;6R457FTH&?\!8H=4T3([B,`"5Z5RH MY33\O?CVY30,K.,JYU(KF(:O8,/+V>=/%VMM7IZU?@D00-EI6#I7GT>1S4JH MN#W2-2A<*;2IN,/2+"-;&^"Y+0%<):,TCB=1Q84*MPCGYCT8NBA$!CEJ&TXNRB$A,6%6 M]=5*2%P]&\6C,)JU)!],D$/!5](MD-X.'?5*QVDZ\?_T4CP*6-O])E\&FR>A MXEPD<$OU$0SVF>@6KH[11A M7U7.;I43[I7=J:WZ0J.%7O4[9):$@3D7^,/%>0G]J6_P0_%E(X2@,I7'6AYD[G;V@ M!\V\T5TGA'P2][==:^PY\YN\`K?&:--I'3\RK0')():'M<-$-T+[=*=G%&@0 MSI;WFR)0H!$.Z[ZC03X[,K`%?Y8=*T:=*1OD\C`?'*^63T(]Q:(WK_TTL!MP M7$C+%K!Q*XI#34T&X3RL2Z>ACL^#>!X&PI'?,^M8/HAK5^!_M.CVCM&'8]JJ M0@WV7^/68"QZRKYY/J-*I-1C+-X%T/C"\2IJ=4@[7]-!8M\:G);/@N*@N'L^ M36"CYA"\*#(N,[S!_*.Y`L;'DVW#T>X2G_T%``#__P,`4$L#!!0`!@`(```` M(0#A[.^>J@4``#06```8````>&PO=V]R:W-H965T&ULE%A; MCZLV$'ZOU/^`>$_`F&N4Y&@#;'ND5JJJ7IY9XB1H0QP!>SG_OF-,B,=.4O8\ MG"3F\\=\,^.962^_?=9'ZYTU;<5/*YO,7=MBIY)OJ]-^9?_]U_,LMJVV*T[; MXLA/;&7_8*W];?WS3\L/WKRV!\8Z"QA.[6!UT<[YF9W@R8XW M=='!SV;OM.>&%=M^4WUT/-<-G;JH3K9D6#13./AN5Y4LX^5;S4Z=)&G8L>C` M_O90G=L+6UU.H:N+YO7M/"MY?0:*E^I8=3]Z4MNJR\7W_8DWQX1VUDO>P?] M4[&/5OENM0?^\4M3;7^K3@R\#7$2$7CA_%5`OV_%$FQVC-W/?03^:*PMVQ5O MQ^Y/_O$KJ_:'#L(=@"(A;+']D;&V!(\"S=P+!%/)CV``_&_5E4@-\$CQV7]^ M5-ONL+)I.`\BEQ*`6R^L[9XK06E;Y5O;\?I?">H5C23>0`*?`PF!KQ,WTV$S M?(Z;OVR!/Y#`YT@RV0(0VOL`/L?-4RUPI#_[\&1%5ZR7#?^P(.?!8^VY$">( M+(#X$A?IQ3%2]P(%$1(D3X)E94>V!3%H(;O>UV&R=-XA(@(7UE_=NY`)PCW(\_-[41$2: M:9D)T4AR$Z&0(#F0=-/E"/#*!O+1^DA[\T9"XCY2Q"6NJX="!5#B&X!,!7AN M8`!R%4!IJ`*0-#@*TZ4),!Q]51K%D=E(B#\&,]47,GTA5Q:0:7`>IILFP)K7 M?$-[)*17BQ3PWC,Q5!@QLNRC$"6H"2NRAZ4(VF1T^`-7FA)D]"I#P:^Z;G M4Q41^M2,;X81,3*^SX!<1411@ER$Y(G)2"GA$AY,QKYIO4I M@H3$NU$6,,2+8)S`! M37=_C];\;_1'P;BRA^,3A=Z-\S/P#$$*7>R[H6>J/'%\(XXYI@D2D8;7*&&= MHL%.3C,BV[':>N(K<6_?9L#X?174'J;#PT&@1^F-%'M$D&L$(45'#$L3[7>Z M--FLD32MXV_$-`DAO"--/ARD$<\\7]FC_?GP\.(:?/BP,-%ZIPN3C1H)T\<% M(C'RW>1.;JJ861P0LT!FB.=.;F*:F*)C@'6*OCU=I^SR2*<^.Q")&732.$+E M5[9HA)D1'PJ]>GJ&0Z@2>4&(QI\>DFL\H8>;'58J>KJB5$SI%,[YXZ(O_K[2 MJGZLCR0#9L@J2LRL3#&$N+?DJC/'+*0WJOY#%BQ6=/BOBY5S`0JO/J`0B1G& M7AH$YGR5(@R$-_+-V&4(1)(;52I'D!D):?(@D4735Q3_3UCEB`#G9)SO8WU6 M(1*CM#IC)3-6(8`[=[4BG:/G0.!=`5BS:/U?URP'!J19'T.(Q$C-8*%V)E/T_*9$ MC>"J8"@MZO,'$CUMB!%A]>$H/\Z_?A<>9F)]F!DP0R&-X4\9UPVT:ILB4.*& M?N!&FB\RA"$Q=<,@4B(F]2)0!'W%"\@U;U!4/6V>F2C9G&L2;739],R7^8UZ M/I3S)-#2/46@>Y+ERZ3OJ`)4[CR"K&GGK)W]T_-S?/;WP#F[K^J\'N)UE<.OCS@&\X[R[_!!W.^-][_H_ M````__\#`%!+`P04``8`"````"$`2IN2G[4"``!1!P``&0```'AL+W=O^#0J@+56G?S(%"D MIAPK7W2TA7\J(3G6<"MW@>HDQ:4MXDT0A^$DX)BUR#G,Y4<\1%4Q0C>"'#AM MM3.1M,$:^%7-.G5VX^0C=AS+_:&[(8)W8+%E#=,OUA1YG,P?=JV0>-M`W\]1 MBLG9V]YCZS4=8&2 MB9]-PR0"N;>E2M\S8XD\:>*A8OZ)(+Y(`^"Z0$%(?\FTX(RX0'"]P21Y>?&T# M*Z=)[>28CM:]!X.1(9+^R":>])^KYAR/*8(8!P31B,!I>@2]!P."=$CP=N]& M/.P]GLY&(SM-9J-8C21SU)0,ZR&*DDS*]AG*8'XW9%]]YW>$&UL MG%?1CJLV$'VOU']`O%_`X"2;*.1JPVK;*_5*5=7>^TR(DZ`%'&&RV?W[CCU` M8"!;MB\AX./#\:P<>18%C!QD MF<<5W)9'5YU+$>_-I#QS?<^;NWF<%C8RK,HI'/)P2!/Q))-++HH*24J1Q17H M5Z?TK!JV/)E"E\?ER^7\)9'Y&2AV:996[X;4MO)D]>U8R#+>9;#N-\;CI.$V M-P/Z/$U*J>2A[_2`L!T88\Z0SLI'S1T&][_0@FNX/9SR8#?Y;67ASB2U;] M):^_B_1XJB#=,UB17MAJ__XD5`(1!1K'GVFF1&8@`'ZM/-6E`1&)W\SUFNZK M4V@'V\`(&<&LG5/6<:DK;2BZJDOE/!+&:"DG\F@2N-8D?3)X,2*,`KLUD MWV'EFOW%=*1U)@M8N"WQ;`^(AHB`O;08EQ0W,J&^'5EC^>P M4:?!6IW.J9:[Q0==*7[[&H.(1A"\A?240-"F*]'@T`;R-@;!TFMY41QB>*LV MZCSHO9GWWZQ3Q^_6`Y&&+F(Z"SH.>`GC;]+5K,%T["?L6,3-3 M0?YLX3//(^&)$&+$];3,/Z-%@ZF6@.0!,=QHH2*:,>TWW;*$'3`](!I,1=R* M#(L!,>,BFC$J0A]8G2W]\=[08"IB1B*!F'$1S1@5L?R,"`VF(N9$!&+JTAB6 M!0X/RX+!.3$]&@9-E2R(DAK45BE;#N503+^2>S7#M.U-SI=!4X4WD\2JJ4&H MD+'YC/$E*>^HQHQ$3'M?1X_VE0"B^'$=,73,OK4-C@`$+7%/.63W1S7'B"1M M@9^7A,;9E<2IG6P9@AY&MWD].")HQ'LGQ`A]M"^(FB]#T!U!]YQ8?\C\CP@- M/9E[)"M;0QW:=P3=LV-&_'AB%0V-F7ND&.K2QBEC@D`A&]?A(UH@]3]0T M]&GN49]F"&HJFY'*C\CX+<9]*R#6/5'@T,.Y1SV<(>B^P'M&SHB33]0TM'3X M3J5&VICV[7.(>\1M(_-^^++I?+%P[V9XO?CYQ.RG:36S^I;*/9+`;0WJR6#T MLZ`%T=/0_Y3'&S01Q$B5;VL0;LLYY_Z">EM$('`*\!M+/W#:F#L&^['70Y=& MSVO.;B6-9U`-0GV!QQ;S!=G(NMO3/)V-BLT;-BBY*(\B$EFFK$1>=&/&P*3; MIVW3^&AZ1K<=@)[M'!_%][@\IH6R,G&`J9ZS`*O#FTJ>3?NSDQ5T:^;O M";IS`0V"YP#X(&75W.A\MOW^YE\```#__P,`4$L#!!0`!@`(````(0";)E;4 M=`,``!4+```9````>&PO=V]R:W-H965T!:1@+6EJ'A[RLA??SY_2$F@-&TK6HN69>2= M*?)Q__-/NZN0+^K,F`Y`H549.6O=;<-0E6?64#43'6OAS5'(AFIXE*=0=9+1 MJ@]JZG`>1:NPH;PE1F$K?T1#'(^\9+DH+PUKM1&1K*8:\E=GWJE!K2E_1*ZA M\N72?2A%TX'$@==B)&C*[:=3*R0]U.#[+5[0 M,J@V]`D[:[G=27`,8%EA*=11'+]Z" MX&#(+#]:_)9#L(8B#ZB2D34)('D%;7G=)^EB%[Y"*(0;['M>?1<*P^^$#N`X4%.#FNICG>GQ4,NC,MYF...[>&/\1:.T"F>XZT( M\7`,@$M)1T_L-RI/O%5!S8ZP5#1;PYXBS;7&/&C1]7>$@]!P'>E_GN'ZR>!P MCF9`/@JAAP=<8+S0[O\%``#__P,`4$L#!!0`!@`(````(0":`NPVHP,``,T+ M```8````>&PO=V]R:W-H965T&ULE)9=CYLX%(;O5]K_@'R? M@,EW%%)-&$U;:2NMMNWNM0,F00.8Q MZRIXX9TL19,0.HU(P)M,Y&5S2LCW;T^3-0FD8DW.*M'PA+QQ23[L__QC=Q7= MLSQSK@*PT,B$G)5JMV$HLS.OF9R*EC?PI!!=S13<=J=0MAUGN7ZIKL(XBI9A MS9JUCU?VDDFZA9, M',NJ5&_:*`GJ;/OYU(B.'2O8]RN=LVRPK6_NS-=EU@DI"C4%K_G3;@) MP=)^EY>P`PQ[T/$B(0]TF](%"?<[':!_2WZ5-_\#>1;7CUV9_U4V'*(->5+L M^)57/%,\A\R1`#-R%.(97_T,2Q$XD1I`)_+_P<$NE?I'7#_Q\G16X&D!8R8J,`'7H"ZQGB",[#4A M,:@KN`90:^)0MP\*E6[#\ZQV!"F0?$$[("F*>$`EA?=E' MN_`%`I?UQ,$0<+4$=8ET(##VH,$*@=B,%X(P"L'XH+*#6;CU&WM^[XF9)1PA M$(7Q0A"&;-[L=VZM&F6&F%NIZ2Y.1CB-D?4:ZAT0'PE^#T:W;<(NTJHUY8' M@SA2_`X:$%_*QI6"PW$&<_GWHP1?\B3][$?3.0:YZ1RSL-"51-T`GTTT4CL/QD3'#T]'B]SD=!NR- M7J_Q4LO,*1_S*8_]?K>,568.2^;\4//NQ%->53+(Q`4//Q2R;U?M::X_9MD' M<"YJV8E_8=VI;&10\0)>C:8K$-V9DY6Y4:+5IY.C4'`BTG_/<&SF\+6/,`:% M$&JX08'V(+[_`0``__\#`%!+`P04``8`"````"$`S-67+D4#``!\"@``&0`` M`'AL+W=O';`!*N`D>TT[;_?M9U0`DG)FH><\^QN69Y_5(6Z)E) MQ4458^(%&+$J$2FO-C'^_>O^:H:1TK1*:2$J%N-7IO#UZO.GY4[()Y4SIA$P M5"K&N=;UPO=5DK.2*D_4K()_,B%+JN%2;GQ52T936U06_B@()GY)>84=PT)> MPB&RC"?L3B3;DE7:D4A64`W]JYS7ZL!6)I?0E50^;>NK1)0U4*QYP?6K)<6H M3!8/FTI(NB[`]PL):7+@MA<]^I(G4BB1:0_H?-=HW_/.)%TV!,`([63.E[;B@Q2K9*B_*O`Q'35$,RVI/`YYZ$ M1-XLBL+);#K(XKN.K,$[JNEJ*<4.P:X!3553LP?)`IB-LS'DX_IHO)ZS"NT9 MDAO#$N,I1E"N8'V>5R$)E_XS9)KL,;<.`^\-AC0('[II6H(VVBV=#OF@;,!& MV21E6KEU/[1E1J=EQL^"%;\$?Q0K>VK$:O\/RIJ@K/^G(.\S,RI,Y MF4W&LP9QU,'D(QV8HFX'TX;?!>`P$$,KI#,]P!YMI_!^^`;\>S/M07V[Q,R3_P[85@TEO`>=T.R,ILMF!G$CZ>@>[H6\![F40SC?X74F MY,[@&@C93:-C\;>)Z.X?:)2=4/V8'V M(=N,>RF[AP!W1I9,;M@75A0*)6)K#G@"=T'S:_/P<3.RP[[Y`\[^FF[8(Y4; M7BE4L`Q*`\\N M_@$``/__`P!02P,$%``&``@````A`)IG,,:7!@``&ULG%G;CN)&$'V/E'^P_`ZX?>&F85:+[4Y62J0H MRN798PQ8BS&R/3N[?Y]J=P-570XP,P\S0W&JJ%-5W7UP/WWZ7AV<;T73EO5Q MY8JQYSK%,:\WY7&WICL7)_%*W[Z?GGGY[>ZN9KNR^* MSH$(QW;E[KONM)Q,VGQ?5%D[KD_%$=[9UDV5=?"RV4W:4U-DF]ZI.DQ\SYM. MJJP\NCK"LGDD1KW=EGF1U/EK51P[':0I#ED'^;?[\M2>HU7Y(^&JK/GZ>AKE M=76"$"_EH>Q^]$%=I\J77W;'NLE>#L#[NPBS_!R[?\'"5V7>U&V][<80;J(3 MY9P7D\4$(CT_;4I@H,KN-,5VY7X62^DOW,GS4U^@?\KBK47_.^V^?ONE*3>_ ME<<"J@U]4AUXJ>NO"OIEHTS@/&'>LN_`'XVS*;;9ZZ'[LW[[M2AW^P[:'0$C M16RY^9$4;0X5A3!C/U*1\OH`"M!Y:ISA[\5Y[,\C$4WOIS#1 M=/KJ)%F7/3\U]9L#(P<)MZ=,#;!80N1S632)2Z'^KTY0(!7DLXJRN`R5H MH;G?GD,_>)I\@X;D!K/FF)E'(?$9HLJOXB9GPS6NH"[I&7%VD=K0UWT"'"]$ MH="8Z'#?SWP46/$Y1UUK`\2^$/1I(C%'S*Q<$PZQ@J0<80>1'.*'EU0(XX`R M5JT-8-W<9JZ<`(>(ABA^WY6UQH27ZL2V(;$-J6V0R$"2#FG2MY-5X)4+%;ET M)?2C2S%TLAHS[X=2>,+S[*'#@$"$#)!@@.]%#)!B0!!,&4!J0%\P0A;V`3R3 MCW5(.=FDIQ9IC8DTZ<5T@#5&^/,P8$DG&!%$\SE#I!0!FZ%=6ZD1G#CL-)CX M[2XKL$78WELTQ/`-A.!-BC7D.K3)?9_4]I'$9SJ?D<*2UL)>^#A#!:8,@^N: MUF.L(9KA#'9\5NM8(Q#!NRZI[2)ON1!Z2A99Q\;]O44Y49JA/[,F5V-,)V=3 MGU2X+T6,(:.I-S!W"8;,Y^'`[&+$*%JHV;4V!JDA?'@7'^&NG&SN/YDE,18S@;[:=ZPA39F3Q!9*1IWZ MB,R=):(U`B'!1)SZI@;;IT[0]Q8LO]@@KBU*B(\8TFW,1V(+Y:1.?L3IP>'2 M>H%RL_:JM:"B@F_7L4%@;L3'X^HM93X26R@W=>HC;G?ZI34"X63+,8%U1']$ M6>,4&P2F=,\G93X26R@E=78_3DF?])@2G)KV(845P\Q?<$T1"Z08S*9PUREE M3A);*"MU)B-6#PZA/LDQ.RZ[!)8$(EP,K3"D"`P[[#0/^>2F)NRUS1);"#G_ M7;JB1UNZ(K#'T("NGQXS2V(L9NN+>%=3YB.QA7*PQ,%C#?('1()O:T,#,GD. M2=J80$:@_/BVD!",Z%MF#7I*(!`FXK,@#::O+*T`C!D>T=M[B:_05A=]6QT: MD%:'7,O%Y'W0D/YJ2>K,*$X=]N2,$S*+!);:.Z6L+BS8+B@X)-#M,%T/O`MTM>0*ZO$ M6,SV,N24,B>)+924I2@>;,B0LK#5DJ]!U]1C9DF8)646B2TT=W5DO_N0]?5! M?V>8;'T0&[I,1P:T.7 M2&(L-YQ2YJ0N?RYA-"E]EZ-O*ZJBV15Q<3BT3EZ_JGN:`)X67*R7.Z3/OGHJ M;=G78@E7"]R>B"7<'X!]6R=0[&%C_+&,UCTC;XTTB^Z M^M3?G;S4'5SV]/_NX7*O@$L+;PS@;5UWYQ?J`R[7A<__`0``__\#`%!+`P04 M``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL M64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`! MP[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7U MVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]= MQ9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK5 M9B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<) M=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[ MQR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF M9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F M8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8 M=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM M`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SV MN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5 M!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;U MKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C< MAT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\ M:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D M1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K. M.YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4 MALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q M/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY M2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-= M`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV M#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO M-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY( M%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4: M.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T&ULG%A=;^HX$'U?:?]#E/>2V$D( M0<#5+55WK[0KK5;[\9R&`%%)@I*TM/]^QQZ3>H;PM7TH$(['QS/C-VU15W-7C'S7R:NL7A759N[^_=?SP\1UVBZM5NFNKO*Y^YFW[K?%SS_- M#G7SVF[SO',@0M7.W6W7[:>>UV;;O$S;4;W/*_AF73=EVL''9N.U^R9/5WI0 MN?.D[X^],BTJ%R-,FUMBU.MUD>5/=?96YE6'09I\EW;`O]T6^_88KF MS>O;_B&KRSV$>"EV1?>I@[I.F4U_;*JZ25]VL.X/$:;9,;;^R>AG78$_&F>5K].W7?=G??@U+S;; M#LH=P8K4PJ:KSZ>\S2"C$&8D(Q4IJW=``/X[9:%:`S*2?NC70['JMG,W&(^B MV`\$P)V7O.V>"Q72=;*WMJO+?Q&D5]0'D28(O)H@`M[>.#@P@^&U'SR2DTA$ MX^L4/%R.SLY3VJ6+65,?'&@Y(-SN4]7`8@J1A],!>5#8[PJLA\!*6ZCA^T(& M,^\=TIX9R.,`A"*6`XBPAWA`J^<&N;F=FP)#45SGBUO4A]7T'Q$2ZNJJ]2RM M!V1BB'+[Q`H\=R'4U\1C-C%")CICT"^1#W\4LK0AT@\TIH<0^&KVU"!*,O@* MC\5%B"$I1&(3T(@E082J-?MU$H;*"&\6"@6FFS$0?5ADAA!K,UH/R,3)/1,K M,$N)9!,CQ*1$AN%`2UV$$'("BF2GY;;"Z5&,YHF0JLAS%WD&$U(8K)R)@HA0 M]=:9THG[1!X%VA:TX$N@L7@ZXI%<#`9DSVW881ADQR$TATJ&;VXMY9B\Q%SH M#0;G!C5-@@%^&.>("?WSTB;N\@.-9L7EAF`P.'D0QE*5C_;IDF!"(059!,W@ M79X@4-!A4;UC!=P4#,;:GO83.OG_4GYU]N)EY-)O,)@E$6C]Y$DBZB_"\_(O M[M)_C69%Y`9@,,WEWB+T[5/^3J;S!V?YW3?\$,X+:3A1Y%"QAR)S`84\`@](=DS/:"T(\O M9$DR+[A<1(UF!+D'&,QQ`XBA*E+,>!*?+Z.\RP`B MA&P">9F$3)P"X@F+$?:R/M5882O,L')![I85&]S(;Y0CRU!$BUD>/!H/TX'=>(DB%3`UM3PBBR422+4TIWN4*$O7= MSF#$7<%@CAD<;#(,,PRA])AO7.DRU'E"C_N%M+W@(9C(*!PP?8Z*F&P3DNHG M\NUG7XVFFA=QSS`83-"#B!-)SHU89@J2$FZ0;.&A%)EKJ`T37M44N,OCY[N( MNX?!X+W(F5,PP9PY!>.E'UYK[=--_GO:;(JJ=7;Y&KCZHQC8-GCEAQ^Z>J^O ML5[J#J[J]-LM7,WF<"?DCP"\KNON^$%=*O:7O8O_````__\#`%!+`P04``8` M"````"$`'$3*9W$#``#H"P``&````'AL+W=OZ?U;D3NOI.:4E3,7>8'KD#)E&2TW,_?WKZ>[L>MP@=DP-QC%2GAS9K5!19P M6V]\7M4$9RJHR/U!$,1^@6GI:H9)?0T'6Z]I2AY9NBM(*31)37(L0#_?THH? MV(KT&KH"UR^[ZBYE1044*YI3\:Y(7:=()\^;DM5XE<.ZW]`0IP=N==.A+VA: M,\[6P@,Z7POMKCGQ$Q^8YM.,P@JD[4Y-UC/W`4V6:.CZ\ZDRZ`\E>]ZZ=OB6 M[;_4-/M&2P)N0YYD!E:,O4CH**2TG72'1>L^*M!J*'2)(.&!,X-"8++*X/#)AC.QV!O,(Y0%%^6X.OE M*'<>L<#S:(#_*.&L$C6^/P;.H.&F70S(7C26-\I%?+6&C(N%E` M$@2!"5BV`<-1V`88`L$X6^!E$V60)7!D?G^A(8D2&'@!,E\OS[XVQ`U-]8DE3T.T/#0>H2@) MDM#$+$W,(`HC^(>.&$->?(L\"3;EQ59)+32D7YZ)Z94WND6>!%ORK))::(CJ MPSJ3K0>&+W)?O+EOR"!+P,EV_4]J2.-/,.Z65AN0G/\ED__1)X,L?5;I+#2D M95#K@6$0@BYZNT,JRI)PZHK:H@9SMBV)F0<)5;7OR"OV^YCN]TCC>F59T!ZY5E]_\J=O;L!Q*?U-_6G,7K?1&$H-\Y.FDU, M,(!Q]X31/NI934\C%=Z0[[C>T)([.5G#GAUX(VC3M9[4](U@E9HZ5DS`A*4N MMS!1$QA)`@_`:\;$X4;.@L<9??X/``#__P,`4$L#!!0`!@`(````(0"'O"(N M83P``*W3```4````>&PO'`HILWD12,SU]0-UZ=*QN\8CL:0P:LRA6)<6:+E;5U$42!UX,#'OEK3<' ML('&K+WWOOTF_23^_;^X9&1D9I'LUFB.`>-<6JR,C/CBN]\B\O-_^G`]+MZ5 M\\5H.OG-@]WMG0=%.1E,AZ/)V]\\^.;\Q=;Q@V*Q[$^&_?%T4O[FP4VY>/!/ M7_S[?_?Y8K$L>'>R^,V#J^5R]JO//EL,KLKK_F)[.BLG/+F'BJBR7U^//]G9V#C^[[H\F#XK!=#59_N;!T6/674U&?UJ53]TO!_M' M#[[X?#'ZXO/E%\^F@]5U.5D6)Y-A\7RR'"UOBI<3-S]@?_[9\HO//]-0-_RP M^&HZ65XM&#HLA_G3?UY-MHO]G5ZQM[-[D#\\6;W=+G:.VA]&,)*UB^]>C29E M\7)97B_^D,_F07U3OATMEO,^&_BZ?UWFHTZN9^/1Z=6H>#*:+@8CL%\NBJ?3 M^2P?Z*=["B;F_3$8&)8?BO]8WN3CGJ[F<\84+T:+`>-^7_;G0D7QK+]L+.[G M?#$:E_/B*0/>3N>-"<^N^V,]?U/.IO,EG`%XU[/^I#'P?-X7XQ1G-]<7TW$. MU\GI;Y_DOX4]3:^OIY/B;#D=?-\KSJ[ZK4TSF/&_+5(BO.;66-/NSM; M__+92?[*"1PT-"YZ,>YW3WA:SD=3<5D[ON+"'KE^^`LX=)&O^"][^2_YVT:: MUGM*?#$;0^FP)";7)17%^508R_?27?UT42."[ MT72U&-\4H\5BQ6M(0ADEH;B,DX#T,,E5_UU97)3EI(!Q)4W%3D8]Q>+T273L=H9:(-D3^"188D6N!AK]0F*93G2OT_GY64)6PX=C8O+^?3: M_?-J.AZB?H"Q>/ZGE41[\UEY.1J,E@]9K``2F*X_ORE*]W2X*NUWMK<0N]CF MF)AQPE%Q6?:7*]AG&PR,%D5_^,?58FETY\?5>`D(([93;6`TZ-N+_66&D>EE ML;';V]\_ZNWL[!3\9>QY"[SW1$0/8`;CE4G-DBW-D-5W_3%[9#U^6+!+)PV" MYMB!@C;6LZ(_&,Q+@]T-;D=(G([-[#W:T6:V`PFG;R>C/Y?%,!`''BDG+*X5 MXH^#Z0(*S\LQ;#$L!I`4U5TL5A=;X]&@G"PD\?VW<\@NQO-X'USU)V]+WJKC M?+@:&,!,X-=::*<;>SN/#]2]&8\G`:(+%,*-G"!4?Q/?>EW,8 MI1)G1'$ZEVQ>("3S.=`QE9>6;)YN@1`:/3;=?*(JB.PG0`GS!X?&05J"/UMV M[`2N>#N=#M^/QN,B8*L_0'X7(U'?7L7:0;3E?#HV.IV=_M:&VC#IBVJ-[\L;$+I8.14&\7`)IC<@`1B<^&K4 M`*.+1>[FF);0!+R&16VY@"J>TP&-M1]O%E])AF(L$EV$A,=E[^-OF=V(%I0\> M5QIJX_C`Z9_`W&L4D`!;K-44/59:S$H4X[MR?+-=G,#C^@EC)89A`O@5$47L,0R^5\=+%:F@5FV_PHS\I,I3==423;H>Y)MKVY[[4@ MXMBS/)-O[.[W'CTR$=HNOJZ`F,$L9K;N!DZ)FD!W;>QL[^P6U;M:@)^.JI]J MB]QKI[<0(-WQ90`'FA\X96=;[3W>-Z+7@*B@O0LX.5>U;SC%06`PUL$M=3*6 M4WX\74"P7TKW_3K=@Z(TJ[*QNT<&A_>"`$@L:(/?#2+8, M"-E[6-%;^F]C_F/S!QYF`/U2!.PG M>PT(V-M-?\R8(H\R\+L7T_%H:%;A27],;%`24Q%[+XK-;\Z>%1L/\U>>E0." MXEV+>_?SAR&>1*,S1>-I?W%E)F2@?\CMP&+)$'90,(BS(AYQB MQ/LCS+MS]9RMGZ(`Y\7`![7M0)Q/ET0_Z\>SI2L@%"W()H?.(0/<=;'4]M%/N8^%F)N3A#(^.2O!_C@P!3RV"_0.I2-T:Y#9+MNQUZ/]1'+2W;BZXHOE1( M"[AMN;1`LF?%\L$%"$%PK]@U`VPNML=*?[6\FLZ)6H>]XKAW>.1B,O_09S9$ MYVF5/<(XMHCI<>\8J7Y\=!PB[.Z7&Q)=;([)54K%BCIN%TKO" M\"XIAUTIO\?[MZ.IJ0IWC_=ZC_8?]1X=[MW^>@,/^59.AD.+'U'U,A-;>/"# M_FR$ZL]'GKK'6_YQL84?3-Z8C`1Y4<K5Z2(3Y&;KQ.9Z4VE87$`,1SMB=,YCGE5T6MY`.K0PN21+ M*0^+WUE2\A2OYDSYR)2&:^C1G/56FG2^XM1SOO_.X6MHTWSG5:+-3\T.2YOG M:X'7RK%.4NUX@:]Q+7-'=_'+ M<@+X+A'7'U[#FJI7*1^1K^G4F:2;QVM6?J68U)+\?BRHR^=Z;8Z]SUML^CTT M1-H2-9L*+1]VYVORJ5.)D4V>3$E;#:F'J;B8#T;ZR*A2SO0@F-><#VH'MG6H M$B&"-Y\"D:[2]5%N[V8$\KG"&G>)^_-W)<0FAN2,""4ITN+$_"H?I14";1SV M(;I_;ZNXZ"]&@SLJ@?4S#4?CE=*7=U/PWY:CMU<:3F%JWJ?`,%E9J`6-O6;A M7X/$Y:GY@2G<;GB#W7[I`NEV.I98HT;NJ,1E3NM>H%/:2>FL(]`W^ MC.@F[;19WES:RIV#$B?->V'DB\U)ZWSE3:F*$LL_[\\G:)5%YTB?S5"Z"P>D MREDT*JUQH-C*T^'6EQJ,FB/*=KX%[P,K3*9ZE`E//NX)^E0>I'(251#G*Y/F M#,5@C>"VEL"7E;.$C?%Q9SZ,H$HC]=,PR=;O#/0'V72GPEU3JUUL"3LD[]628TYYY[2TDUD+5,5]+-? M7+>_=F/B2-$>6P.5*O6R-[Y4;J6E'#HGW5,KIE.)^E#.!R/X_8[#UH'LV8^: MC"IP0^<>J+MA^KXQN^/IMJ'K5D@IF5+`*AXQO/2=#LVNDGN^O@Z2YVJ&0DDY MF7+LN'MYV[TS*65$ZV%2` M*(<^ION%P0OIH62RU&9U4^&T?V--7%T>1B=F0.2[T1#9HL)\EYT*I:$J69!5 M=0T*#R6:Q@7RO>T?DN^.4I=AN&U@CV:ZMZ.)G%SQ+12FJIN#ON9M^HRZWSM; MS4C)"4OXG;(_PQ4:AV4FTPF94'1,V_X;\O*U]<_IO2KM4=K)X8T2O&$ZM MVEAQ/A1(:Q>G5!II6FU(^.OYVSZ]9>8>]]0*Z#,GRI=KNE.5LH`TE-A>Q/;# M)+'RW59J'=*_K+O:+;A,M%"_*BSF]`4D=[3]Z,]OE>(3=OF8C0<]5V[;NS!(^&L M-O09;>C#[2G_XW+VD:XG--&"JE&?]B1VODB4@0&-MRV6K6"1C/,&`;)K6BJJ M5N)R/"+%*+*ZR5P*!_`=9[?N5],I?T2_<\%'EL*C=]1N4^EE$&,+/\Q+AJ[8(XU"Z$!.Z!K_(^6K2(S-=]&GY MI2XR6\T5[B_%WX)^CL9VZG9>OE4S@C$T4JZ'9R5,:HZJ;>7Y![P%]=@R^36> M%T-[EK!__M2$6J],9\@2>/4S>#"LP^^Z/T$07`L$W)TT2N-#BP')`4L@>'6B M).&XP(OU0E(U50=@?3.X[Z5VO\KLM+[S$"K)Y93&8>,@2Z:@N.R/YN+3U9RE MU/UF'%WECV/?VO**9N/0>BO.6-]?9]A2^Q_H86YG"5TD<*=.WOB^_4-35"PZ MF[J6UM9FD(H?KOO#TNG`[ITM5O1U!`W@/`.OIJ;+B+`1"!I-3"NJ_=/3M?*3 MP_2@]:*TA#;ZD5#;;_1R!:5O$)$&YS_U;=U)2MBVFPJ=XP.#P+1/-$83TNNH M3,?#_J0G0(^F\^ MA%?'5*WN^38!^G0U1D[5JMZW#;'B'U<3TUI53ZUUCYK0`O&M,!GF#"D-/'_# MWJ#:#DAH9]BRP0AO<%%0 M\E9M!ZKQ'&4(_+PKY?"-*I#*^0H.MF_QZJ*H%(,H>MW_'CX*T-K&2%G&3F4S MD_W+2UI3;4[7AMHDUS_CKV:QFYUE2ZDL"&I'.F"KG?<*NCNR/MMV''& M2WML@\DWA#A(%CX=WY<@N7X1J2AGC; MNRXF:7W(AXLC#L&;T=[@.L,!R=:9E#`P/Q[0CK+=3J^D/ABW"0D M/-3^@!3ODR9\/SAX5`TZ2M68J_6FLXTVI6@,^LX6@ M6<0'-1?6!S?`(73-Y(Y]U7VNV(X.2G+9UW!UP(`)B>O`_'Z"!REPE],Y9'E) MVH5%'$(L3!D29*".Y&4Z_D2+^H5T!&R3+CR#AAR'*AEP,.?*9!FED#31?&B5 M#U-FT@6*_*R#;O&0<&!9O`^J^CTL#>=`-X!0U@MJ:H,)UD[,>6AV),4L<-6< MF2B\9`N3:35=!^)=.[=+\S58!;)5"1Q)?'NC9CI*$NXZ9-I8W$BA![$[%40K M0G=:2_ZY:J,-NZYD_M0W[IZT=@^'%Z5+')O)QTPMP%WI MZ-1E+M8S#Q@L0JBG#CTS.YP5PF]K1FI/[:@;ZB#5IW!G4)>R_0ITE'OD9X47 M""SCQ7UV2&9\(X+(E:W.\1%U1X/F0L"1QZ15N4&L8[G""2A"+,OPO_S#O M"ITE73`"EM%<0F7R:(H-@\$P]T0]DG$:.XUUP2D9+SQ#B3.436"UE=@B%%C, M<-"TE6H-U]^/6G.G!H<-EG]6V5#YF/Y47"YQ>^[\RES,:DZCCG[]EE.@K+8H M3K%5KY9#"U&D<;:NIN^-9C,+X\>C"PZ#"OUV"BZ>%I,&*2Y"O@HB72C"5.CC M7",>O^6(XELY#F8*1#0.(NT>66,F)MX*RK6^;0"-R&-^4S#FU=B[^[W'>^Y$ MD/29Z3*A1@?Q+/RJM(KMQ4=B-(Q,JUGCFX%X<-'%GE>XMD'=20#][>W3'G1@I=?/&K MQ0S/[3E50P$1KW;\R'G*^?\I]B\\7)V9.':1:^&O%4ITI]&J;8/#E[^K`XVCWN M%<$#@O. M^+TOWDQ1;7IZV;^6\^QFT`^?V<3++PR1+2A,5O\;K1S"@"J8I=6`A&'P@F6] M`UDM;C`SJO370AT'=1H5?;IT0#JN>F(C?98R6/"W=J^'5+0WC&9T,"[-I0)S M,A)'#_^#8`#.X0R]+P05F\N;&;2S7#/,I)!.]'?)H(<.5@>3XE;+[&#`-(!T9]R%&!D< MI(1@69Z)(9J0MEH^]$5Y-TJB9]6/?TVNE4C>MX,BWJHO1UO6<"=#OTGE1#[- MEF6$K7A"P!-")W/.#)14W)"/XGCWT:<5CV=D%=SQ;5\U^YO+1;N^^K2[%B?\ MMAQ2W/&7K_R==FW2\)P85Y`4:OE1A8SDQ(OI'$FT;)BIBYVCK4>_^J1Z\YD/ MH`78MYS,T+E'8NR7\2Z(8A,%_9R&UR%>)E4[*UP^9!.,X3(@?D,=\,9SDBI+ MZH=(T&NF6%N,Y5*QQR M$D6N^*T/;"Y%6.G95E7Z0@'=[\+%+(F5KOI2@O8D./GQAY_^\M]__*$2](2& MC4IYZC9<.W.E'%Y9,SJ723Z](S>J$"A+HGQY:MZA4Q$M,#->%L` MDL_((1,5A0'B:U?B(E6';%JR.2:!(#GY-<@J%TNI*)%"U03+1,`65GY4BC9E MB$U&EA]()MF4UM:AE?A+"7,RD4QP318`KGE'88X2&7Y?ILD0DF7UJ\"QE%5L75B8X*N18<#V%$-,?+Z9U&J7D M*ZY&)/9)XU+U<,G/2!CMT52`],%UGWRH;OD1Y'C%BEZG%_(\+!Z,KG7^\'`/[LT.E->65IYUTO7GU9DCX>.CI:-4:69FIC+X;ID*>ES\*!;T+S00,!` M,^34BWIU=9Q;8:]U!?/DP0_'UL)L0EHRGL^)%#&HGY!A%;5A2.]M)"I$&5-_O9!8A%8AZLCXE+ZZSD\J.6RI M7[(7F)^M@`+.7]!,9#FZ`?>KD-5?;).]>0]IYBZW$*!0<`[V73K*B@9>72#M MA#O*^J=@")8R^J0K46!^XQV=4HNNM0O=M[2N%]=P8&6*<4,,VP'MU8=*'(`[PV4<(%$A/>"9A;[1_JMG7LF#(-Z<**R1*:TQ) M(+SDRJL_2Y$XZ=OW$N/JY8&;8&5G$[XB)(75LRN(EFIGU?61`A_M;FA6FE"Q MG0\LJK`+91`KF/1+QPO8_/6%[Z:@W^[ATDEL750IZ.!DBM/2IZZD%@7#+`D< M2VV+6JG_2^2TFM>EBFM6RLK:'A(;"1/5Z=/`[7-7@:VK6T-H0JM6P8+MX@8K M!$?QUPZM@I&:A[26IXW0-/1'U8O0KJE2@@>=1R!1&+-Y6;YI+UP"%>-=:JNQ MF,U6$T9T%MQPGN\]\V180"R4*HB.XIK*)%A@$\ROJZ`LX4_< MK5(?U*4%+>Q_>"./ZSMWM@2KQAJE]D%ZUIHJ>FN\3X<1^^,MV0!N*9MML089 M*_\:=T&6F))D21QD%6STNW%6()ZC5,C-U36/S^O\F5=BYT!V:(L$#9J?M!AT MQ4%`^5%-9@4,("?:5(6IX'?UV17E%9,X#-@(VQD25.*T6(U-IG(^)KQ3/'MN8A4`@AC+5&%:1G M`,V<*@))='>I/:7@+)"V+BHEO'-)V5AG.92>.=QYM+7WB3,T7P7PGCOPBA.E MLURWW*?*V7S1\.I3#*&Y=/1PX2\0=`B3=;@HY:1%3J5=.X3'=M7GT#O5,$>2 M*/SI+W^M\\[2DMG6M'+BDON-7;.'JYZQOL")_0)P$ M%[_.9SVAM4'LU3+O-)H8J3IXBF2D&$3-^SXY7EG,7TMZ\\F?N6E1;<2`B42B M^&+G@^:6+^=+#MZ[L$R).5G<1@G^F/T&)Z@.I3E]OJW&ZF=2H1SH7LTG#7-] MGC!S\`*E$!13HB."HN%U'\,J&1&+R:$;Q"D/YY#Y[*G70(T%7=4B:A7Y*JA[ MU]:!3\?TZ@16.P8!NK?&E>:H2Y\'J@5MW*9U%Y!6;+T_?V*_/'C*;+H5CS9F6Q?;Z*W>L MIFF."&H>AST"Y1G"!U&BHQ="LE?FB!*/^')=6ST?;^%,&46_KK,VP4GR.01P M*8='S?EI@X65;"H=PDPP8))O$%,+GB:H:!#92;MDU]"'HDMO;`NMZ_)-XLU[ M%_[F/;)KY*60.46**!%)NHI0B*4:$N9#:_IB;1C;CY%8^`V&!CL81SZPN:V7 M*Y2.94[<%H*^2%$OQ%S0E*X#9RX8](DR4=^\"5T_(PTG[9#M1^&WJ6-YR$D# M"-Z<%:16)%5TM)TC`QPH0?=+95[`Q--)<&0B$L7:J425"I*-#>L'WX7YP!O; MQ3?RCT@=BQ75KI2N=>GRMGYP77>9SVL]JWU6E1H,?2!R5IS18B7=/AWBNE5H MB*)0[#D@1XA)K)W<"@5[BV?J\B?D@%S]7S>"T0).F8@R48P\L7MF>Q)\P\8Z M*TUFP7?];!?/_GX]-IQEZ.BQD&>CAISP5LG,'\=YWWV+3#H7 M,69RB2!9#`FMZ2ERJNH+?P'?ZV^7Y@:&CKO@37]HX/J#*IP.)1`UUWE@KUAM M&["U#[.EF`4Y2>X@E&EN6_]I:G=B!=-"Y-<@R)25H@`7RG\XG-]Y M'_MWV\>^4\DI\)%4D4: U.E%X&,]",_N-(,)'5C;TH!WU4M"7RK)'&)WK0 MI*&J*'<,BY3>[N?R4C^SRB@?+1;&'QSCHM%K M!4U5\H2$>%KQ"DF744*;).+F17CSY/73E_[6:,&!QE(F#J,C*FR#7!`!A%;! M::[RR$3TO",LT].ZK`I+=CT\7[O-'ZD1&5T@B+=_)\5K8'O5-"W%(!.CPCA]G7I[E M^_N7N(]5RZ"ZA."E/:[GN@))+"RUA[%DEI2$Y<6@*@UEJ1KV#KE(\I%=??A(Z35\9@/*B9>"G MD-Q)K4HK3^2B=XK"<^'[F369Y<^?(TK$K]W'^I,)K,UKW;J4>)?+ M[X]W@H9C@@06`QV[=E_S8V:&^-!G_44T5;A=QHTE-G:W#W:,.U`"R<_ZC,`V MEZ<1%M]W26=C81`L**D^5V=%3J9L,MD<>LP\++X7#H"?W%4,B$D9N&VK3ALEM`#8@"#C-4^IL)>(8IJ6)!KFG_B2 MG4>D6I1_KR8FZWKC1-+`K.0OHJPYA&K&:4A)`#:CIJEB2XPX3@M?7M%VWD^W M4,EJ+/:;2X.,>V/8%B9?XC,R$F)W$X"0FBS[\R:6B#B>Q@>(THZF5.<57I(E MY]U.=G?^(6SHWFNE;"*?5`;ONN$(OK1*$E<'5.=ZM$EJM'33\M\Q_?@A_71/ M$.I))/;G\&$6J.+CEC:Z&7 M[_57-8L['`QZFHX=1[9-A..F6`%35%!\";?U^>X3V@Y"=2K@/W[S#M=!!Z.@ M&/^-PQS3VG<$8@>+TQTX=*%?6@E*K@Q27YSOF7;P!C- M56@_DIJZPU>CPB(Q?RNZ5FNL60*A-PN_=^@LO*FU?U[A_'A_;7]S"'.8K(4N M(.<,1R)KK:!B*W*#0(RLN?7M3!;4;8--7V<@U7E+0*"XB+3XGA3_%XQ07=&9 M;X*[.[[9TOU34G7WY&A#1`B0987#$<9B=\^^9?7X<8S/6#OH,6?@91#Q[-W5 MC]Y&,(BO,>T>),;"1`)+4IF@<*K<^B9$MHVC[9U@.V?(CK^-B^.V0;U!SWGG`6O52S>4B,)N8S"(?A1%J=]@NE*9*.SCI! M*_/.%`?V2:!=.=2I5D_-1M+$M@F:?-=I=/F1,S6ELO>#WOZC(SZ[E)+IXS'! M3N^8;R@>[Z<,^'.8X",1]=!_4$UX^(A$W>\=[[0152&W[PFL4].+9^2Y5'#: M9/;GH,P[;I6?7]=T&T?)QX:LEWECWWVV,SC3E:6C/=EB\Q-G*ZI/QK%!'[%- MWF(5L`A=_$@8B'JT_$_%RL:`7CJ0XH_&=BFZM@O3E(FJ=J2H*C-=(%)'OYHN]WM'?)UE?W# MW63R%`-RKN^B:#^*C!T>F2!\;+6YZS__EX?Z?W]G36JDQ2DQ+XW?=>6XI";Z M.^@=Z,&?](O1K^`^2^S2M:HE#NQ>!9A+\YJ:J`RC?GKJPBW?2I*$RXUS:=62 M/@GH7XV7>+B,>*458J30LIU_$SZ6,=7?TJ'ZBOB>C(N2.`=\%.KX&+MX#!Y# MNBD8\A;YEL/PN+=?R]6D0JB2*N9=I>&8!G$15+_0U2*J[;>X*=*]C:+*2GEH&GDSH7LO.([%M^Z MO_L,PPL(W("4IDV7?%P7'_N/`6K/R]TBCUZ[` MU],63N=U%==#($+P7[MD8V-_?_L@N)J*?Z!.6IPX:&#OV_20:OSC58CXB^K]DQW&[AEY M$OLZB7+/LA;-/(5=/^*^ZEZY6Q(`;Q/^49G9Q)C(8_!VIRK>20_M;*M)-GG3 MV:BA\%H%:(P,&ZG%A,0:>SN]@[WNG&^WI[+W*`D)38^FN9C@H9Y;KU]^C0VM;](KJ'"^UX7M=9.ZC=.UTH`?OR!1"K_ M#WN5NS^2ZA]_(*O:_CC8.I[N=PSY-G@P;COY`F]T0Z2=EL/EQ9&G[9&<=*/S MZW?Q<%X^P3_D/SR/EZ30!YH_?.0J_OG/SVM9S_SI1O[#"W7SQ.O3@XY4N"(< MJME3KFRC9B$,V$D`=+NZ&A@3JZ^8#EWG/.5RY(ER,W4#XEDA\@ M))FA$K2E%1+"9Y*B;.:(5'[@(M#HRA*YBO8I MLU`*H.4Q#9;#S]"B=[1_P(>".S-=J1I3:$D>_Y'_1K*BXV8OE?36O6)CL4R3 M:5P1^+7[FE4NO$GP!?_*H,6[H=[X$]AV(22?[%69U1\M/777F/*1NLZO4_S2 MB==\K^*`\P]6I.G8T\M)\7JPG.KS\P@(8J(#H1=V;1A['+9TN4`-:Q0R'Z^T MM_P2+VFQH^Q+I5>?\0T>X7N=D*`%01(,Z40HK61C5(B&:O4?Q436`UE]NEOO M&LO1`*%_\XGHG1WWR>PJ#+++VM/@!TE:V-ZIFGC`_!5=3$&9=#R]L0.?R2[9 MG'0.%5/=M]&PY&#K*SODN+=#KJ835\QB8(7HOXZOGWJ1.M8K#]-F9Q/]Z!60@#/@FS%*\1G3K=9XKK M\GW(!D7#B2@T,TWGR(CWERT_S*#]5IYQ<:-*_\%%E90$3V$\G;P-UWW7!0#$ MSXL3U/D0=P%P))3,<*W849]A4"N6:U5UA<;PMA,G:$.O"F\RB58MB%NZ8B M14I+*YZTA%)^7:)-*Q3W`OGS=@Q.1)UTCM7&^.^0.^#"H3P=S4'+ZUH8C;;T MDY[QC92`^W`IGZ6`A$@/I-M.L'F,UI5$(I-'&0T7N*RX;/)K[$P7R0I/"F4J M_94"M7*U]7FY*X.#WG-OJ&E!Q#-\42ES%*(F;VD3[I`=,T!Z5BN$BYFKWO+: MZT8B=QQ?-POJND#[Z8)T-95MOR/SZ.S*!FZ"0HRW[`I?UW/*#SJ0K3*;$%*; MO:ZRO!W@:BG\63FPDZU`/2+%\*G>!*M=79CJZ+,N*ID'0D)K..IGS.S0(K9M MY4"'/%2NA$Z8174?>N\75]"_,OCL(G3B10HS/DI#`K$S7,[PL:R:<<"+ M)Y\[(>NZP7BHBT%=EUJ48R.YH3%E_KJIS0U5=SK7F5MU%G'+YR=-WIZ9?M`> M@M/DW*M/D:FM4P/B6XN^Q10^X'<:L%8@,`K5;_CDDFU=4PF)XETE]3LWG2*9/`D28M)15I%-< M=LD7HMRA#EF9B?O,GU3)T'_RKZ8?(L8AIS]^Z]OQC478L$4X*.;:W3FU[X%* M91N/#JIS&PEX=/(A)^U&+U5G571` MK)&1.M=WGG[\04FN*^Y4?*X3,GD,=S;Z<,L(E]J](QWC[8?BLM\E7.89S$9IMM M=Q3G7#Z7@IH[(0'3EV]O&MLZ,P.63_JM/S7YXP\G:!?<*TCBLV7YT%,Y1_F/ M\:TWX>QU/N*I]\@0^Q]_.&])VFW^7J=Y'N;OO<21HYMC-/CQA]_ICL[\^>OD M&"?J.L8LX1L@^?@OG57(?^92S_RG@(`&7[YPNJK)L,_-A6N,ST!,A;K!LG[1 MD(-;.U:<4-7_R*PZ1/FN251!."6/)JGRRN$T@G-R$5X)>JIAD=[J0`C/2?X= M',1R$,*FG$`S$#IIEN7K*OJ*>M>*2YUB(X741'`PT!E*"E>7XZW(FMHY@.`? M`TGR!2"<7?),C[G^_)!N$97N>!YL0VJML!/5202_3=/XNK/(^9^NLU3-JNSP4HXTO__92Z$E>A->D^3I?(,I-D, M;YVBOXDF=YJ@J5^=F/_X@W22'-4]0\#F%9!GDTT=429Q"4L4&YWOP5DLO^,`8&H*8QA7?4Q/Z^ M:\/@K[O`>T]$*"L3KYF$G+4#?"A7%0Q=U"AHCATHXDDI7N('[IE*CA.U(B0F M%MC,GFL8;N0[HV)%[5^ZDYKA6B4M%G]TMQ(%33OP43.7PG!C#+DC=ZZ#[^F$ ML\'GUCMGHM1`/Z&"P0XU_%IF!#;V?'><4X\64H1Q7]KM0B?1Z38*N>Y\$54X MR7K+&"&#XW5M;;+:HKL[EFEN&]>ZZ,Z^956EUFS5T8?PW=%2WFB=D]K0'80G MX#"47(+DLAT`WTV+[BK6QOLY+;R`.^)[%F?,*@T@DMK%1*34H"B`HO&]#&7S M=(N)]N81Z^:3:@2GZ&VW@[%I? M;W&I417MZ8Q<78?4GTN"6@#I1%U`R3W2!Y`1W7@.K:V?\I[JRG:E^5.S8_8[ M\"&W;2(`.A+7T8,PY?X\8]Y``#"3[J>NI;D]:.]QP*"G#"]T;3&T28$B]MZ' M`'3Q"_TUR=?;'M[(.+7+E6L[XO+R]>V^KHTW9CX@^@%GN+2J\<"Q/\(2^'R- MAA)@,9K72>J&*JFW337X!(_13J=CY\1*S(>*0`\@O&+*>M[#+&=R!T/^%4YX M*/KRH<*U?A/6*^G="%QGM('A'7V($@(OQUX8D)P-NB`>^3,"?#Y(=PVP'@80 MWC&+QR$(8I*+E;Y$8!:_%1R=:=3<.NJ>O*L%^.FH^FD[7>1.4]])M==W?!G` M@05<-4HN#!M_3!4J88%/(,.-I[MW&)HW[1P=VHB`W`]!V3+@9^]A M17ZCPR;G%`^3'YT:BNO=:^/K#/ZM"'`'N0("#GO[=CQPYV,C8#_9:T#`WF[Z MXRT\\K5]2$::Y(ER`+HB62KMC!LO[&-BV?4[)/@&B@(V3_V_&@D9KB/%\C)? M%2;U"AO-[1_^OVOBHF^4VDX^DGV?=^USP8+>_J%0`VNI4W+WF>2<.P7PNYGE M-;J5TJH+&!>$/:I$257=9[I3_Y57WJ&18FD3"[*9$M#WF[D_XLZ;21\Q%R/[V8M(0H M+V/_A_#)1T/%AW?BK&]=:L%`/ZUB51=ZN4#6#LK[;RM5GT2[#X*>15_L7DSW MAIKIA*@7'E.V28;\/JLJBQ,SR^EUK60<52RZSUS/N;8<#QK,POQ&DON\K2LX M*L'7C;+)=5WWF`!OW-=HO[,)BS6JR:8+=>$[`?#<=R\H=V*EN&X6/W%7`/M(W_.!/@X* M&91>M&XT#@J9J[0.R'3_G0)5VTH/BKEJP#WG1TCE/=ID/93N;,2!7,+ MJ@3^PEU;^S)TM-R^CY]KEY[Q89C1>&%TI);PL-C\YNQ9L=$P4W0K*'JY6G#T M"!<\=YVH$VP7OD:PM^[A;OXPM9RFG&0NOWNE+W._U"5L?\A?:-&9+T+Q M%Z.MFWI?T2_82+BZ(B8^+5U0O\X%) MNL!_6+D3LI-A5\9\L0_+;['O9'VON>T#=,)_D<^\F=D^5%(NZ M>:U3(<(Y!L\7N,;M.BE0S*$M0VSQ]>\&X4;Z/?.37,KN4[$*D$ M5V!S3PX0%`;?'2GITA\%*=F$MR$EIDU3--^5--FX*+@GJ^45C5#X=3DB&F^\ M=-]_PKNRWB%K;JA\\EM?/^6:2)S;N[V]7M565%3@RB6>E5)NF+[&-I[YB^** M-VR#`(`C1,2O=)#D.U@/P\O+K7`>,%Y0B+&6=T0[G;O\\)J/+2SXDEQ?3:ZM M#DW@PDQYI"R;*8`UK'N'R1S1ULQQ+R9#"E)>_/KG:UH_C3E;E7VUX(3O"9O% MRLGS\2!-Y3!?)>)4/E#\(XGZO)_1Z=;'=[S=)3RQ4E6\),YYB)U*+?HG?B+) MD`6(:UV5;-7.7:5`)9(:WAR>-\L MU0+G3$&O',&26K;,!Y%=6+V]9;63\NV8+*@T M;%98,V_5-Y@&&'I%>_YE_5OYECM1=%)]G4]%PG2<]\]=S_Y:]>T,'P%(U>9& M?!GN:O'PA0$ONKI%PX".KM'P.`6:5)8\HEL@]B!9 M@)9W1.6[#(V_A>_@A2?]U:`6(-T39[?.UH',6]\+4/U?UJX@-X$8!GXE/ZA` MJ(4+$FK/'/H#W@`2XO>=L1V23>*8K;A"LG;B;-8>CY-NEL.>[O2'/1V[A/U> M-UCXJ#66S`9\,K#I3(*QKI46_.`EHU@OC-HNB+T261,.!5/X=/.%NI='%P@< MK-U&VZ7M;MALC5;5:$.M'''`%HT$+>[&=*1=VXE\9WM$>CK8'CM(UWD2$7^% ML^<;I[?=RFYAI3W$@W-NK;[>=+J!8JIRJ:B\I$*\RG&^_))^$.$1O:UGN#54 MT3[,B)S)+16*]^FNU:T+Q<^HMGP`)R^I$D39U1>H6Y'O$TUX)XWDFRO+E+NI M1?"PG8.MO1J?]@IU_[.D7H>RS'::C]^V?X-M2XBOGY7D`Q4LEU^CG1"M5HQF MQ(I^NFYA=/*MC#_PQZHL9$Y4S)T`4`68M9)$+):2KD_!:`%&CA,"50G0:5D" M9*Z;T['`M/`?+E#6KCZ3P"Z3^>C9WEI;,S.$14$:E?4I!'R$/K5S;7PN0.6\ M7\O19)0,DO:MX!)A:5`%*`<(TS#6@W]*S$I.2:O@]NP1QD^&Z8STC"']EF/P MA](0">.8=+!&D$JQ^*2@\Y$LKA(3!1S_OR-"6%4E3[QQ!M/"V`S\U[[WQ_5Z M._X!``#__P,`4$L#!!0`!@`(````(0!9B2'8@0L``'-H```-````>&POY.M^M][SOCM#&!['`R3+-H;;)ASGO,RS\P<#_;5#\^^IWQUHM@- M@ZFJG?=5Q0GL<.D&#U/UK_?FV5A5XL0*EI87!LY4?7%B]8?K7__J*DY>/.?+ MH^,D"H@(XJGZF"3KRUXOMA\=WXK/P[43P">K,/*M!`ZCAUZ\CAQK&6,CW^OI M_?Y%S[?<0$TE7/JVB!#?BIXVZS,[]-=6XBYF"Q5\>W+3P]!&%D+#Z`^ M:X9EY[+9P8YXW[6C,`Y7R3F(ZX6KE6L[NR@GO4D/)%U?!1O?])-8L<--D$Q5 MO3BEI)]\6D[5"U5)39Z'2P#QN_]LPN3[WZ1_/OSAPX?^O[[[_A\_.P M6=I,UVY>[/CP$%U%K(B>Z&$Q54T3.$3K]]&M-&!'4C:9]T'? MR91=#$]FV<`-R<3=NJ'!@=NG*!H7FQ]'-R=S9O;(JZS(:/E4/P`[7 MK1==Z+HU_7MDXNL4>7+B`>TX$6-2.=)G7:_DQGO7=V+ESOFF_!3Z5H".I8,: M^S8W)G.)=QSQ7`ITK^+(XHOD)9%EM!LLG6<'5W.= MN6D7P1`03`;CR84.0/K&F*DZ*8(!`!@-A^.A-M$-^)^Q__$1=.W3H2H[J@2! MI*@2!)*BRE8/O0Z8/^LI4$B1W%<)`DE1)0@D1774,0./I$>5()`458)`4E19 MS:O#O@H%2LE]E2"0%%6"0%)4.YM\9@P\D1Y5@D!25`F"4T_O6VOBZT:89VZ"*,E7$G*+X]H!JP1TW/75YZS2F!%&KD/C_@W M"=?P[R),$KCN-O+6^1_:UK"E2FX"#55DT?7?@)E7.$C]4VJ MXE@:"M8S<#5AC(S^R!CJ%^F"K2/5OK-T-_ZN=87NO7D);D3?-AM.?!@42K)T M*(MO/8Q"%C[!%BS4+-*"#2`G\I00;-&%C64A6M1&TD+,1M)`T$;20M1&Z#K[ M.E?NR66X@8NBVP$VS7&_G];\1/74"R3`]V3,?A"DS:X_&YOL\6ACF[:V`K_L M](V9CB\V.]YC:4.+73L;&NRQLJ&%J(U\WN31Y807I0NDYSU(MOS-??UU,$!1 MVC#'LT6"&3]A=36]&B%,=_O-;11/K`8)[88K81N(DKS-EFMEVIU#:O1575]P^/[[JI@Q0!'N^NIY178^P'84W!J`&ROP+52ZL[?I["`]@(A4 M-=(K&RG6>NV]W&W\A1.9;(\*4\'.8D6]/)JQ:4UY_-%S'P+?865$-17S8Q0F MCIVP/33L,D`5'MAHL=<(+1,D@N<0_4:%?O"3L#\.T0]EJKWV@U^DZH?D$M;? M93[@;J$LJ2$$-*GK\'2)`(H1.0((@@P$N+LI\P&DIPP$L,C+$4""E@@`3DU6 M'-(/-,)FD`.E2M!_+)7`,;F5G,HC6EE%OZ"_QDJ3H]^#W$SX%A*]=#,=+@1HH,XCW64EX5S0 M60*H]\BLPWD(20JD(MD0`(X4""00FJ3Q5Z,8)(W`-!LD#<$4`C<&G[!/T$AP M(Z0D#(!'2J\HYPD:-V*E+]M MGB)NQ[="7C_*\"`SX7#Y*F;Z>T@XJ5V-4C)N^^`G"0K^;@3Y(MU?6S=9PM?(<2=@WB8_Z;WM!WK'_=@,-.PYZPM$]";J2 MAE\5[4IOPBT?MJ9Q/$?PZ3C++E&T2D]!]Y(I)]=Y./?NPMT_Z^S<"+:CBV># M5DER9`H0]#$9+CD?GP1=ARE\9+R'!IM+6?!YQWSU&GB5=(^7!\7QO8H`WAUC MB3J84!;6S@7'^_:,53ECI;.`5X!NP0&205<1%]?33I#*@CQ;E1@-<-L[^57] M\=!,>5]65*4.-X;@[H`CL^"!J=,`]YVDSONR@J9.Y0#::OP48O*#QTO.R]WC MV\WD8F'<7,7GQAR.2=X-T!.,,Z(433.4KO&X#-#@Z,V1&Y<'#7#?&+F]%:XN.JE:^:C;YJM#OA:+P[VC46 M?BK1[9:O.H^W(%Q@W%5^7;,%W#?LLIK]^*UNL.YV M!HD].L\#TNWK`>U/@DI@C9PV68;V%Y#?JS(_U2QV(RCX`T6X8;0 M_=\J9\I'&RFKJ)MK$,C%QO7@!BD8/MPH96]B^&W^+#V9;6VIDU4L/G6<"!%9 M,%BTE57,]73R`*3V\HJXPB!H[+`Y+:RRC@" M0B++`"5M995QA"A069!N;645<320<$I_#05]?[$WCGRNXHX]$5Q45AE'/E<' M@KE*995QY',536Z+JXPC2"7^,N"#MK+*./(\80CR!+6QC"/O^Z&@[[<9E<]X M73#C4REE[.`=\1'.9$5\E$HIH\9G^4`PRU,I9;SX_#8$\SN54D8*Y!&+#/A` MW*(B1@/>NX:@=V?6,F==/F%PG!&!`8\.L#<>/-(AQ`="L!VI.!TF!N$U%"%) MCX[]I,SA!@.%(+X_X#`J(NCV>>U9@96$T8N"NU`+<7S0AX+B_AB&A8]X"3H< MB@#Z$SP^`Y[,H8!?4@_Q.8P[$-N(*?H"[QZ<;[41`ZU3-'S^806GC1AHG8KA M217G3R)B/@7K31$AGDMQZ!81\=D-GIPEGSF\AW4`*2+ISMDDD57D']^E=$'' MW.%M*0H9/$6D-YO.[Z&1S3_OX"X4N1-Q=RSI.SB1%P'^ETU"W(BMB!!=D)?N MW03N-91W8DX$PA+!<1_"SO!"Q!:C",KXFQ4%V%NXKKN5HQ46E?OL8?:_?"YO M4<+\GN`#9MC-2XKU`#AJZ:RLC9?<%Q].U?+]G]E=O""9LF_]Z'X-$R9BJI;O M/^/MT:`70P4!Z.9S#+?<@K_*)G*GZG]O9Z/)S:VIGXW[L_&9,7"&9Y/A[.9L M:,QG-S?FI*_WY_\#E^'3>"[A<2X'/.V&/94'=MIKQF7LP3-QHLS8#/R7\MQ4 M)0Z1R(WIQ\;2@Z_\#``#__P,`4$L#!!0`!@`(````(0#$V8(N MY`,``'(.```9````>&PO=V]R:W-H965T&\42YR5JU=Y`6N0ZN497FU7[L_OK\\S%U'R*3*DH)5=.U^ M4.%^WOSQ:75B_%4<*)4.,%1B[1ZDK)>^+](#+1/AL9I6\,^.\3*1<,GWOJ@Y M33)]4UGX.`ABOTSRRC4,2SZ&@^UV>4J?67HL:24-":=%(B%^<,)]L"\GY'89*VW/IB0%_F*6>"[:0' M=+X)=)CSPE_XP+1993EDH,KN<+I;NX]H^82)ZV]6ND`_ M?0 MD4ILF7T\4Y%"18'&PY%B2ED!`<"[4^:J-:`BR;O^/.69/*Q=$GO1+"`(X,Z6 M"OF2*TK728]"LO)_`T(-E2'!#0E\-B0H]D(8C6'P3D4[P.9')9L79R8&N M`4U1)ZH'T1*8V\Q,'%VNMU*%'!7)HV)9NS/7@2P$K,_;AL3QRG^#FJ8-YLE@ MX/V,0?,.XT,\75`0R&50U\O<:BNPTE9E5\$\F1\NA7!X78?T=53R!)KCOIZZ M:>V"R#F/>-;QFQ`,)M1-=9E8V!>\+Z3`$%!/Z%PP(V0P0R%HJ_$55&`[HX65 MD<%$>FWQG"S".;E1U'B*M`+WI3&VL\(&`^O],!#8=![G2/M18%@@BY+,&ZJ]%W]>,@LL.)I0,-V1\I<1I==HW\W M60WHBM8D=T+&C?IV87=:`VHZ/`XC$M\JKF59]_L+#;UJ.%X-J.WSF_.%)IF7 M1O?7$^-!WL:^6FDO)L%Y^/M--[8: MT-3ALEQNY'`-[8[,!O4PH"L-/\G3D#&L^]M6`[JB-UI:T#MM.&HVUE,!YBCOSD9EY3O MZ9^T*(23LJ,ZUB/8`;M?NT>.1ZS/=]T?<.*ODSW]EO!]7@FGH#NX-?!F8$;< M/#.8"\EJ?>[>,@EG??WU`,]V%,ZN@0?@'6.RO5!/)=W3XN87````__\#`%!+ M`P04``8`"````"$`49:[&I.`_C6/.M\D-U=54+SQ^_EP?GFZJ;HCHNW6#FNXXZYM6F M..Z6[M]_??Z0ND[39L=-=JB.:NG^4(W[\>7GGY[?J_IKLU>J=2#"L5FZ^[8] M/7E>D^]5F36SZJ2.\)]M59=9"V_KG=><:I5M.J?RX`G?GWME5AQ=C/!4WQ.C MVFZ+7,DJ?RO5L<4@M3ID+?`W^^+4]-'*_)YP959_?3M]R*OR!"%>BT/1_NB" MNDZ9/WW9':LZ>SW`=7\/HBSO8W=O1N'+(J^KIMJV,PCG(>CXFA?>PH-(+\^; M`JY`I]VIU7;I?@J>9#AWO9?G+D'_%.J](7\[S;YZ_Z4N-K\51P79AG72*_!: M55^U],M&F\#9&WE_[E;@C]K9J&WV=FC_K-Y_5<5NW\)RQW!%^L*>-C^D:G+( M*(29B5A'RJL#`,!OIRQT:4!&LN_=ZWNQ:?=+-YS/XL0/`Y`[KZII/Q#5!`GB623B))T2)311X-5$$?%,I'$0SR>P1"8*O/8L MXNXH'F:G2[;,VNSEN:[>':A@N/[FE.G]$#Q!Y#[+F),A[_^7=LBW#O))1UFZ MB>M`1ANHE6\O82*>O6^POKG1K%`#OP=-8"O6%Z($J:V1O4:7#ES"9?H8&R,?KU!47$T,:24/B#QJ*%2J"T.NLA[)#KU-IIZ<*G M#`D,Y\D0'R\$-=%P96MND,1@(<'B4Z3K*%H,R!8*6ZD5:@@*-TABL%!@?U*4 M^[*CG5AV8E9@*]00)#3$7<6*-%Q$:LP9T>RMH M)\X8LSRB!AF#>.'#CZU8HX(P$H/%N+`9K^\-+69L(?OD%6K.G[SF!DD,%DH` M;8+FZSI+I[ZU48V(T(PLDEIL'MV0)Z]?@&WE1%1+G0[6Z31Q/-N MNT0B\<]E8'/J[CR=$WNZQW:;OY\&F?GU^Z<,F;&2ZK-PBJ<;FT2V9\-PWPP)LY':>SBN`(]Z(*%?? M_\G)(&'C6%(W&U5WYNFHV,\MU/'.($W?+"E:TM^C#KSX)(SX_S#]M:,NCE_%P:Z$8^'1K;OP4=GQN&*00R M(PPTM\CNXTT16\D4D^9(I[XU1XR(%.;((JG%YGEHCH@+"';3-)O6Q26)7I*RJT%SL6C,K0B"@IND6F'=\J0QK`AF93Y7J_%N-ILN#5 M9S24E8\7234VSJ3Q(7`.7&_71D1Y1N.#:FP>-C[N:]?ZRSM?TV3!3C%&1+G0 MS?1`N*V40%^QO23ULDD?&BSBPF!)V6>NC(B2]H.E_Z(LJ<;FTEV;]+D;!88] M_L:*DD&`_4UPBZ06FTMOF=$A'2P MW#=^!SD?OR$;*]?+LE,SV)2GU8@HK#5.\*3`]C-ULK/ZT#0)+TR3E-7<01X"]GWF'-B+* MA6Y7.S3ULDD?FB7AA5F2\EM#1D1)T:T_'PB^FZF'3?G0'($;_N.)QTY.*R.B ME.@V],OWO1-?P$'HL$Z/)#X)/2-3V9? MPX.*[JZ^-_P#GA.'_+5JX0E! M]^<>G@@IN&7LST"\K:JV?Z,[S_",Z>4_````__\#`%!+`P04``8`"````"$` M2B+?_/P%```G&@``&0```'AL+W=O,F M2F_B^,L_8_[DB$,S#Y^_EV?O6UXW1779^&PR];W\DE7[XG+<^'_]*3\M?:]I MT\L^/5>7?./_R!O_\^///SV\5O77YI3GK0<9+LW&/[7M=1T$37;*R[295-?\ M`G\Y5'69MO"V/@;-M<[3?1=4G@,^G=5L`H@T^/#O@`':MJ].C]L_">V M3OC<#QX?N@GZN\A?&^MWKSE5KTE=['\M+CG,-JR36H'GJOJJI%_V"D%P0*)E MMP*_U]X^/Z0OY_:/ZO67O#B>6ECN"!PI8^O]CSAO,IA12#/AD<]ZTLE`I?2][:=JJ_$>+F$FEDW"3 M!%Y-$A9-9CQ:+#^2)319X+7/LIKP9<2B^0?&,C-9X+7/`L,::00L=[.QL()' M#R'04]NM5)RVZ>-#7;UZ4/XP>T&'1_FO-8+%4DB>5 M9>-#/(0W4&C?'D.V>`B^07%D1K/5&O@Y:!935[*C:9BKB'N%*A;UR:('MZPA M6[I!LM?T08D&79T$,`_#9,!BV)-QOTY[STJL//=9MQI`[IM!-/P=E7!WK#%5 M+%`2024A6[EIY!T-1[.=4`V?#6F<>8&J'S\O2@Q%9$U#R)&%K=;,AKG;81!C M(#"0&"06<$8/3]OXT2OQQH>I&18QO$U*5W);+;$&K\&RJ_L%;`C3*9KJ&(<( M#"0&R5M)'7NP+]CV^B?X[>)50<@F1Z6XU1K+IP91YY/QV6Q.C>(8@8'$('DS MJ^-T3IW.(/IMIRH(.PV',M"/1$LL/!C$&`@.)06(!9_"KCPQ>B=_;!K7&&CT&,08"`XE! M8@%G]`S:^OBY[]3NY(<<%?C6B"P#A,2$"$*D(?H!G*U"LJ\D=HSK2O7RT17% M=.=WMG>.'O6M$=FN=-B-Q$0C")&$)#9Q7:A>/-Z%[MS0[VY-BK18ID6W,>\( MB0D1A$A"$INX+E0'MER,:T5,]VUW3=`1;FM$MANKW7>[>$PTPA!=5PNVH)U9 MDJ#$)JX]U9(M>V]O7DPW<,<6WHV-QG:%SP$QT0A#M*MPQ5?D<9$D*+&)ZTKU MW_&N=+=V7'%T^-RJ[WBP]]FV>J*^&N##$9$+0B0AB4U<0ZJICC>D6[!C*$0C MW#*K3W>UMB,D)D00(@E);.*Z4!UTO`O=;]_9$:RF;%Q@$C-,!"&2D,0FK@O5 M2BT7(W<$W8"=->%D1["ZM'.SN" M[LR.+;(C6-W;N,(D9I@(0J0A9H^8A_=:JI7&<<4_=%#HU/B@@'<$([)VA('< MVQ&&/PXG3D(D(8E-7$/HC*"J\/TO#OS.62'$YT\CLHV1LP+1"$(D(8E-7#=0 M0..+CBOU>^=0([)=Z+`;B8E&$"()26SBNOA?9P5^[ZR`O[<:T6WL.T)B0H0A M^HF)V)R1?4"2H,0FKCUT5AA9IV.@'QH:K:_HWZ@.%?/(__`@``__\#`%!+ M`P04``8`"````"$`0L%5(:8(``"7*P``&0```'AL+W=OGINJ/JZ#<#H/)N5Q M6^^JX^LZ^.]_OOZZ#"9-6QQWQ;X^ENO@9]D$OSW]XY?'C_K\K7DKRW:B9S@V MZ^"M;4\/LUFS?2L/13.M3^51_^:E/A^*5O]X?ITUIW-9[.R@PWX6S>?9[%!4 MQP!F>#B/F:-^>:FVI:JW[X?RV,(DYW)?M%I_\U:=FLMLA^V8Z0[%^=O[Z==M M?3CI*9ZK?=7^M),&D\/VX8_78WTNGO?ZOG^$2;&]S&U_\*8_5-MSW=0O[51/ M-P.A_CVO9JN9GNGI<5?I.S!EGYS+EW7P)7Q061+,GAYM@?Y7E1\-^?^D>:L_ M_GFN=G]6QU)76_?)=."YKK\9ZA\[`^G!,V_T5]N!?YTGN_*E>-^W_ZX_?B^K MU[=6MSO5=V1N[&'W4Y7-5E=43S.-4C/3MMYK`?K[Y%"9I:$K4ORP_WY4N_9M M'<39-%W,XU#3)\]ETWZMS)3!9/O>M/7A_T`*<2J8),))8JT>?Z^AD8,3'*S_ MO0S.IDF4+I8C),S@=FQU5-$63X_G^F.BEYP6W)P*LX##!SWSI2QP$UVA/JN3 M+I"9Y(N991TL@HDN0:.;^_TICN/'V7?=D"UR-CXGY(S\PC#5-],J`/1W-VVX M[`;-]"UT]Z'K2.^COZT7N89LY%XNM`&`7BCJ+F.EY#YC(>0KGQ(EW2Q,K.[_ M>+&&K%<;+4+LYK7J-L"QVP?D2D`1@$G1/:=23/]CO;F&ZV<&K0-]OZXO<=K= M*D@"SM(NAFPQ-U^D[FV9*D1*$0C M'9/,%ZN0CF&J,ZYZN**&S-7&<<;KM0%.8N5*G?`[N)5%NJ*B;#O49;#Q2+IO M])Z]O;9FD%2[$&J!@XKFOJ(<"*2T!&`23003BQHNI"%S:2NY68#B+IQ+0!&` M*5G=HL20K^U;X!`I$E`$8%)"O4EI5<9M7#N*ER>.G:/"SD424>4AJD.,U[O% MR"4:^Q[=N!#,GIO*2BPJ),&J"I?+5;QT%P?G0XI3KRC"!1K''B\0_)T*7'D9 M!QQW\3R4B*((EV,\>KP<<'3]G9BP7.HAL7TLCT04Y7`]QH^)GI%+#%R06\G4,>'G=`5!RM*+-\B*B0(UV>L=[P^,&JF+Q&'H4U( MW!SU2$11#M=C#'B\'K#K*SN!>#KJD8@*"<+U&!<>KP<\F]?'6V#$V%&/1%0( M2.=VV:<++!)I,+P#+%ND@'/.DY&R'#[1%%$5;`2$3!."NQHZ1.:;E( M;I_`ZA?1DAS^-V MZG7@^II[B.H0>TZ:AB8CR-=GU35&3:I[93N#K;.J>@\/$?%^\!L/48A`5<53 M!._^37D1]>6%?%Q`$BVFEQ?(`7UQ:NK891[79XR`)QB*(<7CB]2&XHG&%?RXT82.[JN8&%U;([V\P&%.H4($&AEFR4`C[\J+N"Q,+PC8R"YJ^<>HBC"]0CG'^=<<4\"I"Y;<&=Z"8##G%*%2-?0-,[< M-%RHB("10ONB0)Y48FG\N8HCKD MIOR/14Z,+"Y$`>0Q'@ZR?MQ?;2C1'RE\K$'252G#!!% M.;QN-\5%`DDP['I(HGI@F$,4Y7`](AVN]+$G%?P^$L>' MB4B)D7V$(&#K+95F9Z=F^]%#%$5XW41:7*D;!,"5/GHID4A$483K$:%P14]/ M&*3R:3#QPL!#%"*X'_4S:S8G'PMSA7?%0=(3!ZF,`R2Y]9Y[B.H0$P?AU"T& M+O(N^T_Z[-^E(AP"D$1%PC"'J(X#F?791P"I"(-QF\*.DN8F'[*0Y#3E'J(Z MQ);R$P-.14",U-@3%*E\?K!3LXWK(0J1%%;F?/K)62KMB0FSYX>WCQTE*IFY M.D"_D40KZ<4$8\LZ.$4.^/3DBB0KW\0`X('?S4)Q6! M,K+O/<'B':/MU+SO7K`@!PTILE*=7?"2WA4M>D5Y?\,@)W7L/9!H226B<"+\ MH_+8SZ=2D3LCRPM!PO(PD^=3.S4OKY<_R!FS8$4@&:$C=E9/,&7R`)9ZP>0A MBB*\ZR*&KNQTB)_AX$Z!1+LM$44Y7,]=B9/V)8[S.%R%,E]R'.:4*D1PO\R7 MJV09.[]E2K.[4L>.$A;D[1EY+KLKANPH*=H=&:"\2**BO><5 MY*!OQNEB13X>YM6]*XDRB!2^L>5!#DE4*`QSB*(0V6:Y#C,*34O2IJ)H*%9N@P35VW0">]!PIM^A_+\ M6N;E?M],MO6[><K(0?VOIDWR]\KEO]0J3][YM^`;;4;_;-IYK\4M?M MY0?S6E+W2NW3WP```/__`P!02P,$%``&``@````A`"@G$9,]#@``O4T``!@` M``!X;"]W;W)KGKFW^^IHLKW,X#1O#2=JFW^VLWI?;I_7[RWWW/__^Z8=9M[,_+-Z?%F_;]]5] M]X_5OOOCPU__[W]\G6U6>QOMA^K=T2> MM[O-XH`_=R^]_<=NM7A*C39OO4&_/^EM%NOW[K&'V]TE?6R?G]?+5=@NOVU6 M[X=C)[O5V^(`_OO7]<>^]+997M+=9K'[]=O'#\OMY@-=?%V_K0]_I$Z[G7]^UN\?4-^_U[-5HL2]_I#]/]9KW<;??;Y\,-NNL=B=I]GO?F/?3TT MQAY$V3N[U?-]]TMU&ZK^O-M[N$L*_7>]^KYG_^_L7[??_[9;/_UC_;Z"W!BH M.`1?M]M?8^K/3Q%"XYYI_5,:@G_N.D^KY\6WM\._MM__OEJ_O!XPWF/L4MRS MVZ<_PFJ_A*3HYF8PCCTMMV\@@'\[FW6L#4BR^#W]?E\_'5[ON\/)S7C:'U9( M[WQ=[0\_K6.7W<[RV_ZPW?SOF%3EKHZ=#'(G^,V=5..;*?9[.$4G)QH."EL8C*J`C]L4)4@CSD)N\:2AI)SW20U MLG%$,$1'ES.,R8EAZ?M4$"1\2VXZE2NT(?M=[2%F(WDE5&L&$FTEB)U"0U(G%$ M$)U+HJ+LVKIVJJ.U"FX9DM4SU7HU M666G0NDK[92D&[V2T3VC5W96KE>&N%X&"O#K5'H.@6B%C$`Z`8_2Q*7MT1:M M6M5W@:1B,ZU8;DC[$*@A1)2*1?]DA,\HEMV6*Y8AVEH=)V^1.4%!0))`=$Q& MX/H*R];+N65(ZC77>C595&$U5631:)P2'**IGHYIVS!G%.&J&+JRD!!0(+`0'EW M+*+9/%XNM#WJ4D]RQ`J$46*"J9E<35F-8`*2?%OY^L#Z>H&H9&H+!0%)`LK7 M3U?1P)IW@605J?ED35DD2NXK,9>7$6#[,&LB@K$JLA"04"2@&/>5U:1 M]>Y!X\J\BO31@4(\BJ*).2,6;?)R`ME4 M.8$,R2K2L^Q!DT6B<$B*$LWTCFG#/$J,E`8<$@2B#;)"*0IP!6S[4&V M6TXM0]@V"@"3;5M8]L-9=(-I:;:$@($%@J*S[M!.E;&G/!9(U MI*?=E-74D(`DIU;V/+3V7"`FBH6"@"0!9<^QAH:S:\YG0VO=!9)5I.?=E$6" MY;[27DF^K:Q[:*V[0%RPG$50$%F2@++N,U5D[7F8(5E%>FI-621*TQ"0Y!1] MDQG!&4[99=GA/LP0*5!;*`A($H@FR0C$*AJ,K[AX&V:WY=PR)(M(3ZU+0]J# M("!)-UHJHWM&KYBMG"!#M+5Z:*`@($E`.?<9`M:?AQGB13349S-*HAIJVID: M:F7/0VO/!>*:Y"R"@L@2FHR4/<<:F@QOZ*;XQ3>54T]RP`J$0:+SV51?BE!6 M(YB`)-]6UCVRUET@4J>V4!"0).!8]U5W3$;6N0LD]=)7(I1%>GWJW*-6SIVR MU1@:FZY+%DD8!"3U4LX="^PZO:RICS(D]=(7*91%>C4-]0$9;_M?;E(I6^EE M3;UD<;UXEM1+F?IIDQI9YRX0-ZEJJB]$*(M$R7W9ZX!1=-F+G3ME*U%B!X#8 MA4C)(B@(2(JBG/OJ,]W(FGJ!9!%I5ZJGC[JQM>X" MR:-.7Z50%HF2^[)'W;B5=:=L-5#6NDL6Z10$)$5QK/NZ^R5CZ]T%DE6DKU(H MBP3[U+O'K;P[92O!N"NG9]IUR>*"\2PI6'30BWURG/V6S;H+)*M(7Z50%HF2 M^W*J*%KOY9QBMA(E0Z1`/390$)`4Q?'NJAI=,\4<6_D).68U:`I)D M6UGWQ%IW@4B:VD)!0)*`LNXX-XA&WU8MZ^F3#(G:FNGI.&616DU#0))L*T^? M9`-G#E$@KI:Q^2"R)`''TZLK[EY.K*,72,JE9^.417)]ZNB35HZ>LE7!9>UX]\9QD@^9#F2&IEYZHEX:<;M/0E!?ZXG1/3V,F,5OI ME2':6EVR"`H"DGHY9G_5+:F)M?H"2;WT1)VRJ+X^M?I)*ZM/V4HO:_4EB^O% MLX1>4V7UIP*"\2PIF&/K5\Y)I];8"R05T[-XRB+% M/C7V*?IJH5C,5HIEB.2I4Y_((B@(2"JFC/V,45GWGF8(NT@3]9F>J%,6B=(T M!"0YM7+O:39A=@8N$"E06R@(2!"8*?>^^MYFZD@.6(%$$%6SC[+!LT.R0+- M&,V<15`069*`X^P7*69M?)8AKE@#G53,S:*)JB0*2-=!)R=PLFL9*QJU\?V9]OT!T#-86"@(2 M!.:.[U]UE9,ZDI91(`PAG2?G>GY*68V-"4C2;>7[<^O[!6)Z62@(2!)P?/^* M6S1S:_H%DFKIR2EED5J?FOZ\E>FG;#6"UO1+%@D8!"354J9_^BB<6ZLO$&R( ME9">?U(6B9+[LG>1YZU\/64K4;*)DP)UR2(H"$B*$CV5V>25=_GFV9J9?Q9( MEI">F%(6J97[2OPEV>B_C.R9$8S92JT,D33UW$!!0))`M%-&(-VV&@VN66`V MS\[,%$<]N4IU@H>S]=[NENLZKW M!N.6->BKJ6C-TI@\V8/:RO&K?O9W9A,-1CIA!,UY`-IQ3&FG;/]< M:5E[K_H9DZ5%L_$B3Y/&Y.&8(A;MF#GL.6(Q79=6QH0\!H,\'%,L')^O)GBQ M'8JV?/Y5]:W1-Q@8,*>G:7G1KCDA,.TXIEBW,OOX;0*KW1%+U7;L_/CY@>/+ M\IO5[F55K][>]IWE]EO\M$`4\>&NP8]?/GC$_L5O'Z0K)QL;Q%BZDK&Q88RE MM[IM;!1CB9F-C6,L?>3`QB8QEES,QJ8QE@I%Q^9HALD)A#<1-,(4P8M@MW$N M]B)S1-*W('1O.`U%#NE3#S:6OB&1OKB@8W,TPZ6)MRTTPC6#%X'TF+-[$0B/ MF;,7@>R8TGH1B(Z)I1.9@0'N5GD1,,"M(B\"!KAAXT6P'=R8\"(8"5R`>Q'H MC>M,)S)%;SB,O0A&'#>/O0BV@UNX7@0CCGNK7@0,<(?3B^7@1:(WG+5X$6N.IAQ?!:..1@Q.9H`T>?WL1M,'39R\" MK?$,V(M`:SR!]2+0&L]!O0BTQE-()S)&&RR4\2)H@T4J7@1:8ZF($YE`:ZS+ M\"+0&@LFO`BTQH(%)S)&&UR3>Q&TP<(U+P*ML7S,BT!KK-WR(M`:BZJ\"+3& MTB8G,D(;+*+U(FB#I:Q>!%IC0:D7@=98SNE%H#4653J1,;3&\D4G,D0;+*]W M(B.TP4)V+P*ML<+!%KCM0LO`JWQ0H03&:`-%C5Y$;3!"VU>!%KC33,G,H36>-_+ MBT!KO(CE1:`UWH)R(@.TP;NU7@1M\-*K%X'6>/74BT!KO/?I1:`UWK[T(M`: MKT4ZD0IM\+:]%T&;XPIK?0ZNH/7Q,9^)0&N\"N[U!JWQ0K83&4!KO/KL1-#$ M;5&A!3Z"X;2HH#2^3N%%H#0^!.%%H/3QBSIF;Z#T\0L4*H)O7'WQ^T(#;QMQ MF#T\'E`._F5T^R5_0TMM^3$>G$Z+1PRC.XH81'?<,83NT8(!3./7:S:,;V=] M+%Y6ORQV+^OW?>=M]8P)<#]=$^R.7]\Z_G'8?F!BC"]H;0_X:E;Z[RL^D[;" MIYSZ<:W%\W9[*']@&'K-A]<>_@\``/__`P!02P,$%``&``@````A`*QVBN6( M!0``TA8``!@```!X;"]W;W)K:>(DJ`-$0'=Z_G[+E"$N`QDR+[G`H7Q\ MRCY5>/7E,SU;'Z(HDSQ;VVSJVI;(XGR?9,>U_<_?+Y/0MLHJRO;1.<_$VOXN M2OO+YM=?5M>\>"M/0E061,C*M7VJJLO2<N'TK/#73=PTBC);(RP+,;$R`^')!;/>?R>BJS"((4X1Q7P+T_)I6RB MI?&8<&E4O+U?)G&>7B#$:W).JN]U4-M*X^778Y87T>L9YOW)_"AN8M=_.N'3 M)"[R,C]44PCG(-'NG!?.PH%(F]4^@1E(V:U"'-;V$UON/&X[FU4MT+^)N);: M;ZL\Y=??BF3_1Y()4!OR)#/PFN=O$OIU+R_!PT[GZ9RRM/_$,14*`S"51#X5D$8_!SYL*<>AN_V MX;$,')Q-+\1'+]LB4$;E3!.;0Z#VS"M M=LJ,SXV1$1/6R>*S('!=ER)V.F+"`AZ&.H:P@QV@ZR)7D3^XMYI,R8=,?4+* M88L831_M`F$04`;WUX@$F_HLC)$1,ZOUF82A3R9?)V^G0V:+.:ASDY"0@XVA MRW.?G`0;Y+Q;7%PVB/%K4N:!)W/8K@-"BD'!&:]6C::TF&?8 MSE:!^HFIF\AL/EL,$Y.N.3J-##V66(/GM5/&/"H0CAWV.`,!^"335#3IK..Y MH0\3;EHZ%#<$(3<_Z-F5LJ+"DD#$8D80E)WT6HV=="T/TGQ_(S!T:/B\F:OG MFPIJ-HYK7SU6.QEE\9"SLZZU=YQ=85"`">-$`<4&PS00=F?=2\/51/J!.&C/ M)(5>IQ%H/%SV";?MIICA3606,,*=ZF8X_LCL=:W?,VL.TWU]$LS)^E8L"81! M*Z\M5$K3\/Z1-+M%@'=HZD8_X9Q8A*))(.&=+#]4"UA?,3`[&P4:<#>]%'#N M#\OW4#%@W6K`/+/Q42"U]H,Y]2\EG%X7)MRC)D@2S!\J##7::'HZ"U"!M*Y' MOT)'?\C]>9_[FXV/`C7>X$K_-W:;W84"#3#3[;^VU4%FAO__('-=WV>^6;4Y@@:8$BF^9K,0Y=L M/317@@EF7+ZDM/T3E=)P_Y%$>ZJ`;U8!KCL\=[U9'U$=$P9R.?;SE%VC[G+C M>-9/&2\)OEGE%0BW*ARJ2)HW%B@HPP6>2>*?*K_49W.O>05GB?7/$YP="SC059L)1'6M@Q+V>S^?8<:RN$,:5GI`ALGY)D1S\QP>&3I[M/W_6[VK3JU M=7.XGXL;;SZK#IMF6Q^>[^=__R47Z7S6=N5A6^Z:0W4__U&U\T\//_]T]]:< MOK8O5=7-P,.AO9^_=-WQ=KEL-R_5OFQOFF-U@)FGYK0O._CS]+QLCZ>JW/9& M^]W2][QXN2_KPQP]W)ZF^&B>GNI-E3>;UWUUZ-#)J=J5':R_?:F/[>!MOYGB M;E^>OKX>%YMF?P07C_6N[G[T3N>S_>;VR_.A.96/.^#]783E9O#=_V&YW]>; M4],V3]T-N%OB0FW.V3);@J>'NVT-#%389Z?JZ7[^6=S*()PO'^[Z`/U35V^M M\?NL?6G>?CG5V]_J0P71ACRI##PVS5<%_;)50V"\M*QEGX$_3K-M]52^[KH_ MF[=?J_KYI8-T1\!($;O=_LBK=@,1!3_`$V<+4^)/"I?4`"IX8BUL;P.2P@N6:\ MQ)ST*<[+KGRX.S5O,]@W$/7V6*I=*&[!H)L2 MRM!+IE-68$I9!Q8L8Y"S"(#&K!K.)"#?CD;GBJF?IMB9\H5N9?%7G"L%L M?,\J(\Z;MR[$(&\_#B*;-R+I=N:\(9>;_(>YZO`G"_KPRO$(%]5 MUC9?1+CYFM9^:!L7!)"H!L4VAW2[)Z25EC2.J7'2"LQ)LY-EA1BC,PT#KLZ$ M<[HB>HZ<0S&8GSN3,4"89)2)*MO@ZH&KC#@C=A"N$.-,TAKGD("J9Y:!?,2V M&)F3[CG"5P`Y,W73]FEOQ1FSRG9W?C9R)+HX3Y[3:(Y0 M7DI53"Y)@1H$SN*S6!#>NPC!AJM![A3JR8&:G<,QZV)L4EZ8I'25C)A.%T4' MI2@WA!44#H23&QP.!PH0&@HLF M,2B;83>M]0B&!GA'L?#8<903C(:PZ!269VF.4'Y*2GR<'PH0PH^KT96Z"8:V MK-G$(K72N"80%R+7")ZCOB,4Q'SALI<7[&D,E*PP8C!^?`H4(90[:Z,K#4+N MPJ&&-<#)*Z?65M@*.D_N5_K`R`O>*6NE*Z:S1A5"6;/:7(E!JKQ7]##BZ$>Y MAF.0H-0%:Q6%Y4^:(Y2-$A33V:#\H&RX!A*#1G&L?3TVF>M))*;*WMJ@Z%IO M#0="7O!/.2M]87">V*11E5#N7"V)0;J\9W(8<40CUW"#L$UYL!\\2O,:A)?O MT$3716!OQ321X)I(@W"A(@ICQ^FC,>ZM21PD:NOQW!*$")/0OH2\<`D:!::@ MIF77=R@IP964!AG2XCSBRJZ>Q*`ISO:];G%V<$ZO.4*)0>F993O>;GV%YFGE M6DF#G"E;CTWF8Y/%V*2\,$FI,AEUA:I#/O&>N/(19.9N&''F#B=UI_']E-5" M8?F3Y@AEP[30%38.#22X!O(1=%X>?$ML[:@U`26.ZLL)0J0.)P6!!+$7Q_:5 M)`$M@C1BTI*&@TFG*^%P2":?]8Z5^HX!&J03$V7V?8!N%_::;`H9D\WL,TR*AH/8)A68@TS0(6 MN9Q`$,%H%99?:8Y0=DPX34RQ2T"Q5:P"!&DN,7T&AD\S",2%R#6"9PCOU8GY MPF4O+]C3&"@],WEO!ZA^R-[V^7V>!N%CR(5(,M_NHVL"$H'C<4].(6E_#NB__4%WH:IX/FG=P/@IZ;IAC_@YF1Y?K_F MX3\```#__P,`4$L#!!0`!@`(````(0!1C%+'MP@``,`J```8````>&PO=V]R M:W-H965T&ULK)K;CN)($H;O1YIW0-PW8',H0%4U:O#YI-5J M=^>:!E=A->`2=G5UO_U$V@ZG,W^6*4O3%PWU.3+2^6=$.B/QXQ\_SZ?!C_1: M9/GE:6B,)L-!>MGGA^SR^C3\[W^<+\OAH"AWE\/NE%_2I^&OM!C^\?S[;X\? M^?5[<4S3+L73\%B6;^OQN-@?T_.N&.5OZ86NO.37\ZZD/Z^OX^+MFNX. M5:/S:6Q.)HOQ>9==AK6']?4S/O*7EVR?6OG^_9Q>RMK)-3WM2KK_XIB]%>SM MO/^,N_/N^OW][\NONVXG&_=.8[?;LN_H# MW)^S_34O\I=R1.[&]8WBF%?CU9@\/3\>,AJ!D'UP35^>AE^-=6(NAN/GQTJ@ M_V7I1]'Y/BB.^8=[S0Y1=DE);9HG,0/?\OR[,/4/`E'C,;1VJAGXUW5P2%]V M[Z?RW_F'EV:OQY*F>TXC$@-;'WY9:;$G1:#;VE1.IEP.1SLWXLR/_]9&QF-J]J)V3B9TMVC MDSL-9TU#^FP:+D?FO@HW3T,*$LJ9@E:#'\^FL7@<_Z`,WCA#B(=Q#I(.F!,TK;Z4E3\$_H*-T)?5F;#H".X)B9; M`\)A36M#/31R>NE MIF%C1(^DCM%*-=JV1BRT!<0&X@!Q@7A`?"`!D!!(!"0&DG2)(BL-OH>LPKJ2 ME<78-$0F^!:(!<0&X@!Q@7A`?"`!D!!(!"0&DG2)(ACM0WH()JQ5P1JB/'', MB19TK1'K;`&Q@3A`7"`>$!](`"0$$@&)@21=HFA(@^^AH;!6-6Q()^B`6$!L M(`X0%X@'Q`<2``F!1$!B($F7*(*)XD_?[)CS$05IS^V.<*1JV1#J6BZ"IKZ_ M:8W:>`1B`W&`N$`\(#Z0`$@()`(2`TFZ1)&7=NR*O/$!](`"0$$@&)@21=H@@F*A9%,;'[GE(IV#\B*U>JG(S4F#2U-5): MM4&)R$;D('(1>8A\1`&B$%&$*$:4*$B56VS2N_E_/T!%5:A%**-.B"*R$-F( M'$0N(@^1CRA`%"**$,6($@6I^HE]>0_]ZFT\[1XYLC:B2!:2JB$YU4.RM>*& MEFS(R$;D('(1>8A\1`&B$%&$*$:4*$B55&S4>TC:[.N[DC:H&Y*`+''64`LO M]0/DH)6+R$/D(PH0A8@B1#&B1$&J?F)'WM6O/K\8/=`*6AZS_?=-3DLJ)?*- M5)_2.45S>M'LZ[NR-FC5!N]6E$%"0XFL!IFTPG<>^S,UGFUIQ>([Z,M%Y,F& M7?=SU;TOK=A]@+Y"1)%LV'6O'=O$THK=)XHO=3[$AK\['S=TIZ=;*[PPUYY: M-3)ISCJ2:G7[5ASU4D/3;*?'8B1K>9O1K#Z16DY7L^54FQV'C>JC77'LY#*2 MWCU&TKO/J/9N+&;SZ4+;\05L(YV'C*3SB)%T'C.JG<^FYF2FES<)VU3.U6D0 M-4./:6A*C&[\UTCL1#K3H)7^6Z.QJ@[ZFR.[MB&'B\U6#]4TT(\R*_N+M@UQ MV*8^JZ]G`9Q[:.4SNN,\8!OI/&0D[SQB)*UB1NQ\\0!WGK!-U4R=!5&(])@% M8:XE0XVT9-#/5L3C5$^&MJ&Z#MEI-W?:ACS2F*V:KN?SD:F--&$3997IC%2=1U'Q])C' MID#J9E.-U&R::AILC<9*QJ3%2,:DS8C&+3-S"OG4]LBRN-Q0NO<82?<^H[ON M`[:2#4-&TGW$2%K%C.ZZ3]BJ:JC.A2BF>LQ%4WMUYZ)&:DY-80_:6,E(L^C! M7Z69&C-:9-EL50??1/S&IOS3)MUA>YDZ+B/9M\?H;M\^6WVR[X#M9=\A(]EW MQ.ANWS%;<=^FMDU)V`"?5J9>!M_?-%3FZCK)J+,)1F0ALA$YB%Q$'B(?48`H M1!0ABA$E"E)R0H1RCYRHS#7]A`=":E9J,[CEAE)E"Y&-R$'D(O(0^8@"1"&B M"%&,*%&0*FF_4I?VH?JCFY$JJ;:YWDHK7J8M1#8B!Y&+R$/D(PH0A8@B1#&B M1$&JI*+>_/S*;3;E:6?E9J1*JI<&TDI*"J6NC58.(A>1A\A'%"`*$46(8D2) M@E1)]>KW;Q9.+'/-!LF4WB*R$-F('$0N(@^1CRA`%"**$,6($@6I^HDJLD=( MUD4G5;\<61NQH\.%4R^3I!4WM!#9B!Q$+B(/D8\H0!0BBA#%B!(%J9**HJV' MI'6-ITA:HTKDVG7]$EC]VLHYO;ZFV_1T*@;[_%V\X$73^_S8XOKMLXTYH]?/ M*A=P94Y7JGVE?L4PU^*DCJ8(KDSI2E6H'UHF M;_1C4C^4[3>N+-;T,^`-_K"F7[MN\.6:?J:YP5=K^C7B!C=H''1P?NL*C8.. MA/$*'7ZMQ=$67J%SJ[4XE<(K=.2T%@=*>(7>%_QZ4Q/1_0W[C1#Q%B<);RGX M=4;^;TI(D7+KAC84)W7YTREZBS`OZX'4^[#ZO.GY5[(5Y4QIAU@*%7D9EI7"]]7<<8*JCQ1L1+^ M284LJ(9/N?55)1E-S*`B]\,@F/H%Y:5K&1;R&@Z1ICQF3R+>%:S4ED2RG&J8 MO\IXI0YL17P-74'EZZZZBT51`<6&YUQ_&%+7*>+%R[84DFYR\/U.QC0^<)N/ M(_J"QU(HD6H/Z'P[T6//F(HAHT#CA1-DBD4.$X"G4W`L#<@(?3?O/4]T%KGAU"/C M8`IH9\.4?N;(Z#KQ3FE1_+,84C-9CK#F@'?-,9IZDUDP(I=)?#L?8^^):KI: M2K%WH&9`4E44*Y`L@'C8#QA![!K!D3MS'9BK@D5X6X7!=.F_0>+B&O-H,?!L M,*1!^"#:*(/:]THU"(JU!9HWH$XVH8RNSR:"C7J3SCIB-T';U;3+BW4_ M#N8>A,^7"H[K2M21SI*18-@-E-CU;A#E$-R5JB/'=@B41M_/5:MC!G9%#J&NH1.;B@"J+7S> MD4'WU)``0@.>>GW!=-K9'-OJA34B=4\P6]/NU4.H:VHT7'3DIE9AT#U3MC4, MF>HU!S0UA\6[D+>F2S3[%#N&S5NK)Y#Q"4.XJUOE?D&M[@'M]-6A@54:Z`M7 M&#KN"F2P+4Q.&+JI+\!]H+^3ZE"K>=L3WQZ)!9-;]H7EN7)BL_^9G!78_!01=XL`:I$/KP`&ULK%== MCZLV$'VOU/^`>+\AD&^4Y"H$;7NE5JJJWMMGEC@)6L`19C>[_[YG`(-MN$E6 MZLNR.9X9GSD>C^WUU_;VQW-+8MEL?\D.2GC?W]GZ9%% M)7X6)T=<"A8=*J.YD49+;=02_>"0&/QZ3F(4\?LU87M9!"I9&)?B+ MMY/U0K\55@'=HQ>T_)O M?OV=):=SB>6>(2-*S#]\A$S$4!1A1MZ,(L4\!0'\M;*$2@.*1._5]YHF:B?$HHI&W%KZ+DV;^UD=N$JH-X31!\FR!$X8;#I''`MW'P M1E-OMEA6L]YPG#:.^'Z:KE.G7BD91F6T71?\:J$\D9RX1%3LKH_`4L*:1BOJ MSS2%F!1D1U$V]L*V()=`(;QMO:6W=MZP>'%C$_1M7-UB+RUHI2ALJ``.^+:D MH?7_0)JB$&DY72`!)0N#H;20+J$":`RQN";#">I[N#*EBN2$&M14G.@,@MK& MG;2L]STD5!&-%198976;#1FC*O!1%G5JT&F,4/&*T4PWVK=&K6PJHC%$H,<9 MDG'%4,8-&J1;TWT/"55$FWNNSTU;P9N-8/[)S4!Q=%H-HN^/N:%2:R2S"55$ M8XI`CZM$QCJ=!E%4ZB&ABFAST^%I-HQIU6#O5#;:TZ$55()TS]7Q+&2M\1L3DM5$XU5"%UY/H:7U\^,U:B,SC%1W^M[('"-SVI#&"%XCNVJC&GA` MKY0!^\#S<;WKQPDF/FY8?7PW]7=U-9@3((O!))##8`K(8"B!8.'C6.Y/'+A@ M!/TPXK13XYUSB4[LSZ@X);FP4G:$R..JS17U2ZG^4?(+Q,=KAY=XX53_GO&B M9;A^C^G@.7)>RA\T0?M&WOX'``#__P,`4$L#!!0`!@`(````(0"G5,L^O`L` M`'DU```9````>&PO=V]R:W-H965T?:2S;1`-R`'W,M]\L5:7J2(T,O3L/@_NGS+]* MF75E"1Y^_WD\#+Y7Y\N^/CT.K=%D.*A.N_IE?WI['/[KC^"WQ7!PN6Y/+]M# M?:H>AW]6E^'O3W__V\./^OSU\EY5UP$HG"Z/P_?K]<,;CR^[]^JXO8SJC^H$ M5U[K\W%[A7^>W\:7CW.U?6FQ/9G,QL?M_C3D"M[Y%HWZ]76_JS;U[MNQ M.EVYR+DZ;*_0_LO[_N.":L?=+7+'[?GKMX_?=O7Q`R2^[`_[ZY^-Z'!PW'GQ MVZD^;[\_PC/^Y=L?ZH@VI`GEH$O=?V5 MF<8O#('SF'@'30;^<1Z\5*_;;X?K/^L?4;5_>[]"NJ?P1.S!O)<_-]5E!Q$% MF9$]94J[^@`-@/\/CGO6-2`BVY^/0QMNO'^YOC\.G=EH.I\X%I@/OE27:[!G MDL/![MOE6A__PXTL(<5%'"$"GT+$FHPL=S)C&CU^KO"#3^$'S>BQ![6FL?") M]^EWF`D'^$2'FQHV%W[P*?S+>?\3P;!J6@B?>,/Y;9Y+X0F?Z'E3 M4RWH,LTMV1_"TQFY]G2^:%+8$TX+D\_^P)O:MS77@L#SV\J>PM[`]Q M5WMD+Z;6]+/^8F&'87]@@Z%CW^2+G8>-#NG[U[UTS$=*,_`VV^OVZ>%<_QC` M;`;!NGQLV=QH>4P,AQR/=#L(_VH,PN!C*L],YG$(/0R&UP4FCN]/CN4\C+_# M8-\)FQ6UL72+-5JPDBMO`,,?PK0G9$.(3$A`2$A(1 M$A.2$)(2DA&2$U(04JI$"R[,4UIP^X/*K&%6@0]E3G"-J`HC=>*PW:5NM&Z- M,/0;0GQ"`D)"0B)"8D(20E)",D)R0@I"2I5H@88.>T>@F743:`S/BI.I*_LJ M(1M"?$("0D)"(D)B0A)"4D(R0G)""D)*E6@AA$W2'2%DUGH(.;&;_6JS%JV% MS;(-ZH83!S8Y;0^WI\:\X;=&F)V`D)"0B)"8$TO>/FEMU-L;2VK:&N'M,T)R M0@I"2D[X[;5`P]#5`LTW$".VM;R^[W=?5S7?<7=,%@YL%/CV@8GH\>=$C;^P MD0'8"!L]_L:JY[=&&("`"(6MC1I)8_L2M48H%!.AI+51A8P6I:T1"F5$*&]M M5"&C145KA$*E*J1EB57(ZC:O(QM0WF`ZF+6>#DYLV-0H7=V8S-?"R)8C1!"Y M:/J<.')!7$JU2]M*A"S[LCJLQ:CRHGK*Y4 MHCHU5C]A-)-1[7)SC&3XW,BQFLVXM9Q.)L;,%!#A\!;A2`C;C?#<<8AP3(23 M6X13(_J(W"8E+@U<0'5"=))C,T+$)H+O3W.J$U.=!)VD3HI( MZ"QH(JE.CDY2IT#$=2R+=K52$](SQPHP=K4CM%HTVHL)#6A,M1/T MZM5.T8JW&PZ7.K).8I*C5Z]V@5:\WO`"JU@C9?=9[HP^YW0DB<# M&^F(?=BG**`HI"BB**8HH2BE**,HIZB@J-20'GA64MT1>%&!J:-;+QL*W:L M"/&#.@G1FJ*-1&KW-HX"?&F%6@%%H42*ULS83432"K5BBA*)5"US3R^M4"NC M*)=(U3(&>B&M4*O4D)X>F#GO20\S-W8B'&GI(6AC$>13%%`42J0^LU&F1M(* MGSFF*)%(U3+*HE1:H59&44Y105&I(3WPK-92Q\6O[2]$Q:8.%XZT?!"T@=F( M)=*6@\JG*!!(T0H%*MUX// M2C(U^)\LL+R"TR8E4=3!NB]7TQG9?[=6^#0;2R"Y3_41\?TWO*RR+;+Y"="( MOVQD;S="1+!DRS:8&\)(6$')S';E\()(7_%C5)'""2+9QE1768[,[46&/E(F M1]3;O@*M^-//W*GENL;P+M&F$=>G*!5E(KI"A"U*L5 MHY742BA*$2W:UF>(I&-.48%(.I:(&D<]%ZQ6NGUS1&848]%J8GK^69E]_^>;U&\ MJ_GFB$T!?W@86:,4?WYE8\YD9R%(3 MUS-\WVD#&Z#FLL=1DUQ=FE6P:N?IKQG@)%%(RW0XEE$@K-!*6\SFAM5:6LF. M(^3E`N13JX"BD**(HIBBA**4HHRBG**"HE)#>N`A./<$GID;VTJ!9+#6-D$; MBGR*`HI"BB**8HH2BE**,HIRB@J*2@WI(65%J-J7?VWAXZ6L6DS9',&^%'OJ MFJ(-(JB6Y%0U-THN7UJA5H"(?PU8^UHJ!6UQ^&I<>>L2\M?_9--.:I=_Y&S'S?-#>6 M^35:R3E^@TCNA'V!'+Z[:]X4PB*OK[\!^M%7*?`VF3Z7-;WSRQZ-BO&,O'S1 MU]^%T;"U<%1S)Y"Z$4;$MS+.8K&!!R147 MKC3BQI5G>^8]\[0:5V#-]=AJTZ%FS^%*LT@8/G"`#O?IN@)SF<=F*JH&/W9X M;KJ'H;6"'T$T&3*Y#3?OT%G!PW<]^[/K/<,;1'KC%<2D*R0K>(9F+!LW?H;P M/O,"WK@"[S,\=I1+[P&O-;P4WBIT79G!E:[PP@DP7.E2@W<=7M9Y!5YY>.QH ME]X'7@MYJ\XK\';(6W=>@9=$'COFIFKP%LACI]WT"KP,\MBKGJXK,[C2]:1P M2`Y7NM0VX-+ED&ULK)A;CZ)*$,??3W*^ M`^%]0"ZB$G4S7D'1G)RD-)%Z22U+^J$15)8U<_W3-\O#E`N/^;MAAA-K5#R*? M)E&>%=FQU$!.YP]*QSS21SHH3<>'!$;`TJ[D\7&B/AONWC!5?3JN$O1/$G\4 MG7NE.&,FR5V;J'Q@"9YUXKZH9^"-7#O$Q?+N4?V8? M7IRBS-)_N9%12W$1LQ:!*XI8=QW@KU54N-8. MQD"SS?Y@6(6]$\JN/>&*H1YSA-%4(>&*(3L#O1/1J1WA6CO:VK#?MYWA`+3N M.`YJ1[ABQ`<'"T(5PQY_QD-*#@^_ZSR^-P^.#RC*1VXP6@/ M#A`ZH@[;*9G'YM'`VF$W&/87@\2B,=JJN3](G7=)U72+L`RGXSS[4.!-!D,M M;B%[+QHN4\-VXV70-.!_]1\T'E-Y9C(3%0H#6JN`E\;[U#*,L?X.C1[5-C-J M(UG,T8)U-9-=R&`I@Y4,UC+P9.#+8".#K0P"&>QDL.\`'5+;Y!?*X?_(+Y-A M^<7,S!"T"3?%=,_1`ET6,EC*8"6#M0P\&?@RV,A@*X-`!CL9[#M`2"8TB)#, MS[\)6)/,&M[^G9HTC8&8I!FW@<[#+,T)61"R)&1%R)H0CQ"?D`TA6T("0G:$ M[+M$2"&T^!=2R*SAS0"73E]+A3:KC;K-;YJ6F.AY8X2)7A"R)&1%R)H0CQ"? MD`TA6T("0G:$[+M$2"N\K[^05F9=I163,:M)V^!S0A:$+`E9$;(FQ"/$)V1# MR):0@)`=(?LN$1(&BP\A8?R[H[$52'E.HM=9QA=IG[2X!=\7_M5A(F(>:S)J M^YF0!2:*'M$V1>4#DR%/N]/31G*Q-SZ=&;:D^EJ34%[CAJ%\*92E M]8:]]I_<"HW_G;!;$C9HW##L3@S;[VORRW7?^'P>2I@XMJ'[PLQ5YN+4U4AL M&4L:_ARM.CV#B!\SL`W)$A&T=]M^EMPW:-4ZKA&U\AZBULI'=%=^@U:MXQ91 M*Q\@:JUVB.[*[]&J+:-5I)$3"]T;^3BS1 MBG=73S/LMM[9G33I*[3GIS]LAM>(VM@>HKNQ?;1Z,/8&[=O86T1M[`#1W=@[ MM,+8IK3FV*-!%4R<4[;9^L*<\KT9;`FPWV?L[`.FN2)P7=@=4(=9WX5%,'"]<8#3REMXBG=A M?DJNA7*)CY"47K7TS?EY)_]19C=(%IQ99B6<4U:W9SB7CJ%*>QI\_X]95N(/ M%J`YZ9[^!```__\#`%!+`P04``8`"````"$`5Q^/^)(/``#;40``&0```'AL M+W=O M>M\WA^-V_WK;]P:C?F_SNMX_;%^?;OO_^2/^;='O'4^KUX?5R_YU<]O_%P_;W:KXV#_MGFEEL?]8;FB5=B_#\6@T&^Y6V]>^M+`\?,3&_O%QN]Z$^_6WW>;U)(T< M-B^K$_7_^+Q].[*UW?HCYG:KP]=O;[^M][LW,O%E^[(]_=D:[?=VZV7V]+H_ MK+Z\T+A_>OYJS;;;?X#YW79]V!_WCZLIEZ_>'=I]9!_]UN?AR-OWO'Y_V/Y+!]*+>O&_(VQ4E$X,M^_U6( M9@\"D?(0M.,V`O\Z]!XVCZMO+Z=_[W^DF^W3\XG"/:41B8$M'_X,-\93, M#,9386F]?Z$.T/][NZU(#?+(ZN=M?TQ?O'TX/=_V)[/!=#Z:>"3>^[(YGN*M M,-GOK;\=3_O=_Z10.Z*SD8DR0I_*R'BJC5Q0])4B?2I%^M(+\M3:]I8^N;>C M@3^>SA=M=R]HSI0F?5[7Q;E2I,\/=9$F5MM%^E3RWF+@^:.9\.>%#MXH/?J\ MKH,>Y4S[C>*/#W71XZ"+/Z[JI$=I(K]+Y\L'0^UQDH@_/M9-S@Y/I\?8&RRF M4W^VF%_VII@"LJ,Z52YW="@G1CO/PM5I=??IL/_1H\6+?'1\6XFET%L*LSS# M9"S/<^ZOIAS--6'ELS!SVZR"Q`6I"S(7Y"XH7%"ZH')![8+&`$/R]=GAE%I_A\.%&>%P=M4] M`R,"CG=9@E5"%T0NB%V0N"!U0>:"W`6%"TH75"ZH7=`8P/(NS3[PKD]IW7W! MX.P56G1I,+/7']G>NY'0"(@,9`$2`HD`Y(# M*8"40"H@-9#&)):CR1U7.%I(MXYF]]PKHE>'`$@()`(2`TF`I$`R(#F0`D@) MI`)2`VE,8KF0=D)7N%!(VRY4Q+JB^1,G,<]"[/D02`0D!I(`28%D0'(@!9`2 M2`6D!M*8Q/(JN>,*KPIIVZN*&(D))`02`8F!)$!2(!F0'$@!I`12`:F!-":Q M7"A*4W/#=7D1%=*V"Q4A^\:*Z3N)>18Z)R:0"$@,)`&2`LF`Y$`*("60"D@- MI#&)Y56J*Z[PJI"VO:J(D9A`0B`1D!A(`B0%D@')@11`2B`5D!I(8Q++A:+` MNL*'K;CM1$9V;DZ=W-12Y^1$%"&*$26(4D09HAQ1@:A$5"&J$346LKTLZH*/ MSW]1PSJIRLC(540AH@A1C"A!E"+*$.6("D0EH@I1C:BQD.U240R8+A4U[&0A M3H34D<3'RUA95]"FE7/S7AP*B`C823USD_HLQ8JA5F04(8H1)8A21!FB'%&! MJ$14(:H1-1:R(R!*!C,"ER]JXHS$36J%S*0&%+*BEHH0Q8@21"FB#%&.J$!4 M(JH0U8@:"]DN%<6!Z5*1U.*,Y_J<5F6&F=,*V3D]=W/Z+,4)'(IJ3DX&1A&B M&%&"*$64()B M::=YA"A&E"!*$66(EJH(Q$_= M!]Y92B[%:"\Y380]_Q.S]OUU_L].8J$.E:2"=U:DS?W)#IIU^EVQ(VZX87;1=LVW9[X6//FG84&O;CKBH*,TK M^Z^MAJHNU5?W^[%$SG1SSVU82N=PJ-!$YW#$R&\CXZ/S8K23L)*VDS(2Z\3W MNSG:R=!.SDK:3L%(V5ET!%.-7H^K8B5MIV8D[7@>9ERC1&C*TB)I1XZRXF^( MG+#B["LDLF?BU#V=$,VD.-;I&BHTH8).SWUWFD4L-6^#,)Y@NL9H.V&MB[93 MEEJTMA]#*5Y,`84(HH0Q8@21"FB#%&. MJ$!4(JH0U8@:"]DN%;7V%2Z5I3F=SG+^W8\EHCJ248`HU,A,;^+66HH5&PM9X:%"XIKP MM.+V4JV0&1Y$(:((48PHT<@H\V< M,JO04MRO$FU5*%4C:BQ%V_G7U?03K.D5LHN,F5MD:"D>3;*BG*1%%ZT.L2]HV1C*UHPSDCW>[#XLV+-,:MR,IBO>/7UZHMH/Y(I%/"Z'V MXLPM.I0B[5IU)*6B@2*6HDV489G%+$4[;XN MQ0(4$U;4YE-&%VUE+*45:-$G4AD[P;G3F$1:"GV6ZB0K\\R(T;RM,_S M9K0ANG%,Q6@J83V:Q_IZA_&6/?7E>5]7O,]#X4[FVC*C@I$Z[AS,8#L(9BK6 MN=C!FJ7D\"V(++LMBY["NF5/:"ZJ9W@&H6( M(D0QH@11BBA#E",J$)6(*D0UHL9"EDO%!N`*E[;B]FK(B)8:G9ESI_(+M!1G M68@H0A0C2A"EB#)$.:("48FH0E0C:BQD>]D]#KBUE4P1]?<<5VQ$U^B9!OW41LC(*`4972P%60B? MVZ!-OST8$9[QK'U=ZIUQR=V\N4]NC8D74RQG.]5CP%*ZO@D9Z0.62"$ZY15' MU.U3-E0[VF5=S'KX)!'=B]#CHDSYM:Q3FWRCJFOMTA"MT\B%TZ^`IL;R!ZSN??H%*]H\TD"A94PM;3BA M94(M[8"@Q:>6MD/0,J66-MG=%N]F*1[3[NC!>+84SX)TMAX-%*Y$(`.C93>`>K2H?'0RRE= M+30>>L>BJX7&0^\%=+202J<&*73*T_`[1^_1Z.E]W8YO\"@WZ+73KA;*#7H= M$EOH'CMYN4N'KDM+<=5!'?H1M<]=MN[%UW?(W].7=\I3L+IB]=E??I8_TN:& M2F1KUQ=0!#L#2/'K&@`]\+`4]WIQ:/3=[Z:[\$MQC[U#9^)12YAAB*>X#HPX]$[$4]WZQA9X;6=YWMM#C(\N@LX6>(EF*^^!HC1X368K;X=A" M3XLLQ;,@'2TT4O%D0E>+1RU=UNBM";+6I4.O,BS%^P9HC9[L7XKG]K&%GM,G M:UTM]-0]Q:>KA9ZAI^]I6X;GT-%/Z[VMGC;5ZO"T?3WV7C:/M*R.VC<7#O+' M^>0_3NJ!OR_[$_VH'EV"Z&I,/Z*XH=O5(_$&Z^-^?^)_4'>'YY]EO/L_```` M__\#`%!+`P04``8`"````"$``S;]=>0-``"'2```&0```'AL+W=OD2#6[FW$LW[YL=JJ;K6:Q6:(DTK>__MR]#'YL#L?M M_O5NF-V,AX/-ZWK_L'U]NAO^^U]??ID/!\?3ZO5A];)_W=P-?]\__E/ MM^_[P[?C\V9S&B#"Z_%N^'PZO2U&H^/Z>;-;'6_V;YM76![WA]WJA'\>GD;' MM\-F]>`:[5Y&^7ANPC;`X7!)C__BX76_,?OU]MWD]M4$.FY?5"?D? MG[=OQQ!MM[XDW&YU^/;][9?U?O>&$%^W+]O3[R[H<+!;+WY[>MT?5E]?T.^? MV62U#K'=/U3XW79]V!_WCZ<;A!NUB>H^5Z-JA$CWMP];],#2/CAL'N^&RVQA MLG$Q'-W?.H;^L]V\'Z/_'QR?]^]_.6P?_K9]W8!N#)0=@J_[_3?K^MN#A=!X MI%I_<4/PC\/@8?.X^OYR^N?^_:^;[=/S">,]19=LSQ8/OYO-<0U*$>8FG]I( MZ_T+$L!_![NMK0U0LOKI_KYO'T[/=\.BO)G.QD4&]\'7S?'T96M##@?K[\?3 M?O??UBGSH=H@N0^"OSY(-KV99>.JF"'(F8:%;XB_OF%^,\FGL[F[^IF&$]\0 M?WNG/6HI<(R:U6EU?WO8OP]0I^CD\6UEJSY;('"@LDVC(_Z& ML^$`M!U1$3_N\VIZ._J!05Q[GUK[9-RC"1YVQ&Q8$P$CY-LE#<[_@*1M%)MT MN%P=@*@7(L/@$9J8"&`98G!EAI,/*S2P:!NA%B,6LZG@J&Y],C>['$F-0DR, ML*PPP'%6Z?D2LK'.J`K\B0:UY(34WJF,G+*I<&HZIXZV&&$9@J/+,[3.+L,0 MM_8(C6FC$!,C[-KH1'QM.Q5FT(4PF2^>##8.3\LC\?S(IC-.9=,YA=Z8&&&9 M(E"8H3E6O%0"\<0"Q(FJ!%'DU3'% M()ZNU=IH7,]SE;7*#'$(H6L/.81'MAIY>>16487LB+E29]X+,X0JI1Q+`CJO MD*6AAH!XFE8U+T_3:VQ,@(>B+Y62*-\/ZD8+[LQ82V4J!@K?)=']C*)1+M:R"NA M&G7FO7C%Y+)B.B\B((8X`58C+T_3>HMI["$JCR93D&$03\`*7Y3`_U$Q7D+C MT>E4E6C-RD(2UGD183'$\[5B&>7[2<5X:8US:B%=,;D0V_.1G;<;"NI:7@GY MK(,7KYB)(("\.@(8Q`C(>XFL\^85$Z"H8C1D&,03$%KLEOMC@#W7^[E7UFAL M`H0"[J9A5HJ'@(:\B"X?2RM,WDN2G;>@J]7?1+T(K?VD7CH]I:X58W&WJ7/O MQ>M%KH7)BPCH&@+BP]5+8NV=0BA,@.)Z\5X$&>;%$[#B%\U86R_%_)I[4NYE M-*X8#_&*$;?Z)C2,\^T:*L*L?$;Y?C*N7FSCG%HH43%6U2Z/[#40(]M-AF(L M;K=U[KW0GSUD"Z80DCM^5)TWN*65(S%\J0.7G'! M%/*.1$[4?R^QI5VN\_[WDMC"KV>C"1.@J%XT9!C$$[#B%\TK6R]E<4/OT"Y^ MG"R\C,;)>8@5S$P(=Q,:4A<,@WB^O22YT)(<(+I:HR'#()Z`%3]!V%7/E857 MT9@O#W&^A&PUH2'UP#"(IVL%-4KWDVE@O<6D]Q!=K2D49!C$$Q#";0OL.KXZ M30_SJBX\A'Q(P&=BUC;D%1H:!O%T>PEXH07<0UJ0)D*9SX^$\U:"));_=?"* M!2F;":^&O#H"&,0(F/129.?-"R9`3NS:5Z0:,@SB"0CAOOH.-O&J&TVP`/&" MD0I.7L27C^5F`4^WEX)/M(('*)I@&C(,X@G\80H^T0H>($Z8?*H@+R*LDWY` M/-]>"F[?V@M%\E!BA@EI_F2&=?I+XE&,12W4$^_%9YA\JB`O(J!KJ`BP\GFQ M)$^LMYAA'HHK1D$F-$R4;$*2KWO3-=&:'"`D%&FR?*H@+R*L$W-%6"]-GFA- M]I"NF&DO37;>2I/%9*B#%Z\8^51!7AT!#&)39MI+DYTWKY@`116C(<,@GD!" MD[-LKI;E<0),7,>/#ZR>.:2_Y==Z"&:_(<2TIR(2&6GVF5A@C^;/W M=UMY?0GT^AK=W5UD),OJ:"Z7S^1%;/E8B601*T[V_"UE:KT%6QZ*V5*0"0T3 M"22T.KOBC>%4*W6`D`XI]5RNGLF+Z/I0J:>]E-IY"[J\>,=T*^U0'B MI(@U1$->H:%A$,^IEZ*77JLCW0P0,=!HR#"()Y!0]"R?7?'2L=2B'B!.F+A1 M-N1%A'THZB5B72[JSEM4D0T@9IV"3&CH:.6$)43]NI=NI9;U`''"Y`*F#'12D`NP,F+"/!*K9>9LUY* M[;S%H&BE#EY1R3"(CX!0ZJO?.\ZTB`>(%4PEE^7D17SY6%H2[`OWRS7)>0N^ MU!J\"5XQ7[$7YRLAXM=ITDR+>(`X87)E3EY$V(ZGXS$MVK$D> MFD=I*LB$ALZ+)3!/J/@EC+EV?/`"%#%&T#G&TEZT*.4)]U+QN5;Q`$6,:<@P MB"<@Q-Z*F/_^?[[(YEZ8H]$+4$R9]\(?TGU59-0P]J(E*\^XE^[/O(RYAQ-:'HC^WFAV]._ID$GB%C]EJ(8=P&H2: M?Q*YTW":$L58K!CKN?="=Z+I);P:\B("NH:`>)J]-'RN-3Q`5!N-A@R#6`)5 M0L.O*!<7ADMZ@'BYR$4H>75L,8@GVTN_*ZW?`8K8TI!A$$\@H=_Y)+]F`U>E M%3U`,6,X"R=V2)(7,>9CN6[QA'O)=Z7E.T`Q8TK1#?/B"23D^[IE:*7U.T"< M,+D,)2\BS,=*$-9+ORNMWQ[2BE0)83ZO2,[;32C2FF(L9D\=O&)%RN4VIX:\ MB``OR?I!K[**>K$D.V\Q[VT`0''%*,B$AHD1$,IMUTA9E5TUQSI9#QVO*P_Q MDJ$5=GO'):_0T#"(EW@O#:^TAGM(ETPV%NI\OF9:=UDTF1"0NG/C54-KYI:# MR*TC@6.,A6S<2YQ;=UXY'1:53@+#85BO[+IXW*>4N'Q=]90X28J9VO.+5!M+ MIMA)+7DY M#M;[[_8LKR7Q_K;#PU'C\7BQ](>-A(*25GFL+@G M/6F9H[-XR$M<9XZL\2R3LB!K/#:D+%-8W+EJ=1UDC?6T;K.I*M*G04RR'$I82T?""-V&9(1K>I&K+6*)- ML@YF8!1O!5-MP"C>R:4L8!03/F4!HW@ME;*@#O!R*&5!3_$2)&$ID1N^+:4L MR`U?>%(6Y(9/+RD+'K0\J"T<:K?VU93B>+)5XZ:PLV(2P,MABD M+,@-'_I3%N2&#^TI"W+#Y^Z4!;GA:W/*`D;QS3=A*5$[^+R:LJ`2\=TS94'M MX*NCMBPGT`/L%=(6;`-;&&SR2EG0'VRU2EG0'^QSTI;E%**)/2?:@LU#Z&FR M/U/T!P]:J3;H#S;':,MR@NM@MYRV8.,H9X+K8'-FJ@VN@ZV1*0OJ&AL4 M4Q;4#G8':LNRP-S&7EEMP2[[A<$F^I0%U\%6]I0%U\&F\90%-8K=W"D+QA0; MIU,6C"EV-*R9!M8#(YSZC9U!M[:=;R\ M,V7(+4OEMLQ1HS@ZEH@&B\%9OI0%-8I#=BD+:@=GW!(64)#N#:Z"8]FZQ3)# MA>)G3;0%QY_1)GF5#!7:_CB$8@!5@/.].AI^KF69CH4&"?_:=C&%V\F1P)N[=Q,X5;54SC&/3GL&/5DX6/,W9"/.B[P*S!OJZ?-WU>'I^WK<3*I`EJ84JI%^/T M8?;MZ&N:.`^Z!&4TCM-7=.EY_OD3FUI3H_4274(2VHW3I??U698YL<05N&,R M:[)4QJ[`T]0N,E-54N"5$>L5:I\-!X,O&;YXU"661W4KF#:*9QO_OZ*E$8'/ M/:P+.V45=*RG`4Y;Y#RFL<:;RR?6+0,6RKI$178%B;:5_S0@=R\BA6=P.N[[=L3S-AZ.M!XWZGD&A(2%#GW$FO4)W M5TW!^ACRJ,N\I6B(&Z#=*?(+7?)K[:E>_+MN3EN:+GF;P\1H9Y0LP6/)+T&! M%LB+@TP_XL^G\/<0A:=(X:8Y;BI^5].!M=JA]$TB/:K^EGLL_W7+!'JGUD;Y M"7YM,7!M,ZNJ7%CN80#_/^GE$T3C_O/UP?]^0?J>8N MVSAUE*"I#%#K;.]W]ST=7IY]2;M;>KWI33>ZE?K9/=0S-=N^XML^RQ* M:D0[^WZ!W5"GM2J(3):@%UCN?`X-X7-X;'[`_.3T>#`:4-_OK+%L_]?EOP$` M`/__`P!02P,$%``&``@````A`!R$&OZ5````J0```!````!X;"]C86QC0VAA M:6XN>&UL/(Y!"@(Q$`3O@G\(G[GI%Y4)18VL!]&4,2^+)&?!NZWZ^X(2IKCQ:7"9.!#`K/=;K1WR5^" MBZRZ@<5`:&T](8H/E)T,927NS:/4[%K'^D19*[E%`E'+"0_C.&'N`K#:JVK@ M/(&*_0.H]$NT&O\C]@L``/__`P!02P,$%``&``@````A`+8/(7B^CW*YTVWR"QMG&G7/V5(;5:(%3F9I_E52N:;@M!B08O\M<2GUGB?34`]"OR;>`*PP?OGG[,O M````__\#`%!+`0(M`!0`!@`(````(0#X\2[1P@$``,X0```3```````````` M``````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A`+55 M,"/U````3`(```L`````````````````^P,``%]R96QS+RYR96QS4$L!`BT` M%``&``@````A`/5IOGVR`0``?0\``!H`````````````````(0<``'AL+U]R M96QS+W=OJ@4``#06```8`````````````````/8,``!X;"]W;W)K M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)LF5M1T M`P``%0L``!D`````````````````3!H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`,S5ERY%`P``?`H``!D`````````````````T"$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"`F&\90!0``,18``!@````` M````````````WS(``'AL+W=O&PO```>&PO&UL4$L!`BT`%``&``@` M```A`%&6NW,1!@``J!H``!D`````````````````9H@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%&,4L>W"```P"H``!@````````````` M````UKD``'AL+W=OHE,$``!H#P``&0`````` M```````````[Q@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$.PL_OF!0``+A<` M`!D`````````````````N-8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``+Q_Z!Q`@``,0<``!`````````````` M````N?H``&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$`'(0:_I4` M``"I````$`````````````````!@_@``>&PO8V%L8T-H86EN+GAM;%!+`0(M M`!0`!@`(````(0"V#R'-,@$``$`"```1`````````````````"/_``!D;V-0 C XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants and Warrants Liability
 6 Months Ended
Jun. 30, 2014
Stockholders Equity Note [Abstract]  
Stockholders Equity Note Warrants Disclosure [Text Block]
3. Warrants and Warrants Liability
 
The Company follows ASC 815-40, Contracts in an Entity’s Own Equity, as it relates to outstanding warrants.
 
In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.
 
In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,195 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $1.4 million for the warrants issued to the placement agent.
 
We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:
 
 
 
June 26, 2013
 
 
July 15, 2013
 
 
December 23, 2013
 
Warrants issued
 
 
28,394,834
 
 
 
1,645,361
 
 
 
4,320,420
 
Risk free interest rate
 
 
.0109
 
 
 
.0109
 
 
 
0.0167
 
Volatility
 
 
160.94
%
 
 
163.08
%
 
 
155.24
%
Expected term
 
 
5 years
 
 
 
5 years
 
 
 
5 years
 
Exercise price
 
$
0.14
 
 
$
0.14
 
 
$
0.25
 
 
From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity.
  
On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity.
 
On June 26, 2014, 3,855,714 warrants, issued on June 26, 2013, were exercised. Due to this exercise, 2,734,151 shares of common stock were issued and $1,590,000 was classified out of the derivative liability account and into equity.   
EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P,3$W-3DV-5\V8F4W7S1B-F1?.6$W95\W,C0P M.3)D83DS-S4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E=A#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;G,\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DYA='5R95]O9E]"=7-I;F5S#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E M;%=O'1U/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E=A#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;G-?1&5T86EL#I%>&-E;%=O'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P,3$W-3DV-5\V8F4W7S1B-F1?.6$W95\W M,C0P.3)D83DS-S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#$Q M-S4Y-C5?-F)E-U\T8C9D7SEA-V5?-S(T,#DR9&$Y,S'0O:'1M;#L@8VAA2!296=I2!#96YT3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#DR,3$Q-#QS<&%N/CPO M'0^+2TQ,BTS,3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^05!(0CQS<&%N/CPO'0^,3`M42]!/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^=')U93QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q-#QS M<&%N/CPO2!I2`H1&5F:6-I="D@=&\@4V5R:65S($(@4F5D965M86)L M92!#;VYV97)T:6)L92!0F4@9&5F97)R960@ M'!E;G-E(&]F("0Q.30L,#`P(&EN('1H92!S M96-O;F0@<75A2!C97)T86EN('=A2!I;G-T2!I;G-T2!T:&4@:V5Y(&%S65D('1O('9A;'5E('1H92!C;VUP;W5N9"!D97)I=F%T M:79E(&%S2!A;F0@82`D,34X+#`P,"!R961U8W1I;VX@ M:6X@=&AE('=A"!M;VYT:',@96YD960@2G5N M92`S,"P@,C`Q-"P@2`D,"XP,2!P97(@2`D*#$L.3,S+#`P,"D@=&\@)"@Q-"PW-#8L,#`P M*2X@5&AE(&YE="!L;W-S('!E"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q,RP@87,@86UE;F1E9"P@:6YC'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2`H9&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N+"!02P@4&QA;G0L(&%N9"!%<75I M<&UE;G0@*&EN(&1O;&QA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&%R(&]R(%-T871E9"!686QU92!097(@4VAA2!%<75I='DL('-H87)E2P@2!%<75I='DL($QI<75I9&%T:6]N(%!R969E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES960\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQAF%T:6]N+"!#;VYS;VQI9&%T M:6]N(&%N9"!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE28C.#(R,3LI('=A#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I87)I97,@0FEO M8V]N=')O;"P@06UP;&EP:&D@9"YO+F\N+"!A;F0@06UP;&E0:&D@075S=')A M;&EA+B!!;&P@F4M861J M=7-T.B!N;VYE.R!F;VYT+7-T&-H86YG92!#;VUM:7-S:6]N M+"!O"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,R!A;F0@ M;W5R(&9I;F%N8VEA;"!P;W-I=&EO;B!A6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!F;W(@:6UP86ER;65N="X@268@8V]NF5D+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF5D(&]V97(@=&AE:7(@=7-E9G5L(&QI M9F4@=&AR;W5G:"!$96-E;6)E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`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`G5&EM M97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE2!A8V-EF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`S)2<^(#QD:78@ M6QE/3-$)U=)1%1(.B`Y,"4G/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^(%1H92!D96QI=F5R960@:71E;7,@:&%V92!V86QU92!T;R!T M:&4@8W5S=&]M97(@;VX@82!S=&%N9"UA;&]N92!B87-I6QE/3-$)U=)1%1(.B`Q M,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$ M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@28C M.#(Q-SMS(&-O;G1R;VP@9F]R(&%N>2!D96QI=F5R960@:71E;7,@=&AA="!H M879E(&$@#L@1D].5#H@,3!P="!4:6UE6UE;G1S(')E8V5I=F5D(&EN(&5X M8V5S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG#L@1D].5#H@,3!P="!4:6UE M2!A8W%U:7)E9"!T:')O M=6=H(&)U2!M96%S=7)E9"!A="!T:&5I#L@1D].5#H@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,RP@ M=&AE(&1I;'5T960@;F5T(&QO2!E>&-L=61E9"!F"!M;VYT:"!P97)I;V0@96YD:6YG($IU M;F4@,S`L(#(P,3,N/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE2!O9B!C:&%N9V5S(&EN(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE M("A/0TDI(&%N9"!I=&5M2!E>&ES=&EN9R!R97%U:7)E;65N=',@9F]R(')E<&]R=&EN9R!N970@ M:6YC;VUE(&]R($]#22!I;B!T:&4@9FEN86YC:6%L('-T871E;65N=',N($9O M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!T:6UE+B!4:&4@4V5R:65S($(@2!O9B!A="!L96%S="`D/&9O;G0@&-H86YG92X@5&AE(%-E"<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE2!R96-O2!F;W(@82!C;VUP;&5X(&5M8F5D9&5D M(&1E2!E2`Q-2P@,C`Q,RAD871E2!AF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T2UC&5R8VES92!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!R96QA=&5D M('1O('1H92!W87)R86YT6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R96QA=&5D M('1O('1H92!W87)R86YT6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`Q-2P@,C`Q,RP@=&AE(')E;6%I;FEN9R!O=71S=&%N9&EN9R!C M;VYV97)T:6)L92!L;V%N(&YO=&5S+"!T;W1A;&EN9R`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!R96QA=&5D('1O('1H92!W87)R86YT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG MF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T2!E2`Q-2P@,C`Q,R!A;F0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!A M8V-O=6YT(&%N9"!I;G1O(&5Q=6ET>2X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UEF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!A6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!.;W1E(%M!8G-T2!.;W1E(%=A'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`Q-2P@,C`Q,RP@2!I M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2X@5&AE($-O;7!A;GD@;65A2`Q-2P@,C`Q,R!A;F0@'!E;G-E9"`D/&9O;G0@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P M)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`N,C%I M;CL@5TE$5$@Z(#DW)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9% M4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXN,#$P.3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ M-34N,C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO65A6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU('EE87)S/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXP+C$T/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO2!T:')O=6=H($UA>2`R,#$S+"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&ES M2!I2!T:')O M=6=H($UA>2`R,#$X/"]F;VYT/B!A;F0@87)E(&5X97)C:7-A8FQE(&%T(&$@ M<')I8V4@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG'!I2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES960N M($1U92!T;R!T:&ES(&5X97)C:7-E+"`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P,3$W-3DV-5\V8F4W7S1B-F1?.6$W95\W,C0P.3)D83DS-S4- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#$Q-S4Y-C5?-F)E-U\T M8C9D7SEA-V5?-S(T,#DR9&$Y,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4 M:6UE#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE MF5D('1O(&ES6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65E#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UEF5D('1O(&ES6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T2`R,#$T+CPO9&EV/B`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`P)2<^(#QT M86)L92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI M9#L@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I M;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI M9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW,S,L,#`P M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,SDP+#`P,#PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW,"PP,#`\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW."PP,#`\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,3,L,#`P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE'!E;G-E/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,C,U+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.#`S+#`P,#PO M9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\ M+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G(&%L:6=N/3-$8V5N=&5R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`N M,C5I;CL@5TE$5$@Z(#DU)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@ M3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^,"XR,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M-BPT-3$L-#0Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXR+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C4L-S$Y+#`P,#PO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$L M-C4Q+#0Y,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE28C.#(Q M-SMS(&-O;6UO;B!S=&]C:R!O9B`D/&9O;G0@F4M M861J=7-T.B!N;VYE.R!F;VYT+7-T&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPGF4@;W9E&EM871E;'D@='=O M(&%N9"!A(&AA;&8@>65AF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXT,"PP,#`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U=)1%1(.B`P+C(U:6XG/CPO=&0^ M(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I=CX\9F]N=#XF(S$X M,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9#X@/&1I=CYR96-L87-S:69Y(&ET M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P M+C(U:6XG/B`\9&EV/CQF;VYT/B8C,3@S.SPO9F]N=#X\+V1I=CX@/"]T9#X@ M/'1D/B`\9&EV/G)E8V]G;FEZ92!D969E'!E;G-E(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q M-"X\+V1I=CX@/"]T9#X@/"]T6QE/3-$ M)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\ M9&EV/CQF;VYT/B8C,3@S.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D/B`\9&EV M/G)E8VQA2!R96-O2!E2!O9B`D/&9O;G0@6QE/3-$ M)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\ M9&EV/CQF;VYT/B8C,3@S.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D/B`\9&EV M/F%D:G5S="!G;V]D=VEL;"!F;W(@=&AE(&%C<75I"!L:6%B M:6QI=&EE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!A;F0@82`D/&9O;G0@2`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"P@6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q-"P@87,@86UE;F1E9"P@9F5L;"!B>2`D M/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E28C.#(Q-SMS M(&YE="!L;W-S(&%T=')I8G5T86)L92!T;R!C;VUM;VX@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG"!M;VYT:',@ M96YD960@2G5N92`S,"P@,C`Q,RP@87,@86UE;F1E9"P@:6YC6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I M87)I97,@0FEO8V]N=')O;"P@06UP;&EP:&D@9"YO+F\N+"!A;F0@06UP;&E0 M:&D@075S=')A;&EA+B!!;&P@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T&-H86YG92!# M;VUM:7-S:6]N+"!O"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@ M,C`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`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!O9B!M;VYE>2!M87)K970@86-C;W5N=',N/"]D:78^ M(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[ M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!4 M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T2!A M;&QO=V%N8V4N(%!R;W9I6UE;G0@:&%S(&YO M="!B965N(&UA9&4@:6X@86-C;W)D86YC92!W:71H(&-O;G1R86-T('1E2P@4&QA;G0@86YD M($5Q=6EP;65N="P@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T* M("`@("`@("`\=&0@8VQAF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T#L@1D].5#H@,3!P M="!4:6UE2!497AT($)L;V-K73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M2!F;W(@:6UP86ER;65N="X@268@8V]NF5D+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]TF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPGF5D M(&]V97(@=&AE:7(@=7-E9G5L(&QI9F4@=&AR;W5G:"!$96-E;6)E2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6UE;G0@87=A'!E8W1E9"!T;R!V M97-T+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W M:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!;4&]L:6-Y(%1E>'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@ M,3!P="!4:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE2`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`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!L:6-E;G-E7!I8V%L;'D@8V]N6UE;G1S+B!4:&4@0V]M<&%N>2!R M96-O9VYI>F5S(')E=F5N=64@87-S;V-I871E9"!W:71H('!E7!I8V%L;'D@8F%S960@=7!O;B!T M:&4@86-H:65V96UE;G0@;V8@=&AE('-P96-I9FEC(&UI;&5S=&]N97,@9&5F M:6YE9"!I;B!T:&4@87!P;&EC86)L92!A9W)E96UE;G1S+CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!F;VQL;W=S($%30R`V,#4M,C4L(#QI/DUU M;'1I<&QE($5L96UE;G0@07)R86YG96UE;G1S/"]I/BP@=VAI8V@@2!T:&4@9F]L;&]W:6YG(&)E9F]R M92!R979E;G5E(&-A;B!B92!R96-O9VYI>F5D.CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`Q,#`E M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U=)1%1( M.B`W)2<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C.#(R-CL\+V9O;G0^/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@.3`E)SX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/B!!;GD@=6YD96QI=F5R960@:71E;7,@:&%V92!O8FIE M8W1I=F4@86YD(')E;&EA8FQE(&5V:61E;F-E(&]F(&9A:7(@=F%L=64[(&%N M9#PO9F]N=#X\+V1I=CX@/"]T9#X@/"]T6QE/3-$)U=)1%1(.B`W)2<^(#QD M:78@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^("8C.#(R-CL\+V9O;G0^/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=724142#H@.3`E)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B!$96QI=F5R>2!O6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,RP@=&AE(&1I;'5T M960@;F5T(&QO2!E>&-L=61E9"!F"!M;VYT:"!P97)I;V0@96YD:6YG($IU;F4@,S`L(#(P M,3,N/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE2`U+"`R,#$S+"!T:&4@1D%30B!I2!O9B!C M:&%N9V5S(&EN(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("A/0TDI(&%N M9"!I=&5M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P,3$W-3DV-5\V8F4W7S1B-F1?.6$W95\W,C0P.3)D83DS-S4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#$Q-S4Y-C5?-F)E-U\T8C9D7SEA M-V5?-S(T,#DR9&$Y,S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!I;G!U=',@87,@9F]L;&]W6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XR,6EN M.R!724142#H@.36QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E28C,38P.S$U+"8C,38P.S(P,3,\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^-"PS,C`L-#(P/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`Q-C<\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXQ-C`N.30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXP+C(U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE2!O M9B!T:&4@86UO=6YT(&EN8VQU9&5D(&%S('-T;V-K+6)A'!E;G-E(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T"!S;VQI9#L@34%21TE..B`P:6X[(%=)1%1( M.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@ M=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,3DU+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^-#`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XR-6EN.R!724142#H@ M.34E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES M:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS M1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C4L M-S(Q+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.2XQ-3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#0V)3X@/&1I=CY'6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XQ.3PO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^."XV,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES86)L92!A="!* M=6YE(#,P+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,"XQ.3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^."XV-3PO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M'0^/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1( M.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=) M3CH@,'!X.F%U=&\[(%=)1%1(.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^,C4L-S$Y+#`P,#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&-L=61I;F<@1V]O9'=I;&PI/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!,=&0@6TUE;6)E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61I;F<@1V]O9'=I;&PI/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,3$W-3DV-5\V M8F4W7S1B-F1?.6$W95\W,C0P.3)D83DS-S4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,#$Q-S4Y-C5?-F)E-U\T8C9D7SEA-V5?-S(T,#DR9&$Y M,S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!4;R!%<75I='D\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@3VYE(%M-96UB97)=('P@4')E9F5R6%B;&4@3VYE(%M-96UB M97)=('P@5V%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%B;&4@5'=O(%M-96UB97)=('P@5V%R M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!);G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E M8W1E9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!P2`Q-2P@,C`Q M,R!-96UB97(@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E M8W1E9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!P3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M-2!Y96%R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^1F5B M&5R8VES92!0'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQAF5D M(%!E'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#(S-2PP,#`\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E(%-E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA65E(%-T;V-K M($]P=&EO;B!;365M8F5R72P@55-$("0I/&)R/CPO6UE;G0@07=A&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92!A="!*=6YE M(#,P+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV M-3$L-#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I&5R8VES92!0'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7,\'0^."!Y M96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA65E(%-T;V-K($]P=&EO;B!;365M8F5R72D\8G(^/"]S M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@ M,C`Q-#QB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,3$W M-3DV-5\V8F4W7S1B-F1?.6$W95\W,C0P.3)D83DS-S4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,#$Q-S4Y-C5?-F)E-U\T8C9D7SEA-V5?-S(T M,#DR9&$Y,S'0O:'1M;#L@8VAA6UE;G0@07=A65E(%-E'0^,B!Y96%R6UE;G0@07=A6UE;G0@07=A'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!3 M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PP,#`L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,3$W-3DV-5\V8F4W M7S1B-F1?.6$W95\W,C0P.3)D83DS-S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,#$Q-S4Y-C5?-F)E-U\T8C9D7SEA-V5?-S(T,#DR9&$Y,S'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&%R(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#,S-RPP,#`\2!%<75I='DL($%C8W)E=&EO;B!T;R!2961E;7!T:6]N M(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!!8V-R971I;VX@5&\@4&%R(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7S`Q M,3&UL/@T*+2TM+2TM/5].97AT4&%R J=%\P,3$W-3DV-5\V8F4W7S1B-F1?.6$W95\W,C0P.3)D83DS-S4M+0T* ` end XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Preferred Shares
 6 Months Ended
Jun. 30, 2014
Equity [Abstract]  
Preferred Stock [Text Block]
2. Preferred Shares
 
On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $1.40 and par value of $0.01. Each Series B redeemable convertible preferred stock share is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shares shall be entitled to receive dividends of 10% of the Series B redeemable convertible preferred stock stated value per annum.
 
In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013(dates of issuance) and recorded the initial liability as part of the private placement proceeds.
 
On June 26, 2013, the Company issued 4,999,999 shares of the Company’s newly-created Series B redeemable convertible preferred stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $5,064,000. As part of the same transaction, the Company converted $5,491,001 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B redeemable convertible preferred stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $3,804,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B redeemable convertible preferred stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $155,000.
 
In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for the conversion feature that contains a provision that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision). The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds.
 
On May 16, 2014, 188,938 preferred shares were converted into 1,889,380 shares of common stock. Due to this conversion, a gain on derivative liabilities of $142,000 was recognized and $709,000 was reclassified out of the derivative liability account and into equity.
 
The Company re-measured the fair value of the conversion feature at the end of the quarter and recorded $6.7 million gain on derivative liabilities during the second quarter to adjust the liability associated with the conversion feature to its estimated fair value of $33.4 million as of June 30, 2014.
XML 17 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Balance Sheets (USD $)
Jun. 30, 2014
Dec. 31, 2013
Current assets    
Cash and cash equivalents $ 12,550,000us-gaap_CashAndCashEquivalentsAtCarryingValue $ 20,355,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts receivable 136,000us-gaap_AccountsReceivableNetCurrent 8,000us-gaap_AccountsReceivableNetCurrent
Prepaid expenses and other current assets 526,000us-gaap_PrepaidExpenseAndOtherAssetsCurrent 297,000us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Total current assets 13,212,000us-gaap_AssetsCurrent 20,660,000us-gaap_AssetsCurrent
Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of June 30, 2014 and December 31, 2013, respectively 1,119,000us-gaap_PropertyPlantAndEquipmentNet 145,000us-gaap_PropertyPlantAndEquipmentNet
Intangible assets    
In process research and development 12,446,000us-gaap_IntangibleAssetsNetExcludingGoodwill 12,446,000us-gaap_IntangibleAssetsNetExcludingGoodwill
Patents, net of accumulated amortization of $108,000 and $93,000 as of June 30, 2014 and December 31, 2013, respectively 385,000us-gaap_FiniteLivedPatentsGross 400,000us-gaap_FiniteLivedPatentsGross
Goodwill 7,562,000us-gaap_Goodwill 7,562,000us-gaap_Goodwill
Total intangible assets 20,393,000us-gaap_IntangibleAssetsNetIncludingGoodwill 20,408,000us-gaap_IntangibleAssetsNetIncludingGoodwill
Total assets 34,724,000us-gaap_Assets 41,213,000us-gaap_Assets
Current liabilities    
Accounts payable and accrued expenses 1,366,000us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 2,147,000us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Deferred revenue 349,000us-gaap_DeferredRevenueCurrent 244,000us-gaap_DeferredRevenueCurrent
Total current liabilities 1,715,000us-gaap_LiabilitiesCurrent 2,391,000us-gaap_LiabilitiesCurrent
Long term liabilities    
Derivative preferred shares conversion liability 33,402,000aphb_DerivativePreferredSharesConversionLiability 40,791,000aphb_DerivativePreferredSharesConversionLiability
Derivative warrants liability 13,115,000aphb_DerivativeWarrantsLiability 16,871,000aphb_DerivativeWarrantsLiability
Deferred tax liability 3,078,000us-gaap_DeferredTaxLiabilitiesNoncurrent 3,078,000us-gaap_DeferredTaxLiabilitiesNoncurrent
Total long term liabilities 49,595,000us-gaap_LiabilitiesNoncurrent 60,740,000us-gaap_LiabilitiesNoncurrent
Total liabilities 51,310,000us-gaap_Liabilities 63,131,000us-gaap_Liabilities
Series B redeemable convertible preferred stock $0.01 par value, 10,000,000 shares authorized, 8,671,000 shares issued and outstanding at June 30, 2014 and 8,859,978 shares issued and outstanding at December 31, 2013 (liquidation preference of $13,390,000 and $13,022,000 at June 30, 2014 and December 31, 2013, respectively) 1,337,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital 707,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital
Stockholders' equity (deficit)    
Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at June 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013 1,872,000us-gaap_CommonStockValue 1,825,000us-gaap_CommonStockValue
Additional paid-in capital 360,917,000us-gaap_AdditionalPaidInCapital 358,828,000us-gaap_AdditionalPaidInCapital
Paid-in-capital - contingent shares 1,837,000us-gaap_OtherAdditionalCapital 1,837,000us-gaap_OtherAdditionalCapital
Accumulated deficit (382,549,000)us-gaap_RetainedEarningsAccumulatedDeficit (385,115,000)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' equity (deficit) (17,923,000)us-gaap_StockholdersEquity (22,625,000)us-gaap_StockholdersEquity
Total liabilities, Series B redeemable convertible preferred stock and stockholders’ equity (deficit) $ 34,724,000us-gaap_LiabilitiesAndStockholdersEquity $ 41,213,000us-gaap_LiabilitiesAndStockholdersEquity
XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Cash flows from operating activities    
Net income (loss) from operations $ 2,566,000us-gaap_NetIncomeLoss $ (16,288,000)us-gaap_NetIncomeLoss
Adjustments required to reconcile net income (loss) to cash used in operating activities:    
Derivative liability (gain) loss (8,848,000)us-gaap_DerivativeGainLossOnDerivativeNet 5,970,000us-gaap_DerivativeGainLossOnDerivativeNet
Shares issued for technology access fee 0us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 3,000,000us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
Amortization of patents 15,000us-gaap_AmortizationOfIntangibleAssets 15,000us-gaap_AmortizationOfIntangibleAssets
Amortization of note discount 0us-gaap_AmortizationOfDebtDiscountPremium 2,637,000us-gaap_AmortizationOfDebtDiscountPremium
Warrants issued as investment fees 0us-gaap_FairValueAdjustmentOfWarrants 759,000us-gaap_FairValueAdjustmentOfWarrants
Depreciation 86,000us-gaap_Depreciation 45,000us-gaap_Depreciation
Stock-based compensation 468,000us-gaap_ShareBasedCompensation 958,000us-gaap_ShareBasedCompensation
Changes in operating assets and liabilities net of acquisitions:    
Accounts receivable (128,000)us-gaap_IncreaseDecreaseInAccountsReceivable (117,000)us-gaap_IncreaseDecreaseInAccountsReceivable
Tax refund 0us-gaap_IncreaseDecreaseInIncomeTaxesReceivable 618,000us-gaap_IncreaseDecreaseInIncomeTaxesReceivable
Accounts payable and accrued expenses (675,000)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (120,000)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Prepaid expenses and other current assets (229,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (87,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Interest on loan notes 0us-gaap_IncreaseDecreaseInInterestPayableNet 224,000us-gaap_IncreaseDecreaseInInterestPayableNet
Net cash used in operating activities (6,745,000)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (2,386,000)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities    
Purchases of property and equipment (1,060,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (65,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash used in investing activities (1,060,000)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (65,000)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities    
Proceeds from Series B redeemable convertible preferred stock 0us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock 7,000,000us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Proceeds from convertible loan notes 0us-gaap_ProceedsFromConvertibleDebt 2,000,000us-gaap_ProceedsFromConvertibleDebt
Payment of convertible loan note 0us-gaap_RepaymentsOfConvertibleDebt (26,000)us-gaap_RepaymentsOfConvertibleDebt
Net cash provided by financing activities 0us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 8,974,000us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net increase (decrease) in cash and cash equivalents (7,805,000)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 6,523,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of period 20,355,000us-gaap_CashAndCashEquivalentsAtCarryingValue 862,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 12,550,000us-gaap_CashAndCashEquivalentsAtCarryingValue 7,385,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental schedule of non-cash financing activities:    
Accretion of Series B redeemable convertible preferred stock $ 1,337,000us-gaap_DebtConversionConvertedInstrumentAmount1 $ 618,000us-gaap_DebtConversionConvertedInstrumentAmount1
XML 19 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options (Details Textual) (Employee Stock Option [Member], USD $)
 6 Months Ended
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value $ 0.44us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 1,918,638us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 6 months
2012 Stock Incentive Plan Member  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 35,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
/ us-gaap_PlanNameAxis
= aphb_TwoThousandAndTwelveStockIncentivePlanMember
2009 Stock Incentive Plan Member  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 4,200,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
/ us-gaap_PlanNameAxis
= aphb_TwoThousandAndNineStockIncentivePlanMember
2013 Stock Incentive Plan Member  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 40,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
/ us-gaap_PlanNameAxis
= aphb_TwoThousandAndThirteenStockIncentivePlanMember
XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Nature of Business and Significant Accounting Policies
 6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Description and Accounting Policies [Text Block]
1. Nature of Business and Significant Accounting Policies
 
Nature of Business
 
AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.
 
Basis of Presentation
 
The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.
 
The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months and six months ended June 30, 2014 and 2013, our cash flows for the six months ended June 30, 2014 and 2013 and our financial position as of June 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.
 
Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.
 
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
 
Cash and Cash Equivalents
 
The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.
 
Accounts Receivable
 
Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of June 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.
 
Property and Equipment
 
Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. 
 
Prepaid Expenses and Other Current Assets
 
Prepaid and other current assets as of June 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.
 
Goodwill
 
Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.
 
During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management’s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.
 
During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management’s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.
 
Patents
 
Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.
 
During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.
 
Stock-Based Compensation
 
The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.
 
Warrant and Preferred Shares Conversion Feature Liability
 
The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require such warrants and the Series B redeemable convertible preferred stock shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.
 
Fair Value of Financial Assets and Liabilities — Derivative Instruments
 
The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
 
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
 
Level 1 — quoted prices in active markets for identical assets or liabilities.
 
Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.
 
Level 3 — inputs that are unobservable.
 
The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.
 
The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.
 
Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.
 
Revenue Recognition
 
The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.
 
The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:
 
•
The delivered items have value to the customer on a stand-alone basis;
 
 
•
Any undelivered items have objective and reliable evidence of fair value; and
 
 
•
Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.
 
The Company classifies advance payments received in excess of amounts earned as deferred revenue.
 
Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.
 
Research and Development
 
Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.
 
In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. At December 31, 2012, IPR&D in the amount of $5,161,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of June 30, 2014 and December 31, 2013.
 
During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. At December 31, 2011, IPR&D in the amount of $7,285,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of June 30, 2014 and December 31, 2013.
 
Net Income (Loss) per Common Share
 
Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For the three months ended June 30, 2014 and the six months ended June 30, 2014, both basic and diluted net income are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended June 30, 2013 and the six months ended June 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total numbers of shares that the Company excluded from the calculations of net loss per share were 24,976,557 shares for the three month period ending June 30, 2013 and 22,348,566 shares for the six month period ending June 30, 2013.
 
Recent Accounting Pronouncements
 
On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.
XML 22 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Balance Sheets [Parenthetical] (USD $)
Jun. 30, 2014
Dec. 31, 2013
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars) $ 559,000us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment $ 473,000us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Common stock, par value (in dollars per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Common stock, shares authorized 445,000,000us-gaap_CommonStockSharesAuthorized 445,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares issued 187,159,093us-gaap_CommonStockSharesIssued 182,535,562us-gaap_CommonStockSharesIssued
Common stock, shares outstanding 187,159,093us-gaap_CommonStockSharesOutstanding 182,535,562us-gaap_CommonStockSharesOutstanding
Patents [Member]    
Finite-Lived Intangible Assets, Accumulated Amortization 108,000us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember		 93,000us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember
Series B Redeemable Convertible Preferred Stock [Member]    
Temporary Equity, Par or Stated Value Per Share (in dollars per share) $ 0.01us-gaap_TemporaryEquityParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember		 $ 0.01us-gaap_TemporaryEquityParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember
Temporary Equity, shares authorized 10,000,000us-gaap_TemporaryEquitySharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember		 10,000,000us-gaap_TemporaryEquitySharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember
Temporary Equity, shares issued 8,671,000us-gaap_TemporaryEquitySharesIssued
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember		 8,859,978us-gaap_TemporaryEquitySharesIssued
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember
Temporary Equity, shares outstanding 8,671,000us-gaap_TemporaryEquitySharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember		 8,859,978us-gaap_TemporaryEquitySharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember
Temporary Equity, Liquidation Preference $ 13,390,000us-gaap_TemporaryEquityLiquidationPreference
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember		 $ 13,022,000us-gaap_TemporaryEquityLiquidationPreference
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBRedeemableConvertiblePreferredStockMember
XML 23 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants and Warrants Liability (Details) (USD $)
 12 Months Ended
Dec. 31, 2013
Warrants Issued on June 26, 2013 Member [Member]  
Class of Warrant or Right [Line Items]  
Warrants Issued 28,394,834aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember
Risk free interest rate 0.0109%us-gaap_FairValueAssumptionsRiskFreeInterestRate
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember
Volatility 160.94%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember
Expected term 5 years
Exercise price $ 0.14us-gaap_FairValueAssumptionsExercisePrice
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember
Warrants Issued on July 15, 2013 Member [Member]  
Class of Warrant or Right [Line Items]  
Warrants Issued 1,645,361aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJuly152013MemberMember
Risk free interest rate 0.0109%us-gaap_FairValueAssumptionsRiskFreeInterestRate
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJuly152013MemberMember
Volatility 163.08%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJuly152013MemberMember
Expected term 5 years
Exercise price $ 0.14us-gaap_FairValueAssumptionsExercisePrice
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJuly152013MemberMember
Warrants Issued on December 23, 2013 Member [Member]  
Class of Warrant or Right [Line Items]  
Warrants Issued 4,320,420aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnDecember232013MemberMember
Risk free interest rate 0.0167%us-gaap_FairValueAssumptionsRiskFreeInterestRate
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnDecember232013MemberMember
Volatility 155.24%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnDecember232013MemberMember
Expected term 5 years
Exercise price $ 0.25us-gaap_FairValueAssumptionsExercisePrice
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnDecember232013MemberMember
XML 24 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document And Entity Information
 6 Months Ended
Jun. 30, 2014
Aug. 07, 2014
Document Information [Line Items]    
Entity Registrant Name AmpliPhi Biosciences Corp  
Entity Central Index Key 0000921114  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol APHB  
Entity Common Stock, Shares Outstanding   187,159,093dei_EntityCommonStockSharesOutstanding
Document Type 10-Q/A  
Amendment Flag true  
Document Period End Date Jun. 30, 2014  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2014  
Amendment Description Amended Financial Statements The Company’s previously issued June 30, 2014 financial statements have been amended to: ⋅ reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at June 30, 2014 of $1,337,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000. ⋅ recognize deferred revenue and deferred costs related certain sub-licensing agreements. This change resulted in a reduction in revenues of $209,000 and a reduction in G&A expense of $194,000 in the second quarter of 2014 and a reduction in revenues of $105,000 and a reduction in G&A expense of $161,000 for the six months ended June 30, 2014. ⋅ reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $460,000 as of June 30, 2014. ⋅ adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. ⋅ modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $7,298,000 increase in the compound derivative liability and a $158,000 reduction in the warrant liability related to 2013 warrants. Gain on derivative liabilities was reduced by $1,499,000 and $844,000 for the second quarter of 2014 and the six months ended June 30, 2014, respectively. As a result of these corrections, the Company’s net income attributable to common stockholders for the second quarter of 2014, as amended, was reduced by $1,848,000 to $13,555,000. Net income per share attributable to common stockholders fell by $0.01 per share to $0.07 per share. Net income attributable to common stockholders for the six months ended June 30, 2014, as amended, fell by $1,440,000 to $1,934,000. Net income per share attributable to common stockholders was reduced by $0.01 per share to $0.01 per share for the period. The Company’s net loss attributable to common stockholders for the second quarter of 2013, as amended, increased by $(1,933,000) to $(14,746,000). The net loss per share attributable to common stockholders increased by $(0.02) per share to $(0.16) per share. The net loss attributable to common stockholders for the six months ended June 30, 2013, as amended, increased by $(1,959,000) to $(16,391,000). The net loss per share attributable to common stockholders increased by $(0.03) per share to $(0.21) per share for the period.  
XML 25 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants and Warrants Liability (Details Textual) (USD $)
 6 Months Ended 12 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Dec. 31, 2011
Warrants Issued on June 26, 2013 Member [Member]      
Class of Warrant or Right [Line Items]      
Warrants Issued During the Period, Number of Warrants   28,394,834aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember		  
Warrants Exercised During Period Value $ 3,855,714aphb_WarrantsExercisedDuringPeriodValue
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember		    
Common Stock Issued During Period Value Warrants Exercised 2,734,151aphb_CommonStockIssuedDuringPeriodValueWarrantsExercised
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember		    
Reclassifications of Temporary to Permanent Equity 1,590,000us-gaap_ReclassificationsOfTemporaryToPermanentEquity
/ us-gaap_ClassOfWarrantOrRightAxis
= aphb_WarrantsIssuedOnJune262013MemberMember		    
Biocontrol Limited [Member]      
Class of Warrant or Right [Line Items]      
Warrants Issued During the Period, Terms Of Expiration     December 2016
Warrants Issued During the Period, Number of Warrants     1,355,164aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolLimitedMember
Warrants Issued During the Period, Exercise Price of Warrants     $ 0.46aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolLimitedMember
Convertible Notes Payable [Member]      
Class of Warrant or Right [Line Items]      
Warrants Issued During the Period, Terms Of Expiration   February through May 2018  
Warrants Issued During the Period, Number of Warrants   7,030,387aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ShortTermDebtTypeAxis
= us-gaap_ConvertibleNotesPayableMember		  
Warrants Issued During the Period, Exercise Price of Warrants   0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
/ us-gaap_ShortTermDebtTypeAxis
= us-gaap_ConvertibleNotesPayableMember		  
Series B Convertible Preferred Stock [Member]      
Class of Warrant or Right [Line Items]      
Warrants Issued During the Period, Number of Warrants   12,499,996aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember		  
Warrants Issued During the Period, Exercise Price of Warrants   0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember		  
Common Stock [Member]      
Class of Warrant or Right [Line Items]      
Stock Issued During Period, Shares, New Issues2   72,007,000aphb_StockIssuedDuringPeriodSharesNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		  
Private Placement [Member] | Series B Convertible Preferred Stock [Member]      
Class of Warrant or Right [Line Items]      
Warrants Issued During the Period, Terms Of Expiration   June 2018  
Warrants Issued During the Period, Number of Warrants   30,040,195aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember		  
Warrants Issued During the Period, Exercise Price of Warrants   0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember		  
Warrants Issuance Costs   1,400,000aphb_WarrantsIssuanceCosts
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember		  
Private Placement [Member] | Common Stock [Member]      
Class of Warrant or Right [Line Items]      
Stock Issued During Period, Shares, New Issues2   72,007,000aphb_StockIssuedDuringPeriodSharesNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember		  
Stock Issued During Period, Exercise Price, New Issues2   0.25aphb_StockIssuedDuringPeriodExercisePriceNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember		  
Warrants Issued During the Period, Terms Of Expiration   December 2018  
XML 26 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Operations (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Revenue $ 101,000us-gaap_SalesRevenueServicesNet $ 314,000us-gaap_SalesRevenueServicesNet $ 205,000us-gaap_SalesRevenueServicesNet $ 336,000us-gaap_SalesRevenueServicesNet
Operating expenses        
Research and development 1,888,000us-gaap_ResearchAndDevelopmentExpense 3,595,000us-gaap_ResearchAndDevelopmentExpense 2,899,000us-gaap_ResearchAndDevelopmentExpense 4,236,000us-gaap_ResearchAndDevelopmentExpense
General and administrative 1,961,000us-gaap_GeneralAndAdministrativeExpense 2,843,000us-gaap_GeneralAndAdministrativeExpense 3,588,000us-gaap_GeneralAndAdministrativeExpense 3,557,000us-gaap_GeneralAndAdministrativeExpense
Total operating expenses 3,849,000us-gaap_OperatingExpenses 6,438,000us-gaap_OperatingExpenses 6,487,000us-gaap_OperatingExpenses 7,793,000us-gaap_OperatingExpenses
Loss from operations (3,748,000)us-gaap_OperatingIncomeLoss (6,124,000)us-gaap_OperatingIncomeLoss (6,282,000)us-gaap_OperatingIncomeLoss (7,457,000)us-gaap_OperatingIncomeLoss
Other income (expense)        
Gain (loss) on derivative liabilities 17,621,000us-gaap_DerivativeGainLossOnDerivativeNet (6,057,000)us-gaap_DerivativeGainLossOnDerivativeNet 8,848,000us-gaap_DerivativeGainLossOnDerivativeNet (5,970,000)us-gaap_DerivativeGainLossOnDerivativeNet
Amortization of note discount 0us-gaap_AmortizationOfDebtDiscountPremium (2,334,000)us-gaap_AmortizationOfDebtDiscountPremium 0us-gaap_AmortizationOfDebtDiscountPremium (2,637,000)us-gaap_AmortizationOfDebtDiscountPremium
Interest expense, net 0us-gaap_InterestExpense (128,000)us-gaap_InterestExpense 0us-gaap_InterestExpense (224,000)us-gaap_InterestExpense
Other income (expense), net 17,621,000us-gaap_OtherNonoperatingIncomeExpense (8,519,000)us-gaap_OtherNonoperatingIncomeExpense 8,848,000us-gaap_OtherNonoperatingIncomeExpense (8,831,000)us-gaap_OtherNonoperatingIncomeExpense
Net loss 13,873,000us-gaap_NetIncomeLoss (14,643,000)us-gaap_NetIncomeLoss 2,566,000us-gaap_NetIncomeLoss (16,288,000)us-gaap_NetIncomeLoss
Accretion of Series B redeemable convertible preferred stock (318,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment (103,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment (632,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment (103,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
Net loss attributable to common stockholders $ 13,555,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (14,746,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 1,934,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (16,391,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Per share information:        
Net income (loss) per share - basic (in dollars per share) $ 0.07us-gaap_EarningsPerShareBasic $ (0.16)us-gaap_EarningsPerShareBasic $ 0.01us-gaap_EarningsPerShareBasic $ (0.21)us-gaap_EarningsPerShareBasic
Net income (loss) per share - diluted (in dollars per share) $ 0.04us-gaap_EarningsPerShareDiluted $ (0.16)us-gaap_EarningsPerShareDiluted $ 0.01us-gaap_EarningsPerShareDiluted $ (0.21)us-gaap_EarningsPerShareDiluted
Weighted average number of shares of common stock outstanding - basic (in shares) 183,590,053us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 90,645,074us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 183,065,721us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 78,842,512us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Weighted average number of shares of common stock outstanding - diluted (in shares) 324,880,957us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 90,645,074us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 325,709,071us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 78,842,512us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
XML 27 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Nature of Business and Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
 
The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.
 
The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months and six months ended June 30, 2014 and 2013, our cash flows for the six months ended June 30, 2014 and 2013 and our financial position as of June 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.
 
Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
 
The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Accounts Receivable
 
Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of June 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
 
Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. 
Other Current Assets [Text Block]
Prepaid Expenses and Other Current Assets
 
Prepaid and other current assets as of June 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill
 
Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.
 
During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management’s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.
 
During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management’s opinion, no goodwill has been impaired as of June 30, 2014 and December 31, 2013.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Patents
 
Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.
 
During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation
 
The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.
Warrant and Preferred Shares Conversion Feature Liability, Policy [Policy Text Block]
Warrant and Preferred Shares Conversion Feature Liability
 
The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require such warrants and the Series B redeemable convertible preferred stock shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.
Derivatives, Policy [Policy Text Block]
Fair Value of Financial Assets and Liabilities — Derivative Instruments
 
The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
 
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
 
Level 1 — quoted prices in active markets for identical assets or liabilities.
 
Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.
 
Level 3 — inputs that are unobservable.
 
The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.
 
The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.
 
Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
 
The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.
 
The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:
 
•
The delivered items have value to the customer on a stand-alone basis;
 
 
•
Any undelivered items have objective and reliable evidence of fair value; and
 
 
•
Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.
 
The Company classifies advance payments received in excess of amounts earned as deferred revenue.
 
Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.
Research and Development Expense, Policy [Policy Text Block]
Research and Development
 
Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.
 
In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. At December 31, 2012, IPR&D in the amount of $5,161,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of June 30, 2014 and December 31, 2013.
 
During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. At December 31, 2011, IPR&D in the amount of $7,285,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of June 30, 2014 and December 31, 2013.
Earnings Per Share, Policy [Policy Text Block]
Net Income (Loss) per Common Share
 
Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For the three months ended June 30, 2014 and the six months ended June 30, 2014, both basic and diluted net income are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended June 30, 2013 and the six months ended June 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total numbers of shares that the Company excluded from the calculations of net loss per share were 24,976,557 shares for the three month period ending June 30, 2013 and 22,348,566 shares for the six month period ending June 30, 2013.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
 
On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.
XML 28 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Correction of Errors
 6 Months Ended
Jun. 30, 2014
Accounting Changes and Error Corrections [Abstract]  
Accounting Changes and Error Corrections [Text Block]
5. Correction of Errors
 
The Company’s previously issued June 30, 2014 financial statements have been amended to:
 
·
reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at June 30, 2014 of $1,337,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000.
·
recognize deferred revenue and deferred costs related certain sub-licensing agreements. This change resulted in a reduction in revenues of $209,000 and a reduction in G&A expense of $164,000 in the second quarter of 2014 and a reduction in revenues of $105,000 and a reduction in G&A expense of $103,000 for the six months ended June 30, 2014.
·
reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $460,000 as of June 30, 2014.
·
adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.
·
modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $7,298,000 increase in the compound derivative liability and a $158,000 reduction in the warrant liability related to 2013 warrants. Gain on derivative liabilities was reduced by $1,499,000 and $844,000 for the second quarter of 2014 and the six months ended June 30, 2014, respectively.
 
As a result of these corrections, the Company’s net income attributable to common stockholders for the second quarter of 2014, as amended, was reduced by $1,848,000 to $13,555,000. Net income per share attributable to common stockholders fell by $0.01 per share to $0.07 per share. Net income attributable to common stockholders for the six months ended June 30, 2014, as amended, fell by $1,440,000 to $1,934,000. Net income per share attributable to common stockholders was reduced by $0.01 per share to $0.01 per share for the period.
  
The Company’s net loss attributable to common stockholders for the second quarter of 2013, as amended, increased by $(1,933,000) to $(14,746,000). The net loss per share attributable to common stockholders increased by $(0.02) per share to $(0.16) per share. The net loss attributable to common stockholders for the six months ended June 30, 2013, as amended, increased by $(1,959,000) to $(16,391,000). The net loss per share attributable to common stockholders increased by $(0.03) per share to $(0.21) per share for the period.
XML 29 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Correction of Errors (Details Textual) (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Dec. 31, 2013
Change in Accounting Estimate [Line Items]          
Sales Revenue, Services, Net, Total $ 101,000us-gaap_SalesRevenueServicesNet $ 314,000us-gaap_SalesRevenueServicesNet $ 205,000us-gaap_SalesRevenueServicesNet $ 336,000us-gaap_SalesRevenueServicesNet  
General and Administrative Expense, Total 1,961,000us-gaap_GeneralAndAdministrativeExpense 2,843,000us-gaap_GeneralAndAdministrativeExpense 3,588,000us-gaap_GeneralAndAdministrativeExpense 3,557,000us-gaap_GeneralAndAdministrativeExpense  
Derivative warrants liability 13,115,000aphb_DerivativeWarrantsLiability   13,115,000aphb_DerivativeWarrantsLiability   16,871,000aphb_DerivativeWarrantsLiability
Goodwill 7,562,000us-gaap_Goodwill   7,562,000us-gaap_Goodwill   7,562,000us-gaap_Goodwill
Derivative, Gain (Loss) on Derivative, Net 17,621,000us-gaap_DerivativeGainLossOnDerivativeNet (6,057,000)us-gaap_DerivativeGainLossOnDerivativeNet 8,848,000us-gaap_DerivativeGainLossOnDerivativeNet (5,970,000)us-gaap_DerivativeGainLossOnDerivativeNet  
Net Income (Loss) Available to Common Stockholders, Basic, Total 13,555,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (14,746,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic 1,934,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (16,391,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic  
Earnings Per Share, Basic $ 0.07us-gaap_EarningsPerShareBasic $ (0.16)us-gaap_EarningsPerShareBasic $ 0.01us-gaap_EarningsPerShareBasic $ (0.21)us-gaap_EarningsPerShareBasic  
Temporary Equity, Par Value 1,337,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital   1,337,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital   707,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital
Restatement Adjustment [Member]          
Change in Accounting Estimate [Line Items]          
Temporary Equity, Accretion to Redemption Value     1,250,000us-gaap_TemporaryEquityAccretionToRedemptionValue
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Sales Revenue, Services, Net, Total 209,000us-gaap_SalesRevenueServicesNet
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   105,000us-gaap_SalesRevenueServicesNet
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
General and Administrative Expense, Total 164,000us-gaap_GeneralAndAdministrativeExpense
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   103,000us-gaap_GeneralAndAdministrativeExpense
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Derivative warrants liability 460,000aphb_DerivativeWarrantsLiability
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   460,000aphb_DerivativeWarrantsLiability
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Derivative Liability 7,298,000us-gaap_DerivativeLiabilities
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   7,298,000us-gaap_DerivativeLiabilities
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Derivative, Gain (Loss) on Derivative, Net 1,499,000us-gaap_DerivativeGainLossOnDerivativeNet
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   844,000us-gaap_DerivativeGainLossOnDerivativeNet
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Decrease In Warrant Liability     158,000aphb_DecreaseInWarrantLiability
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Net Income (Loss) Available to Common Stockholders, Basic, Total 1,848,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		 (1,933,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		 1,440,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		 (1,959,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		  
Earnings Per Share, Basic $ 0.01us-gaap_EarningsPerShareBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		 $ (0.02)us-gaap_EarningsPerShareBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		 $ 0.01us-gaap_EarningsPerShareBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		 $ (0.03)us-gaap_EarningsPerShareBasic
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		  
Temporary Equity Accretion To Par Value     87,000aphb_TemporaryEquityAccretionToParValue
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Restatement Adjustment [Member] | Biocontrol [Member]          
Change in Accounting Estimate [Line Items]          
Goodwill 1,685,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolMember
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   1,685,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolMember
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
Restatement Adjustment [Member] | SPH [Member]          
Change in Accounting Estimate [Line Items]          
Goodwill $ 1,548,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_SphMember
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		   $ 1,548,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_SphMember
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember		    
XML 30 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options (Details) (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Allocated Share-based Compensation Expense $ 235,000us-gaap_AllocatedShareBasedCompensationExpense $ 803,000us-gaap_AllocatedShareBasedCompensationExpense $ 468,000us-gaap_AllocatedShareBasedCompensationExpense $ 958,000us-gaap_AllocatedShareBasedCompensationExpense
Research and development expense [Member]        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Allocated Share-based Compensation Expense 40,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember		 70,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember		 78,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember		 113,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
General and administrative expense [Member]        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Allocated Share-based Compensation Expense $ 195,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember		 $ 733,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember		 $ 390,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember		 $ 845,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
XML 31 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Nature of Business and Significant Accounting Policies (Details Textual) (USD $)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Significant Policies [Line Items]            
Goodwill   $ 7,562,000us-gaap_Goodwill       $ 7,562,000us-gaap_Goodwill
Intangible Assets, Net (Excluding Goodwill)   12,446,000us-gaap_IntangibleAssetsNetExcludingGoodwill       12,446,000us-gaap_IntangibleAssetsNetExcludingGoodwill
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 24,976,557us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount   22,348,566us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount      
Property, Plant and Equipment, Estimated Useful Lives   three to seven years        
Patents [Member]            
Significant Policies [Line Items]            
Finite-Lived Intangible Assets, Net         493,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember		  
SPH Holdings Pty Ltd [Member]            
Significant Policies [Line Items]            
Business Combination, Consideration Transferred, Total       7,172,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= aphb_SphHoldingsPtyLtdMember		    
Goodwill       3,929,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_SphHoldingsPtyLtdMember		    
Goodwill, Impairment Loss   0us-gaap_GoodwillImpairmentLoss
/ us-gaap_BusinessAcquisitionAxis
= aphb_SphHoldingsPtyLtdMember		        
Biocontrol Limited [Member]            
Significant Policies [Line Items]            
Business Combination, Consideration Transferred, Total         8,584,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolLimitedMember		  
Goodwill         3,633,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolLimitedMember		  
Goodwill, Impairment Loss   0us-gaap_GoodwillImpairmentLoss
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolLimitedMember		        
In Process Research and Development [Member] | SPH Holdings Pty Ltd [Member]            
Significant Policies [Line Items]            
Intangible Assets, Net (Excluding Goodwill)       5,161,000us-gaap_IntangibleAssetsNetExcludingGoodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_SphHoldingsPtyLtdMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_InProcessResearchAndDevelopmentMember		    
In Process Research and Development [Member] | Biocontrol Limited [Member]            
Significant Policies [Line Items]            
Intangible Assets, Net (Excluding Goodwill)         $ 7,285,000us-gaap_IntangibleAssetsNetExcludingGoodwill
/ us-gaap_BusinessAcquisitionAxis
= aphb_BiocontrolLimitedMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_InProcessResearchAndDevelopmentMember		  
XML 32 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants and Warrants Liability (Tables)
 6 Months Ended
Jun. 30, 2014
Stockholders Equity Note [Abstract]  
Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]
We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:
 
 
 
June 26, 2013
 
 
July 15, 2013
 
 
December 23, 2013
 
Warrants issued
 
 
28,394,834
 
 
 
1,645,361
 
 
 
4,320,420
 
Risk free interest rate
 
 
.0109
 
 
 
.0109
 
 
 
0.0167
 
Volatility
 
 
160.94
%
 
 
163.08
%
 
 
155.24
%
Expected term
 
 
5 years
 
 
 
5 years
 
 
 
5 years
 
Exercise price
 
$
0.14
 
 
$
0.14
 
 
$
0.25
 
XML 33 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options (Tables)
 6 Months Ended
Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
June 30, 2014
 
June 30, 2013
 
June 30, 2014
 
June 30, 2013
 
Stock options:
 
 
 
 
 
 
 
 
 
 
 
 
 
General and administrative expense
 
$
195,000
 
$
733,000
 
$
390,000
 
$
845,000
 
Research and development expense
 
 
40,000
 
 
70,000
 
 
78,000
 
 
113,000
 
Total stock-based compensation expense
 
$
235,000
 
$
803,000
 
$
468,000
 
$
958,000
 
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
The following table summarizes Option activity:
 
 
 
Shares
 
Weighted Average Exercise
Price
 
Average Remaining
Contractual Term
(Years)
 
Intrinsic Value
 
Outstanding at December 31, 2013
 
 
25,721,000
 
$
0.20
 
 
9.15
 
$
6,451,441
 
Granted
 
 
—
 
 
—
 
 
 
 
 
 
 
Exercised
 
 
—
 
 
—
 
 
 
 
 
 
 
Forfeited
 
 
—
 
 
—
 
 
 
 
 
 
 
Expired
 
 
2,000
 
 
13.10
 
 
 
 
 
 
 
Outstanding at June 30, 2014
 
 
25,719,000
 
$
0.19
 
 
8.63
 
$
6,442,700
 
Exercisable at June 30, 2014
 
 
11,651,493
 
$
0.19
 
 
8.65
 
$
3,017,673
 
Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]
As of June 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:
 
 
 
Shares Reserved
 
Stock options outstanding
 
 
25,719,000
 
Available for future grants under the 2013 Stock Incentive Plan
 
 
40,000,000
 
Warrants
 
 
38,890,451
 
Total Shares reserved
 
 
104,609,451
 
XML 34 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Preferred Shares (Details Textual) (USD $)
 6 Months Ended 12 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Dec. 31, 2013
Class of Stock [Line Items]      
Debt Instrument, Convertible, Beneficial Conversion Feature $ 6,700,000us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature    
Derivative preferred shares conversion liability 33,402,000aphb_DerivativePreferredSharesConversionLiability   40,791,000aphb_DerivativePreferredSharesConversionLiability
Fair Value Adjustment of Warrants 0us-gaap_FairValueAdjustmentOfWarrants 759,000us-gaap_FairValueAdjustmentOfWarrants  
Reclassification From Derivative Liability To Equity 709,000aphb_ReclassificationFromDerivativeLiabilityToEquity    
Common Stock [Member]      
Class of Stock [Line Items]      
Stock Issued During Period, Shares, New Issues1     0aphb_StockIssuedDuringPeriodSharesNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
Conversion of Stock, Shares Converted 1,889,380us-gaap_ConversionOfStockSharesConverted1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Preferred Stock [Member]      
Class of Stock [Line Items]      
Stock Issued During Period, Shares, New Issues1     4,999,999aphb_StockIssuedDuringPeriodSharesNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember
Derivative Liability     5,064,000us-gaap_DerivativeLiabilities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember
Conversion of Stock, Shares Converted 188,938us-gaap_ConversionOfStockSharesConverted1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		    
Warrant [Member]      
Class of Stock [Line Items]      
Derivative Liability     1,886,000us-gaap_DerivativeLiabilities
/ us-gaap_InvestmentTypeAxis
= us-gaap_WarrantMember
Conversion of Stock, Shares Issued 142,000us-gaap_ConversionOfStockSharesIssued1
/ us-gaap_InvestmentTypeAxis
= us-gaap_WarrantMember		    
Convertible Notes Payable One [Member]      
Class of Stock [Line Items]      
Debt Conversion, Original Debt, Amount     5,491,001us-gaap_DebtConversionOriginalDebtAmount1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
Warrants Issued During Period Number Of Warrants1     4,999,999aphb_WarrantsIssuedDuringPeriodNumberOfWarrants1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
Warrants Issued During Period Exercise Price Of Warrants1     0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
Fair Value Adjustment of Warrants     759,000us-gaap_FairValueAdjustmentOfWarrants
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
Payments of Stock Issuance Costs     350,000us-gaap_PaymentsOfStockIssuanceCosts
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
Convertible Notes Payable One [Member] | Preferred Stock [Member]      
Class of Stock [Line Items]      
Derivative Liability     3,804,000us-gaap_DerivativeLiabilities
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember
Convertible Notes Payable One [Member] | Warrant [Member]      
Class of Stock [Line Items]      
Derivative Liability     1,644,000us-gaap_DerivativeLiabilities
/ us-gaap_InvestmentTypeAxis
= us-gaap_WarrantMember
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
Convertible Notes Payable Two [Member]      
Class of Stock [Line Items]      
Warrants Issued During the Period, Number of Warrants     1,645,361aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableTwoMember
Debt Conversion, Original Debt, Amount     829,277us-gaap_DebtConversionOriginalDebtAmount1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableTwoMember
Warrants Issued During Period Exercise Price Of Warrants1     0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableTwoMember
Convertible Notes Payable Two [Member] | Preferred Stock [Member]      
Class of Stock [Line Items]      
Derivative Liability     155,000us-gaap_DerivativeLiabilities
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableTwoMember
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember
Convertible Notes Payable Two [Member] | Warrant [Member]      
Class of Stock [Line Items]      
Derivative Liability     674,000us-gaap_DerivativeLiabilities
/ us-gaap_InvestmentTypeAxis
= us-gaap_WarrantMember
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableTwoMember
Series B Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred Stock, Shares Authorized     10,016,080us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Preferred Stock, Initial Stated Value Per Share     1.40aphb_PreferredStockInitialStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Preferred Stock, Par or Stated Value Per Share     0.01us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Debt Instrument, Convertible, Number of Equity Instruments     10us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Preferred Stock, Dividend Rate, Percentage     10.00%us-gaap_PreferredStockDividendRatePercentage
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Debt Instrument, Convertible, If-initial public offering proceeds meets Least amount     7,000,000aphb_DebtInstrumentConvertibleIfinitialPublicOfferingProceedsMeetsLeastAmount
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Stock Issued During Period, Shares, New Issues1     4,999,999aphb_StockIssuedDuringPeriodSharesNewIssues1
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Warrants Issued During the Period, Number of Warrants     12,499,996aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Warrants Issued During the Period, Exercise Price of Warrants     0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Warrants Issued During the Period, Value of Warrants     7,000,000aphb_WarrantsIssuedDuringPeriodValueOfWarrants
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Series B Convertible Preferred Stock [Member] | Convertible Notes Payable One [Member]      
Class of Stock [Line Items]      
Warrants Issued During the Period, Number of Warrants     10,894,839aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Warrants Issued During the Period, Exercise Price of Warrants     0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Debt Conversion, Converted Instrument, Shares Issued     4,357,936us-gaap_DebtConversionConvertedInstrumentSharesIssued1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableOneMember
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
Series B Convertible Preferred Stock [Member] | Convertible Notes Payable Two [Member]      
Class of Stock [Line Items]      
Debt Conversion, Converted Instrument, Shares Issued     658,145us-gaap_DebtConversionConvertedInstrumentSharesIssued1
/ us-gaap_ShortTermDebtTypeAxis
= aphb_ConvertibleNotesPayableTwoMember
/ us-gaap_StatementClassOfStockAxis
= aphb_SeriesBConvertiblePreferredStockMember
ZIP 35 0001144204-15-023067-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-023067-xbrl.zip M4$L#!!0````(`%"+CT;%F/8768,``!6*!@`1`!P`87!H8BTR,#$T,#8S,"YX M;6Q55`D``XC7+E6(URY5=7@+``$$)0X```0Y`0``[%U[<^(XMO]_J_8[:+./ MN;<*"`;R[NXM\NB>[*:;5,+LS-Y;MU+"%J`=8WLDFX2]=;_[/4=^8(A)2!J# M#>J=[C76\QS]SDN2I0]_?1K99,R$Y*[S<<^HU?<(O@M-'\'_*_MU__CUS==TF5/#X^UBRHP57 M\[L;TJ@94=I33]C\%/\ET&U'GE)OV/NX-_1][W1_'ZND(\_FWI#WN(MU[D,/ M6O7#)E`5%K"Y\^M,`:RLYHH!Y*PW]S&Y!XW'V3'5XDF!=.;#_3`QR?JLZL>F MRFN..=,7_D+?Y_-SZ;8:QM%+ M)<(<<0&+>8*9.+P+RYSL4V$*UV;[?6KZ5?;DV=2AOBLFG^%W7)'I!HXO)K-L MD\RL#=SQ?I2((].LUHUJTTB*!4(`]A:5BU+5D,X6M!C/+@,)&=G9DSG,SH\I M&06X,V;2SRX2IF50XU!NRNPR*@F+&+-%)#>S"T!"5G;?$POR0TI&@4!6!Y1Z M29D^E3TULE%"!NE/]@OX^>4F!>K`%R_`!E+W0(()^8""<"H5Q.]8GRC!./4G M'ONX)SE(+^)7O1L*UO^XAQ)>C:6X]B2M/;(/%86*XL)U?/;DDWMF^J!_E)*` M)D(U84:)'.!\6S<>X#\"J&ZS M&3)CEE]<_WWO4QW^G#0,PVA]V)\O'#>U/]?63`\\)KAKS?<`Y%KXH&[9IQAF M=2.N9YH65Y4BQTH5.JPVZ]/&K:A(NDNIQN-7$0^CNE]CK-%X:!J[QEBC`>*2 M)V-;*<2VRLC8UGL8V\H/L:TM4@6M(JF"UA8A]NV,S0^Q;=EQ2L?0T!WU,S@3 MIZR*,\SKF+V2!4ON$C#B'U5S;J,1%(C+/.`\D=)F7;_"W@ MDF,+[20/(!D"UG[07)5C0$8CRN^I,;?Y?QLX`7 M&\)/XSWX:>2&GQEKIO5.H?1.RC09:W)GM.(HDN)8F]?VG1K@X=JY%:X)"7=, M,BK,81LT%!LSV_60!>DJ[GW07/CRPJ92=OKWOFO^NLTH>K,:>4\77N!JG&6I M,=INY;8*F&H-^3T:PG9_>SI[@UQY"]9D0S%(*>\M]P!=("J&T%'LV8J+RFRK/7MS74"D7 M5$JQRV$682G>?7-])F_IA,)SQV$SV!JZPN\R,;ID/;\[\5CHW^\X.K.8$B'S M-;:NS>_71G*@3$:_):RH!9'>>2F8H[C28FAYQ*XST:B:A81]SQP=`O-]Y?($FA;'D6 M::2]`6E_"^R)<:!1M@!EV>S1"'L3PAS6.-0(6XBP+/9HA&5,3VLK64HKN?X= MW=K,EYQ:F8W%.;;<=\Q6*2XBS9',EILB)K3*9=>3:BVN%Z`?_O@O+. M3^`53"#T[%U^YB%S.G;W%DRFVO4%AF@H+3Z,Y"%[[^O5DPF+\R]DU[:NV\XJ(HV6LJ&ER.'A[!&L&ERE`]=:CJ-= ML$:HT5(VM!1Y]7!.%45K^'?,8FR$*ZT[N^=BN+^\I+`P2UG3.9.-=^V*W'@8;W%JZ"0RT+4L=N47M6\JM M:^>">MRGML9#G.U%!FTW-NZ83[G#K"LJ'#R`38-B.O^;Q9DM0\/"W>3:?RB> M_U#D<'>%G^5L/8KTERUO@9#V7LKAO9006MKY*:KS4PHPS6^IT&`J`9@*MF*Y M`$S:`2^\`UX.(&D'O,`.>#D@I!WP$CK@!8/6W+*F-F]%-&^;..)'VZ=BV:=- M8$`;F'(8F$U@0T?518VJUX8&'1:7QV_(=V.L#0/:;RB=W[`V;&B_ MH01^P]K0<`N<`4:D0?"9.]QG-WS,0#"@V0'N%&Y+R7QY/OE*_^4*M=.XW)!X M$Y&),Y%FUA;B(CT/I7%1)ERL^^#IV0_AQTSZ2$OYSX;,HB5.FR%]NT?Y>ZZO MU`AY#2'OH&[K!^&_X:1@6'4=$.:=?P*31\-A$%GG,7DX4[LVOV M/)`0KH,[:$+D('E\-X)&S0I0\YY^+!B/R"F;'\/M1NS[,/AP[PV70+B&:KY0 M349ARS"Z^*I@K2\+9F57<;+0^F\WU#`J.(PV?+5:9R:HGP)'GK! M,];-=@DS+#4^'_Y0K5[92LS(/3/1DE>K8=98$B^Y-&T7J^CT<:,/"+*Z2.V. MV0!EZ\*5OE2#>4XELV[I!"N374#ON>V:OY((RG>LOW"^;$]1]9E"^]:#L??I M+[9_!APATI_8H*R^MN^^7'\[)77/A[]/9^1SYUOWE!CXNPN:19)O[)'U\PWQSB.S&B]K3/D.`Z`_S9JA&U MAD/"11R)J?O39/43*%PEM=VK7[K5ZV^75TACO=8XX,X962\+Z,@[^Z-Q6-]2 M^JX=TC%]%^TC'O]<(6X@2,^EPB)N'TRF`'ETA234\X0[9A:A#ORU7`^DCOA# MIDI%N$B6'@FN/5;(XY";0_+(B-J!1WR74#DM@WEJY"?'PJ3TRPH6`5$F-/"' MK@!J+"S+<26`!!X^(_N1IIC_:9Z3'^:8]$/E!XGL^2$:FRG_0Q8T#RK@<.!? M-<18KWH?JE1D`_+$5%\\0X-(*9\^Q"331^"9Q,ZQ:,$3AB7%/V`;*"$9V!@) MR-IVHFD'I.4KWM0)8*V?+)85&&L%GJ%K`[KEG+S43]XN+PO*S,H/9-J$_+0J M#2T^6GR6$Y]+9H;1&,8EBR5HUL`TLXQ%4O)\8!O-E:*=D`=5T84(QPJ#,)"3V&>/),AH.<90,((@'B-@F5 MAL*!X*>0!]%H@W=>]9D8/4,?")\@[>@1@(,EH881EH).5G\+J(U3+J'+-RT= M8MD-8P!522=^#I,0F\SD*CXC`O=U)$D#M:=#50C2X@MNHI2':1@.`M21_K!7 M9$0GI,?"0I"M-U%]S&+.>:Q"+A,90B4`32V4+[??YR:+?D#FE+Q5"!VP\/^M M,43T428.V@<"3YR*4O&DH&%MCT,W'@,"NF,,U:KF4YT-R6)/3)A<,L@->=1P M1:PC(\`&<-U'>FTFT>S3:$@H%\`)\2OSR9C:@1I53`A0&=H3[@P2Y1.6L"`B MQDR*;[6D"?;D`0.@$8(ALXA:8`Z9,`I4](4[>EY<$0[,8(+:]H3@9P[J58_A MO>8Q1?A%"P%U)`@%J@)1Q2I).*,$+VS;?<1N9G0NT_UG4--$83`>/3(*C49$ M^I(00/PP&W[@:,!+IL`_!^Z0/0CC3$1&;`#YL#D+L'X`#1YK0DPJAZCHD[D( MH,:+AB`9:JYZ%]"IT[:!9PEQI&-1+1,_P%1#%+@261ZR#A6A8G9M7# M&GPE;0-63%TH%>W["W)D'"NB.+X/M7]Z^DL1K]+FX07(^2T`25"Z#40?2K"I M/DD4B8)9M8>39L2+9LT2A:LD&LN@V"-`0XFNI6U46)6,579JHV=QB!W,"2A)Y(2\<:"MIB%"(O91>UN)2.NOO7$*'$P0K,T(D`LX=X M'N'$,>K5/N-^`)91($A!\+C2MZB$AQS`!B:!VHD?0="7PMESK+_'AG3,75$C MUZ%A`H\`#`MQ@MA:3:N7X'_T^RQM:;.4=]RS.7N!I@QE0.#D6[P2%3HYCBD8 M1=@+Z'STG,T%A_0#16F(^]#9@I^/+/0+)`<1`Z](V?U4*R*<9%=>$C@-`Z`E M\A=?I"#Q1_VA`,:I61'^1"`P`G&/1`_=*8O@YE[2K%=")Q M";`_)UXD"#.H]V`TPB`W<@CIR`V4EV;:`0**+F$F(@BC'5(@QKHQ"'!M;M'0 M"8S6?L.PWL.5.F6;PO!\!%'.$!>4P=&R72E/\QC0=8T>`7=XX'S<0\^1B;UX M/2>UNC.+VS4L^[1OKK]\.[UA?0R*9Z:N<-[JY^O+[H^8O?[G*5I\%8A$C9]W M[BZO[JKGG6ZW\_64_/&$]0[!Y@,7B1KC,Q+EN+GZW,U,3Y@_UV!2\J)S<].^ MO8=NFP!/ZDE@;^?;SH_GQ)T9:`_2>YNY_:E;MQ=?_DQJQ][$''8MO2H M"0C]N%42K?B]!2W23C^L4!V_WES M%4-D=@3GP0=4M"_^_N6N\].W2Z"AK_X\D^LS`LSI7E^T;^+V`!N^.XHR_AQU M]*@.1#URRQ]^W#LP_CRS?IJ!Q33X]GVK#!2V4A1N)8'I(6PT_[R'`@(0!I0> M/*.VB^[!E.2OZ!_(Z>\K=!'*R@<]T"EJ[_F3'N87"-SWA5;?9:!PU5(][ZK4 MU1]B3'V$PK$@/=,?&.=I%&@4&$V-`HT"K0LT"K0N M^'XWT%:3)M_)"M-D;#6LR'("[].[")Y/G;T^X.NE<<0M"Z=RUA;<;68(9V:J MGNN>FYPM]H[OS\F!:=THG.1D3EN*X7ZK2HE$U4"F%E6H<;C4VUZ&C1 M*22S,D3EY&#G124=TNZK4WK2%7WG<4'):46SS:=_K.I,*E5Q;)XC`>*.C2AWP!ZF$7$1W;H04'N:L\O$*)WI/_Z)]QG\IP;.3@#G&A#! M')YS?A MLBZJ-_0APXK)*\'7VZ].+Q:%)5GKO0>5HX:1[PRC!GS!9]IW`.?U6D,CO"#D M:96>[XI1S3@H#18TU+4R?S/"#RNM`Z/2:AFEP4'.JZ*KCM)B<(27FQC--X)C M=9M_LR*W+^$M<9L:^UP_Q=Z\BBLN>?DILWP_.8^(/C#TF.X:>1JRVS>F6T[> MLJ<4%@">>OQVCSP-S[*,7X'CDWQ7EN+="!N+4(H0G>XD>06:;BF9NU?<,=UR M\C1DMV],MYR\U;B`:X&G'K_=(T_#LRSC5^`()=\5E,^NZ#.NUU!VCSP](;U] M8[KEY&G(;M^8;CEY>I*ZW..WY>1I>)9E_`H2]AN)QH5=0A2WS".\\`S3$RS+"!3DO(=\UH[GS M$OX6.(PTZ^JLA-8NA^@;U6]O9L`F/[TMBD^[/J8M.&_!.-EDI*>%9H-"\YUG M'^^6K-1KQHF6DAV4$FU:WG4?1>UP8Z=6:7'11J6`O,H^.Z+5J!SMMO]5D(AU M+=]AJ?.XBQ*Q%F&ZHEPS7P:*?]KQ?N@-,7MVWX&JZSF:NQ MC`.$QEJIPTO5Z&`@V(#ZC/#X4@ MWA1#W+YZ>>&./.I,0GX=-XRC,XEWRX][`@8HMQ)C''$G5]7^F*WTBF`UHMHCO M0LXQD_@<7@^H*J>>)]PG/H(\]F2UD#0J)\9QY;!Y/(M+A_G8,/1$M6H!_>HS MXD`@KQZ'W!S.T,B>/&;Z$@E(""7NF`E"R6-TJ1.AX=4]Q(/^N-9SPOQ'EU`' M\@'+[#Z9X.T\6B#*1UU>UG@I20.`,C$&M$EU<1R6X/Z<7@?&!R5_R(6.87PWTLM7:"ZZS#/[1DWOZ90&OIM4<5S/ZQ[- M9_W9CILT#X_T39JKCD"+QX+E;M),79P7:LK='OZM6Q[-DO7[,)R)/-5\$<@KPO3T#DRK;7XG;A$`7Q!5M[I-,5FJKCVFW%9>9,K+'^`U(A)B M:PLB4HP8\-9'$FK%:P>M&1\SYED\+Q(`">71O6PD]KAR?U/'RMUV&?4'T6[XS45W7 MIS8)IR>2^=M=MFI%(.\]8=BJ)^0*ZJ>]FR59.V[KKN[[$+_Z6;B7 MMGSDM\LC;F:Z"M%S!82+:G4@:E&1>8H+&&=$Y:G:=.(&_FF?/S'K[-55AJ1^ MD3Q926_2CV+Z&//BPWX@JP-*O=-++G$[`\2UG?Y%:BGY+EQ$OG"E+Y4R/:>2 M6;=T,H+X5G;9DW]N0\#[Z?>_^_WO"/D05P>YN.STVZ;I!A`'.X-;@+$Y"?]- M2A$3F`4_[EC_X]YMW7B`_W`!KNO6#Q^:=?6\1[@%PT)-GUL/C;U/G!P6V]9.0"]&(\<'A1=<5KU%4^WX"GN*3IZ@-BFAEU'+1!WNK>*X MLL-'*._*GH6[/[A#'9.#ER9AO)E2*)#3M`.+J?DT&FH/.;>U2FWGP.7WQZ%K MVQ/B/N*V+!GT)+L('#N]S$R+CL--FW&;<%RP-)4`]FN'"QY".0:TSYA!F\Q'0!+2% ME3G!J,>$Q/U8V/U,>K$Z*]&]Z=J$BS.+:OL.EO[_]MZTN6TD613]?B/N?\#S MZ;EC1U!J`N#JGND(6I+=.L=MZ(9ZX^CZ=:]8C+;XP7!<>[4BV(WV]NCB7KCFW MVTO#PE2T@K1(H)OV2`C!H83SPDG%$7R+-#!<-!UP"4XI3`/S'8Y4!/ M30T@P;/+0<>_`M'/,K_S#L[3E+FNYKP@`99;.I1FF!84+5OP^ M_8!+1%RQM%V#DOZTU4RF&%\L-)V=$Y?E8^;ZTWG(A#RA#K`#F6+97D@P`PAD M6#K1^2E,>Q4K`96#Y8&L#TSD\/%0EZ&/0WPZZ3.9+9]UO@V*U?5-'=G:81@C!=_[E6V0!D&"-[O](O%(^ M;MFJ7$`!459/PO'XC=4`K8H='!S5*N,F"'/Y(K#_NT;J)0B2Q,5T$+[BX55"%P.@^GH+T0FFS?7P$J>SF8E512W:25T058XQ-+QW^N@%^>-!/IO6VHLM?JJ-/44<@G=,[HAQC' MM,KJ%+"[CP4:*0:A8PB//'86[;7P;L$Q<+PS+`T%!80E=ER1D08A-T8#9>-A MZ.0ED/-X;882>^D[T[GF"ID?BR:`JP,Z#N6]P_T-=+@!DB=POK#L!/T6FP.$ M7,A?@SY9/'9I@CXP<6FL8.5:US'?"ZN,?`!_@>0H4.%6LBC=2/`4HX/S%/%Y+R[68B.V@2E_P M@`)`"NBSE^#A(-QZS%JGDEY)*Z-[1],9?.L&>,417I5[QZ8,O@]OX-]>6QGU M6V5TFLHHX!`I8I%6#9T"=N'&.N'&AO8^BE]R#'2A5$#(SK1I]`#J#XENK;#V M%"M1SZ5;Q\:ZQ2#4J]O^@S?SS=C%EL-BI=D/&H7=+/):7)=<)^&=@'Q_('BP M-I+Q&!AY#.Z235$!25-`T5Y@G7;\ULQ&D2;]9=G/%H+KV0[HENL9*B_QG/2L M)5HM<"7K6\&+\*5OESSW`!2?2W'I,+J-JDNC,!_5WI+_2+>`&CIRL*;[KB,9 M\)(@F/?L8$01_5$`XE$##[DFJW!&!_9B/&4/!LJ/E M<@B/2`M/53]F?5=)=:7U';`E>*3>"Y9)>/!EU)1+).*V_M?@4%7>OB7+"6K! M@(GXY63`0;M2A*W6JPV[Q$:R8",S_0T>ML-\![:$SPS26E%O'LSJP.3.,Q/$ ML+1@WAR;@SR)2JU(S_DN0V%L&D\LO.T.&J?P@%TG%FZL,UN0.WV@XER,W?'& M)(D,PO.B-,>CT0I5!7Q:,9`6N?`=!QZ=T$9LK@N&K2YX1;J`+34#C8]=@;R-O8BJV-+A;J6JN9X>@EF)]\`1\AS?PP0L=1BDV M1QV+*I"F:<'[R;;U9\,T059?6YYF/:+;Q;\3?+1A%&K4BN%7(X8#5FFE[-%Q M(]5Z4(NSV)6&884W%KS7H&89_+8`4Y'=T':F;@CF"YKA%/SG'30Q@Y-%4CIY MXZU-P20,L&PF1"C(B&W6C#$U1K MB\YA1QXJ8:.'T.64)EX6)<+S(])L>*"Y=J#4SE@9KP!%D5Y>$B$D`R691_'6 MQ"Z(O/,.1EY#L,,5`I%0W5)L#_C185?M@,OI`QX5#4F?C07FD248:ZEY8=KN MH9_N4:<_ZE4[W?(.3_=`50_^=!^/3U?944M[>%$=;[S2E[>&IL5$[RH,V;D; M^GKCH_#UNN=*'[O('KVWM]H8=\_^'[5!.R,FD^)1/'',*,YJA3!+&U+UQS=E3[8\(_T]N/DZX=WV4]< MV'I8VR>]G7R]>"<-Y5%'2C)<#JL%N6E1/CC3,$$[R&I8[9V/Z&%)(I74)E&4 MM&>"2/,2'JZ5\&FI-V!0F(BN8I#XOOJJ\%**H`,_F$G8K`9'2HB>]F^]ER6@ MC@XO/H=.>93)_8[#RF$*J^W`G,''CEF];:"E`D6G+>LAG0=NIB-,D MP6I2R&NM(CPZ]LU5A,^BEV)8HK,,.4$,C)A&G#`3G%!0&(\08A>+^#JDWH3_ MZ!EGNF'Z7!<&WU2Z/V$T\XSZ1H1_E']ZAPE[0>I?MG8&=2J-Y'Y,FUX"!$]4 MX.W&U6CX.2+Z"],?@V[?]$>>?K-@#OY9NG9=T(OWFON7]-%VX$5?@UHFJ3L\ MZ[^/OXRGR^&W_I@SNM@#)_G:@EWPZ0MO@3X^#RNY86?Z/*JW,1]9E2CFU/7 MFY&-_FDRN0VTC\YF&!^.K=K!M$20F(8[Q[0E:>9H"_9L.WRT%`:_:$1ZF M\&JGHCU'O!V']H`]?V*@QUS?=@[:\6&'+)3!.VA54&)KT)F)SZ2D0L3GJ'D) MYN*+7CP:+^WPL-Z0DIZP,POV-9O1?+W(0'FKX1V_X?$EWP67!*(<'_@?F9,2 M,9KIV\A0EB#0WF*,YT_G+2D`(<23CD?<'^&XL<-8@)33P M$DW[`8,R&J^_7/KBO*/1FG[2MU:??9XC.ADG^#S84'?J&`\D:#`KF,HW10X& M+4`;N=!>J![&Y9:BH$%LM7;(W-%A]YD*=>5BV^+?OHW>`1U`H5C(T.`'A/N@ MAHX,/(WT4>RP&5GM&TZ`>*^!-91U6(.B\B"13,TI-$L2W(/,$Y,RF((52;"6 M;XX..\XW:C'?I'<\KK7:/3\Z[.).BVXS7AF+!HD>N:61QV)$#BH:$G.F/U*G M1N$SB/829]BALA-883CWRG:8\6B=\:3[Z0NUE'#/I5_L9V`Y)STV%SM9>CP1 MDSI6".\D&PS1%H**=8$0%)/3W$3$S;3!2K.HBR!Y4SKS-+!V>6`N-HAW)907 MCN/E*?ZK$=72E>@I$<^+'1IF4*S2>$?DUF8S'N%#HQ(LR61#THYDP'-L\6#K M@G#TI:G)-+1_"7]PVG!D=6QP]QP-ZQA=4%;C.L(4M)AW1IU`0-1[9M3TE6+3 MS$'+^86:?E*[PQBU'1:6'(OXY!1P-7AX,L8S,6-!W19CD5XRX2A?`U7:L^XS'IG/+^#?W M5,&9I(-`[<],,ZJ[#"[`X^W8WO)&HI31YVCT[Y.-_8G1B^S`EQ8:OSJ@-CSD MOO&..Z'H(N.H@R6AQE\L^(TB)]@29X8.%W6Z234%CCF.7OH$M=Q_=-B)_F]) M_YM8ODQ'=J2(!:,C$/LXN$F*10'BS9BH/[3_\"_&[>Z42]\)*YE-8$\,A=@= MT8TIR@W1_:AW(JFTZ&Z,=%.@,M)=G"S-%#T!Q2]!7";LOP'N@*X;7$/Q6;XB MW24\L5Q=B#/'ZR-<9F'!QA-=;L7>B9VI@T.:/'S4^BKC$]ZCRC$P9K1D6-$7 MUI;$>H:PE[A(.)>^&JC.2VT;A-O`W!O>*Y)O@PN;!9]B4ZU`Y7F)F"HB`>O; M"\;+1[KR*[7TY=L=;SUY%^4Y;7T'=[!C M7O8MPX[_ZFCE#DZPCQ3CG_;2[.@8,VX)\G89O/\NWUO>3Q;UB6W:CR^@Z*94 MFW\N!;LO\E)6'Y&BW$=1LNWR>1`6B&7X%DJNCN0OS^`=6)W'OP:^&J(36P\; M!;LN_9UD=:!SN(()LE>3)FU8Y1=A`EK(%KU&2.\NF4.M\%$=+4`[@M]H\6L' M<.LL+#V,X.=JU5^**PSP.`U8-=Y9*VR@%5N*W_6$#8ZUY1)PY.W`'L%R;:W1 MX\2NA,_X><"I)'A?)=H0@.5I\X8X840@N/<+[3^JW>5V#X5I]'-,J;)BWP@F M+"U\T\-VVA(S@P[3\?C-S#9I0`GFA@VZ_3,EGA[V:_#=*_Y=:8*!$EZODT@8 M2UVSQ5^`G6_`P'!G/&3!WX?FX0/#0%-("C"A@_PI7G+[VFZYN*$H\/OC^O+^ M%P0"S4,Q,_+BYO/GR>U70`4;Y6E+EU6'M9(YR<$()\6F1SAZ]C)K8*P`-36; M-6.C^(\X"7/^)E/79\^L%.NK&ZV_4M26*E:3P@S*07*NXWK`C;O-0(?B0V?8 MM8KBJQY;B+DI(E[!IZR$?1BQLAY;1EKZF68")Z(N,MPU$"L8I5GWX3O+*KC1[K3LO]S4?LPD&-JW,@V:'\1R>@X61MO:T%4!WR<_9"Z6DQ1PKPXUZ#N-A0\]+N$-9U1-!$3_/;''Q$D5;DGZR8)L, MAN(]T6T^[F-U0;R*+UT6+VEX*&4B:5?1H$4T21TPQX72QB(&%I"&\H;M"$;2+10A2FQ*;3Q%M\4HN46`8.9_5D<1V_TDB#:KB)*FHC;'H5ECP$IDYL]/(# M'&PTR]PY8S31;$XI-534M.3#I;$5FZ.;PN)_%A7H/.=+K!Q,68-#CBD>/.?$ MI_)NWQ5SU0-7(4YZ),P#H^'SO&%`4'V%X-/5'OBD9Z;P.U+X=(*L(8SGQEJ0 M>J(!##;),26QMY0!6,5=@,$Q6)9&1O-",6:&P,[^AB>SZ='>* M8Q+B[YKQXG3Q<-(HIKP9&K.JA<-PM&!(O0A.>W/J^19D[X6#&&8L2G)*$H20 M>&"/6,*PP(KX_]":25F)Q'')W"X@<"*E*W&40M(G6\LB*YO`UE[8>_;\$/J( M/KSD=1I$\'\(FWSF]?5,HMYL^[]^1Q[(=;7_HURL)/2)>5"'V.=S/\WF3MJX MVW>GS_SS]T/8@C.OZ^8NS]ZPHXSZQW3VCBD241I82,MWPX?M]\)311IUB0$N+@"UA8USSO^>UGVW7?8?01[2HLB")&;<,? M1W<"<%-I9,&2Y]93<=N<_#4W&O)I!4\!QH8>U9$],]29*,J?F(.*T/))*671KPH;@`F;/S;HFBOK5?5`F9#&]X+'.G2Q2$DL4^[9 M8#(C4?8J/\T8H4?;D1=PS#/N1D9JZ63(>F.=Z']T)A\TQVY\Z^N": ME?%0J^&A$>T2K:(NSPP9'.>/:!334L/J&VI52^R,LY@'N".L8. MJ1;8'/1H^,[QZI,-FYWA:[$;'6]&]\2"6A2\2B&G%?U%WPNX(0-H02>'7X%0 M3>5W"LCI(FD8W7G-G/IF6/Z23R[N"'HV.-^"46EG!;`K@8["-[G!S)(4P&3_ MU2J#E5YG/!QT^OUATC@38,]662[H"\OX>5OEO'KA4SIJ#ZS9P:`0OI#3BZ`[ M9D.OQ&I+&WE`WZB1\:UC6_#CE(N;FMK,'NQ0]WWKO.,W23(NI*:49AVUQDZR M5&N9'1V7WF!3X`?'QVKC?MP>P"[HU+,`5-/DZV_PI7/Z]*RKB'QZ$&W@;P,H M4:>W(,=>I!Y@\)*2G<"S#W)>Z-Z*#]R:^@N?%PR(,8H):T=84&\G-Q?7[[A2 M13@,"KES,X:Z1IA+WC2+VLHLL,LL"^H\+1#'O$<$FHJQ`M&"U^';2'WE0XX0 M"5L.9]Z'19]N:,J=2]=>U`$#[":\?B-E;_"@^0J=HNZJ,>L1_AZ]*N=%:`PN M_0>0XB$9.L+.R=\9,G%F,Y$ZBN^?P9.P,LW_Y=88%94:"Z%(W2C?#4S9X#D* M@U/@7)O!TU%,1>:\I'#X@`DS013[F0])Z0O4)*QTS4FA\1!LLNOHRZG;3#/L M42]Z7^A@J8KR6M'P/VB2:.BTCV!H^*;'6\:]A/P49+G'C?K,K3IBJV-=,V)E MULMTSG3?9##+'G#Z M(QJBGFJ.&NLBXK(I=N)`_<`GLVLYW4$6MLY,<1$8PP*%""*`W)QH MTGO.BGSB>WBGB2T$@L:-;E#<]MHJR>K"CB?+?V8S3*]=F3P4R^N/Y=+',_]# M>L!NAO\]5^38M\?#XJ*`F]^O[CY^OOGCO82M[6'M4GDL::;Q:/WSC0E@9Y4" M_')U_>D7W!5E^3VK!B"&N32ESE:!PWS_Y^>K8`^2U)0\(B<:!`Z14_HPN?B? M3W`2`R8&/E15Z M8*@EHHDRZ,1^`9G9 M9F:<21;LEJ283AEKSH@+_'/A_VRPX[M%C?3BXOK[]\.KOC4/0#O_/@2-)=I8DRZJCC7F>D]HZ&(TZ4X=OSW)[G M[<^SW!GT^AUU(!\-0YPHO[?'N3W.VQ_G7D=5NIV>TCT:ACA=]Z/9&/)=V"&= M+GJ92R5T;%_[7AG9XY1SA^!5[UJ0U8ASAJ0Z[\K=<;N=[6$\I=UK#^-);6=[ M&(]Y]X[U,';A-`Z&KWD_#\2`;_;^X/=P5-+!^VK'*9D.P14]^.##>L'"0?=\ M?)J!_[\=/%;M(6P/(3^$ZGEW=)+[V1["(]RTUWD(^_USY35JP@,QS9N-K6./ M&%X(Q9S%P3MBQRF3#L'/W%8F]0XJ;M#G]8'MAK;'\91VK_IQ5-OC>`P;VA[' M8]Z]5CL>[88>B.W>;%C]ZCMSI@;.X\`AY@?OH1VG>&K4`?WA%<41NN?R:481 MCHA'VR/8'L%3W,0CXM'V"+[R(ZCT3W(3-S#,4Q,KC[0YUL;-K?*[9%TMEJ;] MPMA7/MJ).GW2N$#L7L8LE[H+3?@\)_CI9G87CMV[I;YG%SB):8LN6L.VB];K MZ:+U,6QV9;@XH=U?++`=I)A_(X9!B!%E-$^!VB^?\;[=TQA'!L.,PCD2TRGO MMH=K)QKDN8FNUW:RZW6R,2.V/FZD1=:N:!RT?.)-#T*A`X_9UF.&Y(Q]T!2S M<3&_>>NL=-.+,7L83!E-[!:57.*)SU;G.C]P$'08Q6?!](?ZY=;?)ZW1;5;K(WUR;!OH,@0%NPL+:28%#6FA630XFM\[MIJZ*RVRX::<#S4 M"[&:M_`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`OT89PC+L!(<<"R\C4S>O)>3$4,'GK[ M)T[6>=1:TWWOW.4)&;C;&V#'_@=PVO@,^[ MYTK+X0>"7BO2F[TS.Y=?]02B0T*O%>9-N&XO+6`. M/MY%WM\P\BS/[1-.V]IHWL')3#]^E>@U)\R:+;H72/?E=D]?&WHMRY[>GIXX M>E7[-!X`>[;[]_K0:]GS6/;O@/V39F^6@FR$O7DHA^"=ODKT#BC<WIB:-7CPFX$_9L]^_UH=>RY['LWP%[*,W>H'RTG1DSVCN4UX=> M&Y`^O3T]S?`7LH3=^A+`VGO4%IL'WO MZ1+@6$/:2EN%TW+\J^)X63V76XYO.;Y6CC\8[MZ_"7O,._SJ"="R^+'L\('T M2VCVSBC5+^&_?8M):I=Z)?1>LXN^5_FV-@'V67I[*#;M[HB6TV]!'N_3TVL/ MS1X/S9;=GU_76>F>R^/VE+S"4]*JEHTF,]L?B'QK-A)U;WN:*?'P1!B_?Y9@YO;#[YK6,QU8=D'PZ++V@O; M<@T@`?UR#X:B.V..PW0YYS95OK=EY9O*?_[VP;#Q,<ZM]_+96Q][N1#[H3Q4:L/^DVWKSX9I)C&; MN#=6K?NI%&*D#E0U@5$`U0;0UD%_M1C:L3*N!.VUY6G6(UX53ER7>>X7YEU] MGYH^@M88W;]=6[>./84/4!IHSG0^L?1+]L1,>[E@EA=?XJNG>0S_>&%JKGLS M(XFR2HY>,3LJHWZ"'%70KIE42BU8U\`Y_4)2]>6!O#6I)A:\R3!]C"Y^95/? M`5"8R[\&HA^4,68N^!X=_9O9E>98A!!S2$E,%K9O>3F"3(TEQ:A)S`8QS'@6 M1!RYZR\?W_RL*&IOU!\,(OQJ@747!.B5$V!8@0"]\7#0[P\;)D#`&=>+I68X MR,F?;=>MDN=4@R0?%7)XAE1,0EDC+MN?UG&]N(`$6C+'>\&0OP?RYPI>3=+G MR@5C&82._IO+9CZ0_HE50C$!K0H@>7.',O\J\(R; M""0.N3TY\;VY[1C_87J![%6_8?X0`"C M;AS_(A02V87)1Z_A5088T0B;_KMF^BPX@+O&.V4G?8/]_$:`Q-%7`/GS7E>X M!551*=[P6\VY<0Z``&I%`G3/NW+>SN?ADJ;`)7OPKBW7":&02[KKF<&/U:W_8!K3FQFL"VJ'+$ZFN[\R,-T^ M,\WURHRK9HDSR%=G9P,PU'E428B-NI!-)FV3"')=G^F7/GT+OFOK7!1_8<_T MD9OG1C=.H`HF7&],_PE"+M7P2=`@N%A;_5IP`H,G]D6&407EJA`A!H(.U7%J MDA1Q869[S+W57C"N=6.Q!!%`WWOWS%D@A]^_+!EW[>HGX[B*C3(:]T;J^!C( M>/]LEY(Q08!>MP(!!KV^.I";PC^84WOK&%.V]X/5DRL;+W*OE"0YN.V`,H=U MSGI5;>(=4)7,R?WS64%\\JR?5O25LV-T")-V<"'T.T5W?>%:'$D<*6-E.*P-6P$UTR.+D-LXG&D:W^DF M#DF%@&5/[0_'ZB"/C&54V1]-J[!3$S2M8$`/^B.YUZ^3I)E>R@=FL9DQ!3$-/*5LIML3Q2!,?LHV8X9*-,X*L+7F=T9[A_?708N\9:,>9Z&,[9%RV4 M@F#4@$*48)%TQY'.#%JD!5%L=K&N>+J^Y)-,>YM MFYIGF(;WLF^^*(K8]O`BH]]7>L7$R$9JQ^2H@3,&9:08J-W149!B:]$Y+"5% M=]PX5Z#%O,^C,7KS\VW_SVI8(JP[P:T&/A\?)E[;,NV@VPA>L7A4X65K,TPX MJ!ZS5/IEJ,=0:1;W[9ETL%Y4\6#PWIJ)JU^P;X3W&M=F2L4(2)CKG!FPX-?9 MF$5E6WB;3:$/`.D)[WE-;@5^[H8!KN,`JT M5L2Z"J42I#T2@O77$B0;8%_14T;)"^>`QN]26MUN4M8'8-L'(ADKP1EY%W:>GNHG:*]>R^TNC.)C3U#NV>VP,5)18V@=5ULO+-PGQ3;O%%YJ+%5KX#QJ>3X`#VIS>!7SY M!N=V\.607ZJU+Q%%Q46]?21*QPJMK@3:/I,4%N\IXN"VT&U*QN#17 M5A4Y61N]#0QYM"G.1%.Z@T&W.@RY15O`EM7)4IPM)LOR.+5?^2_=#L`\FA6H M$`2PU]\8OLU*A_,(6:9)>KW!OHN=4Y0MUB/U0+P^'8M5QK`_2![3+0K^D^08 M%^N"RB_FM*F,[[A8NJN]H=++D`E5WYJ';+&4[LF*K%9YJU")PJ"&\P9_<<#4 M_6QH#WBS"O;DNH)Z7":H!]E&0P48:@4_C[(E,E[N#>L"?QLBEXC]H9P4J_4` MDT>R8A&OJ&.Y(C"B/HV\'^,IYKY0+"3*K`Q6>*E.L&+QKJJ]KA(OD:L.0HVP MY]&W6-#WND-!X+I@#QRY#C(:95,P%+8.= MO]C6=,V3+'>+%4AOW!_GGN7H?1L"E4NL8OTRZ`Y[W:V`6H,^Q?JD#SR5"\I: M`.32HE@C#%0.024`8G=QZP4ZY&Z)Q!^E6D.EW[0^)+GT*+'H1TI_+4@FND[A M8,V\!4_RVA*-S=8@38EL'W3']GAL^N3 MK$1.C]0DP;+?MRE4>>222T3T9E#=,4\S+*8'+7;`/O,7OHE-(BZI9F,-82T7 M"^LS%9B_E_2XRU]?!\"Y)"T6Y`!P7T[9BNL#3&=[;ILZF!<\FV`-BA:+]S-Y M.%:2KLSJVS:!)Y=@Q=+^3%$&*?E6#D],(8!_L!6UBK7`JK=9]NKM0^J@"$FNW>],EHO5R;B?DMB5P&@.^&_9?>_$"O$[GVMK M:B]8>//S&0'(NH:5Y9+(4CJVL&\*?&(6<]%N:03 MZZB[-Q&4"7P3NU?2?'5O[)M-@$:.<+&U,U3WS@1%,K@L*KHW!9()?#,;6'*I M-CXP&C1PBLMBMS40(/OA"88M'PF\#R_1([?:"_YI\JPYNIC)?1,-<.19@X65 M*5>+I6F_,!:;ZAVG#/_+M:6S[TR_MRES*K#@^?]F$*E"OP&E/U228;;:T:Z; MKI]X-I3%,\8^.57;VS9`8;5"7G*-I,W`/--'SZN9B4^,#S+M]+W1KD).@ MC!JF:H7Z/U!&J;RJ@U=&0MIH83_@G=.U7TY761[TY=Y8K9-C4V@WR*]_,"R\ M9?KD"0SI1U:]V+<):J>\CZ*BS&;8N(@::V^"NY;!47TC=BBLAU4VI+N>.JR/ M++7O2+#Z86_*:`^;LA9E:M^7#!/I('=FO(>=69,V#9R9%?/J$/>FUZVH6V3U M7*[WY*Q%GX-1]0UOQQK-I\>'K^JK&W0'M0EK=)6I<1,J4B-S$Q[*7_NP]M[? ML85F8-K(!58"`W%\S<2RS&H=3)K8&/7-S[?C/^5?E=YEBNZ[)<#A[D'S"J,' M>S#Z<_BK/#RM/<@_?GD@Y#5_;GX/^F(/:CT'&Q"@0:U\#6\R+->8EN;6-D+A MX@N_0:^G#!L*&241WR.%&Y;EQ=>)@UX?1(V\+PK73@8 MIN-SC6!>&Q<'G5#X#Q0>V3F%JS17[P:#/)K&?J4L(*N78.P< M[)I:51JPJZ/1N`MG/U9R4()%03%$M;'J.R=#I;&8/>R=FZ##NG@U?04.OUUJ M'BM2([LSB?K5?;9>K[G+\4R:I#GPQ0GMJ/%@Y'C=]([YRK2TJ%Q_)HH,;Z8N^$"#NC/-]_.(+B3_C< MWMR#/KIHRI^#7W=`[4S$,VJ[HZJ3I0-\0>O!SR:C\V;IDX7M>,9_Z.^Y?2.J MUU;T2T:X]Y,WOG4!N#O$\RHU^B65&D-U)XC?L\72=C1'\&CUN<3QR>"\!=8= MTQGXGV#GU-@,2^Y7NL);&5%<$:_:R+$Z@:XANC_[.-KY"5ERUC:_FAF^B_5,05^_WVQUMF@*WRF1UJI7,ZPE1)OS7`C.7JA4FG]<,9KE^ M2H%8Q8X8#<'>Z,83)'/>NS%X>12LU-E\I/35?G^@;`]>19F?@K%*E*P"":N) MJ+6DV*6'WCP[DK?QBKE\.FFW"N=LY+MW'+>NQUX M!65VZ1[7*STY^\V!5Z&.-=UU.DT]N=<\>$74*^GETY4W`:^PC&X##BR^]NLI M*18L?'T=L!81M*2Y\VB<[@[3$*Q5>+.XQ8&:;CS6.*P%="WI]"R/1J/-82TI M?5V?8TM:/H-83S8R*@&@'GB+J%O<*0#[5.T.W@J<6](,6AGUU-W#6T3?8B4E MCP?R-O#>@(\`GUN/XO."(0.Y%"TIM1^.DQ1=>>6F,!51K2RA9C2L%Z8JG%>6 M@J*.FH&IB$XE.1NC5$>RZC#Q,O?/^87+190JUBYGPUX_9_NBMVX.6`&Y2AI% MGPV4D5(_8!5XJZ25]-E`3C7WJA6P(HJ5-9$;]G*X/A^PJ,'J)\VP\`D<;!K\ M;2-/I:3S]%E_G&J:4@I#74`7T;98-8Q&*=(V#G,51BU6%F>#;NIH[PSH(D*7 MN#K#0:J_Q-I`QV\];V8XB.C2<*D[^*W#%H9?,+XXE]+%ZD89I#IBEH)0%\Q% MA"Y61[N$M@HO%ZLI!3N#[Y3"Y:RLE+2RW@;::P#%8>[&SKI2TLY:2:FPU/LV M`Z>(5,6JJRY(RAE-*>EC+:<:`=<"3A%ABO5.=4A`$&YA)BHE?:W/9##'DI1) MO'`3:(JH4M*TJY\:7K$Q+%48IECVG\F]0=3Q_5_^:ZWFL]4B;5*FERG>@AN`%-S:!7L1$F7[(&J'!Y: M%=B]I+7V0>Y6A7-3TH!;E4=UHY4X>&'"_[T=NST2?94_:*XQ7?] MVT5D'*X)8JJV-EG3%4L"V)!+E0IY$\/1J*?TY5@VPEI`-8%1T6942K!0NP/L M*GH`*%4X`XF.V#DHC;N#7K\[[!T01D6;5"&G$#8)ZR[Z:DTHK3710DG!6S*" M21GW&IU4HGRKD,;)5\$2'-O"ECHKJ9Q*26/J)N&/*=]-@2^Y?QN,F]V!G/E, MFV)3N(C0J!OER\AT5M>0"$;36J*905G9CH7IXH]CO;0[Z&MBB M)1<2]86)L_&HI[37/F:LF;H M:SC-QFQJO2B]A0% MZB[=D3'M*/32M_8-8W"(%*OG$*?;+A;":!6+)-40K M-^HSQ7J53,N M21=\8<_TR08W1B4]"=65_LA5P&@,]IK$;F7K?\_8UB`P2]HD]`YJ=VN6=R45 M1\/!02%?DZ0:5+90Z\277VSOX2Q7Z0Y8=6CP+I#>_DA7:0VH]"K*[;+_UJTNS`Z10#>>BLHEV9*2I M5RNF^QZ>#)GJTI^U&(=UT8?+YT,20A4://:[\J`[DBLJGT,D50W2J$*7R:KJ MN3*%M.7\H9I9ES?_H)$C-2PU2=<`O"%<4Q`7AS0/`N)ZSO.P.`0IC(H#P';[ M(UG28/,PT*Q7V9P.^I5$T?EP.T8SYIXO#B:=R;+QTJ>&LY"21,*N7^LM*E7)90T M>!V,1677$1*J)G.UI*GLL="F@;2IDO:U9\KQ<$[="4\EG7+E(SI43:8JE33H M)=ESG'2J2_B41C&/CS8I#(L#D,/N3H]*Q0C+#HV\485)+V#I]0=R5ZEBVQ\@ MG6H0MQ7"D()&E1R@@R!2$QJ[0ACR3!Z-QCC^]2C)M#TOC2M-W$$2UX8R;#NHF/CKVX._;R!3BRM4=H8F)U@4Q.?E_8X.'`J;,W@:DF;]U'% MF,1^R5"K0E1+NLN?'0=-ZM&(:GEO^T;I(*3FOB6%FFBLO\UMXYZ)48/`J#*D M.R3MZ96TMJ);,!9#[O4'%2]<(BH8`KXF-2Q,@#P#3&GBTY"Y=63>S MIS%<:]9<)?,3>L/>P?!S7?II>Q-N/5Q322,[/+QRM;:1ZP#?&,+;GV&Y2K]H M.,C#BHIF%>F$PX:3#P`R_<:YT$PS:X$=;G2%*I>T^UT.?Y-HU[#=%0PL11D- MZD&[:NO:NC:T.,0V[`Y78VSU]=^M97M*+*61TF\6A7H59_K#2$WG4#]*_ZD6EYMLZ-3TA8N661FWBD-1YF::F)TBL')+AVLVIUT.A MWD.2'C:QC MZVP?7HK`7=M31V,@5\R_N^U-9G2$&7WCDV9\823Y3:@ M8TERAYPTJJL`42/@130NFX.4GF1\$O@%;#J:0^TS\;VH-AEE2OYVY$6"7+!T'6Q_5_8^O.OU9+A"(K2*Q5U:2!J!+QH#RKW6]H$9OC3A>;. M;QW[R="9_N'E-U#_U];-DCF@_:W'"0#Q1.?K`@`W+!_^)CZTK4U.2[&>/U/4 MTN!2<(OP'M=J39J+FXQD+ M:4MS@STLLQZ49+7;.M`T@$G1_I1<;`]'W7[#J$Q@WQWG!;8S8]9&P1!OM:3S M]&B@5(`\]?::0,YEG&)=/U1'5:A=`O,'WS4LYKJ7S)TZ!E7!\)@#1B$P;\3/;/-[].[CY=?WDO=9<>_/?[3]+' MFR_W[R49?[\W%LR5OK!GZ:%:'_Z$C?06VF4EO_L^C]Y.46N[B\]7D[OV# M[?_[S?6JIG^BSK]?_WQ5_U4_W5__O_=GUE\LK?'GWO&]8/TD; M@_:3-`/*G+G&?]B91O<4[R7+MECP=\]AWG2.?W-@#R,\?@1$ZD1JYP@\X$_R MN?2%CT&P9U+`5))FZ=)7X]$R9L84W`8IXBLI8"PB`2UQ.L3`'PSZ05LL?_HO M>=#ER!DAFJ>*\"H/[`KQQ%F6^_"7'1_EY%:?&':3Q=(T;N>&],&P73BVX&JX MTH7M+&UN4TEOO3D3-!@I2OK`/1&!2@SAQZRM(63+K7G$>&7_W$+.89TP00Y]*U)7UD M#XZO.2\2*"*Y4_P%:3K7K$<$Q'/Y^IY=BNJY=`_0"/PZTIQI^K_AA1A^)(SN MC.E\85MZ1_K=7*_(&4=I`XDE?BG@!T* M.0,O58P%FOP@D@R=Q->,.]DHIH)\-A+KIJ\S$M2:N,)$OO`B44FR!@7M\]PF M.?5LP6JN_^`:NJ$Y>-\*$A>]"\%B3ZB.9#O2 MUZL+,IWP*VB4H&64/+N!&2P!QST;X#`BRYUI%FFN&@1/$= M6-#U32Y[["@4.;.Y#>G-'<8DL,Z\.7^3:WP/?F5T;/_;MYBD=CMH/O;H$0S, M=&CM*9BGTLRTGZ,%*WZ??L`E(JY8VBX5!D@:`9O\7L07"TUGW.+,Q\SUI_.0 M"9<471-&H>V%!#.`0(9%-JCQQ(+]M8/;UG!Y(.L#`T&U9%-B8X'HS(>=?@%A MULJHH\/N@CE8LP';/\._8FX@;33+\H%W,V5;Q+,@ M`W1,?M%1N-@+PR-&A+J,K(3-O:I."&MUU67U_6;2_+[ M"M0LG&;6AMA.`CO4\=P*Y!(:=CC'AD0AA9(<2_5(BFE16'T))M/46*)1^,@L MQD-"\#FX'9%,_\TB64?U2"X(1TKPB1MV*.\7VE]@!P0\1F(/+#5_P3NE\:"2 M-IN!F<`-4;:T'5Q56X3>G\:3,?&K9BRM-JE[\,$IW=(^XIOSOL/?HHM(89YC MQMW$/'@<]L0LGWM>C"=HNI).]>FQ[Q`9R8I"_>/Y9,!RXVA*"D4W`&TGT&BV M&R-3JQ-:G;`7G8"WOL37]$/L_K=5#J>`7>S*@4Q4`XN@N4/*HKT6SAO8O8YW M!E;R`@0^YOEQQ4$2FZQT#82[AY&!ET"N@O@BN;KTG>E<>0X;^`DI]3!ESO8[T/#?`.]:62\?^ M+E09A@N``LY?S"-(&-<:(G2!*G3!_66`%-!G+\'#032QE?*ME-^+E`^J@Z2H MD*N5[Z>`7;BQ3E0D&!BN*-?(PM6%M`;I-=.FT0,F3[5YP6BL_8PYPN<2I4:Z M88A0M_T';^:;L0L1)S);\8*9PC46F=^N2SZ`,+-!<#Z(HD739#QV0J:ONV13 ME.S2%%"T%V`1)VY;;*Q[DOZR[&<+P?5L!X3V]0RU@GB.$@)TAHH*.XH([>5; MP8OPI6^7O!`!-(I+\A8`1"/&J@FKOMB5)MDQ&(1ETO8%;P4DE2Y(P+",6G(37'U>L->M%&VE:/U2E`J\I:L@<(@GC(J[I0O? MP1W3H56QJ$HZL:AME1A*58'VQ.WR';D&+@C)(`CBV< ML._-:N771O+KDVWKSX9IMN+IZ#C^`@PZ$D#Q<"ZXOT&T%F.7&!LV>*04LPS= MT%RC#'H3"\!XX),BGI24&`+" M#GU>`V`Q'(22'/X@7HWWC_0)TSO1,O0_,>]X'^BUTU?'U]A?I M%]M$?G"E6W"+/GMZ(E,1@T]G<_N9I]I2[81I/#@\V?B980XN;VY!-^.:]!#4 MK<%Q>L"4X#!/"(-6CX\.>\03$IZ@'^J4UL../%0P2SCIY4@3+XL2X?D15_H\ M%E@[4&IGK(Q7@*)@',]V%I*!\D>CD%AB%T1*:0>#8R'8X0J!2*AN8K4'_.BP MJW;`Y?0!C^H!I,_&`G-6$HRUU+PP(^_03_>HTQ_UJIUN>8>G>Z"J!W^Z6V>H M=89J#^9PT7&:OM`!W,"G.BLHNV^MR'I M#FV4O>#7K)52T2+),PF"99JU"'KC3'L@+&X,#8)[JL58Q@Y9=):"PP(.?'A( M9E1\9?N/\P@YI:L,CEG=[^<0GN31VZ5HVD MG>9XSF^8/43UGK3'/&5+I$>YL48IC[[!4Z)`.7P,:R1BK9>^XG`8S=%=Z8,- M_TAO/TZ^?GB7_<2%K8?%N=+;R=>+=])0'G6DD)5Y#\QL5@NR;Z,*$Z9AR4>0 M7C9-SGP`PPS1PYIBJHE/HBAISP21YB7BV%8BE-*NO"DTZ M@LX%O2VY?%:+J/Z0WGHO2V/*VZ7`5PQ26RX(Y@(\=LU9KG=AC MD?5B`@ZQ>]@35A(S0GDG4\P`E3XRWI4K&"'PTBJ#HSLBN M7\LH#SE;0X%*D49R/Z91+@&")^I2X,952?@Y(OH+TQ]!%D>?\]S&!<..6X\2 MC166[C7W+^FC[<"+PM%K4G=XUG\??QG/W<5O_3%GE/NA6=*U!;O@TQ?>`I&O MP%_1T1D41^D=O`&>T=EW+O/A&U=`&2])RIMG2R+UF*L1>>N&E2T,]\"A6;K! MR)BPUB:]-?D;S5.JX_>W6EA6R=,(.0-R-&)Z%:^1-0(T51+9:K;#$4HGJ]EP MX)OT>W`1$S-BH^+@V#R<&)'Y3WTY%O*,Q$GL5)]HY/?5J$#A2+B\$#R1UA*5 MA>>4DF?4C7R:3&X#T:RS&0;E8JMV,.H+0MAPYYCV*;>X(,+MF8H&+/&&*]H#=G6*@1[SC7800#XY6;AO[)"%,G@'52[=&P2]MY8. M>IA4B_LEMQ2TBCVWL'.==AS(*Z]WVJ8ZF5X?,EW0618 M=(``_D?FI-L._0G,"^V1V;X;E+(&?9W"5T7KXOD`G]FAM+%XTSP`U7OFY5>T MQE(#RP!?1>T5^-OC'CXZY>><,)KIVLE3E"#2W&".YDSG+RL1`\21+"O>DN*[ ML8!-X7EMO$K9?D"O7>,ER$M?G'>TZ-)/^M;JL\]S1"?C!)\'&XIMT1](T&`] M`E4PBU0\6H`V-/^SQ_IEIUN=BV^+=OH^E,!U`H M%C(T^`'A#IJA(P-/(WT4.VQ&5L>0$R#>:V`-91W6H+`M2"13LD42K.6;H\..\XU:S#?I'8]KK7;/CPZ[N-.BVXS7L*-!HD=N:>2Q&)&# MBH;$G.F/U(M3^`RBP\H9]B#M!%882`F0+LQXM,YXT=+TA;JJN.?2+_8SL)S3 M2;1AQMP\9@7MZG%)X9UD@R$ZHU!9/1""`E::FPA'F398:1;UB21O2F>>!M8N MCUHM%F`9B@AB.LYEB)%FHD1J-=Q8NA(])8)=L4/##`KD&>^(W-ILQL-?:%2" M)9EL.=N1#'B.+1YL71".OC0UF8;V+^$/3AN#GX/*5]P:-*QC=$%9C>L(4]!B MWADUPP%1[YE16U\*W#('+>>7((DB06V'A``_Z#?HO0+,)<2$RHD,0("";]"N^'/P-7 MV[$&3!Z;SBWCW]Q3!6>2#@)UW#/-J.([N"&-=P!\RUO%4LJ4H]&_3S9VH$8O ML@-?6F@\KDZ=J,A]XTVG0M%%QE$',^Z,OUCP&T5.L"O4#!TN:O:4:OL<XAK+IR(E\B/#$)LVQ\"8T9)A17188ACK[L->XB+A7/IJH#HOM6T0;@.3,WA[4KX-+FP6?(I] MY0*5YR5BJH@$S@]:,%XU"!:#R=N/&FZ(.2IX"L]D$3F@;GN)=3CBYV0OL>Y$ MM]F[*!.IO74Z.N:/FU*\TPWOF"W1=9#ZN/ M2%%VF>@9X?*1&1;(-?@6>CT=R5^>P3NPRIE_#9P=1">V'C9W=EWZ.PF[0&AS M"1WD!R9MPK!:.L($Q+@MV@21XEHRAZ8%H#Q?@'H!Q\OB<7OPBRPLX8[@YWK) M7XH[`'#9#%@UWD0N[!476XI?EH1-J;7E$G#DG>\>P?1KS;GCQ*Z$S_AYP,$M M>.$C^J#0-#SBE]"E#B[.0@.*>B!PPX'B'/HY)NQ8L6\$0Z@6ONEA"W2)F4%7 M\'@`9&:;-,,%,X\&W?Z9$D\^^C7X[A7_KC3!2`.O>TRD(Z7NJ>(OP*958/VX M,^[S\_>A??7`,%(3D@)LT"`[A[&W71+SAK\#OC^O+^U\0B.[??I(^W-Q= M7MV=7=Q\_CRY_0JH8$](;>FRZK"^D:;,--VEA@/!<6(R_;Y$HYK_'H'A!##\ M?G5W?WTQ^7PV^7S]"0CDV6XC1,L+AYX-HPI:CV*$$NZ-: M^IEF`B>B+C+<-1#[T7-B/U-'W:8.WUE.:0W_]WQ(GU5F[_9PI=DKGQ;M,4M# M-\'(H)5YT.PP(,*3F##4C,KT"6^R>6`@\LHI\;8];>UI:T];`727_)R]4$Y7 MS+$RW*B]-AXV]+R$.Y25FQ^4&?,TL9<5/1F?\$#UR7SHC><[UOFAG-%#L3U/ MP+).#`41=YKHHF.Z'U:Q!:6!87IAHC=N_/\>E'*763WZFO1`:.*[Y_0OQ_PL'\ M6,#J,@I8M1']HY.1=_FQ1S<6170UDUK)=<3?,=?<]["3:4S13AG,)D`#^< M7E@02'5Y$#5?*)[`7IYZ2Z)K"X<^D,D6LBWAC/^-RR'I[?7M7?C)Y;L@R]AA MP9#TJ;8T/,TD-4JWZ$N3>2QB(*&AA1<1-P3"ID5!!Y^LOD5X^<]S`WEV<^*& M7U1$Q`88Q5L,4_.&6.H'9_5D51>_"DB#:KB)VE;#\C3KD7(2@US[P$2(375^ M@(.-YHP[9XRFRSV%3R=(5\$X:*P% MLB=:4V#[#E,2>TM9*;#P`X@&VPINXW(%!L,L21(9R8O`F/4&._,;FI:N3W>. MV-DI_JX9+QD6#R>-24K8H)&R6C@O29B?X71Q;TXMIH*TL7COJ#"[)DD00N*! M/6+N/&\_)7IHQ64E$L>? MOQ_"%L!Y+?YV>?:&'674/Z:S=]`>_+ZYOG7J-W+J&^.K+V":7/-,U;>?;==] MA^$N-$BPA(4:-+5Q@Z,[9+BI-&MDR;.AJ1QI3HZ.&PU0M8*G`&-#CRI_GADJ M&Y2!3\Q!#6+Y)/%X;[IP+9=""9C/@&I,C[29:+^#_8R$L1R;SLVUW*IH/*L0Y=QL#GH"O"=X_4"&_9NH@ZZL"#OK?7$@NH!C-V3MX>. MEN\%W)`!M*"3PV/N5`7WG2)9NLA213]8,Z>^&18LY).+>U">#5ZK8%3:60'L M2H2@\$UN,&PH!3`93K4*=Z77&0\'G7Y_F-3R`NS9*LL%K1X9/V^KG%A%T.[*06M.K-;V:N4^94G9MU'/VUK$M^'F:3K5M[:,C.0DW MV>P?&Q2K,?U\K87IAJO4%!3+[^!E\ZIT_/NHI(H]9T'=Q%`"7JD!6D5HL; M9XR]48X+.*9!J@-=N_!Y=5-_X?,\<3&^,V%S"#OF[>3FXOH=5VT(AT$18VY, M4+6]N>3-AJ@=QP);5[*@/LYREQJOK4>#+5985_`Z?!LID7S($2)A41E.K%C. M#0TJ<,"]J',`6"]X>T0JU^`QWQ4Z12T;8S8<_#UZ5;P=-1 M2$#FO*1P^(`),T$4^YD/2>D+U"2L=$M'D=T0;+*NZ,NIRS@S;/XL>@;H8"^* MLD3123MH+F?HM(^@[GW3XZVV7D)^"I*;XZ9UYE8UJNZ3B6'BERC'\8$Z@U$6 MHGC[LZ%[\_<\VY&>.3.U%V#P]S/C.]-_JI2]R),7PY_T$)CXCT[T8Y"6]H\? M???L4=.6[S^(H-LEM>PB>WUBZ9&"N0623H%?[MEW[X,)IO?/__M__>__)4G_ M"!8(6RA3S];P,3+TX9<[-OOGF]NN_`W^'SVG>[L[^*9VZ>G/B6E'EI-2>W>&'8'H.?)$T&)&2GY MK'Q5/EX`U-PEJ(LI3Y98DEK%@:[`!K9H)*TS+,OG/0!JM3GE;JXX8!(-$X2#S)84K`+.*(<]O4.1@4*A#1(X_L",]8B,C-AD#`/WP:L^9[ M-O;D".N3!5"\850B7ADFFZ)YB`<8#7*+UWD&0YV#DR%,-QNL-`IL\I,3CMY< M8JH+TT-#*#"P<,7@MKW>6[`DMRP,TZ24!!HXS=M@1/$J`52(0P331CW;XT(B MBX;<8(QMXC5D2Q_8M]B+NJN1$_:K5B&0H_8W77E M7.>P"5G+L8XIG*%YBZ-G^PRL9IRH(CZ,!\,W`_!<^DTDQ03-\3OIUVY[6.)B M1"1-B^B_Q3&I6:4EF/9O`:FV8L`EC3T`$==(TD-DGGQ_#8&0:RI*MP2;QY*H ML"D._&MJT[`YPIJ[MI*A+W+?8NV;*9E,Y&5]QW9>?')%K"_#+G,/QLQW MQ(`G7IR/A?%?!?0CN<_%0]9"(E76)6-.9[P+4-".KQ/5X0>'(>S4UT$SZQF\ M0/PW?&QU?H5H\*=)T7013-B;SJE+D9@L$U=1+6/04]/T*)+D$ASS:WY>E!6.CW"+OOZ;<5)\*C[_'?F M3`V715W1:G:OY%X2FLC@#*8!1/9Q0)9F8!F>=S/M82[[$A(NHQ-IHCTJ93R$ M35I!1M7K`W=&H\%J\EJ0*;`VI"LCLVJ'N-_I#GHK$)]+DZ3TINR$V,2%Y(&/ MW+":8>N-,0TWZ>;SKH&1]9W3\/=M-&XBC)Z#"GY7OVL/LDGM#SMC-??T'JC4 MZ79&XUYGI.;*U(.2.@=XV`>]U:-SR(==[8RZI8<=+Q^%G9>IUIMGS%)=?U!\ MN1)E39K=]2K"_CB;X6@>3[V\TN^NOBK@U-"&UQ[Y#>V$NUIT=QAPD;@@M!X[ MO&5SCLSFXIIRKE+AO`P!6BN?59/&J\3./`')B"L9R#$?2J3UAR5$Y0JLPY/< M\(%:]W6DC#O*<+BB4K/592=S8VK=A4%_U)%[_5+=>;A;7Z]6!JW2[Z@#^2B$ MW\$IY<'PN%2RW%\M=FD#(D>'W4:1U7U+M(HQVYS`(05K,04%5)I+MU(B[,D_ M@5\]ZJLBKC,H`1M+;*>@TUB0[T4V922V\OM+Q61>Z7#G")1W)Q*";>.MKUN\ M@#GYJP;L,`AJ8^HU.4:CSE@=I53\BNIKVA#$X-FXH^9GQ"1-[,N@Z:H1'S`. MOH;TB$.C*'DG:RI1_8DO/675Y'C6W$1[**MF]VS8S?`$Q4M7DGESS1W1Z2$P M^6TQB*J5$$>'W7U"DY^MKX1$X11>AHJ'_NV#.J'K]YCNJ==8/\_)F7:(:M_[;>FY_QKV?=P9G:32*66#KK MW1^ION!/ICD?X2_N!F_O\['%LV_NXKFL-] MQQX-%Z^HO"]X6;7^:X=O?IXLEJ9Q.S>P[88[-;"KM`MBU5ER:+)>M`K(!<.Y M#^:UI;/O_\->-H!D].9GT.W=L2++P19D+AU_]P6-V(QMT>:<-W[S\]F9K)RI M,G]WWM*KJ'\T3.9/MK,!XL/NFY^_@DJ#1:2[L%A(J+4X'1+OB8-QS_,* MO[XL'FQS`P!DX(';7S[P=R46R]AG,D=)J/':@9MD4#=Z]<2]L;JC;]UAUBN5 M-Y(/SAP]R6W=-^@E@P(RW7^^N?[R$83;:"CWQ]VQFN"%@M>G*TBN-`?#SBX< M('KV4M179Q-(C1%(34&KQJ#][>OEMR5SOM&2<:!!'F.30-@=FK0,Y^=7+*@X;A+"+GH#HY>VN#^8?H0#'A#2B^4#[[S4P\77*V M*G'ML/R,#4>CGM*7E0CZ-<%J!JNB31F58Z4J??`4NT/Y0-"J MOSOL'1A6!9LUZE;9K-YHU!WWA[6A=8.5H5]LR^:-3ZQ'WN3DBK>37/\@C>2D M'(BC`+K[;#12P=OH1O`7`U`+N$5$5PK!A1,_VA6T%1A_I)80MR^/=PUN$7%[ MA>#*PX&R#2]\I':8G[$;YBUO==`U])-MZ]3EM#KIAH4P*EUUK":@K/+Z M>D#.)>NH!.1>=[0UR+'-2']]$G5ZF,0:OA;1_)O8T%^IVM]W\14%;_CP\JOV M+]NYP.CNY+OAIO`?%Y_&%/;K8]($+:+-K)46XVXA+5*\NSTI+L,HY>=8D+(( MVS]X_D,$+;*0*I8]]WAZQOG^VF\&ZV!(8#`\>Z63,-_%\T"SD MBJZ:,+AC6WCT,\A08F'T^[L@0SVH%!LC??!G#OWTUD.'8NL'W*0UZ*`MYP_O MQ?%RKRD[F7=9YG'BP%D*GI#S_9UZ2)1"M4+0H3>F__SCQW51J4B"*Y$8>(L) M-ONCQ*AR]`C#W1OBM$>25!&)*9*,=TF2T-31#.=WO,RBFN&"!L_L%LMBHTWM)YV](L#32%Z$M]?B M:1X,N@@2=/(8.N'1?XM=(FPFT7O=2O<7HS&(]@C14N";P;8.%=;KJE41KA]? M?O2K(;N^W=GK]BJ@UE,2/%L,:4(HT\B+YQB@M3K2?^:V:9I/[O4+6,D]\]Z M79XO2DUKX;AZCD8CJK"=D,3ODA/)UC?/\&*XQ@H3]1'4/E+O(0I MJ.=H$P>/#KNT MCS-(,G5\Y>VB2"0JRW`/J42$5&(`(C8F=IGGF6')A(`XEF].,X'##Y)F/FRN="J5=RKW4X7[!)YG%OW>WAEK@T+5+Z-K3"M2YBN49077W?'Q7BT M6#C>M>Z&O-GU!4%19XBS$`/9UD2KE8X/NQJY*,%"?["P-B:GA-:EDAS?X:>R M]7=Q\_W_SQ7D*%`6N7EC!) MFFD\6O]\8P+8,;B<`*A?KJX__8*[HH0M8*G,*?@\AKF$@X&8$QR3^S\_7P5[ MD*0FM;OF8V,<(J?T87+Q/Y_N;G[[^J\9_6?EM/TD`7+WUQ>3S\'[8)\\ M>R$>_$,`2CJ"U$M$$S);8+R`S6RYX)0B> M/)N;+Q%-P!9OV?Q5(GCB;!Z$56/._-&7%_ M)#WS#79\MT@N#%TWV0Y%VW[V4,B>^YO;3,&S,^P=+`K+1O]V73V1V' MHA_XG0='DNXJ39111Z6&Q+VCX8@39?CV/+?G>?OSG&QE>@P,<:+\WA[G]CAO M?YS#K)6C88C3=3^:C2'?&>Y?TLQA+.P#CL.MV+[VO3*RQRGG#L&KWK4@JQ'G M#$EUWI6[XW8[V\-X2KO7'L:3VL[V,![S[AWK8<1V=X/A:][/`S'@F[T_^-TV M-2^J[#ID7^TX)=,AN*(''WQ8+U@XZ)Z/3S/P_[>#QZH]A.TAY(=0/>^.3G(_ MVT-XA)OV.@]AOW^NO$9->""F>;.Q=6QW.J41@\Q9'+PC=IPRZ1#\S&UE4N^@ MX@9]Z85ICMMN:'L<3VGWJA]'M3V.Q["A[7$\YMUKM>/1;NB!V.[-AM6O$@TH M#MY#.T[QU*@#^L,KBB.$_4Q.;1./B$?;(]@>P5/Q'M M`HWLGH:&Z$:/C9Z0X9.M"^T%?(Y#?RULF)_993"SJZ"_Q%_K9$!IV.FJW8XZ M2LV6CUH+&EZRP]TNNOOET3O9[8^ZP6%C5]'JD-HGQ;K;[K/E(8(%>^X:.G-X ML[@']DH:EYYTL[@;*];L6:$6AW*N$/A@V-C=T;%-Z0&;L3$:?;AX,"QJP+;7 MYUZCY[:&<'1 M&Z:521^[+>7(BT?TVWH82 MCVN]+5H[_7%WM>G]LP:""F=;&C,#J>:'C63US\SOC/]I])VC.'Z M3OB3'GH-\1^=Z,?`9Q%CL-:>(I.807/'`L).26.A,;PZ9.[EWN9+5YZ9V^L6 M3[;#*>PX-F<3(%:'Z*R.`*/A6`$1@GL*?8,!.L6C?^7^6([P6`N69K&H:;93 M\13A0\2[A@E>Q:.#E=%A;O@$A`H>'LV\U0S]VKK0EH:GF1L202Z>1R?W!^IA MDN&.8:]UIE]ICH43`3;%OWA276.8\VEA>SSR;CMZO%TK1?&*,S=;/$ M5\7/,?_+M:6#&Z3?VW3H`HN7_R^-9;Y_MN_GMN^"\3^Q]/MG9C[Q%:\M[/H) M]N2MJ246QM^_:(N,^8_RJ%P>\)FE<1:HG6JGMRU?0$-OO"GC"G.DE79/UCXJ M<\/Q&+,VW1>E6V%?NCL_+!]Q&`WXD$],3ZN-+\Q;I7(X]EC^=@N&`XC)./H% MJWUX^57[E^U;09UB>[(W5I/SG0NA3N/XR;;U9\,T81?33Z=_O[5-8_JR MOGY1E$,=)+OO4&(3X=&=(_`0A)=HNJE@?,+,"`-/X3,GAFTJ!+@#A)/38LZ5 M/HY\V2D5Q`[3K48XNDM#<>AZX2V,QHUN^"2:,P2K:9CY`/86CD*0E?VGSUR5[(>D.+TSV@A_W;VDC,;M?8A;R3'B9I\K! M52D^0=E1=,,9NR'];"Q`J863\FBRGN`)?JV@3<$X]BL#I`)'.HXZ>8XW,_&5&^<.=6@&VL5W-<6IP:$(<.,CBY-6H\.>#-MWS3"ICM)HU"[/YI%FX6)NM%ADJ&GBG9[] M7ICMHW%7_@D-.$Z.%\J-"P>4WT4#RF,1\F` MV(;WCK)Z`EJ+#!5)#\=`\VR;!-(X)GW!*3UCFN<[S$5+TP`#DTQX&E$,?_1- M+S"AG=3^HHN7I!2:R')'58=HV-)4]C7@7Y-`F$4Y-7T]<".6VLK8Z2CIZ(<1 M!PF=43+IIU-P2A`'X4T6$BA<%I!3^I12=)[>:OO1`H,<3HB`$7B*6?`M?&/X M1W2(<663O-HI8(:3O%W_`1S@*;/X/-]'AW$>$_LQG6/T^C@N8P!?_[6N.!VX#/$$;F[%8XJ5RM[_6 M2P&/-.T](177)] M`WH`]$MT-ZW'`H;$K88CI04;W!F,^@%?A0`'C"^$4AS."`6>!RAW^KU1V0+Q M;Z&PN?TE2;"%K2.;!+.J@6M\?J)A,_F=!RW%CS<^-44#T:<3&V8"PK=L$/[X MVC!1>UU9'HB=+.U#H[>C7$YX.YR["D.]Q2X@\6-X):7$#\..,@[(*+9'L&06 MJK&D1SK'/\A]_N7$@8X-MX]]([8U"8S.I4]X1.&K&2]"(F(Z)JW/CQOL?&\< M2;`?1KU>4E3D"ZAR2=)!^F"',`#"?#F7)BY)*R19I#7@J#H\,S]9:9/8-8MY M2%)[@2GEGF,\^#Q^`NC'$UR%ZBN!OH-G7Y@1G0R"C,11@,5_D-5.O]_G*NA+ M!$28:EX-'`:'"=?&CM6Q[^(+X$_#>.;ZEPTQ+=F(.,8A.+#WO6Z$:F>L]K;$ M-$W,;(3C?PH06)(Y?YYK-2('F+;K;K__:I(:P4GE`+]%*E"@D(PD^+W7&?8& M]`<.7`C(>I1)O0:HH+Q+40;^*`_>ITPW^?X[4Q!?;FJY-L^)0I=H=CC+ARWOS]I#F$K(XSK@UI*$; MSOTNBE%4T[D<`TZ%P<+9?`'$]!O`DTS&.7N1W$P<-AM'*%)X*#>VW>A M(TH+3R)O8^W+"K4XVC>01T5X58%I1VC5A%D?]SHZ('MO?=?2*HWW'089Z M;T%ZQ6E61\0>-5V2](JMD$.E10.%#;UBT^=LH"J'RQMU5SKT*M\)'S`9:A8= MQ1;=$;%'7:*C\HUR#;3`\@,>CW/A81&9P^37('0[H90>>?WZC5ZQ99A6"54! MJ1F!@ENR7K$)N&*L;XK!A)=-`\=<4*#2G5CZ%<:6+Z+P6EA$O`$:XT/-(-X8 MC%1&:?]:YK(*:(S79G:VD+5[Z9:\T6Z#>?A\B\R"94GM(:0AUHCO*P'7; M_(9ZMT/D2B1`S$A"KM9/L95,^Y-,!Y/<4B=_BD29C)YA60DLJTDLM9Z506\5 MENU2R$0Z8F7(,G(3VV-X9,>PS1^M\PR%N:CI,[1!8FJM M9[N?`=4N,U[K%50B>W;55J\W^-#+<%B:R-'=5&@>=)3U0(/A1Y$.7>]I&66I M=4S]K/4U8YF3T?#=ZHXJ)^KDK%@51K-G.U[>D3K>M94Z MU`HOU8WLZH#S@I15Z9'C::FT M5H;6QMF&%7,,PRR:**DO,]'PZY19&E!^-<&P7]*M0NEW-TNY7.E=HYG,%35, MH.V>C"E;;?[9)*+%6>ER-]GL.@?@1PIO,IF[_1&E?!:'26$,=W&>;`X;7NHC-.)YQE0 MYJ."$>O/8/+=6-'?=JK3BBOQ1BN5Q"6`;XMI!6#DK,D_XH+BWSP$UO("!Z3:$MI,#D23-,-&CO[5CQDO!#/FBN M,:U2V%$/ML5FRYD\[B?W8N#0`3X4,O2:8X=B"PC8054/CPX- ML$/)/)Y12MEN28:@-NV6.<%\AUW*@)3%]&W)G&\$1QQM!;8?XQ@1TIE0;X-: M`_LXK(@:AMX;P*S!DSI:8].4!E%K8-/&]6\:J>O\D,FMYNPVVC,L-J-&P\C( M*(>Z)+CUV8!_=$J@X8DYS)JR0HN?Y_=\B+)[8LD]%B`#]1(#2U7' MA9&N3'3J(4&LXT"S)"BVNF2UJQ365^>3X!__S]G91]OV<.JM]%447\)KSLX" M"IF&]=?[&3QBV3A3Q_I+^DY_`A>=_?/-W/.6[W_\\?GY^?S[@V.>V\[CCP"* M^B-^_",^^$8\[[TLX7D@']TKO/F9%O]Q977X^S]^Q*6,]_B_!,7_#U!+`P04 M````"`!0BX]&T=0M[=L(``"]=@``%0`<`&%P:&(M,C`Q-#`V,S!?8V%L+GAM M;%54"0`#B-`L``00E#@``!#D!``#M76UOVS@2_G[`_@>=][/C M.&GWVJ"YA9LW!,C6@>/>+;`X+&B)CGF52"\I.?8=[K_?4);\)HFB%+L>._NI MJ<*AYIEG.!H.1\JGGZ>![TRH5$SPRT;[Y+3A4.X*C_'GR\;7_FWS0\/Y^>\_ M_.737YM-YXYR*DE(/63CR8(8QG.'%%X#2;^CX^X]\&1%$' M%./JLC$*P_%%JZ7'3P?2/Q'RN75V>GK>2@V6[_^\O#D MCFA`FHRKD'!W*:6GR9-K?_SXL17_%H8J=J%B^0?ADC`V5:E>3N$(_;]F.JRI M+S7;9\WS]LE4>0VP@>-\DL*G/3IT8@4NPMF87C84"\:^5CR^-I)T>-D@X]%` MF_G=Z4_GIUK^QZ=0N-^Z8ZVD:CAZGJ^]^S5U"4S#QB,V8$+;O:7'M-;%6J#% M*_6X@HF$SSSM+I^)KVW^-*(TK**488XM:+@*^9J&A/EU#;:0WHU69Z]3ZVSK M?#[!NJ4!Y:'J#KMC'1(J>IO-9#O4^8JHT:TO7K:A\LI<6]#X$:Y3*>$6(R)I M%?TRD@MM7.*[D1^;]0'NO:85G8:4>]1+]=)3O69=QM$+[ND+=^T^OHZ;0J[# M3VX3!\"3=_!&Q<);>TR<#ZL>:_&XOFAIQ;Y#LM%]3=(7OCES7F4@WG1!^ MS)"]_IA*1K14%`3Q;$T&7I_*#Z4(JEHS4448<$0*5!)Q_")^PQ$2Y"$O@;3D MA;+G40@_(V#E*H*5QD,[J,0=+@8 MK[1MJP<8\=*N5#HH*18<&IEY(Q&OW2L1!(+'2L=^9R`J.Q0!3?;$9-5'O$>K M'C4Q!T9[D@XQVG7#$95+QKZKAN%&@K M4P_R+^8R4\YI(WQ0!-H`RB?S799,0-S:.!W9W:%)[LG<'LY+5IXHB?O/]\,] MJJB<4.]6R-LHC"2]5RI*CLHM'JZV<^TIM]-J?2:*>J#RF'*5^#CL/)_CD[S/ ML^601S+3ESHO1'H)8=THU'T#.K7]$@4#*DVIX?;OA6")UG:;3*JY??,@3HEJ MHYUCZP[G5NY,(%[H^CV8^4Z72W;A?Z6W_-,-;:R$..F[\HE2W6%2T@YOM#PGH..]$&HY8KIBQ6ZDN0/5AMS M#5Y8>:;]K+,U-6WAH%A!-:G:7#\;P!`_H).5P9^M",L=C8VVPLUOGO*(J7DB MO@[=\]FJK,I8^=:SMC#(B@' M0'G6U]QC"4E1L,:HP[UK\"I?C'5:D.ANK!X9Y3!QMNEUV;J1$0KBA35_Z<+7 MC5M>P#A3H8S/S=L55YR^"B_4(4\Y@F2`"`NTRCQ(E6=*H5 M[8L>]>!W^N>XSZ'C_3M286#NJ*LU&P*BMU1DJ07??OFB*%PN7Z_;QU$IW!P2 M3OV/-O$$MN7Z30IXR@D/")24*'I-Y_^:2N>5IME;Q5+K]RC%A`%YGV=?%07E M[OD$0HMNZ'/AL3Y_8T%PN!#!M=6W-4TESE=-C&"YUG&#G(+HJ\R`.)=*#L=4 M7W1<,(^D`!(T#V>//N$A&$X;;5P2RJM,@L`EMK-<-IVDBA'*'6)_3_D"ZRSV M^ML.)M83(_"<'083:S,@WFX?],G9%IS^<`_2CK]0LAN&:Q=2D&RYDTZ*[C#> MMT!H2U_HNA4R/;SJRBN?L,"TH"O.<[3N4-$.B!N7UVM)]SPD_)GI5]"5BC_A M8UE@RPH>+?=EP*T;F_=-]C$65+\'Y14*KN\QL'Y+F-RH,"V:YDPKO$3N:-DN MP9W/]$\8F+ZF8TE=%L,S)G*KPXZ6QW68^;3]#0-M^5W.E9O'CYC*(L#YI'[` M0.IFF>">IQ_YZ5&7PL9AX)N/OFS$CY9P._CY]'_$L>7*()B7"/ID2NNZ0,$, M;\@+"BQ05'%!Z@DVG_NJ%1O,$[XA/[$S2(';H*C493'!7F-,F)=^SR5I)0!H M\_>ERS;L=2=\0UYC9Y`"KT%2ZG>M9F0%P*!DPNI9ZZ!<,M"]S+#_(EE>[Y!:H_)ZVO MF-H%:DZ(P%6VLXPRK0,U#8+X0'$5TOQCC:$NANL:J:5G9*3>!/T9U(B/^WN0 M%VCKW_I<"R@\>L_N2[ZZ>Q;?*U\5;2A\*A%1C<&[_\!F9SK<@LAH8\0S9N4!_QRMML.9IW MG\X_Z7PGA/?"?-,G0NW$T=-G!P/QJLL!L/@R=ST:<\01T%C%72U(S@&).+>! MW218YX%-].?I0IV9W4ESSWRAQ(%368@+<:2U6(9'L]1JQ,S\(L6GQ1]7C0WR M?U!+`P04````"`!0BX]&Q%@`J<\J```DR`(`%0`<`&%P:&(M,C`Q-#`V,S!? M9&5F+GAM;%54"0`#B-`L``00E#@``!#D!``#M75ESXTAR?G>$ M_X/<^ZR6>.CHB1EO4%=;MD9D2!R/-QP.!`241,R"``>'CG7XOSL+X,TZ@2HB MR=;3:-A5A?SRJS,K,^OGO[Z/PX-7DJ1!'/WRI?7U^,L!B;S8#Z*77[[\-KPY M//]R\-=__>=_^OE?#@\/OI.()&Y&_(.GCX,K-W.'B>O]/9W5/VA];7T]/Z!_ M=`][D^2P?=PZ.?CO5NNG[LE/[<[_'/SOX-?_.[A^'!X<'KR]O7WUH86L:.&K M%X\/#@_I=\(@^ON3FY(#$"Q*?_DRRK+)3T='M/S[4Q)^C9.7H_;Q<>=H5O!+ M6?*G]S18*?W6F95M'?W7KW>/WHB,W<,@2C,W\A:U:#.L>JUOW[X=%?\*1=/@ MI[2H?Q=[;E:H2BK7`;<$_;_#6;%#^M-AJWW8:7U]3_VY7%#&S^:?66[@Y*C\ MQR^@KH.#GY,X)`_D^:"0]:?L8T)^^9(&XTE(,1:_C1+R_,L7=S)ZHHQTCT\[ MQ_13?[EWLSPA_>>+/`TBDJ:]R'\,7J+@.?#<*.MY7IQ'&72$01P&7D#2*Y*Y M09@.R7N6N^&7`_KEWQYN5W3APH>#R2AX"F)*ZA$M`M";6`?Q.DH3X MCR,WJ0%%THX!27]WDP2T0I4T^_,N<)^",,@^II_3D%>IM>U(K:]LG48-8+B, MHQ1ZH$]GN`LWI-/$XXB03$??@C8,2/B8Q=[?^Q,Z`Z7Z?8%9VXY4K7IBM6S) MU:XG5]N67/IC0]2(S;$P@&DORD8D@[E;1U[5!@W+_@A;##*&#Z3]Y_Z$[EZH MPBK*S6O,HLP/Q">P[W@*"92`?586P)^+18AV`KJ:TO^.XM"'C=CUGWDQ/<+B M&F0&@-:6P*)V+MUT=!/&;R8(76K+@,17L9?3AD$UU["WR3YNH^K2Y_O-UDL1)]1E)WM1<7C?Q9B)/_US^PGRS&T39D1^,CZ9ECMPP M_"+%R-EVSW;-=+]]4D`O6JLK$OQ-(GKX.?3)LYN'F4$!&6T;%#<>NT%D1]II MT[6%+=HY')/Q$TE,2KK:;ETQ1R!1XN5/Y'"N`H/",ENO*W(49SVC8VG6X%PP MZ+%!%-#)X`Z:6_D0S`8D\HD_^Q25R/H9LC@K@UQA[*T($](#?9S(IDGZB[/T MO=E7`!RYA24DG340ND\D+)IUI'6SADB[:&8$5YY^1X1:8%D;UD M53KH3+/&I_U*:P9_3N*QEJ*FWXY50>0I"!07.V2Z^,0)[$U^^0)'B[+S_N3% M40:]XSHL=@`P`,@+_6/Q[V&<$O^7+UF2$WV:EC7Q[*9/A3KR]/#%=2='E+XC M$F;I[)>"T,/CUM0*])?IS\Y\@W(9NBEL4LKMUGO`ZF_2.LY)RR*U@FE03O6" MM566U3"QF6XW1=JRC%=75W5 M1(C8=)UBHHO^F1`BG4&E=9V3+HH53\2'.H.;T-A<5MC[[P:7N!9'.Z3*5LIS M

[R>C?XI!>R*>#[.,N\[F+G:BXB']O3N6KVN:+3F=;^=IK%?(MD6MQFP^`S>C][Q22\%*.8#TK?EEN]+H M9%/*0,QS[;\'B5HC!Y*R(<]+@6*S%T@H"#@.-67;6IY1[DEV_ M>V%.3UL*[*A4=TYMWBG:9$X9'8?5QFP\O2@+_"#,,U@U'HF7)Z!NDI:R$_\& MM`-3QB3/W*F_CIM$Q>F:)(5C2%ILU^8@\_I.!7L1V8G MY-OQQ`T2>HEP%Z>BDS*[@G/:X%6*DY_K-`O&U,'QMY0\YR'=.HHHU&K'.;5YWV*367V8',<"C+8M6)FJG6BA M(BBM0>MD+4Y5@'%8G*X]`/=HU5O-F@^;.'A(RT7-O"/$G<"535C>Z39WJJ=1 M?7X>DJE,%Q^%A#S'-X5:SIG-V8WI_J:@7';?E\'X=(!;=XXK-[&F++@!L>[W"<)['0NN)%5 MDKM^I=K.&8*K9\Z(8-WUJX-"YM+V.(J3;$B2\15YRH;P-=DZQ2KOG#5^FUQS MC>*B0N;2MB&H=`[DU'#.<-P%\S6OR-02'&0N:R:Y0K9H&2-M>RYI2W/S?9R1 M=.!^T$FA'Q'Q>B6KYYPAN&T5C0K&(X5M>\P8L;LX2L M8L+FM'8+,J<9W;LJ[!LV"SOGC4=VU=LT<"!A\S=;%?,2CALO<1+\H[CE48A! MD55V.DC.O!PZ5+CCX\+F+[8%,G%M-2RPBM??:YHP2DKD2CF`A."LK#J@V,0Q M`&%S\9H;:LI,,?2J/(ZH7YJJ89=5#Z#NBW67#P^;^]::I-)3&;.\TVWAB/]2 M((#-G``6-GY90$:@D@PP8#AV.G9.+!Y M3RE:[T7%`1B"/8@V07PH^+RFEB4M73%Z>3:B>ZR%1X>4K?6*SCFRY`%W*CX$ M"IC,.4%QK%>K,MQ2I;EA,:'[_^F&.9EY3?*L6*KUG?,&/=>T&=*')O9S:GJ@ M#=RDGZBQJM>`1FF6%*DIE^VM.552_[E<< MP?ZGYG@6(.,P:LZGA-O3;DL]NN$@?PH#K_\,`M.,B32#$/'37VDVYCOBIADW M^L-H^\ZY34\'*\NQ4>B*I\_$]>2O^*64% M4>I4=\X;#)ZL1J,.,@Y+%>PW')9F+QMLRC-;&68E>$2IM^"<([A@U^-*$QR' M+G-Y5OGR7+_#1!^D9)`$'JG#&J`E`,/IKN?**4@9(ZSK?=M'$HP:+ MXYO>F$?,JM33K18-\IKMOLK5NNREZJS*&G*^[9*-J`9&#M^-&8NX6^L+$A4O MB;CA`N$-*;+!5S$K")ISONVB(:DR4DX/J&!6XAY$D^#5I2'R:X&/"WGFSWGQ M#YOJ;3C?=LDP5`T>A[3&[$$+`#,Y`V&H.;.\T[$:=6EOY'&Q<&@R9^11/Q9Q MS_<:30"HG3OD:\/C<&;.'J-]&JI`':\E@+A'1W\Q2@Z1C;GOX? M>>G8)SQB*M5S.AA\\[7G3`5,'/H:<[<9N!_3)^+F=D/Z>N%EG`K9$U4#H+MD M%U"'Q.&N,7^^I`HH3O&[.<>>!>%3N(F\/_0K->[:Y*?X8QN7=-F\WH]D,@-NY:R%TU%ZB0YK%HP$JR> MXY2#7\0T:%"WC`MGQB.S[.$*A+%`X_;2(:U:?/K1O^<1:9]"N4X94"#.9J!6 M&Q#A.7OS1X[4'B;&9RPUDC)3X4?KI#I3K-J`!,_YNB93?'S&LB(I,G5%O.+K M[4Y5MO@M`"(\A^E:C,DP&LN/A,$KL'6,YT"M<6"H!--8;B33=P,@_[@0*WT( MTK_?)(3CB-I5RRQ_/U^X1X-.(G#MVL M,*948)K=".@`CW.](:Y%2+'E.[B#5.[P(RK$Z\.J`6FZ=)4Y;M@CPVY1)HR&S;2S+2 MUR3[S\7K@:Y'Y9/GVY56!LQ(TCR)6>%0J8@/F<5["YSBLG];)->"'=Q44#YU M)""#T/6*M4$A[Q"K`F!$8`=2'6AL)D7(L#T78"4+8LMJ]JAMK)ER>,@>$C"3 M4J_5LFJQ,90$L=`_FS@!+&2O"1@C#-G29YPY"T\*8$B!V&HAL*`)A@OG_,C& M@QQDP=G,>U%,Y@@GH`&4'B M%>%`XIW(I*BPO1UPD:=!1-*TY\'Q,RUU+%[E.#4`GDUC\1;6.2$P;`\+L(2E M?R9$/H=*ZP)DJYZ!RJN?D!)U%AG@L#U"8)U/7*NC+6)E*Z7!5PHN@IAZ8`#R MNV`<9,07G^\XQ4%H!(Z9BH.&<;X3PL+V`('9,,M6VZ;5>`L+G@0:MF<&S`?K M=:T>S4V$6A9$:+"W#`S;4P%6^,.UK-D@4KJD[5BX9=>N9:5^2%AW\XRNC0]) M+O\VCRO%ZM!M\3NB,UQL]3%:3^O/D6;%+;XR;YQ6G%8'3TXX0_0)H3:8[9]: MB@#E]?LD2(J4/FK3I+`)`(7GMD>7/VV<#:;YMQ%#V\&ZS-6AC@W37-)_?(]L MM#H(;-'&>12B-9?Z7X%.4>I,?F$0%(%KL@%:UA"9R\(O4?VL`VP^Z"'C@5_3 MZ=IU6=T**3)XUK/D+[GU<9YDC0Q9", M)W'B)A_#&/",W6CNURLPGFBU`VK=R=-"#;#BM/Q;C$"^!''C,/#I@Z\7;DA7 MA<<1?22PB8#CN?O=G4*0\69AI]5MS@%H)HTLF'BU((AL\Z`E#"#F*9#=R5ER M[T6@L%DW\2X:GSL681)JV7"0!0?7=CKN(G&P$VM=:++?P(,LV-<`1[CN5PR2 MM;TDEE,7Z`?B$S*FDT`]#W'E=F"+@V>$V7*I*R5!V0($N6QM"WBA0D"6>#M MI9N.>I%/_T./9:]N6(2G9I=P^ON`DSO/(*55'Y`C,$L)2.$L6^K8D`7C]CR/ MOB.;PH&<@-S4&YID4^2BL2>H!C@1K&7:',HA(8O6A65VX@8^S;\7I02Z7S\; MD60%MX!!A=J`&H%'@3:1RLBP!?"J4K<&Y02!)5!_M&UBP!:J.TCB">QH/P:A M"Y@BG\[L$[KA@GE!.+#XU0`H`BQ_Y;$(8*>TN=9IS.*8+C@#JI^MBP!?LR$%R_KR'0(W>C.O1N!.\7 MZ%.E3#D',;8HX1NJ='(7O!)_`.==V)]]3^)4^/(JNP:H!\'!T!2A0I#8(H<5 MAN12)T3@BF6*I554V.*!55#67")!.0B.\Q9G40YB;)'#I;S2(P7T4P0.=+K& MLU)J;$&_LZ3D`:&IR@M+^"@.0:BT=&I0V(2J-@$*0+`!U;-'ZV'#%@&\)+VZ MO9I?"4`BV)OH42*EE8G17*2O6?/G-/L#X(9?DISXFT`4K*$*K8`:$*R(,IK$ M%E)EF-ABBJ^F]Y(/Y)5$.9$3RZ[@=*VFS[#*H0@1MB!BK3'([(,([B&JT<1# M@RU.>$G.^SCRJJR%F_4`*H)[!\/+(0^F]4#AQ5/U"[^,(JRR]-A("\?8Z0,Z M/'<6G3:#AA4@;SQW)V=JH`D(CN("H2PX'EKFX8+/; MC:'[SD2LL/'@584%&]>)08U'/7CF(H0M+G:ZBQQT5007"Y69$V`R%Q-LG"XU MD@`&`N.SX7U'"&6VJZ,W%SUL*K*D@IE4I+13!/9L$Q3+,)J+13;^QH?4+W2M*`!" ML+61*9Q-$QN+N3!D0T9/[?F5-XFT,%SO5:-*"`E;C''IP3B76$X8NP*`0V`1 MJ\:7")$X-+B)D/`,%$'\:S>)8`E.>YZ7C_.0!@S#R2?P`M%R)J_LM,X06%BJ MT:B*CD-I@P_^K:/5VI$`*`1VEVJ4\=!P*&K,W"+;9]6X:0?`N`[M)DZ&`J0< M:L^VGFNA$+!?ODH_?=V]B2P+UR!;_$'((TE>`YKNP4W(A9L2GSX!1Z*TR&'1 M"PL)X*_^\P/QXI8;8)*WV!,\?;T]UGQHN-^/<(7L7 MF*UUCC&#@V??$F><87T*N#Y9:%^]OXU@BT<6+J/3644RI0IJ`5HT+SQL?5*5 MZ@59W@V.O-+1*ZP'2*UZ#2E/ME(VM$AS82HB1);KXSN)2.*&U&_; M'X.^J;6(NE.I,JM4'Y`CL'16YE8#([)T(--MQ-1C<6.7,04@NN13:@"P(W"2 MV:)I1$?&Q*#)P/^A/O3G5OU*#%AX:1:5S>:G?/]27:8(UPG:H-DH;5PEINO6]BZ MO1-_&!=O7,PNV:?7]>(95:T!T(%-JQ>^Z55'+!XS,.+I%LG%-[MMD':T)=6Z?6)S#I>8U;AU`BL`C7F-]R6M\06-@MG]SM*`V96;]T+QN=1>\=5F\,E(+`#]MR7ZJH M%6SIL^N.B9LX>29!E@/JV<"P.'$QO@9J17#3A7OBXJH-6U[PND`7#Z!OHS;5J=V%+TUU;`#&/C'5M+$"`#00)0Y'V[@D:Q/4M06P>,XV=3'5Q3 M%*=]_&F@MZ)3;`]!&!CH&Z?:YF9Q+5&`D$_3OQ6=8GL0P^!YN:&#I*($H/Y/ MH[!)56)[$:1`]B0'_Z1]BGX@E%OX_3*.BCP]N1L.23)NRWKU=J4!6GX,0W,3 M:L7V(DI=1?"'.D\1+8N]O8(T0`N"MUQP]_;*:L7VH(Q!"^DMX`VB-/!DZ6VM M?1-4_'D-4T]YV%[3,3A05^%N:=)=^R@H^<>X=+&H/?'S0,U&%+<_(XHW^TJ[ M0:^"G8HH;K=L&D!M1Q07-'.F!+,J^HPH7@\2;+=L6A4;"GDKN.9YA`HUL6<1 MQ>TU)T%\$<6%UME4\?#L640Q8,(5=&:0K!\^HKAK==>.;WK54#\NS`2=14T'V$*%EY[-G+[K5_99FF@Y>24^=-F; MG+J!TBV"&PG]P+3;`I7LQRV5J%M44XHXB+?9RZP^OH-KHKZ#:6K<:[3V\@FKO MSA64+EEHKZ`&H1O=NV,BF3>7BP$>FP$3^*;*3?#(+HUF`DI'W6I!IV,WCYOR MK+BI8#$1R^(CN]*I006NR:\Z)Q8N7-S)Z*G0^/%IY[C0-_W%&;[%PU&OO]['V=](MG@7=OF.665.L_E] M4/U^^#4)^O`6%8DMK:,UZ.5XOHF3Z4^TG"CV>[N"`!G[X8#51*\6:'3GTCHJ M>BSFV2A.*/8M>);.OP7[^+V?>BTI39QY<8ON8I/."DT(EG:-%H! M==HT4UM:[+0!(G.*$LB_D%[):TJS)=@<6HV*5EXXM1G4[@A\^,C"WAOM#+A6 MZ.9ZA6Q!;^Q,.H`Y,0*Y91>1*^6YZ7C_.0VF.N MR"0A7E!8G.#OD!1ZC_S>.(;MR#^*WP=)#"MC]D&=HC+X-WHE.YF>JWD4F_H$ M#!T$6SL]RX59[-AH055%B\S`;DO$D3MQD MZFV4M@(GA>K@^<\MPL+F`,056RZ\BJPJ`,232J,_? M!B9L/E!+Z3PJ+(D*M0$VAL=EM:A4AH7-&VA)<(UE4%`+8"+([E>9/38<;$XN M&P)+ESY.#:?=16".J,G6,A1L#W!N"*N83DQ0#8#NW)E0C@?;HY)KB_-=`/_Q MIQ8,>F5%Q)G`5*H[W3,$@0BU]BP"7.*W%1MRR)J#3?O/_0F9/GVZB\Y8W79S M.3RK.F-U;9HY=)VQN@H>.TMR?SIC;;AF=&W:.FK=3W?Y3V:)X>R;,U;7JE'# MA#,6U3IGS\#!LV_.6-U37%>]!LE"FTMJCO'1(Y&;!+'J++A<'A#B>:Q$?P;< MA(+,Y6HFX&]1.B%>\!P07SK`N'6L`0IRV<0%9$C#8 M_'5H4GG0QZ@7^5?0P\*X\"V:RB[@3%C/:9\@L))+FIX`+F]_-=Q(!T)#Z MC?EC4#,%2;.4R4F4U`2X"-:S2C0J(9#,Q?S M-O+B,;F+4R6"%J4!%DYO597E;!T&-E^9?C8BBZ9SN'D-\(-A<8:Y( M$KP6\_!WT`/M2_UH\9MX/R^M"]T2@5>H@`TV?8JXL/G!++LC]Y^OR%-V%:1> MG$?9("'C(!\+J)36!<@(W$*UJ53$A^B&""P2QXM7(6H+#8:JYY,QKHEX%89X)@R(X-6#_ MC>">P`1;*X`X?#5F+_.7->7EFNP(! MO2#;Q7B-]EES*;&KQFNVZQ;O`:2'(`2K7/.XQP\^Q:O@2TUGT&R\,=KE/L`:OJ)([J74)T-6?5@24&; M3EQA1N1#0A;'L2:H=-`QRP,R9(G%^?KG',[YL)#%KX?E+(, MW,"_C2[=29"YH90E83U`BL!319LQ!4SX0D`R`$7\F;E-RAN[`H!#X+2G39@( M#+9(CZ5TL(5'%.-&5S[H5-L`%2"X*M4?@'KXL,6`;-IPA:>U]<(`"J>?D=`: MR4:!+?Y#Y[Z%D;3K#*J(W16]')]B"5510+SDNT,BHWX-L5/Y$;9$WQ,UR81YL M4Y\`!2*PTIGO5.K8L<7)B);/>_)6_(OXRDJA/D!'8/^K<"Y2`X8MWD:XLM8@ M=:T!`(_`1FB$528R;($THAZYF&WZSTN3T2/QH&065!["TG9!53MS7C`(&%O( MC;!?6^@=@<7FR!/LWG)^AV=J8;U(8I#O=!LW4N9"_^K5_(*K375VX+!L1>648$(#F\ M8[-\E5.9(>(%C8%2]LMZ(D#)B:FH8""KL(\KI7L@(:%&_QM0P74*.GJKLGOC MM04P$7A?&=JSB4%RN*Q@%:NR4S-$IK@Q`+HS-JVZ*#ET5C!DU;%4M&M9*MH` M96?,3-JP.`Q9MR6M'#>WKXK(.+0V]\:03/:R=];AM6P!>O7.V!4K0>,P>XHFZ<2EFXYN MPOAM)Y_[[!PW>)ROECZBI8_H'%O=M!M('U%HG4T5#\^>I8\`3$BCHNN3A39]Q#W)Z.H_2.+7 M`/83%Q^_P>1\&\T?`^EY6?!:7*C`Y@%^R.&WQ?/@"ODYS7P`=(ASCRA8/$TB M1Y:WHEH@3J>%(!#')"M1F?!]''JBCZ,ST.@UV;UX0DA4,PUA1 M8PK3@>U/@[X1>#38[V3;T2.RW!UV7Q7JK,4"-])SML,KNT\IJ@A9MA!J&W4C MC\SV9Y$_"^BZB9/9(ZK]!/9E@="TH-4.:`*!,;+)SE)!7=B2F:P\XG0;96[T M0GV(>FE*,E%/$5=T.AA<69OL&BKZP98:Q>XK9YT6`O\+/%V"JR)L:5ANW"!9 M.9C>4 MZ]I`F>GE8CU"6W0+P*P`X!`XA31)M4@OV-+(@`H2ZJ!T1QE@K&#+4 M&P$E_.`;0EU=87O->%/^GE=L7E)0'H'SL?CV5Z4Z`$=@X-8E2I5N'EYL;QUO M2EZ.B*'[3JIRS6S!Z;01V,)MT2V`C"VK#K^O#MP/*G8O\FF\24[\N\!]"D)9 M$'.U!D$Y",S6MH>_7`/8\MUL8H'SZL0-_*MI+N7IP\0`JZAK`%M&&];45SXY/NWJXCL)E>H`'(&EV=Y*P<:++_//$@( MH`31LX]!Z$89+,$TXGHBB4)7;P24@,`D:I)0=I?1U0BV=[CK:3"%L'>HJ;Y`5`>`F-M8XM:)6UA>^X<0'F$^"F-/UZX MJ6P\HEO^0.`?BU]$"URE!IU.!X&-SR31G,6NAG:PO;R^C&4MT:YB_UBK!3`1 M&/:VVPF8*L"6B.F!3*:;M)4$4A*F!;6<#H;T>/:9EJH`6]*E>BJQMN.`88'` MIFN_OYC0$K9\3A00+>/_0D]^J&=#R4D=_K1DY!!])I!A2!P-2G%P&EC\]< M]B:;1/>@1R?)!W1466H+I?H`'8$AS02U3&#FLCB9XY1F.YC9JN>GZLAG3$K4 M3S6,TSPA"F?0NDT[W0Z"RQ[]GE`?L[G<4*;\/9^R18[1Z3Z'KEL@=$YUTQO3 M*VU6LE;=)D`!"&9V,S2RNXB>)L1)J+:8+N4J]DKI(O\:=B;9QVWT'"?CTD6T MY4WI'EL]HQK( MFU)HG;,SX>#9L[PI@&E7\J9HDV4Y;XKJDE8N_P_D):";G2B[=\>\Y8Q5U.F< M-'C`J[JH\9%8R4:BQ\4E@$G<\!9V=>__05A/9W/+`H8&G1#JL<&$8B6[B"H= MEWF2@%`W<"!PP[\1-[F._"L8_QQ&>,4!28-7^U5)$:.QDCU#;YCC^.HV%1LO'$O7C,$%9W.:8,7^S47$"DN.YD9=(T'0VA68C"@ M1:"C[2`5FPCL)#Y057H/A/&I0#>ARQL6*V5`Z`:]&JJJG0'!3IH!WWHB) M-T[,L@"BP3ODNMV?`<5.?@!=/LK]7"G>#?PFL[=NE`DOXS7U#I*P&J;3A=J]LOX0,"RCQPKD_T,.[5 MU=FC1R(7%E75:[/E\J`.FSL]O4<&]#B4W*-MHD1VAS83\+`Z(+[VF MX=8!A%8M:_HW:IOZYXU<(21DEVK&24-ZQ6:$/;2O$SR0=`9T$63^Z\IVCNFD MSZT%:!$XZ4N&$IM!*2ID;P1R MIP)8LI8AS40ZGTKKPD;1JAE1>3$4,J).(@,87)JH#0"-(X M521RVG.7?X]A_"T*6`]EZ$0"]^S/@*AAL"<$7W4E-@`Q; MUFN6'G<[."HL5KP:(C"!G7+VU2HP-6\[LE62O MO54!&H*[FIIT"I"9RW'-F4;Y)H&!F_"L)XHUG>X9@N1V=:9558S8 MLD.OR5U(>OWNA3EUX>_Y?E!*.G`#_S::)F=7MY(I-0>*09#4SJS!3`.X.(DS MT\OOYR,JPQ.LXH72_A]02P,$%`````@`4(N/1D@.;%G$00``-I@#`!4`'`!A M<&AB+3(P,30P-C,P7VQA8BYX;6Q55`D``XC7+E6(URY5=7@+``$$)0X```0Y M`0``[7WI<^4VDN?WC=C_`6-W=)0CGLJE*MOM``_`Q3F`'+X]?/LCP/_X[N!HFQ^\?W?X/?A\>/C3=]__]/[#?X#_ M??/+_P%GG^[``7A^?GX;(0XEX?`VS#;@X`!_)XG3W^Z#`@+4L;3XZU>/9;G] MZ=MO@OLS`HR5`I^P6$+?!/!U6S`_RK M@\/W!Q\.W[X4T5=H#`#X2YXE\!:N`>G`3^7K%O[UJR+>;!/<7P3U,O@*XY:^W%T*!/G9X,:)O42]M M]?,&YG$6G:7C.MRGMM_S3V60EQ/ZWJ:WV?N[K`R24?UN4]KL\14<-\X-G=7Q M1483CAO?%N7:"?[Y$O6ATSOX4L(T@E'5/TPML:N$.;''Q$1B MMEG889A@XYSE@_(27NN@N"<,=\7!0Q!L$>/#[[Z%25E4O\%+UG<'[PZ9-?Z: M_?H_/Y59^-MCED1HZ,_^:Q>7KU=9"8_N"[Q^E=47B9RD'_^I2UB-435*'8%R M6&2[/(1&(T3'OMNAX%Z[0VA91&1X]8?IP:^?OOK7-@&@%`"3@,\5T7_\A7ZU M)\I1WIV>(`^K?J%_*F1A+;X-,[18;\N#CECK/-N8#3/K1V8V%NW)L8>UT[@( MDZS8Y?!Z?9)MMC`MB,]Q"Q.L_2=941:?'H,<8O-S`M"PTL3F5L':N3 M1Z*/Y88AR-:@S1(PGH`P70'"]H#P!15CKQ`_#TKZ&C$G1#S4F.-VK^_0`G2, M>O7;'"HCXNROS@C'8FZEP;P!8;Y/:B.'RFB]T<&)/<6YSA^"-/Z==/4D2XLL MB2/RPU$:W2!THDZ2'Z_7YW&*MLUQD*#M2`EU5YR9^%M7HKG&I:]*;;XKT.$, M@A0I38LW5K::.VC8>[4*S0J@OE(M@!Y[JH44/2ZNUT=AF.W2,DX?;E#WPU?Z M7YVE1Y>!=>70EJR/?D*(8=V0K@`E`Y_9_[U:+,SFL`_?,1-H#Y^_%FBI.BO* M>(,TII#@L-_0.MZXGO9QA1I@5-5-_`;5\,#WP2,;=7L@.0F*1V1L\?_P_O@I M2+!IU;=AFO36(:4K5Q]IF(`LU.0?+5*_(6P"]RX,(HMY=EX\P M9Y:VN(4A1/V\3R#MI02@FO36`:HK5Q^@A(X@E%!6*VT!&EJ_H6HTH7VHCIA- M>U"]R;,MS,O7&S1A)>HD5J8M=E7US:D^"^N`-9"NC]F*%`$3$Q/TUN1^H]5T M3ON`'3>A%L\'L"*=[/(<=>FH**#>H9F4ROY>7BH#MT,G9I,U![2]9T=8&I/" M[:1U9\0>M'[.LN@Y3A*$^@NTCT\?8F2A:=^J/RE7;P,>UF%G(E\?A%4#8@H; M:@;'%:C^[K=Q-)[A/FI'3J\7&.[_/`7+(EX^85HHKRFV!WZUIR"70\``[#KS M;S$4HK[&:%]T7&_9P>P%&K:TC)\@]FG4L!_%S7[0Q"B9N4B*UO58F\\*4$Y, M)1@OX@T77H-_`A2X4(RI.-!1@&#[>$]@_>Z'#^\(J/%O_O/O09Y3__L&-8/( M2XI(=XJ3+&6AK>8!JUUI.G(TP<FX:3:`^=9T&>QNE#<0-SXCCHFT@EI754JF7I([*B`(B$.N9^ M8U!SMOKX,YHJBX.'=D^@QRPI4'`':4%&>X/,=OC7V"^:3@<$=O,R#"A>J<;;9)MDKA)]@_A2' M]37`/@?$QZ'--S%A M\U5`/TN?&WBNG@N!4ZR^BR+3RU$@?221XH0:[),A!Q-U<9"EYPD1_PN/(;BGR]L"MZ<#%['.N M;REFU[G.-<5""C?%QL3(*UC'8<#"$&-8D"\)38:PO64+(.XWI]!-4U"U9?KI M<"73&OTN>+2&WF::#/;\[B0)BH)M*8]>8MG[(@F-@^08XOYS;T%PD_I,`7S& MS7QP@U13P"?!T!I_BX^.6OTXS39!S*UA[:73@M0(5F4<62GNR=$`GF:DI3O/V\6]9$I&K MI/+ULHQ^@9M[F`^@2-[L, M_`0<',<9ZG*)^GX9;^(2*G`@;&X7!^)>8G0> MIZ@3ES':Y/=C_8]??PG^F>7$\U)X.$9I#P@Y_T0$IR,F+`!U MLGUQD4;,:W\%&SVI]EVIDVQS'Z=UMIXXPKFBT0]W>9`6-`#W4,.KTF/CS,'2 ME%+H:[7H:0:HF@-HL5@!DD37/83'3*[("S.?6?M/^20`;9HX>W@W`*SJ3PO= M)3S!_#ZKLPW/WT$7;_5$.!V>8'L8[!OX*UB>O83)#GNK&OC4([>.74VI^K`9 M>`>**,&;FK9^!?V-6^B/E@]L\RS$2T+>#OZ-FBA8]QIC@LB^-IG#T9ZF':5E M',7)#K_)^`3#71Z7,2QH]V!TCL8!W^_OJO2"_2#1HPW.+"-1Q9GX6]?5N<:E M#_8V7]`P!A5G@*$'6KQ)P-A`!#+]@GO%F!5`?BSR:%6B:`MS6/2[EHR]R>&1#[T&"K"H-8O1K`=>[!&^&98`R MY.-/JBR!G(;YLFHN@+(!A(][:(Z:7NV$6>JYM?APB`3/:Z3'[C>T_RRHWU/N M%1!](N%3RNGAT>7>]4B&UMDSGN-7RKN.K M#&9%\4I&/"53KA!ACMR\8YJ>H,0;IR9Q`?ZHXD91D]KR!:.N3!R.""$X!BW2 M=J80&D/CQ\V3V<1UKR-'S)K-5$]97M[!?',*[\L[]#55*-]P>P?IFH;[S2=D M0NT.2M00X)8K@-MZIU"^L*GI["YI&G)PH9^M-8S0`$8$$)4OJYCN_'36 M+[/)F1\]=\_9*/2TZ+Q`3UL.??0@*L_1P\V/#GH$DV/S(NX)%B4^5M!P>H8: M.[AD&^@Q?^54-?++T1$/-W^G)!]KFX>5;3>=/M0ZVI5H#<4/JJ6GDW)"!\>1 M"DGX\\?.+FQ5/7YLB-Q#2F]Z^--%_;F9L)9U/W.!4W*QRF71OP?)#E87.:(U M39_>[MIF()<24XR:UKV+`*%O+@)=/IR=(&4E5$&%>B)";9%0Y!4L/C)KI>\D M)QQIEJ(?(-R0]3[+0>NG`G4Y>05!"B M!)AT!1IB]V`UF3BYY=69M0G>NE`7+M8Q=4IN=O=)'%ZO49]PE5<HS0*A:D M8)=&,'_.X[*$*1"-:ZON`!U9_(D-:KW9;:K/!P\Y8NMZRS&WMG:V),NHZI20 M`;(UPGN]Z'1'OD@R^=&3BROX3/Y4#+VZ,B.W'#2@+15W)4M\8@/'!6_B*J/64H\B]'*+C1:N<;!3-$U4J)A.9T2G M$UN>+6'G.NK#3/>Z81]C%&]ZA:."_V3ET%X`#`A2:M`#K?X_51*G)(`^8IX[M)ZSIXK MF456Q+7#8JZ:0U6.C/5R$6-R]H*V7W$!;_(XA%-LBI"1+Z9%+.D("U,Q`X2; M!4LS447UA5=K*JQDWU:R[['&*O"OJ;A:X%]$?\G!]12]Y1CXHJ^\9"/TE-Y? M>*^>:EG5:OE4B;K'VBA`LZ862J%L]QJG*5AXG<P>/`AF@%*C(6=^O+HV#MN1JZ;C&8*%?H8P=>.!-1=09&=ZQ4>_2AJ&;D M&)<:DBI!6O/HG&2S6"G9#LP=9'4G6(Y?L]GUX$;\&*9P'8=QD'"E8>VK<>UIGW076562%=8TKHL9B^\;37C8OE,T MDD]<0UA:![NN?^WP(._+D%3S]G.2J.=!G#?[D:@1O!:.7D\V]YW$4'R?^5T.$:5XK6.A,8/3*FJC?"0\N05CW(VM`#E0>&1;H=T M*Y`,4_F!*75-$AY5WCQCUI@5+63-_)RY>W)XG?Z/70K?_X#:?:!O%^7/4G6I M79Z?2V12'9XCUQ/3@O<_K``F!Y32E\>J9G,G.3#6F[A949:\'GX_'F7#U*Y1 M)I!)"V7)*SC\?D]0)IL[!BZER-.=2,=>VF60WB1EA`!H\0O3R3`TV=AORJ+OG2#YW(T M)*)%O`*8'&!Z4#$@KX_<)FF?(">19XWEB2MY6*%]0@EU]:]B`!H.GBJ@MJA-`S^U3HY*';W3@:0? MFHK>E\+>^Z));929Z`\/,==:TXKE-5:; M#JTG>M.51U]QVB'N/FJ.7*ZS3IBZK[HS@#4]Y1$"S6+.V-U]$4=QD+]^"NH\ MVZI\PV(:^WEC)?WGGJG6;5<`MVY5A??D,D\Y&USV6+VIL(BGIAM7P0;]DU09 M#$*,>'4Z8@UB^PC3D8B#6AM>*X`)\8\M4H^N^O3GC(.?X8393%"#HW/@31*$ MY+V%\!Q=1>`@"8V@YWS:&=(0U"T].`O7&WX^L8QZ["V:,)Q-C!2W(=F6<-&O M+,4/=53+HIS.ON%2R"$H.M.T\V=9U)D1SC;I3X?M&D5U7Y0KHJ"]HXI%?+]5 M&/)HE9,._7`=(^FX6[QZRS:;+)47HY&TM7_!-M!?/KLZ;N--01GE4'.W9O)Q MM@F.P63N&D"1TCD`C5P._?3\/J%)8VYX9&E/S.(IK-Z+`D^TR7U,8?5^:,-F ME,+JO?P"JG]I:F>UEG>!-BLXQ0UPO+O55JK(8%-TEJY?I!BJ)`C M\EJ]7]IX=`XT1]L0(1&1UYQ7H) MU:EF5N3BF@1`POHCKO5R!+HU,]`HH#V31F(_["0K]+(]M1J[T[)VCZ7Z1%Q, MTM(7A9%U7;UD=12$"!=B7L1K]FZ]DF),J`$"@#DX<[]>G]/]1Y#<9$6,9UBC MHKL>N;L3>+E4O.?(R+#)K0E!1>E567B3B1.>T&O/F@-`*JO&]QJZ`YFP-GP- M)V^>P0^/KA`?3I^[U[VXU'CL,M38'2(N)8]:6JBX].D1BWBXA?`0C+4]B!P5 M!2P+C76JW]`Z-+B>]F%!&RB7F*5/.@W[ZQZVPQ#H0U8V_[;A>K++AB$N!8O%R]&@>#Q*(_P_?*/_%"0D M`*0\07N?5[1Q(R&YLDM2/7K[EZ6:%ZIA4UC21?@;NL M#!*W*C-9T!#_`S:D"XE#-__((\E+ZR*MP#U\B-.458R256F928 M=_P?B;9H4;NH@*HATT`!5$P%&!FQWX00]%QQM\HS33A(R0HB74:D"SUSU`T0 M.5#;U0R.CK:KNMM4U]M3];9TV?6DQ+R--J1#=V.8B7-Z!QD$V]-$5V7U''P=J)YNI?V\N(7&JG^@*\@UK?;O&- M)*DZGS1$7FF+YJ6^+I3LWU&QU[%(:]%O\AV,^*YJ7%EI<7%V@Z4GH_#NIWH7 MCE5F4`]W@,15^=NA MWDMJP-8O`_TJ;>NK%(9E:W7$T*M26TNX'Q5IA3HD*$"K4"#['M]=\#)H=S1\ M/S&I,R]0(HW0GT(TW3T6N?9N:/WP#\=(5B+)%(;"A;^H@IS(<]3#FQ,?4L]C M=.L?JKQ!YR%.\K[2`"=?O3P-G\X53._@9IOE0?Y*S\=)N/K9"[M0/HHB\H8[ M2&Z".+I(3X)MC,99@N=Q[*P#?Z34'.HJ-NPF905N`E:^P>VZ,)-\]3U3WMPS MA:U[IFU]ST1S/_WAW=MWAV`;,$]N!0[?X6MBB,EN^/7W_X^&<2P(GOKR-O M[J_-;ZS]NZ-N9416/JOEFKK,42U\BMA*4;VJWL32?&&.'\5J][V@?><6V.^^ M^UZVPA[^^*?5(0Y;_OAAS!I[^./[U?VT4(5F2`]SM>TUC M?]L?EUK?JVQ:`MP4Q"E@C?VXN!XC"'YR=8`$"6EC]]`W=.L\\]SHF[6Z3VH] M$!%85P-AS_O@8<\J&PB=R*!C"_S:W;^A@#]@@`<'>&-8HJ4`NY=TK7"O!'(8 M]75`!T/V5.`6ED&`<@O+%K1_W[=7>C*PEUHM*+^-4]C\1`4`U'__IV:Z"+7--K?V<%C M^`BC':ZH>;;9)MDKA&CNGN(0DD(>QT$!(UR1#*8%.8$^2DA?T+^NU[-.$MEW\'E_]27`/D6+!!W M)FR^R$H-T%3I'N7F71*%W#'F\A"T^:8\S#:P24O+NJHH&RJEE0S7FA'\KK3DASI&E+!^JH/,%7<)RHA)\>5-75&MN-#'FML[H M+2P@$AXG)CR%3S#)2)(.EA)*65!2B]K!Z8&.3/SNFE*QF_J:KLYP)J\Q:6]C M/5FXJ"48PCQ(\)NM:!.G,;ZWQ5$?NIJF26]= MUW3EZ@.2T=$'BAU*S_1M#@&#KH#^Z9P1.OM:-P*:%HNOS[+%N-0H`S+[E^P7 M?)]]K+A2\;/OH"]]JF.R$-BX0O5+(LUB"`/M(8R&!6#F0Q;1H,G`?H"#KF3< M!4A%*%2,:G5T#W:SZ>.B"$;,G8M368%RX<=7#V0;5QR_-FUN@E?\NZ/G((_T M3V(G?\/AZ>OT\9&=N`JUH/T!"M`OKL!Q763GF+X==U]*R-JX=L>D-13W%H9"H]J0JX$XH_];=A1T M'\78&`,2(9)1@G8DO_OU9C&;S+E6RQKD_5G%?J;EPU-ZCJ#*U;S(U_9N)1L> MLR77LI]9[?J4'99YD6O:XC!60R!ZM+5/-DJB<7-;*:6Z67Z/2]_=G>YR9#9I MG^CLDC^R/I^]P#R,D3PR,S2"F9OWNZ82+VE$JN^T[(C+ZBWSC4]+-L>/.N>1 MJ>.?P:HE>(.FC;ZN\2!L=[P^#SZ"GJ#,^^-KG6?Y&L;E#LE5V>0%?:W!K^V= MKS4\9DN:R=87/3&4]H:P$?]+\+0D^C:WIZ54MOVQ4F-4JK:/MDHX@J2$M)+W[T,?&L/[1,_ M7A:VFJS^.OGBOM\N:`]A5WPNN_P9)JWOZ8J]9MP=]A_/"(O.NC M)Y@'#[#:T][D<2B-+;+5@[TS;?IC:^VRN>H'8!VI3Z<`Z/>IS7(T*(N>/VK;TX]6J^$X8*#%T=+K5ES]L*_=6O6,1ZS=LGC M:*6WRPK;XO4YPZ+CKC2Z^W--/;\-,+:R2QF`/;*T]:6L:V-KV)']L[>F([VH MR1VXB_^RK>[4T5<:7D4$P%Z9WE%&87;K.\$B[)$!'KBY/@-*4[Q/(00+F8?9C?$DV[!'YGC@DM*=1VS8E?TSQ^:CO;!7 M/!#4\&6;X^DSH.$9[TNLQ$+&80'/>()E\,@8Z]^_.KJVU.Z!?Z9WMK&U%J?A MQLRZ".!8Z.SARX_W<''7-LH&6#:R]VKQ[HVO$F\ASB.*?G^2I:0HW"Y([F"^ M>:\RN+9[X\;X6A]S=_$C=:]`JUL`]\NY[^M\%M1C!-[\`P9Y\4UGE#TQRVX, MQZ")=FDU]L=9Q9,S'7KB_MOKB<8 MCKG-]62KL3]'&*V5Z0))%*=%'*H*&R_XS;T[II"-GS5_N/XRK=_LW(A:&L^> MV#ZZKTMJYH(QNS*UW$M7M"N0)8^3^^@^.Y;\"%KS'^V8-[-S5EN#RMFX+]7G M$VCH@JZ=5#WWP(.C3_Y8[N/BZ"F($RS6>9:3L.`E'#CE)_?'?U./W@+VC7ZT MSO-=@/J[8)WE-#9^3W/6F8]G5_;U#L?N@`?ZU&*71FB(KX@^`)KQZ0+9 MI)34D[E!C#RQ?@MJ[FP.GI':VK-\)TE0%-?KOP=8@O(ZO\5;[987*K%@:E+K MEDA#FKX&$!)L#1@10'I`R#2V,K8,P@BQ6%M!]DV;&JJ+L+ZFF<'+HL9DFTV6 M$FMX$FSC,DBH2N,RL,A4RYV5?IT;(RRD9X4&7D!5@ M;*KUMV)$EB#*"E2\7!9%GT-P6B6="9HS0@]TLWO[\_6 MSW!<;>N==>;'C&('GI7-\:,/:L:.=5EC[!`E]&8K$*LKZW_XZ+ M'%YEY3]@V90_;.<'EM@(2]_WL\#G#.,ZH>QG_75J')!1Z!@5]&'P"DO0?'K% MCD/8U]V;!:O@'54:=%[D?@%F@1I!Y"&S7^%VLELQVQWY<@R%:*27LQBX%X-F M@]41QEO=5F>^8/LA1;DU0Z(!<8LEB,-PM]DEN`[M*=SF,(Q)O]&_$TC\J30Z MVF1Y&?].?G^39UN8EZ]X'U6BO^&JA%OL64ELQ7R?L%_&>+[1X6X[&M:@S7L% M:NX@2)%*M_@CE65?6)$KCW)%FM2?<1GHLV=#18J#1%F2X,A)]R9O;C7DBDTO MHH/VS-1YC.PDO(R?8(0V:`@<\7T"CXH"ED5+M+8($H,TAIEUTS-*XK[F4"8' MA`MHV`#*9P7:FM5FY5XAQD]X'_I39]L>R._@9IOE0D3T/FB2TM/AJ#E6$?T0N'4I'YHBSQF3*@RW@3"S2(44QZO:LKK8D]+C?P* MDANQI=*B=AD(9[#'Z(:^>;R-FB1>0<7;(O&>B%"^;I4,@"F)=?-MB]3JFL'V M2$KE4KTT]A!=M?)L2S1*%*9"'FZ%--`ET15?MD!]T0[A6&]&+E MQ9['6(:N0OBRUU'`2*D(;O*@'I!>_N!RH)^ M1-A+!YR+SU6/MD6H!`E^"/($TUT5T%-<0>F;:!&%?;@(^\X!!K<$K.FJBAQ# M:RYJO@(D.,GQ:V)M45@C#S`O1PZ'>AW8V,/]-=KO!F6(N!'@$CHQZ,T.D7: MF60DG(GU3J(,"CKK"J&2@[>CM#V)?FM15#KBQ;(P2:BHH7"O*%HPZRN+`<;L M*!%B'$16.RA_!3F M\1-91WX.XA3WY#IM?B<_.]*@M:X!.O+T\=3\?04P%=,'D*6@_2=$[/+ET1C) MJ#1))4U4-P=)'-S'25S&HL5AO%`?J5`I?,"7]4N(=/"#Z;P`6UKTQ MT%:KOFDPU"F++RA;+T>NUZ?POCR-BS#;I>5-#C?Q;B,Q%!JT]M\\:LC#O=!K MT>#\=9@*5&3@#2,4A-S84J@Y!$NS$H*(D;G=^UD2Q^HK2%U5XIXWFNF1S3MN MM(3!0N.@D6OIX$Z[W]>!Y-.DQ<)G(&9J;=!M6'4[%7DL=B_?!['!7[I+@&%Q MUU<^PMSD%FFXO?V=GZ#?W-X/M_/PYLBH^S';MC*@>Q#C*H4-M_U38\8>X)%+ MJ77`T6MG'>#]?O:1@?[>/[DN3:+C,<"`[3A0,$M$XY=$01;V/L M[#9U^EBI(=E?NK4?QMWU[_QH4!'[ID.BA;1V%84ZR:]QEMS!"?\/_)C'Z M1]$_=T6IR)LSBIOKMUV:,JM?1M6,L(5J6%5E3QIN;KW/><1OA,6E(&`>(P_D M&.2(`]P0*QWB/%-HBX/_O46(A3GZ(XU*7E;^.QV;N.0@2"3'R(C+@HP30\>3 M'XE1)Q@"Q:LZW"XB=(.XQZ?KV^"UXT-OY:U"Y>+6G(-/#ZIZ'J7PIC"*.5"G%8";94WIPB MC).>GBF$G3'0V-I8?@&E"]6!UU!F.+68YC?(<4WAHGK*JUHN!>WM)\T5])O+ M;M7Y>``W&,J;]^<2Z'%IEW2I'?W&DPA%_?8IWY1B+=++4JVA?;JH:'1Y`E?DNG/G,5B/M6>E'3M%X@K MZTE0.-S2_/$F$VIS=]!W#*5;`;ZQ`[]_H,>\D\_[]2ZN M[[>D9@ERQ/-2M8O6DNLX2'`%SJ5N\FEWSU+E]9T/G=4Z<=?J*'WEU#XZ_^/7 M'S[^&4`*G#<17,=A7'IP#"%65W[S)]=5RW4[-9.P^I!U52.98$R%1M0\W%SR#Z+O+4P<&%AH@SYN\BK&BPE-):H>*VJHIWZZ8.7 M"DM_VL&]Q.*CR5]MU)_$QS&]FP[0W'2L)#5\ZZ_7]7Y9==Y6![Q(.>1@@(D> MLU$+6PS=;Y)LZ2Y_YV13T_8DL5KM9P5% MD>%2N\APD5'"6SQ\UH.=L?;#AB0+4O(8WX-8Y[EU<(SM,E=`RS=-@FWK%7PF M?Y%G(=>B=W,?I2'7B#,H1$X;+'6%HIM^>JR([;(/8)WEN)9R#E]\<$&,X#AX MN6*&1>>*1B=C@J9Q#'Q1-5ZR,>3BI\'7%TW5'H<1BV7+DT9>8MO;;CA[J=FC!^6BY17W MG_B2;`1A9TA\=9QGT1F3%=I089Q;#VK;%C`?VHQ]L1_Z(S'&`]A;"S)^6&8Q M(7OD7LQM3T9IT$*A';7SKIX=6J6AX6 MB1MOMD%81VD\5>$<*9JL3DA'ZY*57:[B2/%D%R&;TRDIB0]:D36*\5%\D(#M M[CZ)0\02#1AF@+9"`2@@,B`13I73^[.G-[8"G=8.!1$I]$+61VD#1UDE':[^ M6"NM,="W8JRV>,LMN1:Y);Y:MU$CMJ#_ILY73MQW:UL_4<"P5&3>[6=1GZX5=-!@%`\/( MCCKWU#).&!-MT[@747BCAJ`)R^NZ@+Q]'(@(WF-+:6I/]$/ZEK"5RQ^GD[]= MDSQ^TKCC";Q\.?:2RCMB5TR;,%ZNXY#GESUC@BD>.WAP**4&LLFYM@:*%]K\ M43MR"Q.(X^;.D?AG!1J?YS%;/C$O+QP:E;QCU)&N8Q4[>O!*&?KGO!C+3X7+ M.\+!)86;O'TSD&[J@1:YIB_$0^2I+Z*E]-I[-3V-7VJ'-I/M4C'SPG@I)1YS M;;97YLM\!,3*N1=[+->3[=I4Z2FY_F;)E;'JGNF_GW3%]]X3<\3+-.F*[[U_ MYD8M8?N*KW.`@SV#4QB2[$!@':>H$6+KH9U1R_C_K_W&7ON]-W:F1$IN^=#F MEM3@@-%U?A(DR4`_52NOR-6]2.LJ\T=A&3^1FX&3+$6_V*'?L3]F MJ0X4Y_J`B_(U\XS,4&Y\@NJ*-;A_!6\P=X"+D-*-[+&0(1_KYLY43MF)&]V8X]P3=2(S?.Y6 M<2$[=<+'K>&9*C+_-+B$X6.:)=G#*S(*B!C)#3TH`#H*PWT%GP!@BR[0)LO+ M^'?BCUVO+](2S1>.NCHJ"EC*U%-%:-_]4$G"K6DM`JR$#0F@-(Y7^:GR;-&. M/A5)876%U<(8MSX:`,R>OIP'<=ZKUWN]KO1:HBX*.NO:HI*C#R[ZK4$ M[C:SKA*]7O8AT_ZS%ZD<#?KK'LQ#$.AC5SS_EJM$'/?3+LJN,P0$;NI%#/5\ MT`L?S&+J`:CUI?`VJZ@<0H/U%Q3XL;AY3\,<1Q2=0OK_B_0H#+,=6CMN80CC M)URT2+9GUR*WOU77DXK;H3,R\*8B_`:?8U6TH"&>6V<^4KE2^("33RJWY>/$ MJ^7(%7)8W7D;`)#;`!GB4*UB&B#T8?FZ"5YQQX[2"/TF1UN^RSBXCQ-5QJJQ##W0 M04W)31<]QHX<5C.&H,71"R=RML&HI=ZVI`Z8U/`%NVL^G!1,@[W^,JJ/>9;`]EJ$'*J\IN:;*,VZ`L2'8IU5S*:>%5'WJ MJCQR$"II*ZTFXF9$W*JR3B"Y%7"K[B:05ZN[.=[=^M$E1``KF7&Z@K*P&SUR M#U1Y4"IM]YG25FLU?IQ2^K8B:PK(),E2KW+%FJ!0QX660]"E=M4!)JRT@T9H MFPD3#S1-(J&FOC7!8HS%\I%B6J\H)LEZ\HA^PL$:G<`M8OO)TI@TKA^)_>V8KSJN$'DMM%(P_X(OM,!\90QM2?V#_-PK3QZJ_4:@3S>R#01FI M1)J&99(&6=PHY%D(853@5%3-RY`QRD@6%W,&WTV5K5:.QNN^8 MI`;<'F0&'7!C`EH)O'$):$T]YZB<*C,O@QRL[Y>+\<@NJ^HX^%L M3W./=T6N3@%^H4<\!O`C0F8$*R]%.6MQK?"B*PEJ\7Z3K+-^1D3G)V;D!K-U&Z MICS$-*A7@H1)_19TWE#M1@<9-Y62$9X*1#&ZL3W^\?EX"!_AW0!F[G>G`LV[,L&"EKTB9'6%N1:E#S9"9XX&W`OM"5IZMWJ'V"IVJ+2)DUTI MZYUP)XK_[L?6LSV.0]M-?A"7FMDC]+D(?_(\"41FHM?&ZMSV^\=GS65_![B! MV]D=',OV]$H&[W5ZC4[*;4CXV!=+2'%%TRU$LC@NY( M:`?.T>^&7I0HVCM!QE"_A>A@>T<&$M+<#X0(1W\()8JAMX,4O'?5QTFKM4.4 MM/NLP@@Y7_`.(=RHB_$A&')[-ZMG09XBEQ0'-!`_]31.=B6,)#>K0@KK-ZOB MOG/;#=82&Q6ZS5@!UMIMQ*B^"%='BM@UK\\UL*8/27Y.XP?'M'WC]"L!@_P:H,`:`8 M+]%:VMP#51T%]KX"3T"Z<[5FQD;G0&XT)U]46R+K1.7V8GF=4>J1"MY>F'U7 M<17P-95<#_7VU)RD4+S*TCJG%LV?S'(L2K1:16A=B962]-%+V*>J2G(Q( M@$9;"CI2HLH19IE#OUGA?&CN]4H/:7TU,H&9Q2IURFITSJK.":NQ+9DCU^2Q MA;"'I&?>)+55%(-SG'2V6WR.%F9-=G@A^3G+HN'RJ$6!PR1/LTT0RRIQ&7.R7W316%:N#"/A<$!8\`5+5X"P`80/ MB8H%GRDK#YYLC)QHKL#AE%FVF3>1%%_]!>)MB`2TO78.LA]V^\F_=R9_!Y]I M"P]P-#BR?/(^X;!:?,-L%E"E1V;_C;)9,-50%-5*'49E:X\W3IJ"2E,=LO@0 M$V8",NX9\6+Q8%-\;)*IHRAN80'1&.!WSJ?P"289R;&I-*2:]`Z\;#VY>#<; M,$)049(7P2U:CXRRT>SQ[JGQU-FL79S'3T&)_`V]BF&"]@ZJ&0_WFR\37+6K MRW@YC(;7&G6^;K!RR&W:L:J,.([!9''ZK(R]AA%3$SNP8!H2\>:K(BH\VH/H M3PYOH\QFQN+%(2WNKL16KYW]2[]>/[G++?IWCQ:UP9'E[IW$PSHAH0#C6N"D M?S`ZW>4X`08)WZLNMJH6AP-3;L[";GH!,^D$0"D`)0>4O@K19!?!UVM0\UAH MQQ&QX+G!"O'SB'KW&!<`)I!X>SGGKW`/(P+>)/'."?G!'44<_)%*R6RFBEGQ0@0 M3GN@I`:2JW455M)OB?3[K;,J_&NJKA[X[=>[N5Z3XY$JZ>Y)5DCOG^5DSFK: M"*005K'!X5,D;JA./DU(W+MB.M,B*N"BGA.;1\(XNV:!;!'K%3U_8TDW832T M?!C0.C@<5LO#GZE6-#7>ZN>V-:%[R&E/%7^Z:C1/SL%'C?((Y-6$OL"ND<0$ MZ"AH]&9D4[7O`<@M]A-S7T"JT: M$DB'I'9_\<5&CN-W"]<.[VB<=_S=B2"?H*>W,,0!$/$Z#LEDX[3W_/GXZUU& MNR724F,V=G747$H^(WV7`\`LP-!E"+C+F`J[5,XY)48;35+E`6\SHT;BI):X MS"H-C780_Q36BXQK_1R)[XYV3@*W/7>-&)%;4O<&1M?Y29`DW;TS7>DE?ILV M!^L.G+YL@TLKJ$@!CG8CQ-V3ILJYI[BC>6^,/"**T1/.P>N1C*QQT,/F>@HB?E02B'ZKJQX@$(KN0A M8)/E5#P5F$-G*&/`VCE"&8_4V53L*DXG*IB<@TOU4LBF5"Y, MOR>J92@J/H/9&\72@:A$K?3Q.=^Z]1CG)83IQ)5+R<7IVJ664;UZ,1Y[HF0C M1$9(^;`WBJ8+6]D:9H19B[<`^#3T.$#;FY-L@Y.PT%IC^";Q@<0:'K\V35C( MT]%SD$?=-&='N_(1/UB09M-K M"D>3;ZWX?&7-!]UOI!;#''<7L"S@O,AB<05E5=U5A#[EJ*"2F*:DN/(A&9;> M_!CDFN`F9TIL5?R0DLOHM*R*W%XBU^^BA)NA0V(-&LL14_+^<]:S:=XJ:HPI M`"%Q71Q49SJZT3[:NN% M;=2="T7U6^>6<;3/*4/=G,SW9\LD7>6G[I$\@?W\L)EM$^1D:BV, M[C+RYJ`*>,9I$I3WG+H,["(3U)IUU5YLJ0T-@O+"/I/Q'M>4?]% M'5IW[^!FF^5!_GJ7H1YO@A0!2/CF="0?ZUZ4J9RJ5Z?$TZHYX-UBS4/ZYM2F MTS5J;OO.V(2)7;QP^2DLPCS>#AFW?EWN3E,W9_'$18R6OAE40<4)PJ^0E"8@;[=WB?-.OZ50;UKZA7:I!!3P289WG&A]]!;R M/'PDJ!=A9TKT#/*'87%,7Y0']PEDB;9PK,X-(H3H#F$:H!W>KVFQA2')UJ*\ M1I/0V+],EO2?PR-KNP*MUAY=BRGG@KO*U9N(2?F=BA*G'I';LGXKV]F9>GWD MM\&T@2\&9GA0>SF#Q"-J\?8I*![/D^P9+Z/HG[0H`7[NG$8#3Y^;/&-']T69 M!Z',P9O.VOZ=UO31X,Y>\:-ZS),ZC?BGFBW)4C>4>*"3S*]B[NCQSX)C\VFW MW=+TUL@OQ?F)HEU"#E[3+#T@0S64@>`G]V9\+JWA;AAG51F;)8WNRR9M:)V7 M]B)%W2('_4<;'`0JRPBKS\)!X2-MZ?A:2/78S3:84N/,G2U( M5PP0>C$+#X!K/)W\(>>HN;0'V#JRA(:3U/N=NPR?_F](9($H1'<$#^N`-9&/ MNU6L@XVJIRC-=K#,0,-`%K]K$Z[&D]F'Z\B9M!D\1XZ6R=XS^N>.5IE5/E&1 M4CD(C)/)(#C_IV_]ZN8>W`883`D?X:8Y'Q9O"X3F^5+GY8H.M?TS?RV9N&-] M^=)\Z=4C%_U9XPZD3:=LPD7D<9PA@4HDF?PJDF]G]S)RH)]]=#1-/#!!TL'M M7$G*1W9*1,WV41$JTS2P'`/3ZAGGBM_\S9?IXP:P&XDR/'H3)NP4(I\F*)#F MLQ7K%R,I;MO%@2$(R(4#WD%& ME7AHH1HJS.3Z98L:9QV@ZX)L2O92H7-_$^329Y@ZE):SE.K(HMK/M;9S=QE` MA.[?88Z2JWX(5M8"LI)D:)<:(\W9(M&>2"/OGF7J@[*;C]00D&UL550)``.(URY5B-NR/\'^2^SSVM6KJEGCCC&Z6M+5NC4D@:CV\X'`R*1*EP#HNL(5E: MQN'_[@19>V$EP4(66R_3&@D`\>67V#(3B7_\^]LD.GHA:4:3^+=/G5^./QV1 M.$A"&C__]NF/QZO/IY^._OV__N?_](__\OGST0\2D]3/27CT]'YTX>?^8^H' M_\H6]8\ZOW1^.3UB/_0_#Z;IY^YQY^O1_^YT?NU__;7;^S]'__?N]_]W=/GP M>/3YZ/7U]9<06LB+%GX)DLG1Y\_L.Q&-__7D9^0(.A9GOWT:Y_GTUR]?6/FW MIS3Z)4F?OW2/CWM?%@4_E25_?%J)3].A*68/_W>5'L,_O5YT[W)WXY2,?OOD3\=/3,S] MXV^]8U;_WRZ28#8A<3Z(P\LXI_G[=3Q*TDG1ZT]'K-T_[J\WNN]#LW0ZID\T M83Q\866^R)OY`KVLV<\__33UXSR##RQ^O*'^$XW@6P;]E#=CH9\/>1+\:SAE MN#.#?FU6L]"/\R1-2<#:&XXNTS1)37K#JVRA3[=^/DO)<'0VRVA,,D;"`WV. MZ8@&0,0@")(9Z$[\?)=$-*`D6_QKT//JGVA81Q_]I\@(B4YCEO75N(^\R@[T MY(+D/HVR1_*6S_RH06W9_I`%K'?P>P*C+7P8^VD-*(IV&M;N^>R-2OS M8)P!>R';AISY$5O+'\:$Y&;3H;"-_OUJ]M4O\PU3]9((_N:RCU5-]7D_','TW2Q(2.)#!'@5*P`$TI_#C:M%D2LM6?_;O.(E".*%> M_C4K)DO8#-#<`M#:/6A0.N=^-KZ*DE<;A*ZUY6`OV.#NKXG]7O4=WEIOIO"_ M(/MB%-W`QS>Z!7,9B4,2+CK&VJIYGB]L#O#=*`DV/A4Q:T>2JD3`?N/)/C!X MRIB=)U\T%/E/)"J:][3K>KW^R4I$NIV=BZ6POV0D^.4Y>?D2$OJ%]9_]4`#Y M?-R96U_^#7ZU[,U:)XJS$*?WLN+0X=.-#J^S.D@W.^^GP:)Y^'&'TDW[T;S$ MEVFQ0'P.QC1::L,H32:5)#OO3:(+;)9!%Y-B6\!6IR2%">ZW3["?FB[4^J:4 MDQ!&@:$09CU>1W[V5+0ZRSX_^_ZT))=$>;;XS3;+\U][RUGN//(SF.G*.?N- M9ARJE76\_G'')=]JRC8IU@3$Y[E[4#RO([M()CZ-)03O%@9!=%TRJ\D4GUX1 M'#ZO/0>\UIB787$DUR`3WH!558$Q\?V0QJL>'CZM?<2TENO2/7FF;#F*\UM_ M(EIJ>46]WM>O"&G@:-J=O_X.\2SG<*@O`OQTN MB5PP?!:_(6;Q?)8R&5W1+/"C_R!^>AF'%[#B"(@4%0?X)X?(I1P/G\X3Q'26 MNGE%(Y*>`XSG))4/R8V2`-KIX:7>@.1`X?-WBIB_Q]1G41@/[Y.G)!(PMU$& M@&+(1F%47JP$@"!F*J\@7#<*-,H`4 MHR%'R18'A(`N%]8;TZ%U1U*:A/(M*+@K&FW$Z7F*[@ M=RI+S4YYD$#_D.D4`!)0BME0LXF(G9#T"5V6!O2]PZ=S"XZ`3,PFF^5B<4&R M(*73,JY7OCBN%?7ZW8,1:_SW7R(")S6_"\MI'DKBK(!W3R(6M7.>9'E6G++9S9+P MSG\O0G@TAER]AKUNUY5K5[OC9^L=EXUG2RU[7:?['(O$\OW*-L1S\/,!YUZ- M@UEA%=EV/O;C9\)V`$5O5MW3F0-,FO'ZO6^NAKQ./W4&N%$[7M]M-%=UDOC# MMP+X@Q^ME>^2.1C3P_39C^G?!?Q58"[3M3B\6Q/-<'1%8S\.J!^M8G8U!KN5 M]KWN5U>3`*PJ-!N.MDA[+_^K,_KU&O"Z3N,2[+/%GPT,A-&&N,\_,I@%+K.< M3D!&LF#/S8)>UVE@P[Z4@0.Z%4&@?C8&";%_V)'UQ8^8//0G#*WZ7A?%+J%I M%=&7!9XPT^J:PP(4",`=YF.2SN?([)X$!("S*S\%;(GF:-7WNDZ#-_:E.?JR MP!/)6EUS[M)D2M+\_2[RRSL8,%BFA9-/>]K1;<+K.0TQV)?^&(D#3R1MC8,` M&RCSV,1!EA$]XY6DEM=S&MVP+T5120!/?&YUW?B1).$KC2(0V36(*WYF-U!+ ML(L_*1((0(;TA;`E7:UA%5KS>BA<,4VK6%7)N`VV%GCFY[[D4C3K MU^3+7`LLW>`5*>RYRQ@'70N@U?:]'@HW?E.Z95]6B**]:WB=20KG53:8#`Q( MXDI>S^D5QGU-4`H!((HMKZX9]^2%Q#-R3X+D.:8,B[Z"*.MZO9_"&Z$G!T2Q M[774)2,@?&9,O0#445+8,B[?V/*M-BQJU/9Z/X7/0E<2B"+IJRO-I9_&-'[. M[DA:K,/Z,XRBIM?[*;P7.E)`%)]?75%NR>N:2S=-8O@Q*,5DZBXW;"Z`*)0\WG>X!8%G/<[SDPGP9B$LXC,\_<((ZZ'Z3U]'NNY!BJWZ?51 M&(`UR!+81VH!/_CH-TYN[X\(]I7:]-V/\4N@+7DGY(&D+Y1E@>79\P91-'^# M@F4@+4Y(?P.>XGYA`=)L#K#\3:^/PI)A01E4ZK;?$MI94Y-R?TAQV[85!FID!TA<2 M7B7IU8P9I*^S;,8R:BLUS.X'O#X*JXMU+6M`2O8#!)'?*MC*2?]QMT!PZ.Y; MO.:[XF/!@BBCL[2\YS:-CWWY\D:W#'LK-BA6DSZ[316D9DRP2Y#B:46T?\V4 MSVYS".GQQ.=6`*8-@?C7\5V:!+#&\MT]OY/)$TDE/&O5]WHG*+@7\,@GW0!9 M&^+JEWNMX*\9S0H7L6(&%]3PW&8CJCI_R]"T(>B=AX_]F!*BG,R5=3VW"<5T M.-1G?1>9V\!VT0Y\.OYO21067M?\_28/A7.UK+CG-M6[&0^\O;4$EMM(<@%M M9S0)DCB'EF_HA.9$09N@N.*KKKJF"/%DL6Y$-U:(V=L5RG79L"6O]QU%,)(IZ<:J(P;? MBE#I.SC!QH!2=3;;*`?X480/5:*-KP$29Y:4=0#K0VX=%--F5'\"T<;8BW'AQ M=5&B`(LBGML72&J1NX&A%>&_VTO6+]?(FACG-*31C%V_>B#!+(4#,,E*P"2\`I&R"('9PG.X'2,_F#`WMD1;K+3O M?4/I3M-2)WL":"`5N;M5XWHR]6G*G!`W22:S'_`K>-^<.F.LK"@<1`**#RMQ MA#`7SR)Y7/A'1D:SB)V?9,P;M>-]0^FQT5((R]L3J+P M-8U:W@F*;"@<`?-'B@K*1TS:=FS0"0K_MHHW`=M25!^1:;%W@L('+N>)SZT` MC-O(-)$5G*2PE)^5&6YRMCBOUC+6?T7\@E9M[P2%7UQ`"\\JK@^K#5%F#^,D MS1]).KD@3\4;J*H9F5?>.T%Q%:3B;"Q$U(8HLQUTRNE84,,[0>&J%K.ER>X: M&I119&L3#[NPG=WY[TR!AS&13\>J>MX)"F^SC`_.;*R%"F58F:#GCZ]))1Z7 M];Q3%/=S[/"XB:H-<6;7@#/+%P^**Q;3W<+>*8K$U=564@&<-H2(;4([AW/! MR.)Q9:6!WF@DPU5,&LP:\4Q2[[9K#7(JN@6`H%^^&/.77<9:GL\)UOF;XG;$M MRW!4[GQ6162KO'ECWBF*;;NQFE1$*H@6.2SCVN80N:`O-"1Q>`^#!(8'>]') M?]:?/_C5O5,4N_Z:LX<$FT`1'%^T%&KU]8B62^/=["FBP7`$72S3RP>$A-GO MA.39#?&S7'@IPVK[WBF*"`:SK895\`+]<9T.M=A$9=F,A!>S`D.15[C<+-^2 MU^)/&>_>IDEU[Q1%;(,9^R;8!.0ZCC];)*/?!;%8\Q8E1/SJM^"=H@A_,*/8 M$)Z`Y7V9^(Q9OGR#)8QFY"ZE`:E#MJ`A[SN*4`E;G,M0"JC?EPG0F/KB[%.' M\JT&O.\HXB9L4E%SF-)G"FC8;\NMB"P#@[*N]_TP#8%Z MP`3\']9URDVH\RTKNQZVV,66VY=R1.@K@ZHA[_MA61)KH!2HR6&9%(4GFS,2 MDQ%EV;YWWN6M8D62-.=]/TQS8V6L`L5Q_$;VZCW=K7N6*Q#+5]G$1@+]-KSO MAV4^K`90CHLRQA.[!BH!ZP<6RS=_BFLNF\7S6<6#73)GGZ0:2.>PS$#ZH`24 M'UB,W\K(,5H+>EJ>:V4'?F5=D--AFG\TD0DTX+#L?P*L:GN/O")(Z#!W\3JP M!,0[#@*\)P$#6^2%8EUCR?]VSR3OCTD9MR+:X!DV`Q(YP/-Y)9`"VNL8\O:< M&6NQ:1G$X>+')=9YFBP7^;'DCZM+YB#%J^Q;*<#W'SL_%_+\;7=5^BQQ)0_' MJP0:XA9,JG)D;4BFQ86HN+(A`09L!UTM0+480O=H`']/95\R0TOHE1^@V MZ98VP=%[YVMU@GFU`3ZF\VU-@L4(W6;=TB3X@@1%E[N]JB2+6P`Q8#K,UB): MA=)M"JX&%^@;_2NL@HH@($P1"!:V95O04*;MVFM,2/B49N<'AL0+LDP)2=D^S?UVEA%S'.0$>S*PO(L5E01 M5A6$A<*@UXQBK!#:RDJ&5QW60D&,]6&M+H@+K\6OAD+L0+25K&Q7(_;L2F%/ M,"81#5G>@#,_8L$!#V-VC=.-`V6><&PXNJ(Q](7=-$WFKXWKN%'4U3W8ESO/ M"ZA\@&2C('09A0%.7[S\H<5#U0:7B=WW1SI]%,8X'ED*6OE06N0IJ?SJ2*>/ MPNZF8$IJ<-F!@](?,G]CXYZ$A$R8XM9[@D2[':_?Q;01WB&+8V2I!K$5+Y,L MAH&.*76W,$@4A?FTP@R]A:$-SY"4K_YI;`XW"X(`4%A(1=3PB>1AL.3HP'`T M+>&=SU(F.6U*M\J#5%"8-7E3L&0<#2$&3W)""`F>6D(_E< M:K)Q+ZD&,D*Q$S/6`#6H%CDP8(,Y]6G(+*UQ1D#QA_F8I!LRD_"O41LDAL(0 M::P&VMC:Y*+0)7Y+#%]11!N:C_1=%+8<#'F2^Y'CD2UXI5W^6+FL&H@(A?U3 M?T>G1F/+?Y"3U/'8Y3S`?AT'T2R$7E@3?U1>%5L<;R)R]:[+!A( MU9%0S:T!"!:%X:?!^5^`V=9++NZ/#B52Y?$/Q@<*_XNI@;?LMZV'6=S3M98= M#(XXNW=J-3;]NDV`Z%!L^,V\-6;H;#W1@F'"7T.N[\T15P(!H=C-F1&J5`HN M2EO/KF!0@X5)>_XF.\@,?I/.`,&.$#2L_1JM@`A1[`)4),L]`-I`;;W,@D%7 M+N8=OBD8%`]E&XY^K_2A\?-5(%N&Q]90* MJIWA;1('578`N_5`2"@\>I8W`2*@MIY3.[GQ#X>K3X&V3\(I(;3VZ MTC#Y.[FWU%SO5`'`*)Q[=:D5`+/UM@J&57NQ.WGTW[C2TMBLB:K"%@?;"4]/ M"\P`VGII!8,VF*H`7RR=;RC<=I5YEZ"R]5X*JOV<'L$@`!2N&=, MW//Z2";3)/73]U(:18SITLL\"$-:8KSS:7@=G_M3FOLR/TV5YF!>Q&:QJ:PI MU?';>C4%P[I0R1$@$_@W%-X>&PJB0FGK>14,:G">3"9)7"!61O9O%05AH-@, MJNCBD\Q'8^LY%0S4FJ\,HLFO@\-I7XUH*2A;SZ=@X+N,0%^B5=/-KP""06&U MK<:V#).M5U,PD'W/TJ?')+STTQBV+=D@"&:36<32@UP4K_S)EG%U9:]S@L*2 M5TT)=/'9>E,%@T+L2LIH'P<"06'?JT:X"(^M)U/3*9)G&1V$,S.R"O'H@'A7FTXE2OAM:&M%1;Z)0S/+<\B`.) M?53)&9]L":I6O,^Q,O4KI_&=LB`&%.90"4=*!\/;J#,Y-I!$;!:Y5E=Z^5R5:4W[711V*E%Q&S2 M:`S,5K8HM]/S.$ES]BK#!7G*'^%KJJF95Q[D@<(X5G%:%D.RE4,*%\5JVPB_ M!L@$A4%,0I@FP^MX;*6-@3;:B5N&QE M@W+*^]DLHS')LD$`1X[YLQ'R"5Q0`V2"POA5;0J7@K*5S0D=T>S'E*BG41GWF.=ALY7.RNPD_HTF0Q#FT?$,G-">A?-=IE'X):\%G_*NJ(!KED=)D:\+HLMGG@&41.4MI(G[87G MC1=(*],M:,7K]%`X,NRR+@5K*YE2DXOX.AAF4`+17+Y-:5K0HK>22YL`2>"= MRM6T&R.UE5]I7YS?SMB69"D8WIIMV`+(`>\&K@[C?*"V4BCMB_"-&:L.[X*& M0"HH3.36Z9?BM95+J3DM8&]NGR>9'M/+PH`.KQ'!DV*[&Y&+4#7!SH<:T&7%M)E];4 M9<^7*HLQ,BP09/-+E"YN3U[0+(B2;);"1HD%_9(X*U#>D^(:>[$,%P:3)S]C MC\V\3XI`;_7MRGH->YV3OJM1_!",23AC]U@N@;CDG9`'DK[`5K+H[AGK[CJ@ M053T!7X:CD"3D^>8_@V`BAFO0*FZN-G(]T"`*+:#-M2`/VLT*+967">U&[M^ M@B+(HD'.!4HFET@;;J+6#GL_07%643`E=0#MP&G#S=+K&/8:9/5$S7PD**8` M22T0#8JCR=XG`:5,VG`W50!2.2-(ZX%X4#@0E0P:$;^.K0V74^^!$Y#G>!"' M%^2%1$GQ-O'\R7%E&+9&;:]SBN*(JL&GZ(2JB='2-58,B;Y^D)BD?L2>'0HG M-*9L1\XRV^OJA59]D!H*IV-ES3!`:>E&+`;=L+/PWFB$'UG^$C"!(A9Q[WN8 M1N38AEN_<\SS-UAV1#(?QQ(-U6L`!(;"U]Z('O!5SD0P]N\9NS?G=C[LN6N& MO-.O[NVY`FUG#HOG8MW/SMY79>88!J]^&NK;<&M^`P2%PM)F@VZ5W=:*J#YL MM3OVKE,=\A+LVJ/](D:V3&%7\-6$'A>\.MS$+! M63)98W#G22]*KUNV93<>JC<&\L3AE&M6$2O*Q5:JSASVR([5K.90O$K2$:'Y M#.2U&(\-SIB!L920]?$U>W47?AR9SO@:$X#A^H=9DH>!L MY5T]?$UV?1Q#89?$K<4"L=G*(5N>QR[C\*#U>+[I8I:@#DX0A30*WS1L*TE2CX M8"QL0HL\UW;3U'BPUPN@$4>LAMLQ85N@MK(P'\!N726ZA72<#PJCC@"-.&)8 M<(^+"C*UE;&Z!4.#8[9R-3@,N^(!#Q_#HQFIVDKOW8(!PK&&N5L]C+H"5'YX M.AN2JJWLZ`_PS^UGT*TU:6^'88H=8L=8Y&@F8/@+P/AZY=8=K* MHX]H)#RI1?=D/(G<$Q:D#+\_9Z]'^4$^\R.6J9R7Q-]A;X#4G\51[$*PMAX> M0+)[JB%"\20C$F&GP9%2H3=`Z,_BC'8A6%O/-2`9*78VIM<@*1IG-!`E'&_\ MFT#.A^NZKOALO4R!1+?M3`^;@MK39+_U4:#G9W%2-R@_6T]N\(X$[M.\=#_2 MO*SR?G2/OSN;>@XJS4NW@\)E8X-NP:1B5U0?:5ZVTV9T.SA\&G9Y%MV=D4KA M(\U+#(+`8=.7,\6G5P3G(\V+?M*+/I*=ZCZF`Q.1?*1Y,:E^30OW0X.!^M>=JF6Q/61YL7UO<)NIRU. MST*A&C=JKXO-4IH7%'DQJDIH\0!U\==L\.+3B$T>5TE:W%UH0I<5GP1NVN*= M;$*EM:37HHPOW,E*PE;L%AMKO(CV_]"5&,\_5B`+YM9DGQT-X%W@:?V`*5 M[I(B)V^]]VX]5OYT_%20BG]+M=P M3HG9DY@,BM`K9=P&B`+%=,PC:)/*BM!0/"6K1?8MG&WK42UK`:2!8JZN1+0: M&(I78?7&])BF.2%QS5&M:`6D@L+W4FU<:X%KD8=D7]%-/23O+NQCOV8B$OOO MIN+2(:O133@"9DWHK1?=)`Z--?=`M"F\"4>DK`F+QN%-XNA9<[?`8<:1["F^ MJ8_C'L=^;(26Q&4K>_IA*J;@71GXOPL_)WN[T:OU?=`&%)MQ6YK73""4@2AM M)5W'L1R3](4&A"^^VR1^(1F[WL\DE3TRW_+ZWYGCZS;)_X/D]R1(GF/Z-PG7 M/<`Z2WN3WP>^VA(P)5']/8K25I[V=JI^.7=<)>G\5ZR<[,[[?CL"#+8EILO% M8)#(U%;.]L/<"VV%7<[R<9(R@>TA0';Y+3AI_P03?4-BLY5:?4U]]QQU=IY` M)P/6X'!TF:9)BB#V;!`$R2S.62ZD,>,G&\1AT;=59W4BS4R:\?I?CYU-'\O# M:]G/ZWC5\\LLIQ/83.O'C2G:`*`HS(#FY*BBP+2`MRK*ZR$@L0]+JVZ$UWIY M$`<*,Z`A?XKHK5V$;8C<6J#Z(\ZF)*`C2D*E4T!8!\2"XI:SA#/12)"&B`2'%=$;$SH4HQMR%C``\A^3(G:WZNLZ_6_H=CC25G4)YZ#S6WJ M`D&XT!E-`I:[-8GD`4';Y0`2BJV8INPY44!\1&[O\0M(>IB.Y>PL"P`(%(%W MU6G9@F(I[LKM)0;AFJ+C\-:H#:)"YM&NL8QJXVU#'-4CF4R3U$\7441!D!(& MZ#&Y)R'\C?VL\BIKMP%21S$Y:#/,5Q!#O*V(IGKP(W:E^(7$LX6K([LETJ04 M_!H@$Q31`35U0(JN%4%4/TA,4C\:Q.$@G-"8,JLB"TR^?&.>`-E\H*@),D+A M.ZFI`5HH'4>6!WFT80Z68&M%C,0* MWP\XLMXD63:,5[^3[[^4=4%.ASQO&^)L(.C`RDH,9P<_`_3S=4=C(1;5`)PH M;-GUUF$Y.EM/CSL=U:"3UW&03`A3UF7:N,=D+9/3.(D`67;F9S20C''#ED"& M*+R8-4=\)=2VWN1V&TGJI^RQL^R.I(O`*ZE^<,N#/%"X-VMJ@02;K>>E+2<[ M$)J-[OQ49&/3K.GU3U`88.O,_;HH;3V;C,GN6L"[?`NB&MV3YV9PQ?]4X:8;A2$+J-8 M>O7%*[!^6@E8^E#9$A=;.Y]=#L68JF!(XM@5PW`:! MBD).2$I)=L8\JF3"%/>!$KE2"V M(0X4%B_*MHDO!/9V.6PC&>1!EA&6L.!W_Y])6HA1,8,;M`(BV%R* MU(&O/';16XJ:S4GJ.(VE9)I=D]BZ9*KM,P2-P6R,ZRBJI4M5<;8BB';+5'WG MI\.T$%]86*T7GBQ].[^H!1AI***WS'3#")RM&%L,"7&W@!LD-E'4!%&A"/.J MI0=\4+8B:]'R7^3V-.:^K`4B0A':98'W=4"V@G#1!V,KT!M4]_HGN-R1579Z$F0-!/(ZC-!;2BD;CH93DA;?R5Q$ MYY7A\\O^:`3D"6K`J.TY=^*8QN#U4=C&I!)5>''6@'R$W>U$0/5QV;S6R%+0 MRH?R$787@R!PV;/X3`EV/0(X;K:K>/RUZE/V)W8;0AK,YRZE1D8="[ MG`E(EB-"^:#N//MG*(^)W2P%<'"<)>7RWB1)B*,-T6=UPY/ZR&Z9Z,^G6QA: M$6MF+7-6MX_5FM^71)[)P+3J4=OB0!\_S_,_Z;RU(*P#TL$U@K6H5L"Q%/B% M@6Q8>`A(&FDDA)H86M3X-:.E$PF>Q`'"N-]):H%:&Q%9>7LA30B0NRH-`L$: MZZVSAF\#L15[A8#9?$Q2DUT:K[S7PY'GW)!=,90V!58UFS:OBR.!L81+/OF: MR&Q%5;F_H+%^BV`XNB!/^07-BAPS=RF9T-E$H@;*NB`L%&XF8S701%8[T.I[ MJ08Q>68F.J>*IB3NPZL-@57;>2`E-"]40Z&`2Y'H]:FC0/!5ER4^\VX]EL:J\?L]&/F M=%H#@1Z@5;TRT-K)$Q&M`>[RZ':1/!!9?1[1!6DK1Z+[F88]89Z2,2R'<-HI M!0$2&8X>_3<-(X!&;:^+XT4Z,ZW0!B;0A(.\<+F=.UA#`415O#ZRT#0MUN5H M!%0?Y#U+.RFSNSC>MY/3ID?U&B`!SP=I\]N&>4&C62Z]3"6H`6B@VA19U1@Y5H#46+FXBN;FED69U$(?KQZGRC'Y!1C2@ MN>-D[+O],LO&+JX/D\8W5\.[\E4P'"\F&/5.2*ZT'XD$1&V-,M`:J-N1!OR^>/<$EQE,_UBUA<'6W3+';&Z;`*5L;A<&2>`R)JXN1(/,%E[=*CE@_#UH4R+,Q6C$@^Q671TF*4`\'6];$Z MMX9$+TFRJ:7,+7LQ2T'_[@J-*<)C__33U(_S[/*-I`'-N/$BYHUXO5,4FR<] M5JOBPY%^VXST1 MV%JD"KOP^2?-Q^6O,BA[1?Q\)GUJPM8G0/@HS/_V55(??9LNX/I3M@I@/Z(QF$;*M&WV(-:L<40VHEF;#(.@#.@C: MQ(SCDF`%0]!R^NUPM,*@-HCA@*SOQL!PW`RL8O.I3/!V=1#$`1GAS9'AN!18 M80@KIZA*0UO=JM?]?D"&%FN`<5PGK#(56%<4W69!<`=D_["'N$TW"=TGK.GW M#DB):@.M?9]P,V'-H_.LA+*YM_C;L``K=4Y5;@O&8\N,:1*8`M5IDZFUG(L<':$L4P!#P:AS4R>,52>ZQL>X[!IK M9"EHY4/Y2!46@R!P&2_X3/'I%<%I5:JPFVJWUWO'N$P6^F-U"T,;,H'=DIPM M1W=I\D)AVW/V_D=&PNMX^:SD(,CI2Q$;`'L<^,4,?C?_(^QY-+83=CX``L=Z M?BU4@:\X-K%;RDB&P1!6[>9UKX/BYK5-3H5:LPW;4M(R#.2OW(`1%D, M(Q97$L#_TXALX'],-*6M,14U_6G@"H79I7D5W8\D+65VPZ#US;YPV^N@L`KM M1ROX&JDII+IYXQ#9B)F?S(\#LCB1Q.'B_O]5DL[O5&?#%$XB5+I#-VH'I(C" MN>12U2H(S%(Z.PPSV>9SQ-=`??S,@H@'649RF9[)*WH]'/=P7"J6CH1LY;_# MITJVW_ON=5!$0.)1**&0;&7APZ!35SY-M^+2AZ/%_"S1)VD]$!,*'X)+7=(0 MD*W&VX/6Z*'PV32F+!'3MC(6H]64Q2N[\=P9Y$(?L@O`,^DG])QJILO54 M:Q`$B\*]TO34HY9!FW(2[LKA+B53GX87AH?"(-+?&\1&W*>%A/8=Y8\%/ M(.B?WH1M0X*V,BCF"8PBC(IZ';_`"&TP6L_P`R!V%/;RO<1J69,7CER,=A05 M5HM%`N[@KQE-"4@(8.?O=Y$?Y[#M8!>\IHID2_J-@`!1F-YMJ@-?X4QE4CL! M)*+=7#WI-C;K@:!1F/.;5SX;VWPB&U:.\A<$_EC\1K8P5VK0Z_506(-MJHE@ MD:XAGS;EWER7P]:+*YK:M54+1(3"!+Q?%>(*H7:>341ZG]Z45**RBS6B%.,%KQRB``\(S) M=3!A(4B\]U1,FP#AH=BIV%$"OH*9R<)6VM)=1=ISMKO;XGGALEL$PS#(0 MY0-]CNF(!LP'58:QL1R=240#%@GH(/G=,'WVX_G5MU5V/J9ZA=UM*9+A:*X% M?K1*W*9P-C!##!_N$@]E#<+>KV^LQ27FQX"G9$GJ`$@4)P' M>:(5V;LE0/8V'/[QA77NR<]((;K_#U!+`P04````"`!0BX]&:@8GM7\*``#1 M9P``$0`<`&%P:&(M,C`Q-#`V,S`N>'-D550)``.(URY5B-B!" M4L[.>O[!80\1%O"0LONSWL_C*^]-#_WXP_??O?V3YZ&?"","*Q*BR3.ZP`J/ M!0X^RUP>^0?^P1ND+XZ\\UAX@T/_&/WJ^Z='QZ>#X6_H/W1.NO]D>"(3BD)>PAL9?(4Q[.)HSXC ML%3W<7C`Q3U4.?3[OWRX^630YIHCRCXOU7Z:B"BO/^SKX@F6)*^N2T.U$"A7 M/NZGA8NJD47O+S>@N*R46BI3)A5F00%B#71FHG]R+RE,L M)Z9J5F`ZSCOTO:&?BP0\84H\+]LH27!PSQ_Z6:$6&ZZ()4+`:U@GEY56M!<2 M6BT#!175R5,PJZZO2RH$*'L@4E6+I&45UC!,`UDM8XJTB+\L(FE0+0`%%=6! M`/4<$UE)C2FIL$6J6-0T`B45K80D%B30X[_V_3KI8Q$('A%`$"B//,419EAQ M\7P%]XL.X8PE\VHEH1)]C;@/E3RH100-%G*;A3(!\"0(O<6,<7`QX)K,O7X2 MQY1->78+#_3[?:H!CT$WG,F>41#_=*^PY%V M?)]FA"B9DE1?;&=H`+1\@BXD&45E/2A3A%)->WK:T'.'P<.K&5$4D&W@:KFN MG;BA.W'HUR7%O^V)="1RT;]R-!W%.F$$,!4#KJ:>G<`C&X&%1L2GJ-"YIZX% M=1])2""WG40$:D"&KRA?(:`9/[/>!3"%.#RCP1B$R3>-*#* MSO>VRNTOR;'[2U(`024D:`$%&0P(L^PJ0_.7/P]/_HY23.A5ANJO^_>LQ7OV M'LO95<0?-WB(HIJ=^]?NW&N5R.C<$V49#PVEK+3^C>="%,91%R"6KA)]6L:\Q;205JT@8I&4-[* MGF@+T87_G4'FD_&X^M!.TYM5FDJ.U,CO";`0\&\L!+RX>JSDES<43V@$429E MPUK#3LW)*C6Y`C-N%C<+=7NF+$R97&`4ES+;I2=6)OS#52;2'",3WO>[-8D` M7Q+H5D?32R&X6&0-:\_M'/BK'!0:=$Q)=>RIV&%:L%UZX)8F^(/=I`GH57ZU MS^G;!JRQGE3)S6$KJV?G==@P>*%7J=H]?:Y1K$Q7Q7,[/4?6B+8GXTOXTPNB M,(WDF#RI)%\CW5*'G>3C7?G6K%64-;M_+1I,RJI8MU>QD_IZTX1M3]?.(F+6 MD9M#8E[13MW:DLC&F)CIW3.X)8-+HZ]!?3N?:VLGKGSN1V;39&=I)%85V)E: M6TI927?VXZP='WXM(;Z=D8%]2:48*?Z>DX:<#&HY&6S@9&V)I8:3P9Z3AIPL MQ1]+N9V?M;62&G[VT:75PF055QMKV1E;6P6I6K3\OR9._]%;;#^2*3)[5T_U MML"SGJ1`FM[S:I[-8(YSUM/[@+U\K^_O8/3!TSS*J^@6++MH#>>K_90UG*O( M=D+:]]:"$A[K70=$]G/P/=3?H6'`2%/#EDGLIED1GC0U"T1(U%V+8``TM6AE MS.S6KG2\E7?,PEUY1ZUY!&9QH1"KW*E?M_4\W>1_PP.CRB*B[[Q:Y(B"4I[;Y.M-OT7V\-P]%YEB"HG31O/]KB"JFLY;)0T@*A M]8"3RYN2R^B+%@/6?@3'J4-6I;;EJ?KT4#,DG-VV!F,_=]4^\AI=]11EYQX- MH,6*]#D+5[X,I3N<]5'-*V*^W2W6DLW'N>ROGC:^BWCPN8?2U#4]KG6J\N?7 MBLSU[*N'\$3J`YSJK#?%D3G8J$\?GD(^27DX-L)A(K)348Q&D?X.?-93(M'Y M5P+25"6Z]"?!D_BLEXI3T)_.EW6"_/ONS*GI+WV(,TPB,IJ^Y_,Y9V8=Y#V. MJ<)1VM)'F.B)!Q)><7&5Z):NI4QT2FH^;'>MPW9H3UV/%9]X\\^Z1C+O@!06 MF$K9?97QJ3T[L#U4IS.0%$$R(=/8/'NF3S_)./=^H\`.93XA8 M(37D-`,?JT^9A/_" M44+NB#`>=V$C&!AGSQI%A70-1+4WT1UIC:D79**N`84PAY%+/7:=+A;BZ"Z9 M@)\=3:$=O<=(\("04'[0AREO");J?*YGR\LQ`L(345@\[RA$IG4GZ4'.LUX` M]NJC:*Z=M#L;Z_R9Z7P(MB2\2(P&8U8:E6_)HRG2WT&7XJ@I_=I)A"M2>Q(J MUU5`=@U#:C3-:W3`V"9@&]M[^03Y"940$&A`ULUN[1*^I-FUF!M;;YQ+'=G= M&OT-C*CUD8(^`+@'4CM5*1WHV;HG:H/"UFZPB1E.K\2(_3-A9/!:+Y2F,;4S MP=\5J+.=T;-__"+LK`;J:.<%"8S`8/@";+6!W2I4#SH0O9R1-K-T*0:L&_P- MXU93P(V#UIB(N1Q-+Y]BFF-U6]CX)L&Z`JV#Q3HTO.?RZX;DD$S:1N02WHW1 MM^+T[`L(MA6HFXU8DZ;D6O+1$'8YY6IH2!M7O:$_NN>QM[;;]%[=9/+E\.\P MR;2)%[FJ7@=?S.0_D0!JZNTN+[9C7"QK,U*:]ECWAL[N>\9T>/[1)"(8AN.5 MX/-+&0C^^%)?H'I[VKPV;KW3O9=E5[VP[*P&+_6E<$B8;;]I>9Z9]=4_`:XG M5$XHMUZV[((S;(1V5PN7?@=F@&U`VT;UTH_,Z4]`N5RQW;YS7_F;XZ[I@8\D MB+"4YF.Y;E6[PF)64OQ0`T^;Z?!2FQ>PQF4#7[NS8K&]JXN+00T[HI4U]GU##C\SVYGAW1QR M;3B79EM'9RQ;!;1QUUIGD*]#JM\[V!G0)2RU"^606,&D]YIE(VJ7Z^1?RCW8 M0->%>*+W:8,!:;IW'H`&W-"TV36!;TV_&T_W5=N^N!_4$L!`AX# M%`````@`4(N/1L68]A=9@P``%8H&`!$`&````````0```*2!`````&%P:&(M M,C`Q-#`V,S`N>&UL550%``.(URY5=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`4(N/1M'4+>W;"```O78``!4`&````````0```*2!I(,``&%P:&(M,C`Q M-#`V,S!?8V%L+GAM;%54!0`#B-`Q0` M```(`%"+CT;$6`"ISRH``"3(`@`5`!@```````$```"D@`L``00E#@``!#D!``!02P$"'@,4 M````"`!0BX]&2`YL6<1!```VF`,`%0`8```````!````I('LMP``87!H8BTR M,#$T,#8S,%]L86(N>&UL550%``.(URY5=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`4(N/1J'6!RN[+P``[$$#`!4`&````````0```*2!__D``&%P:&(M M,C`Q-#`V,S!?<')E+GAM;%54!0`#B- M`Q0````(`%"+CT9J!B>U?PH``-%G```1`!@```````$```"D@0DJ`0!A<&AB M+3(P,30P-C,P+GAS9%54!0`#B- XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options (Details 2) (Employee Stock Option [Member])
Jun. 30, 2014
Dec. 31, 2013
Employee Stock Option [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options outstanding 25,719,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
Available for future grants under the 2013 Stock Incentive Plan 40,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Warrants 38,890,451us-gaap_ClassOfWarrantOrRightOutstanding
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Total Shares reserved 104,609,451us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  

XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)
Total
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Balances at Dec. 31, 2012 $ 12,943,000us-gaap_StockholdersEquity $ 0us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 $ 669,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 $ 332,806,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ (320,532,000)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Balances (in shares) at Dec. 31, 2012   0us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 66,908,810us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Net income (loss) (64,583,000)us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 (64,583,000)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Stock-based compensation 1,437,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 1,437,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Beneficial conversion feature and warrants associated with issuance of convertible loan notes 2,635,000us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature 0us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 2,635,000us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Shares issued for Intrexon 3,000,000us-gaap_StockIssuedDuringPeriodValueNewIssues 0us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 240,000us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 2,760,000us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Shares issued for Intrexon (in shares)   0us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 24,000,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Issuance of preferred stock from conversion of convertible loan notes 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities 50,000us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Issuance of preferred stock from conversion of convertible loan notes (in shares)   5,016,081us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Issuance of preferred stock 0aphb_StockIssuedDuringPeriodValueNewIssues1 50,000aphb_StockIssuedDuringPeriodValueNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0aphb_StockIssuedDuringPeriodValueNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 0aphb_StockIssuedDuringPeriodValueNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0aphb_StockIssuedDuringPeriodValueNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Issuance of preferred stock (in shares)   4,999,999aphb_StockIssuedDuringPeriodSharesNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0aphb_StockIssuedDuringPeriodSharesNewIssues1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Preferred stock converted to common stock 7,084,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1 (11,000)aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 115,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 6,969,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Preferred stock converted to common stock (in shares)   (1,156,102)aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 11,561,020aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Accretion of Series B convertible preferred stock to its redemption value (618,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment 618,000us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 (618,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Stock options exercised 13,000us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 1,000us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 12,000us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Stock options exercised (in shares)   0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 61,018us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Shares released from escrow 0aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow 0aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 80,000aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 (80,000)aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Shares released from escrow (in shares)   0aphb_StockIssuedDuringPeriodSharesSharesReleasedFromEscrow
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 8,000,000aphb_StockIssuedDuringPeriodSharesSharesReleasedFromEscrow
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Issuance of common stock for December financing 15,464,000aphb_StockIssuedDuringPeriodValueNewIssues2 0aphb_StockIssuedDuringPeriodValueNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 720,000aphb_StockIssuedDuringPeriodValueNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 14,744,000aphb_StockIssuedDuringPeriodValueNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0aphb_StockIssuedDuringPeriodValueNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Issuance of common stock for December financing (in shares)   0aphb_StockIssuedDuringPeriodSharesNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 72,007,000aphb_StockIssuedDuringPeriodSharesNewIssues2
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Escheat shares 0us-gaap_StockRedeemedOrCalledDuringPeriodValue 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Escheat shares (in shares)   0us-gaap_StockRedeemedOrCalledDuringPeriodShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 (2,286)us-gaap_StockRedeemedOrCalledDuringPeriodShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Balances at Dec. 31, 2013 (22,625,000)us-gaap_StockholdersEquity 707,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 1,825,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 360,665,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 (385,115,000)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Balances (in shares) at Dec. 31, 2013   8,859,978us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 182,535,562us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Net income (loss) 2,566,000us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 2,566,000us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Warrants exercised 1,591,000aphb_StockIssuedDuringPeriodValueWarrantsExercised 0aphb_StockIssuedDuringPeriodValueWarrantsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 28,000aphb_StockIssuedDuringPeriodValueWarrantsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 1,563,000aphb_StockIssuedDuringPeriodValueWarrantsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0aphb_StockIssuedDuringPeriodValueWarrantsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Warrants exercised (in shares)   0aphb_StockIssuedDuringPeriodSharesWarrantsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 2,734,151aphb_StockIssuedDuringPeriodSharesWarrantsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Stock-based compensation 468,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 468,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Preferred stock converted to common stock 709,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1 (2,000)aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 19,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 690,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Preferred stock converted to common stock (in shares)   (188,938)aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 1,889,380aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
Accretion of Series B convertible preferred stock to its redemption value (632,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment 632,000us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 (632,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Balances at Jun. 30, 2014 $ (17,923,000)us-gaap_StockholdersEquity $ 1,337,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 $ 1,872,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 $ 362,754,000us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ (382,549,000)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
Balances (in shares) at Jun. 30, 2014   8,671,040us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_PreferredStockMember		 187,159,093us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		    
XML 38 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options
 6 Months Ended
Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
4. Stock Options
 
In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to 35,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants.
 
In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to 4,200,000 shares of our common stock in stock incentive awards to employees, directors and consultants.
 
In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to 40,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014.
 
The Company’s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company’s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plans.
 
Under ASC 718 Stock Compensation, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.
 
Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three and six month period ended June 30, 2013 and 2014.
 
Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
June 30, 2014
 
June 30, 2013
 
June 30, 2014
 
June 30, 2013
 
Stock options:
 
 
 
 
 
 
 
 
 
 
 
 
 
General and administrative expense
 
$
195,000
 
$
733,000
 
$
390,000
 
$
845,000
 
Research and development expense
 
 
40,000
 
 
70,000
 
 
78,000
 
 
113,000
 
Total stock-based compensation expense
 
$
235,000
 
$
803,000
 
$
468,000
 
$
958,000
 
 
The following table summarizes Option activity:
 
 
 
Shares
 
Weighted Average Exercise
Price
 
Average Remaining
Contractual Term
(Years)
 
Intrinsic Value
 
Outstanding at December 31, 2013
 
 
25,721,000
 
$
0.20
 
 
9.15
 
$
6,451,441
 
Granted
 
 
—
 
 
—
 
 
 
 
 
 
 
Exercised
 
 
—
 
 
—
 
 
 
 
 
 
 
Forfeited
 
 
—
 
 
—
 
 
 
 
 
 
 
Expired
 
 
2,000
 
 
13.10
 
 
 
 
 
 
 
Outstanding at June 30, 2014
 
 
25,719,000
 
$
0.19
 
 
8.63
 
$
6,442,700
 
Exercisable at June 30, 2014
 
 
11,651,493
 
$
0.19
 
 
8.65
 
$
3,017,673
 
 
The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $0.44 on June 30, 2014.
 
As of June 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $1,918,638 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years.
 
As of June 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:
 
 
 
Shares Reserved
 
Stock options outstanding
 
 
25,719,000
 
Available for future grants under the 2013 Stock Incentive Plan
 
 
40,000,000
 
Warrants
 
 
38,890,451
 
Total Shares reserved
 
 
104,609,451
 
XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 87 188 1 false 27 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.ampliphibio.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.ampliphibio.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 103 - Statement - Consolidated Balance Sheets [Parenthetical] Sheet http://www.ampliphibio.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets [Parenthetical] false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 105 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) false false R6.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R7.htm 107 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies false false R8.htm 108 - Disclosure - Preferred Shares Sheet http://www.ampliphibio.com/role/PreferredShares Preferred Shares false false R9.htm 109 - Disclosure - Warrants and Warrants Liability Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiability Warrants and Warrants Liability false false R10.htm 110 - Disclosure - Stock Options Sheet http://www.ampliphibio.com/role/StockOptions Stock Options false false R11.htm 111 - Disclosure - Correction of Errors Sheet http://www.ampliphibio.com/role/CorrectionOfErrors Correction of Errors false false R12.htm 112 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) false false R13.htm 113 - Disclosure - Warrants and Warrants Liability (Tables) Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiabilityTables Warrants and Warrants Liability (Tables) false false R14.htm 114 - Disclosure - Stock Options (Tables) Sheet http://www.ampliphibio.com/role/StockOptionsTables Stock Options (Tables) false false R15.htm 115 - Disclosure - Nature of Business and Significant Accounting Policies (Details Textual) Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsTextual Nature of Business and Significant Accounting Policies (Details Textual) false false R16.htm 116 - Disclosure - Preferred Shares (Details Textual) Sheet http://www.ampliphibio.com/role/PreferredSharesDetailsTextual Preferred Shares (Details Textual) false false R17.htm 117 - Disclosure - Warrants and Warrants Liability (Details) Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiabilityDetails Warrants and Warrants Liability (Details) false false R18.htm 118 - Disclosure - Warrants and Warrants Liability (Details Textual) Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiabilityDetailsTextual Warrants and Warrants Liability (Details Textual) false false R19.htm 119 - Disclosure - Stock Options (Details) Sheet http://www.ampliphibio.com/role/StockOptionsDetails Stock Options (Details) false false R20.htm 120 - Disclosure - Stock Options (Details 1) Sheet http://www.ampliphibio.com/role/StockOptionsDetails1 Stock Options (Details 1) false false R21.htm 121 - Disclosure - Stock Options (Details 2) Sheet http://www.ampliphibio.com/role/StockOptionsDetails2 Stock Options (Details 2) false false R22.htm 122 - Disclosure - Stock Options (Details Textual) Sheet http://www.ampliphibio.com/role/StockOptionsDetailsTextual Stock Options (Details Textual) false false R23.htm 123 - Disclosure - Correction of Errors (Details Textual) Sheet http://www.ampliphibio.com/role/CorrectionOfErrorsDetailsTextual Correction of Errors (Details Textual) false false All Reports Book All Reports Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 364 days and at least 24 values. Shorter duration columns must have at least one fourth (6) as many values. Column '4/1/2013 - 6/30/2013' is shorter (90 days) and has only 4 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 364 days and at least 24 values. Shorter duration columns must have at least one fourth (6) as many values. Column '4/1/2014 - 6/30/2014' is shorter (90 days) and has only 4 values, so it is being removed. 'Monetary' elements on report '116 - Disclosure - Preferred Shares (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - Consolidated Balance Sheets [Parenthetical] Process Flow-Through: 104 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2013' Process Flow-Through: 106 - Statement - Consolidated Statements of Cash Flows Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2013' aphb-20140630.xml aphb-20140630.xsd aphb-20140630_cal.xml aphb-20140630_def.xml aphb-20140630_lab.xml aphb-20140630_pre.xml true true XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options (Details 1) (Employee Stock Option [Member], USD $)
 6 Months Ended 12 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Employee Stock Option [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares, Outstanding Beginning balance 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Shares, Granted 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Shares, Exercised 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Shares, Forfeited 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Shares, Expired 2,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Shares, Outstanding Ending balance 25,719,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
Shares, Exercisable at June 30, 2014 11,651,493us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Weighted Average Exercise Price, Outstanding Beginning balance $ 0.20us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Weighted Average Exercise Price, Granted $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Weighted Average Exercise Price, Exercised $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Weighted Average Exercise Price, Forfeited $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Weighted Average Exercise Price, Expired $ 13.10us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Weighted Average Exercise Price, Outstanding Ending balance $ 0.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		 $ 0.20us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
Weighted Average Exercise Price, Exercisable at June 30, 2014 $ 0.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		  
Average Remaining Contractual Term (Years), Outstanding 8 years 7 months 17 days 9 years 1 month 24 days
Average Remaining Contractual Term (Years), Exercisable 8 years 7 months 24 days  
Intrinsic Value, Outstanding $ 6,442,700us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember		 $ 6,451,441us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
Intrinsic Value, Exercisable $ 3,017,673us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember